var images_info;if (!images_info) images_info =[]; images_info["101"]={"101000":{"type":"graphic_algorithm","displayName":"Initial approach to suspected bladder cancer","title":"Initial approach to suspected bladder cancer","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Initial approach to suspected bladder cancer</div><div class=\"cntnt\"><img style=\"width:394px; height:334px;\" src=\"images/ONC/101000_Apprch_suspected_bladder_CA.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TURBT: transurethral resection of bladder tumors; EUA: examination under anesthesia.<br />* Biopsy of normal-appearing urothelium and prostate urethra in patients with positive cytology and no visually apparent tumor.<br />¶ Refer to the topic on malignancies of the renal pelvis and ureter.<br />Δ Low, medium, or high, based upon depth of invasion (Ta, Tis, T1) and degree of differentiation in TURBT specimen. Refer to the topic on treatment of urinary non-muscle invasive bladder cancer.<br /><FONT class=lozenge>◊</FONT> Imaging and laboratory studies to assess optimal treatment approach.</div><div id=\"graphicVersion\">Graphic 101000 Version 2.0</div></div></div>"},"101001":{"type":"graphic_figure","displayName":"Siewert classification esophagogastric junction tumor","title":"Siewert classification esophagogastric junction tumor","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Siewert classification esophagogastric junction tumor</div><div class=\"cntnt\"><img style=\"width:498px; height:557px;\" src=\"images/SURG/101001_Siewert_classification_esophagogastric_junction_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Z-line is the point at which the esophageal mucosa changes from stratified squamous to columnar epithelium, and designated as 0 cm.</div><div class=\"graphic_reference\">Modified from: Siewert JR, H&ouml;lscher AH, Becker K, G&ouml;ssner W. [Cardia cancer: attempt at a therapeutically relevant classification]. [Article in German] Chirurg 1987; 58:25.</div><div id=\"graphicVersion\">Graphic 101001 Version 2.0</div></div></div>"},"101004":{"type":"graphic_table","displayName":"Patient global impression of improvement","title":"Patient global impression of improvement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient global impression of improvement</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">GPI: Global perception of improvement </td> </tr> <tr> <td>Overall, do you feel that you are:</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Much better</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Better</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>About the same</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Worse</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Much worse</td> </tr> <tr> <td class=\"subtitle1_single\">PGIS: Patient global impression of severity</td> </tr> <tr> <td>1. Check the one box that describes how your urinary tract condition is now:</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Normal</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Mild</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Moderate</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Severe</td> </tr> <tr> <td class=\"subtitle1_single\">PGI-I: Patient global impression of improvement</td> </tr> <tr> <td>2. Check the one box that best describes how your urinary tract condition is now, compared with how it was before you began taking medication in this study:</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Very much better</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Much better</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>A little better</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>No change</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>A little worse</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Much worse</td> </tr> <tr> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span>Very much worse</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003; 189:98.</div><div id=\"graphicVersion\">Graphic 101004 Version 3.0</div></div></div>"},"101005":{"type":"graphic_picture","displayName":"Poison ivy allergic contact dermatitis","title":"Poison ivy allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Poison ivy allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/101005_PoisonivyACD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large bullae on the hand of a child with acute allergic contact dermatitis from poison ivy.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101005 Version 2.0</div></div></div>"},"101006":{"type":"graphic_picture","displayName":"Pediatric ACD","title":"Subacute allergic contact dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Subacute allergic contact dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101006_Pediatric_ACD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythema and scaling on the dorsal aspect of the feet in a child with subacute allergic contact dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101006 Version 1.0</div></div></div>"},"101008":{"type":"graphic_table","displayName":"Examples of inflammatory versus noninflammatory arthritis","title":"Examples of inflammatory versus noninflammatory arthritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of inflammatory versus noninflammatory arthritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Noninflammatory: &#60;2000 WBC per mm<sup>3</sup> (2 x 10<sup>9</sup> per L)</td> <td class=\"subtitle1\">Inflammatory: &#62;2000 WBC per mm<sup>3</sup></td> </tr> <tr> <td>Osteoarthritis</td> <td>Septic arthritis*</td> </tr> <tr> <td>Trauma</td> <td>Crystal-induced monoarthritis (eg, gout, pseudogout)</td> </tr> <tr> <td>Avascular necrosis</td> <td>Rheumatoid arthritis and juvenile idiopathic arthritis</td> </tr> <tr> <td>Charcot's arthropathy</td> <td>Spondyloarthritis</td> </tr> <tr> <td>Hemochromatosis</td> <td>Systemic lupus erythematosus</td> </tr> <tr> <td>Pigmented villonodular synovitis</td> <td>Lyme disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">WBC: white blood cell.<br />* Synovial fluid analysis in patients with septic arthritis often shows more than 90% polymorphonuclear neutrophilic leukocytes.</div><div class=\"graphic_reference\">Reprinted with permission from Diagnosing Acute Monoarthritis in Adults: A Practical Approach for the Family Physician, July 1, 2003, Vol 68, No 1, American Family Physician. Copyright &copy; 2003 American Academy of Family Physicians. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 101008 Version 4.0</div></div></div>"},"101009":{"type":"graphic_table","displayName":"General guidelines for responding to requests for aid in dying","title":"General guidelines for responding to requests for assistance in dying","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General guidelines for responding to requests for assistance in dying</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td>1. Carefully evaluate all patients making requests for an assisted death of any kind. Explore their fears, concerns, and what makes their current (or future) situation so unacceptable. Comprehensive palliative care and/or hospice care, where available, should always be offered. Ideally, no end of life options, be they legal or illegal, should be acted upon because of lack of adequate management of pain and other symptoms.</td> </tr> <tr class=\"divider_bottom\"> <td>2. Have the patient clarify exactly what he/she is requesting and why. Make sure you understand if he/she is asking about hypothetical future assistance or assistance <strong>right now</strong><sup>[1]</sup>. Regard immediate, intractable suffering as a medical/palliative care emergency.</td> </tr> <tr class=\"divider_bottom\"> <td>3. Recognize that pain and suffering do not always coincide. Treating one does not necessarily relieve the other. Explore, understand, and address the root causes of suffering as much as possible.</td> </tr> <tr class=\"divider_bottom\"> <td>4. Clinicians should know and respect their own limitations and boundaries, but also do their best to respond to the patient's questions and situation<sup>[2]</sup>. Articulate what you <strong>can</strong> do as well as what you <strong>cannot</strong> do to help. <strong>Do not mislead the patient into thinking you will help in ways that you know you cannot.</strong></td> </tr> <tr class=\"divider_bottom\"> <td>5. Be aware of the legal options and limits in terms of&nbsp;end of life alternatives in your area<sup>[3,4]</sup>. Because something is legal in this domain does not mean that you are obligated to provide it. If you cannot provide options that are legal or your patient prefers an option that is illegal, be clear about what your own approach is and what you <strong>can</strong> do to respond to the patient's situation.</td> </tr> <tr class=\"divider_bottom\"> <td>6. If there are legal options for which the patient qualifies that you cannot provide for personal moral reasons, it is generally agreed that you are morally (though not legally) obligated to let the patient know such options are available, how to access them, and to whom the patient can transfer. </td> </tr> <tr class=\"divider_bottom\"> <td>7.&nbsp;If you are planning to prescribe a potentially lethal medication under the Death with Dignity Act, be sure you are aware of doses, prices, and availability.</td> </tr> <tr class=\"divider_bottom\"> <td>8. Remember that under many death with dignity&nbsp;statutes, \"coercion or undue influence\" is a felony, so make sure that it is the informed patient's values, preferences, and circumstances that are driving the process. </td> </tr> <tr> <td>9. Make sure the patient understands that they can withdraw their request for a medically assisted death at any time or&nbsp;for any reason, and that exploring the request with you does not obligate them to act on their request. Also, make sure that, if you have committed yourself to help, your commitment is sincere.</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Quill T, Arnold RM. Evaluating requests for hastened death #156. J Palliat Med 2008; 11:1151.</LI>&#xD;&#xA;<LI>Meier DE, Back AL, Morrison RS. The inner life of physicians and care of the seriously ill. JAMA 2001; 286:3007.</LI>&#xD;&#xA;<LI>Quill TE. Legal regulation of physician-assisted death--the latest report cards. N Engl J Med 2007; 356:1911.</LI>&#xD;&#xA;<LI>Meisel A, Snyder L, Quill T. Seven legal barriers to end-of-life care: myths, realities, and grains of truth. JAMA 2000; 284:2495.</LI></OL></div><div id=\"graphicVersion\">Graphic 101009 Version 3.0</div></div></div>"},"101010":{"type":"graphic_table","displayName":"Legal status of physician-assisted death in US, October 2017","title":"Current legal status of physician-assisted death in the United States by state as of October 2017 ","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Current legal status of physician-assisted death in the United States by state as of October 2017 </div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td>Physician-assisted death is legal in seven states: <ul class=\"decimal_heading\"> <li>Oregon Death with Dignity Act (referendum) <a href=\"https://public.health.oregon.gov/ProviderPartnerResources/Evaluationresearch/deathwithdignityact/Pages/index.aspx\" target=\"_blank\">https://public.health.oregon.gov</a> </li> <li>Washington State Death with Dignity Act 9 (voter initiative) <a href=\"http://www.doh.wa.gov/YouandYourFamily/IllnessandDisease/DeathwithDignityAct\" target=\"_blank\">http://www.doh.wa.gov</a> </li> <li>Vermont Patient Choice and Control at End of Life Act (legislative action) <a href=\"http://www.healthvermont.gov/systems/patient-choice-and-control-end-life\" target=\"_blank\">http://www.healthvermont.gov</a> </li> <li>Montana, not illegal (state Supreme Court decision, Baxter versus Montana, 224 P.3d 1211 [Montana 449, 2009]) </li> <li>California End of Life Option Act (legislative action) <a href=\"https://archive.cdph.ca.gov/Pages/EndofLifeOptionAct.aspx\" spellcheck=\"true\" target=\"_blank\">https://www.cdph.ca.gov</a> </li> <li>Colorado End of Life Options Act (referendum) <a href=\"http://www.sos.state.co.us/pubs/elections/Initiatives/titleBoard/filings/2015-2016/145Final.pdf\" target=\"_blank\">http://www.sos.state.co.us</a> </li> <li>District of Columbia Death with Dignity Act (legislative council action) <a href=\"https://trackbill.com/bill/dc-b38-death-with-dignity-act-of-2015/769584/\" spellcheck=\"true\" target=\"_blank\">https://trackbill.com/bill</a> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Assisting a suicide is illegal in 40 states</td> </tr> <tr class=\"divider_bottom\"> <td>Physician-assisted suicide is explicitly illegal in four states (Alabama, Arkansas, Idaho, Rhode Island)</td> </tr> <tr> <td>Legislative or initiative action concerning physician-assisted death is pending in&nbsp;many states</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101010 Version 10.0</div></div></div>"},"101011":{"type":"graphic_table","displayName":"Requirements of US state laws legalizing PAD","title":"Requirements of United States state laws legalizing physician-assisted dying (PAD)*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Requirements of United States state laws legalizing physician-assisted dying (PAD)*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>The patient must be an adult (18 or over). </li> <li>The patient must have decisional capacity. </li> <li>The patient must be terminally ill, defined as expected to die within six months, as determined by two independent physicians. </li> <li>If either physician suspects that depression or mental illness is distorting the patient's judgment or decisional capacity, the patient is to be referred for psychological or psychiatric evaluation. </li> <li>The patient must make two oral requests and a written request, separated by at least 15 days. </li> <li>The physician may write a prescription for or provide a lethal drug. No physician or pharmacist is required to participate. </li> <li>The physician must advise the patient about other options, including palliative and hospice care, and must tell the patient that his/her request may be withdrawn at any time for any reason. </li> <li>The patient must self-administer the lethal medication. The physician may be present at the death but is not required to do so. </li> <li>The physician must file a report with the designated state health agency. The identity of the physician and of the patient are not matters of public record. </li> <li>The death is not identified as \"suicide\" and does not affect life, health, or accident insurance policies or annuities, wills, contracts, or claims. </li> <li>Physicians and other persons are immune from civil or criminal liability, or professional disciplinary action unless they act with negligence, recklessness, or intentional misconduct. </li> <li>Pressuring or coercing a terminally ill person to request the medication is a felony. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Although there is some variation, as of&nbsp;October 2017, United States state laws permitting PAD generally follow the basic requirements of the original Oregon Death with Dignity Act. Check individual state websites for specific requirements and changes.</div><div id=\"graphicVersion\">Graphic 101011 Version 3.0</div></div></div>"},"101012":{"type":"graphic_table","displayName":"Legal status of PAD/VAE in other countries, April 2017","title":"Legal status of physician-assisted dying (PAD) and voluntary active euthanasia (VAE) in other countries as of October 2017","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Legal status of physician-assisted dying (PAD) and voluntary active euthanasia (VAE) in other countries as of&nbsp;October 2017</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Country</td> <td class=\"subtitle1\">Legal status of PAD and VAE</td> </tr> <tr class=\"divider_bottom\"> <td>Belgium</td> <td>PAD and VAE legal for adults; euthanasia permitted for terminally ill children of any age.</td> </tr> <tr class=\"divider_bottom\"> <td>Canada</td> <td>PAD and VAE legal for adults, subject to guidelines established under directive from the Canadian Supreme court; not all provinces permit euthanasia, despite court finding.</td> </tr> <tr class=\"divider_bottom\"> <td>Columbia</td> <td>PAD and VAE legal for adults.</td> </tr> <tr class=\"divider_bottom\"> <td>Germany</td> <td>Opposed by the German National Medical Association, but 7 of 17 state medical associations do not prohibit. Assisted suicide (not by physicians) is legal for competent, uncoerced adults. Assisted suicide by organizations prohibited if Gesch&#228;ftsm&#228;ssig (\"like a business\").</td> </tr> <tr class=\"divider_bottom\"> <td>Luxemburg</td> <td>PAD and VAE legal for adults and children age 12 or older.</td> </tr> <tr class=\"divider_bottom\"> <td>Netherlands</td> <td>PAD and VAE legal for adults and competent children older than age 12.</td> </tr> <tr> <td>Switzerland</td> <td>Assisted suicide legal for adults if performed by someone with no direct interest in the death; some clinics will accept nonresidents.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101012 Version 11.0</div></div></div>"},"101013":{"type":"graphic_table","displayName":"Websites with additional info about physician-assisted dying","title":"Websites with additional information about physician-assisted dying","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Websites with additional information about physician-assisted dying</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Website</td> <td class=\"subtitle1\">General content</td> </tr> <tr class=\"divider_bottom\"> <td> <p><a href=\"http://public.health.oregon.gov/ProviderPartnerResources/EvaluationResearch/DeathwithDignityAct/Pages/index.aspx\" target=\"_blank\">http://public.health.oregon.gov</a></p> </td> <td> <p>Information about the Oregon Death with Dignity Act, including detailed year-by-year data.</p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><a href=\"https://www.deathwithdignity.org/\" target=\"_blank\">https://www.deathwithdignity.org</a></p> </td> <td> <p>Information about efforts to legalize death with dignity laws in the United States.</p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><a href=\"https://www.compassionandchoices.org/\" target=\"_blank\">https://www.compassionandchoices.org</a></p> </td> <td> <p>Information about support for patients and families going through this process and about efforts for promoting legalization. Also provides the&nbsp;\"Doc2Doc\" and \"Pharmacist2Pharmacist\" consultation services for professionals.</p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><a href=\"https://www.knmg.nl/advies-richtlijnen/scen/over-scen.htm\" target=\"_blank\">https://www.knmg.nl/advies-richtlijnen/scen/over-scen.htm</a></p> </td> <td> <p>Support and Consultation for Euthanasia in the Netherlands (SCEN) has information about consultation committees in the Netherlands; site information available in Dutch and English.</p> </td> </tr> <tr> <td> <p><a href=\"https://knmg.nl/contact/about-knmg.htm\" target=\"_blank\">https://knmg.nl/contact/about-knmg.htm</a></p> </td> <td> <p>The Royal Dutch Medical Association website; has practice guidelines available in Dutch and English. Refer to the Publications in English box, \"Guidelines for the Practice of Euthanasia and Physician-Assisted Suicide.\"</p> </td> </tr> <tr> <td><a href=\"https://www.canada.ca/en/health-canada/services/medical-assistance-dying.html\">https://www.canada.ca/en/health-canada/services/medical-assistance-dying.html</a></td> <td>Information about legal status and practice in Canada.</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101013 Version 3.0</div></div></div>"},"101014":{"type":"graphic_table","displayName":"Potential options for end stage illness","title":"Potential options for patients in the end stage of a terminal illness, listed in decreasing order of societal acceptance and consensus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Potential options for patients in the end stage of a terminal illness, listed in decreasing order of societal acceptance and consensus</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Stopping or not starting potentially life-sustaining therapy </li> <li>Accelerating opioids for intractable pain or dyspnea </li> <li>Palliative sedation, potentially to unconsciousness </li> <li>Voluntarily stopping eating and drinking </li> <li>Physician-assisted death (by patient-administered lethal prescription) </li> <li>Voluntary active euthanasia (by physician-administered lethal medication); legal in Europe and Canada but not in the United States</li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101014 Version 4.0</div></div></div>"},"101015":{"type":"graphic_table","displayName":"Chromosomal abnormalities associated with Hirschsprung disease","title":"Chromosomal abnormalities associated with Hirschsprung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chromosomal abnormalities associated with Hirschsprung disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Chromosomal abnormality</td> <td class=\"subtitle1\">Features</td> <td class=\"subtitle1\">Chromosomal locus (gene symbol)</td> <td class=\"subtitle1\">Percent of individuals with this disorder&nbsp;who have Hirschsprung disease</td> </tr> <tr> <td>Down syndrome</td> <td>Intellectual disability, short stature, congenital heart disease, craniofacial features.</td> <td>Trisomy 21</td> <td>0.6 to 3 percent</td> </tr> <tr> <td>Deletion 10q</td> <td>Intellectual disability, hypotonia</td> <td>del 10q11.2 <em>(RET)</em></td> <td>Unknown</td> </tr> <tr> <td>Deletion 13q</td> <td>Intellectual disability, growth failure, craniofacial features</td> <td>del 13q22 <em>(EDNRB)</em></td> <td>Unknown</td> </tr> <tr> <td>Deletion 2q22</td> <td>Intellectual disability, microcephaly, craniofacial features, seizures</td> <td>del 2q22 <em>(ZFHX1B)</em></td> <td>Unknown</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Parisi MA. Hirschsprung Disease Overview. 2002 Jul 12 [Updated 2011 Nov 10]. In: GeneReviews, Pagon RA, Adam MP, Ardinger HH, et al (Eds), Seattle: University of Washington, Seattle 1993-2015. Available from: <a href=\"http://www.ncbi.nlm.nih.gov/books/NBK1439/\" spellcheck=\"true\" target=\"_blank\">http://www.ncbi.nlm.nih.gov/books/NBK1439/</a> (Accessed on April 15, 2015). Copyright &copy; 1993-2015, University of Washington, Seattle. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101015 Version 2.0</div></div></div>"},"101016":{"type":"graphic_table","displayName":"Motivations for seeking a hastened death","title":"Motivations for seeking a hastened death (data from Washington State)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Motivations for seeking a hastened death (data from Washington State)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Illness-related experiences</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Inability to engage in enjoyable activities (89%) </li> <li>Feeling weak, tired, uncomfortable (69%) </li> <li>Loss of function (66%) </li> <li>Pain or unacceptable side effects of pain medications (40%) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Threats to sense of self</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Loss of autonomy (97%) </li> <li>Loss of dignity (75%) </li> <li>Loss of sense of self (63%) </li> <li>Desire for control (60%) </li> <li>Long-standing beliefs in favor of hastened death (14%) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Fears about the future</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Fears about future quality of life and dying (60%) </li> <li>Negative past experience with dying friends or family members (49%) </li> <li>Fear of being a burden on others (9%) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from Quill, Timothy E., M.D., and Margaret P. Battin, Ph.D., eds.. Physician-Assisted Dying: The Case for Palliative Care and Patient Choice. pp. 94, Table 6.1. &copy; 2004 The Johns Hopkins University Press. Reprinted with permission of Johns Hopkins University Press.<br />Additional data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>​Loggers ET, Starks H, Shannon-Dudley M, et al. Implementing a death with Dignity Program at a comprehensive cancer center. N Engl J Med 2013; 368:1417.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 101016 Version 2.0</div></div></div>"},"101018":{"type":"graphic_picture","displayName":"Pernio in a woman chronically exposed to dry cold","title":"Pernio in a woman chronically exposed to dry cold","html":"<div class=\"graphic\"><div style=\"width: 875px\" class=\"figure\"><div class=\"ttl\">Pernio in a woman chronically exposed to dry cold</div><div class=\"cntnt\"><img style=\"width:855px; height:596px;\" src=\"images/EM/101018_Prn_wmn_chrncl_exps_dry_cld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo above shows pernio in a woman chronically exposed to dry cold in an austere environment.&nbsp;Pernio is a painful condition.</div><div class=\"graphic_reference\">Courtesy of Alice F Murray, MD.</div><div id=\"graphicVersion\">Graphic 101018 Version 2.0</div></div></div>"},"101022":{"type":"graphic_picture","displayName":"Severe frostbite of the hand","title":"Severe frostbite of the hand","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">Severe frostbite of the hand</div><div class=\"cntnt\"><img style=\"width:783px; height:580px;\" src=\"images/EM/101022_Severe_frostbite_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo above shows severe frostbite of the hand showing well-demarcated dry gangrene preceding significant loss of tissue.</div><div class=\"graphic_reference\">Courtesy of Ken Zafren, MD.</div><div id=\"graphicVersion\">Graphic 101022 Version 1.0</div></div></div>"},"101023":{"type":"graphic_picture","displayName":"Severe frostbite of the foot","title":"Severe frostbite of the foot","html":"<div class=\"graphic\"><div style=\"width: 801px\" class=\"figure\"><div class=\"ttl\">Severe frostbite of the foot</div><div class=\"cntnt\"><img style=\"width:781px; height:578px;\" src=\"images/EM/101023_Severe_frostbite_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo above shows severe frostbite of the foot showing well-demarcated dry gangrene preceding significant loss of tissue.</div><div class=\"graphic_reference\">Courtesy of Ken Zafren, MD.</div><div id=\"graphicVersion\">Graphic 101023 Version 1.0</div></div></div>"},"101024":{"type":"graphic_picture","displayName":"Early demarcation of severe frostbite of the hand","title":"Early demarcation of severe frostbite of the hand","html":"<div class=\"graphic\"><div style=\"width: 875px\" class=\"figure\"><div class=\"ttl\">Early demarcation of severe frostbite of the hand</div><div class=\"cntnt\"><img style=\"width:855px; height:636px;\" src=\"images/EM/101024_Erly_dmrc_svr_frstbt_hnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo above shows early demarcation of severe frostbite of the hand. The violaceous hue and lack of blistering are grave prognostic signs.</div><div class=\"graphic_reference\">Courtesy of Ken Zafren, MD.</div><div id=\"graphicVersion\">Graphic 101024 Version 1.0</div></div></div>"},"101025":{"type":"graphic_picture","displayName":"Early demarcation of severe frostbite of the foot","title":"Early demarcation of severe frostbite of the foot","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">Early demarcation of severe frostbite of the foot</div><div class=\"cntnt\"><img style=\"width:784px; height:583px;\" src=\"images/EM/101025_Erly_dmrct_svr_frstbt_ft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo above shows early demarcation of severe frostbite of the foot. The violaceous hue and lack of blistering are grave prognostic signs.</div><div class=\"graphic_reference\">Courtesy of Ken Zafren, MD.</div><div id=\"graphicVersion\">Graphic 101025 Version 1.0</div></div></div>"},"101026":{"type":"graphic_picture","displayName":"Early post-thaw appearance of frostbite of the toes","title":"Early post-thaw appearance of frostbite of the toes","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">Early post-thaw appearance of frostbite of the toes</div><div class=\"cntnt\"><img style=\"width:783px; height:584px;\" src=\"images/EM/101026_Erl_pst_thw_appr_frstbt_toe.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The above photo shows early post-thaw appearance of frostbite of the toes. The lack of swelling and erythema makes this potentially severe injury appear deceptively benign.</div><div class=\"graphic_reference\">Courtesy of Ken Zafren, MD.</div><div id=\"graphicVersion\">Graphic 101026 Version 1.0</div></div></div>"},"101027":{"type":"graphic_picture","displayName":"Nonfreezing cold injury (\"trench foot\" or \"immersion foot\")","title":"Nonfreezing cold injury (\"trench foot\" or \"immersion foot\")","html":"<div class=\"graphic\"><div style=\"width: 802px\" class=\"figure\"><div class=\"ttl\">Nonfreezing cold injury (\"trench foot\" or \"immersion foot\")</div><div class=\"cntnt\"><img style=\"width:782px; height:527px;\" src=\"images/EM/101027_Nnfrz_cld_inj_trnch_imrs_ft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo above shows nonfreezing cold injury (\"trench foot\" or \"immersion foot\") in a homeless man soon after his presentation to the emergency department after he was found intoxicated outdoors with wet shoes and socks.</div><div class=\"graphic_reference\">Courtesy of Ken Zafren, MD.</div><div id=\"graphicVersion\">Graphic 101027 Version 1.0</div></div></div>"},"101029":{"type":"graphic_figure","displayName":"Pancreaticogastrostomy after pancreaticoduodenectomy","title":"Pancreaticogastrostomy after pancreaticoduodenectomy","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Pancreaticogastrostomy after pancreaticoduodenectomy</div><div class=\"cntnt\"><img style=\"width:538px; height:385px;\" src=\"images/SURG/101029_Pancreaticogastrostomy_after_pancreaticduodenectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pancreaticogastrostomy with (B) or without (A) a Roux limb for biliary anastomosis.</div><div id=\"graphicVersion\">Graphic 101029 Version 1.0</div></div></div>"},"101038":{"type":"graphic_picture","displayName":"Milia","title":"Milia","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Milia</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101038_Milia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple 1 to 2 mm cystic white papules on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101038 Version 1.0</div></div></div>"},"101039":{"type":"graphic_picture","displayName":"Miliary osteoma cutis","title":"Miliary osteoma cutis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Miliary osteoma cutis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101039_Miliary_osteoma_cutis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple firm papules on the cheek.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101039 Version 1.0</div></div></div>"},"101047":{"type":"graphic_table","displayName":"Differential diagnosis of RLS","title":"Differential diagnosis of restless legs syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of restless legs syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder</td> <td class=\"subtitle1\">Comment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neurological disorders with \"urge to move\"</td> </tr> <tr> <td class=\"indent1\">Neuroleptic-induced akathisia</td> <td>Looks like severe RLS but affects the whole body, not just the limbs. Less circadian pattern&nbsp;and less relief from movement. Entire body rocking often seen. Associated with dopamine antagonists.</td> </tr> <tr> <td class=\"indent1\">Hypotensive akathisia</td> <td>Feeling of restlessness, brought on by sitting still,&nbsp;which may be localized in legs; should not occur while lying down but might be relieved by movement; occurs in patients with orthostatic hypotension.</td> </tr> <tr> <td class=\"indent1\">Volitional movements, foot tapping, leg rocking</td> <td>Occurs in subjects who fidget, especially when bored or anxious, but usually not associated with sensory symptoms, discomfort, or conscious urge to move. Symptoms do not bother the subject, usually lack a circadian pattern, and do not&nbsp;cause sleep disturbances.&nbsp;Probably a type of psychic restlessness, very common.</td> </tr> <tr> <td class=\"indent1\">Painful legs and moving toes</td> <td>Feet involved more than in RLS. Movement is truly involuntary, no circadian pattern. Usually&nbsp;a continuous slow writhing.</td> </tr> <tr> <td class=\"indent1\">Isolated leg stereotype</td> <td>Fast (&#62;3 Hz) rhythmic plantar flexion/dorsiflexion movements oscillating around ankle, but sometimes involving&nbsp;other parts of the&nbsp;leg. Usually a tremor phenotype, but not considered a true tremor. It is easily suppressed and is almost always seen only while sitting. The condition is common, not considered pathologic, and may be an alerting activity. Overlaps with foot tapping/leg rocking.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Orthostatic tremor</td> <td>Fine leg tremor manifest by a sense of poor balance while standing, but not while walking. Therefore, patients cannot stand still but need to walk. Unlike RLS, there are no symptoms while sitting or lying down and no circadian pattern.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Disorders without \"urge to move\"</td> </tr> <tr> <td class=\"indent1\">Nocturnal leg cramps</td> <td>Leg cramps or charley horse cramps that come on at night and are relieved with stretching or walking. Experienced as an unusually painful muscular contraction, often involving the calf muscles. Unlike RLS, sensations are&nbsp;sudden onset, short duration, usually palpable contractions, no urge to move.</td> </tr> <tr> <td class=\"indent1\">Arthritis, lower limb pain</td> <td>Discomfort centered mostly in joints, increased with movement. Unlike RLS,&nbsp;does not have prominent circadian pattern,&nbsp; does not respond to dopaminergics, usually no PLMS.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Positional discomfort</td> <td>Often comes on with prolonged sitting or lying in the same position, but usually relieved by a simple change in position, unlike RLS, which often returns when change of position, movement, or walking is not continued, no circadian pattern.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Vascular disorders</td> </tr> <tr> <td class=\"indent1\">Vascular claudication</td> <td>Pain in the legs. Usually worse with walking or movement and usually relieved by prolonged rest, often best in a lying position. Unlike RLS,&nbsp;no urge to move, no circadian pattern, usually no sleep disturbances.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Varicose veins</td> <td>May have discomfort in legs, some relief with massage or inactivity.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Pain disorders</td> </tr> <tr> <td class=\"indent1\">Myelopathy, radiculopathy</td> <td>Dysesthesias and pain in the legs, frequently one-sided, often radicular, with atrophic changes of musculature. Although symptoms can be initiated by sitting or lying down and improve with movement, there is no urge to move the legs,&nbsp;no response to dopaminergic therapy.</td> </tr> <tr> <td class=\"indent1\">Painful peripheral neuropathy</td> <td>Sensory symptoms commonly reported as numbness, burning, and pain; more superficial than RLS, no urge to move. Complete and persistent relief is not obtained while walking or during sustained movement.</td> </tr> <tr> <td class=\"indent1\">Isolated leg pain</td> <td>Undiagnosed leg pain&nbsp;or ache in the muscle may be seen without other explanation. The examination and evaluation is normal. This is often worse at night and may improve with movement but there is no true urge to move.</td> </tr> <tr> <td class=\"indent1\">Congestive heart failure</td> <td>Nighttime pain in the lower limbs that spreads to the lumbosacral area, causing sleep disturbances; no urge to move. Attributed to nocturnal engorgement of the lumbar veins causing transient lumbar stenosis.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Fibromyalgia</td> <td>Multiple, alternating,&nbsp;varied complaints in muscle groups and joints; sometimes leg-accentuated but mostly whole body affected. Frequent sleep disturbances, but&nbsp;no circadian pattern, no relief&nbsp;from movement.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Sleep-related disorders </td> </tr> <tr> <td class=\"indent1\">Periodic limb movements of sleep&nbsp;</td> <td>Diagnosis made by sleep laboratory assessment, positive response to dopaminergic therapy. No urge to move or dysesthesias while awake. Sleep disturbance and complaints of daytime fatigue and sleepiness may be present.</td> </tr> <tr> <td class=\"indent1\">Hypnic jerks</td> <td>Involuntary muscle (myoclonic) twitch&nbsp;that occurs while falling asleep. Described as an electric shock or falling sensation, which can cause movements of legs and arms. Occurs once or twice per night, common.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RLS: restless legs syndrome; PLMS: periodic limb movements of sleep.</div><div id=\"graphicVersion\">Graphic 101047 Version 3.0</div></div></div>"},"101053":{"type":"graphic_picture","displayName":"Histology, solitary fibrous tumor hypocellular variant","title":"Histologic appearance of solitary fibrous tumor, hypocellular variant","html":"<div class=\"graphic\"><div style=\"width: 888px\" class=\"figure\"><div class=\"ttl\">Histologic appearance of solitary fibrous tumor, hypocellular variant</div><div class=\"cntnt\"><img style=\"width:868px; height:351px;\" src=\"images/ONC/101053_Sliry_fbrs_tmr_hypcllr_vrnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnification: 100X; staining: hematoxilin and eosin&nbsp;(H&amp;E); site: pleura. Panel A and B are from the same tumor demonstrating the heterogeneous cellular nature of SFT. Panel A shows a relatively more cellular area of the tumor, while B shows a densely collagenized hypocellular focus.</div><div class=\"graphic_footnotes\">SFT: solitary fibrous tumor.</div><div id=\"graphicVersion\">Graphic 101053 Version 1.0</div></div></div>"},"101054":{"type":"graphic_picture","displayName":"Histology, solitary fibrous tumor, hypercellular variant","title":"Histologic appearance of solitary fibrous tumor, hypercellular variant","html":"<div class=\"graphic\"><div style=\"width: 801px\" class=\"figure\"><div class=\"ttl\">Histologic appearance of solitary fibrous tumor, hypercellular variant</div><div class=\"cntnt\"><img style=\"width:781px; height:625px;\" src=\"images/ONC/101054_Sltry_fbrs_tmr_hyprcllr_vrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnification: 100X; staining: hematoxilin and eosin&nbsp;(H&amp;E); site:&nbsp;dura.</div><div id=\"graphicVersion\">Graphic 101054 Version 1.0</div></div></div>"},"101058":{"type":"graphic_picture","displayName":"Frostbite of the foot prior to thawing","title":"Frostbite of the foot prior to thawing","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Frostbite of the foot prior to thawing</div><div class=\"cntnt\"><img style=\"width:515px; height:775px;\" src=\"images/EM/101058_Frostbite_foot_prior_thaw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo above shows frostbite of the foot at first presentation.&nbsp;Prior to thawing, it is impossible to distinguish mild frostbite from severe.</div><div class=\"graphic_reference\">Courtesy of Nicholas Kanaan, MD.</div><div id=\"graphicVersion\">Graphic 101058 Version 1.0</div></div></div>"},"101059":{"type":"graphic_picture","displayName":"Frostbite blisters","title":"Frostbite blisters","html":"<div class=\"graphic\"><div style=\"width: 801px\" class=\"figure\"><div class=\"ttl\">Frostbite blisters</div><div class=\"cntnt\"><img style=\"width:781px; height:573px;\" src=\"images/EM/101059_Frostbite_blisters.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo above&nbsp;was taken two&nbsp;days after&nbsp;the patient&nbsp;sustained&nbsp;frostbite from cold exposure in the Himalayas. The trekker's hands have become edematous and blisters have formed on the distal fingertips. Frostbite blisters may be larger than those shown here.</div><div class=\"graphic_reference\">Courtesy of Nicholas Kanaan, MD.</div><div id=\"graphicVersion\">Graphic 101059 Version 2.0</div></div></div>"},"101060":{"type":"graphic_table","displayName":"Evaluation of diffuse alveolar hemorrhage","title":"Evaluation of diffuse alveolar hemorrhage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Evaluation of diffuse alveolar hemorrhage</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">General tests for most patients</td> </tr> <tr> <td class=\"indent1\">Complete blood count and differential</td> </tr> <tr> <td class=\"indent1\">International normalized ratio, prothrombin time, partial thromboplastin time</td> </tr> <tr> <td class=\"indent1\">BUN, creatinine</td> </tr> <tr> <td class=\"indent1\">Urinalysis including examination for red cell casts</td> </tr> <tr> <td class=\"indent1\">Blood cultures and testing for influenza</td> </tr> <tr> <td class=\"indent1\">BNP or N-terminal pro-BNP</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bronchoalveolar lavage (visible hemorrhage, hemosiderin-laden macrophages, eosinophils, microbiologic cultures/immunoassays, cytology)</td> </tr> <tr> <td class=\"subtitle1_single\">Tests for immune-mediated diseases</td> </tr> <tr> <td class=\"indent1\">ANCA</td> </tr> <tr> <td class=\"indent1\">Anti-GBM antibodies</td> </tr> <tr> <td class=\"indent1\">ANA, anti-double-stranded DNA, CH50, C3, C4</td> </tr> <tr> <td class=\"indent1\">CPK</td> </tr> <tr> <td class=\"indent1\">Anticardiolipin antibodies, anti-beta-2-glycoprotein I, and/or a lupus anticoagulant</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rheumatoid factor</td> </tr> <tr> <td class=\"subtitle1_single\">Tests for celiac disease when idiopathic pulmonary hemosiderosis suspected</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Anti-transglutaminase or anti-endomysial IgA antibodies</td> </tr> <tr> <td class=\"subtitle1_single\">Miscellaneous tests based on clinical evaluation</td> </tr> <tr> <td class=\"indent1\">Antihistone antibodies</td> </tr> <tr> <td class=\"indent1\">Antistreptococcal antibodies</td> </tr> <tr> <td class=\"indent1\">Drug screen for cocaine</td> </tr> <tr> <td class=\"indent1\">Serologic test for leptospirosis</td> </tr> <tr> <td class=\"indent1\">Skin biopsy</td> </tr> <tr> <td class=\"indent1\">Lung biopsy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BUN: blood urea nitrogen; BNP: brain natriuretic peptide; ANCA: antineutrophil cytoplasmic antibodies; GBM: glomerular basement membrane; ANA: antinuclear antibody; CH50: total hemolytic complement; C3: complement component 3; C4: complement component 4; CPK: creatinine phosphokinase; IgA: immunoglobulin A.</div><div id=\"graphicVersion\">Graphic 101060 Version 2.0</div></div></div>"},"101061":{"type":"graphic_table","displayName":"Risk assessment algorithms pleural SFT","title":"Proposed risks assessment algorithms for solitary fibrous tumor (SFT) of the pleura","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed risks assessment algorithms for solitary fibrous tumor (SFT) of the pleura</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">England DM, et al. 1989</td> <td class=\"subtitle1\">De Perrot M, et al. 2002</td> <td class=\"subtitle1\">Tapias LC, et al. 2013</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Histologic risk factors for malignancy</td> </tr> <tr> <td class=\"indent1\">Mitotic figures/10 HPF</td> <td class=\"centered\">&#62;4</td> <td class=\"centered\">&#62;4</td> <td class=\"centered\">&#8805;4</td> </tr> <tr> <td class=\"indent1\">Hypercellularity</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Pleomorphism</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Necrosis</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\">Hemorrhage</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Stromal/vascular invasion</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Anatomic high risk factors</td> </tr> <tr> <td class=\"indent1\">Size</td> <td>&#62;10 cm</td> <td>&nbsp;</td> <td>&#8805;10 cm</td> </tr> <tr> <td class=\"indent1\">Pedunculation</td> <td>Sessile</td> <td>Sessile</td> <td>Sessile</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Site</td> <td>Parietal pleura</td> <td>Not included</td> <td>Parietal pleura</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Number of criteria needed for malignant diagnosis</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>1 or more histologic criteria</td> <td>1 or more histologic criteria</td> <td>Any 3 histologic and anatomic risk factors</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>England DM, Hochholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of the pleura. A clinicopathologic review of 223 cases. Am J Surg Pathol 1989; 13:640.</li>&#xD;&#xA;    <li>de Perrot M, Fischer S, Br&uuml;ndler MA, et al. Solitary fibrous tumors of the pleura. Ann Thorac Surg 2002; 74:285.</li>&#xD;&#xA;    <li>Tapias LF, Mino-Kenudson M, Lee H, et al. Risk factor analysis for the recurrence of resected solitary fibrous tumours of the pleura: a 33-year experience and proposal for a scoring system. Eur J Cardiothorac Surg 2013; 44:111.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 101061 Version 1.0</div></div></div>"},"101067":{"type":"graphic_algorithm","displayName":"Algorithm for posttreatment follow-up, pleural SFT","title":"Algorithm for posttreatment follow-up for solitary fibrous tumor of the pleura (SFTP)","html":"<div class=\"graphic\"><div style=\"width: 722px\" class=\"figure\"><div class=\"ttl\">Algorithm for posttreatment follow-up for solitary fibrous tumor of the pleura (SFTP)</div><div class=\"cntnt\"><img style=\"width:702px; height:274px;\" src=\"images/ONC/101067_Algo_tx_posttx_pleural_SFT.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Original figure modified for this publication. de Perrot M, Fischer S, Br&uuml;ndler MA, et al. Solitary Fibrous Tumors of the Pleura. Ann Thorac Surg 2002; 74:285. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101067 Version 2.0</div></div></div>"},"101068":{"type":"graphic_table","displayName":"Molecular prognostic tests for prostate cancer","title":"Molecular prognostic tests for prostate cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Molecular prognostic tests for prostate cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Test</td> <td class=\"subtitle1\">Proprietary name</td> <td class=\"subtitle1\">Mechanism</td> <td class=\"subtitle1\">Potential applications studied</td> </tr> <tr> <td>Ki-67</td> <td>&nbsp;</td> <td>IHC of nuclear protein associated with RNA synthesis</td> <td>Prognostic value in predicting risk of recurrence in patients undergoing definitive treatment<sup>[1]</sup></td> </tr> <tr> <td>Cell cycle progression score</td> <td>Prolaris</td> <td>RT-PCR of 31 cell cycle-related genes</td> <td>Prognostic value in predicting risk of recurrence in patients undergoing definitive treatment<sup>[2]</sup></td> </tr> <tr> <td>PTEN loss</td> <td>ProstaVysion, ProMark (as part of panel)</td> <td>Assessment of PTEN tumor suppressor by either FISH (DNA) or IHC (protein)</td> <td>Prognostic marker in untreated, localized disease<sup>[3]</sup></td> </tr> <tr> <td>Genomic classifier</td> <td>Decipher</td> <td>Genome-wide expression array of 22 markers based on RNA expression</td> <td>Assessment of risk of metastases following initial treatment<sup>[4]</sup></td> </tr> <tr> <td>Genomic prostate score</td> <td>OncoTypeDX prostate</td> <td>RT-PCR of 12 cancer-related genes</td> <td>Assessment of risk of identifying high-risk disease based upon needle biopsy<sup>[5]</sup></td> </tr> <tr> <td>Proteomic marker</td> <td>ProMark</td> <td>Eight protein expression in biopsy specimen</td> <td>Prognostic marker predicting prostate cancer aggressiveness and lethality from prostate biopsy<sup>[6]</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RT-PCR: reverse transcriptase polymerase chain reaction; IHC: immunohistochemistry; FISH: fluorescence in situ hybridization.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>J Clin Oncol 2004; 22:2133; Mayo Clin Proc 2014; 89:308; Br J Cancer 2013; 108:271. </li>&#xD;&#xA;    <li>Br J Cancer 2012; 106:1095; J Urol 2014; 192:409. </li>&#xD;&#xA;    <li>Br J Cancer 2013; 108:2582. </li>&#xD;&#xA;    <li>Prostate Cancer Prostatic Dis 2014; 17:64; Eur Urol 2015; 67:778. </li>&#xD;&#xA;    <li>Eur Urol 2014; 66:550; Eur Urol 2014 Nov 29. [Epub ahead of print]. </li>&#xD;&#xA;    <li>Clin Cancer Res 2015 Mar 2. [Epub ahead of print].</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 101068 Version 4.0</div></div></div>"},"101069":{"type":"graphic_table","displayName":"De Perrot classification of SFT of the pleura","title":"De Perrot classification of malignant potential of pleural solitary fibrous tumors","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">De Perrot classification of malignant potential of pleural solitary fibrous tumors</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Stage</td> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Risk of recurrence, %</td> </tr> <tr> <td class=\"centered\">0</td> <td>Pedunculated tumor without histologic&nbsp;signs of malignancy*</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"centered\">I</td> <td>Sessile or \"inverted\" tumor without histologic signs of malignancy*</td> <td class=\"centered\">8</td> </tr> <tr> <td class=\"centered\">II</td> <td>Pedunculated tumor with histologic signs of malignancy*</td> <td class=\"centered\">14</td> </tr> <tr> <td class=\"centered\">III</td> <td>Sessile or \"inverted\" tumor with histologic signs of malignancy*</td> <td class=\"centered\">63</td> </tr> <tr> <td class=\"centered\">IV</td> <td>Multiple synchronous metastatic tumors</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Malignant behavior is suggested by the presence of the following histologic features: high cellularity with crowding and overlapping of nuclei, cellular pleomorphism, high mitotic count (more than 4 per 10 high-power fields), necrosis, or stromal/vascular invasion.</div><div class=\"graphic_reference\">Original figure modified for this publication. de Perrot M, Fischer S, Br&uuml;ndler MA, et al. Solitary Fibrous Tumors of the Pleura. Ann Thorac Surg 2002; 74:285. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101069 Version 3.0</div></div></div>"},"101070":{"type":"graphic_table","displayName":"Effect of selected medicines and agents on bladder function","title":"Effect of selected medicines and other agents on bladder function","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effect of selected medicines and other agents on bladder function</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Medicines and other agents</td> <td class=\"subtitle1\">Effect on bladder function</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Allergy</td> </tr> <tr> <td class=\"indent1\">Antihistamines</td> <td>First-generation H<sub>1 </sub>receptor antagonists (eg, brompheniramine, chlorpheniramine, clemastine, cyproheptadine, dimenhydrinate, diphenhydramine, hydroxyzine, others)</td> <td>Decreased contractility via anticholinergic effect</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Decongestants</td> <td>Pseudoephedrine, phenylephrine</td> <td>Increased urethral sphincter tone</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Analgesic and sedative</td> </tr> <tr> <td class=\"indent1\">Benzodiazepines</td> <td>Chlordiazepoxide, clonazepam, temazepam, triazolam, others</td> <td>Impaired micturition via muscle relaxant effect</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Opioids</td> <td>Codeine, meperidine, morphine, oxycodone, others</td> <td>Decreased sensation of fullness and increased urethral sphincter tone</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Anticholinergic*</td> </tr> <tr> <td class=\"indent1\">Antimuscarinics (overactive bladder medications)</td> <td>Darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, trospium</td> <td>Decreased contractility via anticholinergic effect</td> </tr> <tr> <td class=\"indent1\">Spasmolytic</td> <td>Dicyclomine, hyoscyamine, glycopyrrolate, methscopolamine, propantheline, scopolamine (hyoscine)</td> <td>Decreased contractility via anticholinergic effect</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Anticholinergics (antiparkinson medications)</td> <td>Benztropine, trihexyphenidyl</td> <td>Decreased contractility via anticholinergic effect</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cardiology<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">ACE inhibitors</td> <td>Enalapril, lisinopril, ramipril, others</td> <td>Decreased contractility; chronic coughing</td> </tr> <tr> <td class=\"indent1\">Alpha-agonists</td> <td>Midodrine, phenylephrine, vasopressors (various)</td> <td>Increased urethral sphincter tone</td> </tr> <tr> <td class=\"indent1\">Alpha<sub>1</sub>-blockers</td> <td>Alfuzosin, doxazosin, prazosin, silodosin, tamsulosin, terazosin</td> <td>Decreased urethral sphincter tone</td> </tr> <tr> <td class=\"indent1\">Antiarrhythmic</td> <td>Disopyramide, flecainide</td> <td>Decreased contractility via local anesthetic effect on bladder mucosa or anticholinergic effect</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Diuretics</td> <td>Various</td> <td>Increased urine production, contractility, or rate of emptying</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Psychotropic</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Antidepressants</td> <td>SNRIs: duloxetine, reboxetine<sup>&#916;</sup></td> <td>Increased urethral sphincter tone</td> </tr> <tr> <td>Tricyclic antidepressants (amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline, others)</td> <td>Decreased contractility via anticholinergic effect</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Antipsychotics</td> <td>First-generation (chlorpromazine, fluphenazine, methotrimeprazine); second-generation (clozapine, olanzapine, risperidone); others have lower effect</td> <td>Mixed effects described; decreased contractility via anticholinergic effect; increased micturition and stress incontinence via stimulation of alpha1 receptors and/or central dopaminergic receptors</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other</td> </tr> <tr> <td class=\"indent1\">Skeletal muscle relaxants</td> <td>Orphenadrine, tizanidine (also cyclobenzaprine, baclofen, and methocarbamol; but effect is lower)</td> <td>Decreased contractility via anticholinergic effect</td> </tr> <tr> <td class=\"indent1\">Estrogens</td> <td>Oral estrogens (hormone replacement therapy)</td> <td>Increased urinary incontinence</td> </tr> <tr> <td class=\"indent1\">Beta<sub>3</sub>-agonist</td> <td>Mirabegron</td> <td>Decreased contractility via beta<sub>3</sub>-adrenergic effect</td> </tr> <tr> <td class=\"indent1\">Alcohol</td> <td>&nbsp;</td> <td>Decreased contractility</td> </tr> <tr> <td class=\"indent1\">Caffeine</td> <td>&nbsp;</td> <td>Increased contractility or rate of emptying</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ACE: angiotensin-converting enzyme; SNRIs: serotonin-norepinephrine reuptake inhibitors; BPH: benign prostatic hyperplasia.<br />* Inhaled antimuscarinic bronchodilators (eg, ipratropium, tiotropium) and ophthalmic drops (eg, atropine, cyclopentolate) can be absorbed systemically in varying degrees; urinary retention has been rarely associated with their use particularly among older adults, men with BPH, and administration of inhaled anticholinergic drug by nebulizer. <br />¶ Increased micturition reported by ≤3% of patients in clinical studies of calcium channel blockers; mixed effects have been described. <br />Δ Not available in the&nbsp;United States.</div><div class=\"graphic_reference\">Prepared with data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Verhamme K, Sturkenboom M, Stricker B, et al. Drug induced urinary retention. Drug Saf 2008; 31:373.</li>&#xD;&#xA;    <li>Zyczynski H, Parekh M, Kahn M, et al. Urinary incontinence in women. American Urogynecologic Society (2012); available at http://eguideline.guidelinecentral.com/i/76622-augs-urinary-incontinence</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 101070 Version 2.0</div></div></div>"},"101071":{"type":"graphic_figure","displayName":"Night blindness in preschool-aged children","title":"Night blindness in preschool-aged children, by country","html":"<div class=\"graphic\"><div style=\"width: 834px\" class=\"figure\"><div class=\"ttl\">Night blindness in preschool-aged children, by country</div><div class=\"cntnt\"><img style=\"width:814px; height:592px;\" src=\"images/GAST/101071_Nght_blndnss_prschl_ag_chld.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data from surveys and regression-based estimates, prepared by the World Health Organization.</div><div class=\"graphic_reference\">Reprinted from World Health Organization Global Database on Vitamin A Deficiency, Global prevalence of vitamin A deficiency in populations at risk, 1995-2005. Available at: <A href=\"http://www.who.int/vmnis/database/vitamina/en/\" target=_blank>http://www.who.int/vmnis/database/vitamina/en/</A> (accessed June 20, 2017).</div><div id=\"graphicVersion\">Graphic 101071 Version 2.0</div></div></div>"},"101072":{"type":"graphic_figure","displayName":"Night blindness in pregnant women","title":"Night blindness in pregnant women, by country","html":"<div class=\"graphic\"><div style=\"width: 848px\" class=\"figure\"><div class=\"ttl\">Night blindness in pregnant women, by country</div><div class=\"cntnt\"><img style=\"width:828px; height:570px;\" src=\"images/GAST/101072_Night_blindness_prgnnt_wmn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Data from surveys and regression-based estimates, prepared by the World Health Organization.</div><div class=\"graphic_reference\">Reprinted from the World Health Organization Global Database on Vitamin A Deficiency, Global prevalence of vitamin A deficiency in populations at risk, 1995-2005. Available at: <A href=\"http://www.who.int/vmnis/database/vitamina/en/\" target=_blank>http://www.who.int/vmnis/database/vitamina/en/</A> (accessed June 20, 2017).</div><div id=\"graphicVersion\">Graphic 101072 Version 2.0</div></div></div>"},"101076":{"type":"graphic_table","displayName":"Causes of recurrent or refractory IDA in infants and children","title":"Causes of recurrent or refractory iron deficiency anemia in infants and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of recurrent or refractory iron deficiency anemia in infants and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Ineffective treatment</td> </tr> <tr> <td class=\"indent1\">Supplements not given as prescribed (eg, due to intolerance)</td> </tr> <tr> <td class=\"indent1\">Dietary changes not made (due to intolerance or non-adherence)</td> </tr> <tr> <td class=\"indent1\">Insufficient dose or duration of iron supplements&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Incorrect diagnosis (ie, other causes of anemia)&nbsp;&nbsp;</td> </tr> <tr> <td class=\"indent1\">Thalassemia&nbsp;</td> </tr> <tr> <td class=\"indent1\">Anemia of chronic disease&nbsp;</td> </tr> <tr> <td class=\"indent1\">Mixed nutritional deficiency (combined deficiencies of iron and vitamin B12 or folate)&nbsp;&nbsp;</td> </tr> <tr> <td class=\"subtitle1_single\">Gastrointestinal disease causing ongoing blood loss or malabsorption</td> </tr> <tr> <td class=\"indent1\">Cow's milk protein colitis</td> </tr> <tr> <td class=\"indent1\">Celiac disease</td> </tr> <tr> <td class=\"indent1\">Parasitic infection</td> </tr> <tr> <td class=\"indent1\">Duodenal ulcer</td> </tr> <tr> <td class=\"indent1\">Meckel diverticulum</td> </tr> <tr> <td class=\"indent1\">Inflammatory bowel disease</td> </tr> <tr> <td class=\"subtitle1_single\">Other causes of iron deficiency</td> </tr> <tr> <td class=\"indent1\">Pulmonary hemosiderosis</td> </tr> <tr> <td class=\"indent1\">Mutations causing defective iron transport (rare)</td> </tr> <tr> <td class=\"subtitle1_single\">&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101076 Version 2.0</div></div></div>"},"101077":{"type":"graphic_diagnosticimage","displayName":"Imaging acute eosinophilic pneumonia","title":"Acute eosinophilic pneumonia on radiography and CT","html":"<div class=\"graphic\"><div style=\"width: 904px\" class=\"figure\"><div class=\"ttl\">Acute eosinophilic pneumonia on radiography and CT</div><div class=\"cntnt\"><img style=\"width:884px; height:362px;\" src=\"images/RADIOL/101077_Img_act_esnphlc_pnmn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These images were obtained from a 42-year-old man with progressive dyspnea over one month; acute eosinophilic pneumonia was diagnosed based on the clinical presentation, a bronchoalveolar lavage showing 51 percent&nbsp;eosinophils, and response to therapy. An anteroposterior radiograph (A) shows patchy opacities predominantly involving the lower lobes, middle lobe, and lingual (arrows). This pattern is unlike heart failure since the left atrium is not enlarged, there is no vascular redistribution, and the opacities are diffuse in nature and not perihilar. A CT with coronal reconstruction (B) shows patchy opacities involving all segments of the lung (arrows). An axial CT at the level of the carina (C) shows a combination of ground glass and consolidative opacities in the anterior segments of both upper lobes (arrows). A CT scan through the mid chest (D) shows pulmonary opacities centered along thickened broncho-vascular bundles (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 101077 Version 1.0</div></div></div>"},"101078":{"type":"graphic_figure","displayName":"Stapled hemorrhoidectomy","title":"Stapled hemorrhoidectomy","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Stapled hemorrhoidectomy</div><div class=\"cntnt\"><img style=\"width:540px; height:255px;\" src=\"images/SURG/101078_Stapled_hemorrhoidectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stapled hemorrhoidopexy<br />(A) Prolapsing internal hemorrhoids<br />(B) Placement of the purse string suture at least 4 cm above the dentate line<br />(C) Placement of stapler<br />(D)&nbsp;Completed stapled hemorrhoidopexy</div><div id=\"graphicVersion\">Graphic 101078 Version 2.0</div></div></div>"},"101079":{"type":"graphic_picture","displayName":"Kidney biopsy from patients with Mesoamerican nephropathy","title":"Light microscopy changes in kidney biopsy specimens from patients with Mesoamerican nephropathy","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Light microscopy changes in kidney biopsy specimens from patients with Mesoamerican nephropathy</div><div class=\"cntnt\"><img style=\"width:728px; height:489px;\" src=\"images/NEPH/101079_Kidney_biopsy_Mesoamerican.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Light microscopy changes in kidney biopsy specimens from patients with Mesoamerican nephropathy.<br />(A) Glomerular enlargement was seen in all biopsy specimens (hematoxylin and eosin). In two patients, focal segmental lesions were found in glomeruli.<br />(B) In one patient, the lesion was of cellular type (periodic acid-Schiff).<br />(C) Mild to moderate tubular atrophy and chronic interstitial inflammation were seen in most patients (Ladewig).<br />(D) Most arteries showed no intimal fibrosis (hematoxylin and eosin); three of eight patients displayed mild arteriolar hyalinosis.</div><div class=\"graphic_reference\">Reproduced from: Wijkstrom J, Leiva R, Elinder CG, et al. Clinical and pathological characterization of Mesoamerican nephropathy: A new kidney disease in Central America. Am J Kidney Dis 2013; 62:908. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101079 Version 1.0</div></div></div>"},"101082":{"type":"graphic_figure","displayName":"Changes in the incidence of extreme hyperbilirubinemia in the US","title":"Changes in the incidence of extreme hyperbilirubinemia in the United States","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Changes in the incidence of extreme hyperbilirubinemia in the United States</div><div class=\"cntnt\"><img style=\"width:724px; height:486px;\" src=\"images/PEDS/101082_Chng_incdn_ext_hprblr_US.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Comparison of the incidence of extreme hyperbilirubinemia (total serum bilirubin &gt;25 mg/dL) for 302,399 infants born at one of the Intermountain Healthcare (IMHC) facilities from 2001 to 2010, historical data from the seven-year Collaborative Perinatal Project of 41,324 singleton white and black births with birth weights &gt;2.5 kg initiated in 1959 (prior to availability of phototherapy and most [85 percent] infants with total bilirubin &gt;20 mg/dL were treated with an exchange transfusion), and from Northern California population (Newman et al) managed soon after the implementation of 1994 American Academy of Pediatrics (AAP) Guidelines.</div><div class=\"graphic_reference\">From: Brites D, Bhutani VK. Pathways involving bilirubin and other brain-injuring agents. In: Clinics in Development Medicine: Cerebral palsy: Science and clinical practice, Dan B, Mayston M, Paneht N, Rosenbloom L (Eds), Mac Keith Press, London 2014. Copyright &copy; 2014 Mac Keith Press. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 101082 Version 1.0</div></div></div>"},"101112":{"type":"graphic_algorithm","displayName":"Algorithm for diagnosis of celiac disease in children","title":"Algorithm for diagnosis of celiac disease in children","html":"<div class=\"graphic\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Algorithm for diagnosis of celiac disease in children</div><div class=\"cntnt\"><img style=\"width:704px; height:741px;\" src=\"images/PEDS/101112_Algodiagnclcdiseaschild.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">tTG-IgA: IgA antibodies to tissue transglutaminase; ULN: upper limits of normal; EMA: anti-endomysial antibodies; DGP: deamidated gliadin peptide; HLA: human leukocyte antigen.<br />* Children in the following groups are at increased risk for celiac disease: Children with first-degree relatives with celiac disease; children with autoimmune thyroiditis; type 1 diabetes; Down syndrome; Turner syndrome; Williams syndrome; or selective IgA deficiency.<br />&para; An alternative strategy for asymptomatic individuals with Down syndrome is to assess for the HLA types DQ2 and DQ8 as the initial screening test. Those who test negative for HLA-DQ2 and DQ8 do not require additional screening because they have a very low risk for developing celiac disease. This strategy is less useful for members of other high-risk groups (eg, first-degree relatives of patients with celiac disease), because a high proportion of individuals in these groups will carry HLA susceptibility alleles, so the test is unlikely to be useful to exclude celiac disease.<br />&Delta; The most valuable test is tTG-IgA, which is highly sensitive, specific, and more cost-effective than other antibody tests. Alternatively or for confirmation, EMA may be used. In the setting of IgA deficiency, we suggest measurement of IgG antibodies to tTG (tTg-IgG) with another IgG specific antibody such as deamidated gliadin peptide (DGP). For children younger than two years, we suggest concurrent assessment of more than one celiac-specific antibody (eg, tTG-IgA and DGP).<br /><span class=\"lozenge\">&loz;</span> Antibody testing should be performed while on a gluten-containing diet (ideally at least 3 g gluten/day for at least six weeks). Serologies may become negative within weeks of beginning a gluten-free diet, but may take up to a year. For patients who are already on a gluten-free diet, a negative result of an antibody test cannot exclude celiac disease.<br />&sect; For patients with mild elevations of tTG-IgA (positive but &lt;3 x ULN), we test for EMA before proceeding to endoscopy. This practice is based on expert opinion, with some support from a study showing that this approach helps to distinguish the patients who are likely to have celiac disease<sup>[1]</sup>.<br />&yen; In symptomatic patients with very high results of serologic tests (tTG &gt;10 times the upper limit of normal) and positive EMA, some experts suggest that the intestinal biopsy may be omitted; in this case, celiac disease may be diagnosed if there is a clear clinical response to a gluten-free diet. If this strategy is chosen, some expert groups suggest HLA typing to add strength to the diagnosis (because celiac disease would be effectively excluded in any patient that does not have HLA types DQ2 or DQ8)<sup>[2]</sup>, but the additional diagnostic value of HLA typing in this setting is probably modest.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Gidrewicz D, Potter K, Trevenen CL, et al. Evaluation of the ESPGHAN Celiac Guidelines in a North American Pediatric Population. Am J Gastroenterol 2015.</li>&#xD;&#xA;    <li>Husby S, Koletzko S, Korponay-Szabo IR, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of celiac disease. J Pediatr Gastroenterol Nutr 2012; 54:136.</li>&#xD;&#xA;</ol>&#xD;&#xA;Adapted from: Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2005; 40:1.</div><div id=\"graphicVersion\">Graphic 101112 Version 5.0</div></div></div>"},"101135":{"type":"graphic_figure","displayName":"Cardinal positions of gaze","title":"The six cardinal positions of gaze","html":"<div class=\"graphic\"><div style=\"width: 587px\" class=\"figure\"><div class=\"ttl\">The six cardinal positions of gaze</div><div class=\"cntnt\"><img style=\"width:567px; height:282px;\" src=\"images/PEDS/101135_Cardinal_positions_gaze.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The six cardinal positions of eye gaze isolate the individual extraocular muscles. In order to determine which muscle is abnormal, the six positions of gaze are observed to determine if the eye moves in each direction.</div><div id=\"graphicVersion\">Graphic 101135 Version 1.0</div></div></div>"},"101137":{"type":"graphic_figure","displayName":"Strabismus types","title":"Direction of eye deviation in different types of strabismus ","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Direction of eye deviation in different types of strabismus </div><div class=\"cntnt\"><img style=\"width:480px; height:637px;\" src=\"images/PEDS/101137_Strabismus_types.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 101137 Version 1.0</div></div></div>"},"101138":{"type":"graphic_figure","displayName":"Anatomy of coccyx","title":"Anatomy of coccyx","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Anatomy of coccyx</div><div class=\"cntnt\"><img style=\"width:463px; height:688px;\" src=\"images/PC/101138_Anatomy_of_coccyx.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 101138 Version 1.0</div></div></div>"},"101149":{"type":"graphic_diagnosticimage","displayName":"Abdominopelvic SFT: Cross-sectional imaging","title":"Appearance of an abdominopelvic solitary fibrous tumor (SFT) on cross-sectional imaging","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Appearance of an abdominopelvic solitary fibrous tumor (SFT) on cross-sectional imaging</div><div class=\"cntnt\"><img style=\"width:435px; height:283px;\" src=\"images/ONC/101149_AbdmnplvSFTcrsssctnlimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">52-year-old male with a pelvic mass found to be an extrapleural solitary fibrous tumor. A 4 slice computed tomography (CT) of the abdomen and pelvis from an outside facility was performed. Axial images were initially obtained of the abdomen following ingestion of 900 cc of Readicat with subsequent images obtained of the abdomen and pelvis following administration of 120 cc of Optiray 320 (4 mm slices, kVp 120, mAs 250).</div><div class=\"graphic_reference\">Reproduced with permission from: Boe J, Chimpiri AR, Liu CZ. Solitary fibrous tumor originating in the pelvis: a case report. J Radiol Case Rep 2010; 4(7):21-28. Available at: <a href=\"http://www.jrcr.org/430\" spellcheck=\"true\" target=\"_blank\">http://www.jrcr.org/430</a>. Copyright &copy; 2010 Journal of Radiology Case Reports.</div><div id=\"graphicVersion\">Graphic 101149 Version 3.0</div></div></div>"},"101150":{"type":"graphic_diagnosticimage","displayName":"Cross sectional imaging SFT of the liver","title":"Cross sectional imaging appearance of a solitary fibrous tumor (SFT) of the liver","html":"<div class=\"graphic\"><div style=\"width: 573px\" class=\"figure\"><div class=\"ttl\">Cross sectional imaging appearance of a solitary fibrous tumor (SFT) of the liver</div><div class=\"cntnt\"><img style=\"width:553px; height:433px;\" src=\"images/ONC/101150_Crss_sctnl_img_SFT_lvr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Single mass in the left hepatic lobe.<br />(A) Computed tomography (CT) scan demonstrated a mass (9.0 × 6.2 cm) in left hepatic lobe.<br />(B, C) Heterogeneous contrast enhancement in arterial and portal phases was found in the mass.<br />(D) Grossly, a large, gray-white, lobulated, well-circumscribed, partially encapsulated mass was removed after hepatectomy.</div><div class=\"graphic_reference\">Reproduced with permission from: Sun K, Lu J, Teng X, et al. Solitary fibrous tumor of the liver: a case report. World J Surg Oncol. 2011; 9: 37. Copyright &copy; 2011 BioMed Central Ltd.</div><div id=\"graphicVersion\">Graphic 101150 Version 2.0</div></div></div>"},"101152":{"type":"graphic_diagnosticimage","displayName":"Imaging appearance of solitary fibrous tumor of the kidney","title":"Imaging appearance of solitary fibrous tumor (SFT) of the kidney","html":"<div class=\"graphic\"><div style=\"width: 670px\" class=\"figure\"><div class=\"ttl\">Imaging appearance of solitary fibrous tumor (SFT) of the kidney</div><div class=\"cntnt\"><img style=\"width:650px; height:248px;\" src=\"images/ONC/101152_Img_sol_fibrous_tumor_kidny.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A, B) Axial images from a contrast-enhanced&nbsp;computerized tomography (CT)&nbsp;scan showing a well-delineated mass arising from upper pole of right kidney measuring 10 x 10 cm, with contrast enhancement.</div><div class=\"graphic_reference\">Reproduced with permission from: Naveen HN, Nelivigi GN, Venkatesh GK, et al. A case of solitary fibrous tumor of the kidney. Urol Ann. 2011 Sep-Dec; 3(3):158. Copyright &copy; 2011 Medknow.</div><div id=\"graphicVersion\">Graphic 101152 Version 1.0</div></div></div>"},"101153":{"type":"graphic_table","displayName":"History for child with UGIB","title":"Key elements of the history in an infant or child with suspected upper gastrointestinal bleeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key elements of the history in an infant or child with suspected upper gastrointestinal bleeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">History</td> <td class=\"subtitle1\">Diagnostic considerations/implications</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Characteristics of hematemesis</td> </tr> <tr> <td class=\"indent1\">Sudden onset, massive hematemesis</td> <td>Vascular bleed (either from varices, or arterial bleed).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vomiting preceding hematemesis (usually with small blood)</td> <td>Mallory-Weiss tear, esophagitis, or gastritis.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Characteristics of stool</td> </tr> <tr> <td class=\"indent1\">Melena (black or dark red stools)</td> <td>Moderate or brisk UGI bleeding (versus lower GI bleed).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hematochezia (bright red blood in stool)</td> <td>LGI source, <strong>or</strong> very brisk UGI bleed. Hematochezia is common in infants with UGI bleeding, due to shorter transit time.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Accompanying symptoms</td> </tr> <tr> <td class=\"indent1\">Epigastric pain or heartburn</td> <td>Gastritis, peptic ulcer, or esophagitis (peptic, eosinophilic, or pill esophagitis).</td> </tr> <tr> <td class=\"indent1\">Odynophagia (pain with swallowing)</td> <td>Pill esophagitis, foreign body, infectious esophagitis (eg, candida, HSV, CMV).</td> </tr> <tr> <td class=\"indent1\">Jaundice</td> <td>Underlying liver disease.</td> </tr> <tr> <td class=\"indent1\">Epistaxis (recent or recurrent)</td> <td>Ingested blood from nasopharynx, or bleeding disorder.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Easy bruising or bleeding</td> <td>Bleeding disorder&nbsp;(see below)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Underlying disease</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chronic liver disease</td> <td>Can&nbsp;cause either&nbsp;vascular bleeding (eg, varices, with brisk bleeding) or mucosal bleeding (eg, gastropathy, with slow bleeding or oozing of blood).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Bleeding disorder&nbsp;</td> <td>Many causes; may be congenital (eg, Von Willebrand disease) or acquired (eg, ITP, liver disease or vitamin K deficiency).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Critical illness</td> <td>Risk factor for peptic gastritis, esophagitis, or ulcer disease. Also consider bleeding from a non-GI source (eg, traumatic NG or ET tube placement).</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Medications</td> </tr> <tr> <td class=\"indent1\">Tetracyclines (eg, for acne) or NSAIDs, or bisphosphonates</td> <td>Pill esophagitis, peptic disease (gastritis or ulcers).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Beta adrenergic blockers</td> <td>May impair hemodynamic response to hypovolemia.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Other history</td> </tr> <tr> <td class=\"indent1\">Breast-fed infant</td> <td>Swallowed maternal blood.</td> </tr> <tr> <td class=\"indent1\">History of choking episode (including several days or weeks prior to hematemesis)</td> <td>Esophageal or GI foreign body.</td> </tr> <tr> <td class=\"indent1\">Alcohol ingestion (especially binge drinking)</td> <td>Gastritis, esophagitis.</td> </tr> <tr> <td class=\"indent1\">Severe cough, chronic lung disease, or congestive heart disease</td> <td>Swallowed blood from lungs.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GI: gastrointestinal; HSV: herpes simplex virus; CMV: cytomegalovirus; UGI: upper gastrointestinal; LGI: lower gastrointestinal; ITP: immune thrombocytopenia; NG: nasogastric; ET: endotracheal; NSAID: nonsteroidal antiinflammatory drugs.</div><div id=\"graphicVersion\">Graphic 101153 Version 3.0</div></div></div>"},"101154":{"type":"graphic_table","displayName":"PE in child with UGIB","title":"Physical examination in an infant or child with upper gastrointestinal bleeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physical examination in an infant or child with upper gastrointestinal bleeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Physical examination</td> <td class=\"subtitle1\">Diagnostic considerations/implications</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Rapid assessment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tachycardia, hypotension or orthostasis, poor capillary refill, cold extremities, altered sensorium</td> <td>Shock (eg, due to massive gastrointestinal blood loss)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Skin</td> </tr> <tr> <td class=\"indent1\">Bruising, petechiae</td> <td>Bleeding disorder (eg, ITP), physical abuse, trauma</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vascular malformations (eg, telangiectasias, hemangiomas)</td> <td>Disorders with generalized vascular malformations (eg, hereditary hemorrhagic telangiectasia)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Melanosis&nbsp;</td> <td>Peutz-Jeghers syndrome (with intestinal polyposis)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nasopharynx</td> </tr> <tr> <td class=\"indent1\">Blood or injury to the nares</td> <td>Epistaxis with swallowed blood</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pharyngeal bleeding or injury</td> <td>Posterior nasopharyngeal bleeding with swallowed blood</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Abdomen</td> </tr> <tr> <td class=\"indent1\">Hepatomegaly, hard liver edge, and/or splenomegaly</td> <td>Portal hypertension (eg, from cirrhosis, portal vein thrombosis, or Budd-Chiari syndrome)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ITP: immune thrombocytopenia.</div><div id=\"graphicVersion\">Graphic 101154 Version 2.0</div></div></div>"},"101156":{"type":"graphic_table","displayName":"Medications for child with UGIB","title":"Selected pharmacologic options for a child with upper gastrointestinal bleeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Selected pharmacologic options for a child with upper gastrointestinal bleeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Category</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Acid suppression (IV)</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\">Esomeprazole</td> <td class=\"sublist1_start\"><em>Intermittent dosing:</em></td> <td class=\"divider_bottom\" rowspan=\"8\">PPI</td> </tr> <tr> <td class=\"indent1\">Infants: 0.5 to 1 mg/kg/dose IV once daily</td> </tr> <tr> <td class=\"indent1\">Children 1 to 17 years:</td> </tr> <tr> <td class=\"indent2\">&#60;55 kg: 10 mg IV once or twice daily</td> </tr> <tr> <td class=\"indent2\">&#8805;55 kg: 20 mg IV once or twice daily</td> </tr> <tr> <td class=\"indent1\">Adults: 40 mg IV twice daily</td> </tr> <tr> <td class=\"sublist1_start\"><em>Continuous IV infusion:</em><sup>[1]</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">1 mg/kg IV bolus (maximum 80 mg), followed by infusion of 0.1 mg/kg/hour (maximum 8 mg/hour)*</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Omeprazole (IV preparation not available in the United States)</td> <td>Children and adolescents:<sup>[2]</sup> 0.5 to 3 mg/kg IV daily, in one or two divided doses (maximum 80 mg daily)</td> <td class=\"divider_bottom\" rowspan=\"2\">PPI</td> </tr> <tr class=\"divider_bottom\"> <td>Adults: 40 mg IV twice daily</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"7\">Pantoprazole</td> <td class=\"sublist1_start\"><em>Intermittent dosing:</em></td> <td class=\"divider_bottom\" rowspan=\"7\">PPI</td> </tr> <tr> <td class=\"indent1\">Children and adolescents:</td> </tr> <tr> <td class=\"indent2\">&#60;40 kg: 0.5 to 1 mg/kg IV once or twice daily</td> </tr> <tr> <td class=\"indent2\">&#62;40 kg: 20 to 40 mg IV once or twice daily</td> </tr> <tr> <td class=\"indent1\">Adults: 40 mg IV twice daily</td> </tr> <tr> <td class=\"sublist1_start\"><em>Continuous IV infusion:</em><sup>[1]</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">1 mg/kg IV bolus (maximum 80 mg), followed by an infusion of 0.1 mg/kg/hour (maximum 8 mg/hour)*</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"5\">Ranitidine (alternative if IV PPI not available)<sup>&#182;</sup></td> <td class=\"sublist1_start\"><em>Intermittent dosing:</em><sup>[1]</sup></td> <td class=\"divider_bottom\" rowspan=\"5\">H2RA</td> </tr> <tr> <td class=\"indent1\">Infants, children and adolescents: 2 to 5 mg/kg/day IV divided every&nbsp;six to&nbsp;eight hours; maximum dose 200 mg/day.</td> </tr> <tr> <td class=\"indent1\">Adults: 50 mg IV every&nbsp;six to&nbsp;eight hours</td> </tr> <tr> <td class=\"sublist1_start\"><em>Continuous IV infusion:</em></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Children and adults: 1 mg/kg IV bolus (maximum 50 mg), followed by infusion of 2 to 4 mg/kg/day (maximum 6.25 mg/hour)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Acid suppression (oral)<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\">Omeprazole</td> <td>Children and adolescents: 1 to 3 mg/kg daily<sup>[3]</sup>&nbsp;(maximum 80 mg daily), in one or two divided doses</td> <td class=\"divider_bottom\" rowspan=\"2\">PPI</td> </tr> <tr class=\"divider_bottom\"> <td>Adults: 40 mg twice daily initially, followed by 20 to 40 mg once daily (maintenance dose, once risk of recurrent bleeding is low)</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"8\">Esomeprazole</td> <td class=\"sublist1_start\">Infants&nbsp;one month to&nbsp;one year (daily):</td> <td class=\"divider_bottom\" rowspan=\"8\">PPI</td> </tr> <tr> <td class=\"indent1\">3 to 5 kg: 2.5 mg</td> </tr> <tr> <td class=\"indent1\">5 to 7.5 kg: 5 mg</td> </tr> <tr> <td class=\"indent1\">7.5 to 12 kg: 10 mg</td> </tr> <tr> <td class=\"sublist1_start\">Children 1 to 11 years (daily):</td> </tr> <tr> <td class=\"indent1\">Weight &#60;20 kg: 10 mg</td> </tr> <tr> <td class=\"indent1\">Weight &#8805;20 kg: 10 mg or 20 mg<sup>&#9674;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Children &#8805;12 years and adults: 40 mg twice daily initially, followed by 20 to 40 mg once daily (as a maintenance dose, once risk of recurrent bleeding is low)</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Pantoprazole</td> <td class=\"sublist1_start\">Children 5 to 11 years:</td> <td class=\"divider_bottom\" rowspan=\"4\">PPI</td> </tr> <tr> <td class=\"indent1\">Weight 15 to 40 kg: 20 mg once daily</td> </tr> <tr> <td class=\"indent1\">Weight &#62;40 kg: Use adult dose</td> </tr> <tr class=\"divider_bottom\"> <td>Children &#8805;12 years and adults: 40 mg twice daily initially, followed by 20 to 40 mg once daily (as a maintenance dose, once risk of recurrent bleeding is low)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Vasoactive agents</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Octreotide</td> <td>Children: 1 to 2 microgram/kg IV bolus (maximum 50 micrograms), followed by 1 to 2 microgram/kg/hour as a continuous IV infusion (maximum 50 micrograms per hour).<sup>[4]</sup> Initial bolus may be repeated once in the first hour if needed.</td> <td rowspan=\"2\">Somatostatin analog</td> </tr> <tr> <td>Adults: 50 microgram IV bolus followed by a continuous IV infusion of 50 micrograms per hour. Initial bolus may be repeated once in first hour if needed.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Pharmacologic options for a child with upper gastrointestinal bleeding (UGIB). Acid suppression is appropriate for most children with clinically significant UGIB. Children with signs of significant bleeding and active blood loss (eg, hypovolemia, cardiac instability) require immediate stabilization and should be transferred to a pediatric intensive care unit (ICU) if possible. In general, initial pharmacologic treatment of serious UGIB includes the use of high-dose or continuous IV PPI therapy for acid suppression which is continued during the period of highest risk for rebleeding (eg, first three days). Vasoactive agents may be helpful for selected cases of vascular bleeding (eg, from esophageal varices).</div><div class=\"graphic_footnotes\">PPI: proton pump inhibitor; H2RA: histamine 2 receptor antagonist; IV: intravenous.<br />* Continuous dosing of IV esomeprazole and pantoprazole is not well-established; this protocol has been used and reported by some centers.<SUP>[1]</SUP><br />¶ H2RAs are less effective than PPIs in controlling bleeding and preventing rebleeding of peptic ulcers in adults. IV famotidine or cimetidine also may be used, where these preparations are available. For additional information, refer to topic reviews of management of peptic ulcers.<br />Δ Optimally, orally administered PPIs are given once daily before the first meal of the day (or if given twice daily prior to the first meal and the evening meal). Other oral PPIs may be used, including rabeprazole and lansoprazole. For dosing, refer to pediatric drug monographs or topic review on gastroesophageal reflux disease (GERD)&nbsp;in children and adolescents.<br /><FONT class=lozenge>◊</FONT> In general, the pediatric dose should not exceed the higher end of the adult dose range. On a milligram per kilogram basis, doses of some of the PPIs needed to obtain a similar degree of acid suppression in children are greater than those for adolescents and adults.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Neidich GA, Cole SR. Gastrointestinal bleeding. Pediatr Rev 2014; 35:243.</LI>&#xD;&#xA;<LI>Owensby S, Taylor K, Wilkins T. Diagnosis and management of upper gastrointestinal bleeding in children. J Am Board Fam Med 2015; 28:134.</LI>&#xD;&#xA;<LI>Hassall E, Israel D, Shepherd R, Radke M, Dalväg A, Sköld B, Junghard O, Lundborg P. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. The journal of pediatrics 2000;137(6):800-7</LI>&#xD;&#xA;<LI>Eroglu Y, Emerick KM, Whitingon PF, et al. Octreotide Therapy for Control of Acute Gastrointestinal Bleeding in Children. J Pediatr Gastroenterol Nutr 2004; 38:41.</LI></OL></div><div id=\"graphicVersion\">Graphic 101156 Version 1.0</div></div></div>"},"101158":{"type":"graphic_picture","displayName":"Axillo-axillary bypass for traumatic injury","title":"Axillo-axillary bypass for traumatic injury","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Axillo-axillary bypass for traumatic injury</div><div class=\"cntnt\"><img style=\"width:756px; height:726px;\" src=\"images/SURG/101158_Crtd-axllry_bypss_trmtc_inj.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient sustained a gunshot wound to the right upper chest, injuring the right axillary artery and leading to upper extremity ischemia. The supraclavicular incision (cephalad to the retractors)&nbsp;was used to obtain proximal control of the subclavian artery. The infraclavicular incision (with retractors) exposed the area of injury, after which the axillary artery was debrided and the axilloaxillary graft was placed to restore flow. </div><div class=\"graphic_reference\">Courtesy of Jonathan Gates, MD.</div><div id=\"graphicVersion\">Graphic 101158 Version 1.0</div></div></div>"},"101159":{"type":"graphic_picture","displayName":"Gunshot wound upper arm","title":"Gunshot wound upper arm","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Gunshot wound upper arm</div><div class=\"cntnt\"><img style=\"width:505px; height:540px;\" src=\"images/SURG/101159_Gunshot_wound_upper_arm_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The image shows a large soft tissue defect caused by a gunshot wound to the left upper extremity.&nbsp;The missile caused an&nbsp;open comminuted humeral fracture and brachial artery injury. Arterial perfusion was restored with a saphenous vein interposition graft, and an external fixation device was placed to stabilize the bone.</div><div class=\"graphic_reference\">Courtesy of Neal R. Barshes, MD.</div><div id=\"graphicVersion\">Graphic 101159 Version 1.0</div></div></div>"},"101160":{"type":"graphic_table","displayName":"Causes of chronic knee pain in active children and adolescents","title":"Causes of chronic knee pain* in active children and skeletally immature adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of chronic knee pain* in active children and skeletally immature adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anterior pain</td> <td class=\"subtitle1\">Medial pain</td> <td class=\"subtitle1\">Lateral pain</td> <td class=\"subtitle1\">Posterior pain</td> </tr> <tr> <td>Poorly localized <ul class=\"decimal_heading\"> <li>Patellofemoral pain syndrome<sup>&#916;</sup></li> <li>Patellar subluxation<sup>&#916;</sup></li> <li>Patellar stress fracture </li> <li>Osteochondritis dissecans<sup>&#916;</sup> </li> <li>Referred hip pain </li> <li>Referred back pain (L2/L3/L4 radiculopathy) </li> <li>Patellar stress fracture </li> <li>Tumors (malignant and benign) </li> </ul> Localized <ul class=\"decimal_heading\"> <li>Traction apophysitis <ul> <li>Sinding-Larsen-Johansson disease (patellar apophysitis)<sup>&#916;</sup></li> <li>Osgood-Schlatter disease (tibial tubercle apophysitis)<sup>&#916;</sup> </li> </ul> </li> <li>Patellar and quadriceps tendinitis<sup>&#916;</sup> </li> <li>Fat pad impingement (Hoffa disease)<sup>&#916;</sup></li> <li>Anterior cruciate ligament injury </li> <li>Bipartite and tripartite patella </li> <li>Prepatellar bursitis </li> </ul> </td> <td> <ul> <li>Osteochondritis dissecans<sup>&#916;</sup></li> <li>Plica syndrome<sup>&#916;</sup></li> <li>Pes anserinus tendinitis </li> <li>Medial meniscus injury </li> <li>Medial collateral ligament injury </li> <li>Medial superior tibial stress fracture </li> <li>Adductor magnus muscle injury </li> <li>Referred hip pain </li> <li>Tumors (malignant and benign) </li> </ul> </td> <td> <ul> <li>Discoid meniscus<sup>&#916;</sup></li> <li>Lateral meniscus injury </li> <li>Iliotibial band syndrome<sup>&#916;</sup> </li> <li>Lateral collateral ligament injury </li> <li>Biceps femoris tendinitis </li> <li>Referred hip pain </li> <li>Referred back pain (L5 radiculopathy) </li> <li>Tumors (malignant and benign) </li> </ul> </td> <td> <ul> <li>Popliteal (Baker's) cyst<sup>&#182;</sup> </li> <li>Hamstring (semimembranosus&nbsp;or biceps femoris) tendinitis </li> <li>Popliteus tendinitis </li> <li>Referred hip pain </li> <li>Referred back pain (S1 radiculopathy) </li> <li>Posterior cruciate ligament injury </li> <li>Deep vein thrombosis </li> <li>Tumors (malignant and benign) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Chronic knee pain means that the pain has been present for six weeks or longer.<br />¶ Symptomatic popliteal (Baker's) cysts are typically caused by large knee effusions.<br />Δ Common causes of chronic knee pain in children and skeletally immature adolescents. </div><div id=\"graphicVersion\">Graphic 101160 Version 3.0</div></div></div>"},"101161":{"type":"graphic_picture","displayName":"Forearm and hand fasciotomy for upper limb ischemia","title":"Forearm and hand fasciotomy for upper limb ischemia","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Forearm and hand fasciotomy for upper limb ischemia</div><div class=\"cntnt\"><img style=\"width:766px; height:625px;\" src=\"images/SURG/101161_Frm_hnd_fsctmy_upr_lmb_isch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient presented with severe ischemia of the upper extremity due to embolus related to atrial fibrillation. On initial presentation, both sensory and motor deficit were apparent. Following embolectomy to restore upper extremity perfusion, compartment pressures were 80 mmHg, necessitating decompressive fasciotomy of the forearm (A) and hand (B). Nearly 100 percent of hand function was regained postoperatively.</div><div id=\"graphicVersion\">Graphic 101161 Version 1.0</div></div></div>"},"101167":{"type":"graphic_table","displayName":"Examination adolescent scoliosis","title":"Important aspects of the examination in patients with suspected adolescent idiopathic scoliosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the examination in patients with suspected adolescent idiopathic scoliosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Examination feature</td> <td class=\"subtitle1\">Potential significance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Scoliosis examination</td> </tr> <tr> <td class=\"indent1\">Lateral curvature of the spine</td> <td>Scoliosis (any type)</td> </tr> <tr> <td class=\"indent1\">Asymmetry of shoulders, scapulae, waistline, or distance that the arms hang from the trunk</td> <td>Scoliosis (any type)</td> </tr> <tr> <td class=\"indent1\">Thoracic or lumbar prominence during Adams forward bend test</td> <td>Scoliosis (any type) </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Angle of trunk rotation (as measured with a scoliometer) &#8805;7&#176;</td> <td>Approximately correlates with Cobb angle of &#62;20&#176; </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">General examination</td> </tr> <tr> <td class=\"indent1\">Height and height velocity</td> <td>Risk for progression is greatest during peak height velocity</td> </tr> <tr> <td class=\"indent1\">Arm span to height ratio</td> <td>Increased in Marfan syndrome</td> </tr> <tr> <td class=\"indent1\">Sexual maturity rating (Tanner stage)</td> <td>Risk for progression is increased if sexual maturity rating is &#8804;2</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Skin examination</td> </tr> <tr> <td class=\"indent2\">Caf&#233;-au-lait spots and axillary freckling</td> <td>Neurofibromatosis</td> </tr> <tr> <td class=\"indent2\">Vascular or pigmentary changes over the spine</td> <td>Spinal dysraphism</td> </tr> <tr> <td class=\"indent2\">Lumbosacral dimpling</td> <td>Occult spinal dysraphism</td> </tr> <tr> <td class=\"indent2\">Skin laxity</td> <td>Ehlers-Danlos syndrome, Marfan syndrome, osteogenesis imperfecta</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Musculoskeletal examination</td> </tr> <tr> <td class=\"indent2\">Joint laxity</td> <td>Ehlers-Danlos syndrome, Marfan syndrome</td> </tr> <tr> <td class=\"indent2\">Intrinsic wasting of hands</td> <td>Cervical syringomyelia</td> </tr> <tr> <td class=\"indent2\">High-arched feet, hammer/claw toes</td> <td>Neuromuscular disease (eg, Friedreich ataxia)</td> </tr> <tr> <td class=\"indent2\">Asymmetric iliac crests</td> <td>Leg length discrepancy</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"2\">Neurologic examination</td> </tr> <tr> <td class=\"indent2\">Abnormal reflexes, balance, strength, gait</td> <td>Neuromuscular scoliosis</td> </tr> <tr> <td class=\"indent2\">Absent abdominal reflex</td> <td>Intraspinal pathology</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101167 Version 3.0</div></div></div>"},"101168":{"type":"graphic_table","displayName":"History adolescent scoliosis","title":"Important aspects of the history in patients with suspected adolescent idiopathic scoliosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the history in patients with suspected adolescent idiopathic scoliosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Historical feature</td> <td class=\"subtitle1\">Potential significance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Scoliosis</td> </tr> <tr> <td class=\"indent1\">When was scoliosis first noted?</td> <td>AIS has onset at &#8805;10 years</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">What is the rate of progression?</td> <td>Rapid progression may indicate nonidiopathic etiology</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Associated symptoms</td> </tr> <tr> <td class=\"indent1\">Is there associated pain that limits activities, wakes the patient at night,&nbsp;or requires frequent analgesia?</td> <td>May indicate nonidiopathic etiology and require additional evaluation</td> </tr> <tr> <td class=\"indent1\">Are there symptoms of neuromuscular etiology (eg, muscle weakness, bowel or bladder problems, headache, neck pain)?</td> <td>May indicate neuromuscular etiology and require additional evaluation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Shortness of breath or difficulty breathing?</td> <td>May indicate severe thoracic scoliosis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Risk for progression</td> </tr> <tr> <td class=\"indent1\">What is the height trajectory? Has the pubertal growth spurt begun?</td> <td>AIS may progress during the pubertal growth spurt</td> </tr> <tr> <td class=\"indent1\">Has menarche occurred (for female patients)?</td> <td>The risk for progression decreases after menarche</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">For male patients, have they started shaving every day (or do they need to)?</td> <td>The risk for progression decreases after the need for daily shaving</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Past medical history</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Leg fracture, joint infection, or arthritis?</td> <td>May be associated with leg-length discrepancy</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Family history</td> </tr> <tr> <td class=\"indent1\">Is there a family history of scoliosis?</td> <td>AIS runs in families</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AIS: adolescent idiopathic scoliosis.</div><div id=\"graphicVersion\">Graphic 101168 Version 2.0</div></div></div>"},"101169":{"type":"graphic_table","displayName":"Syndromic scoliosis","title":"Clinical features of selected causes of syndromic scoliosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of selected causes of syndromic scoliosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Syndromic scoliosis</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td>Cleidocranial dysplasia</td> <td>Partial or complete absence of the clavicles, short stature, brachycephaly</td> </tr> <tr> <td>Ehlers-Danlos syndrome&nbsp;</td> <td>Skin hyperextensibility, joint hypermobility, joint dislocations or subluxations</td> </tr> <tr> <td>Familial dysautonomia</td> <td>Progressive sensorimotor neuropathy with autonomic dysfunction (eg, orthostatic hypotension, excessive salivation, decreased tearing, temperature dysregulation)</td> </tr> <tr> <td>Homocystinuria</td> <td>Nearsightedness, muscle weakness, paresthesias</td> </tr> <tr> <td>Juvenile Paget disease (idiopathic hyperphosphatasia)</td> <td>Macrocephaly, short stature, bowed extremities, muscle weakness</td> </tr> <tr> <td>Klippel-Feil syndrome</td> <td>Short neck, low posterior hairline, limited neck motion, elevation of the scapula</td> </tr> <tr> <td>Marfan syndrome</td> <td>Long limbs, arachnodactyly, increased arm span to height ratio, ectopia lentis</td> </tr> <tr> <td>Mucopolysaccharidoses</td> <td>Coarse facial features, hepatosplenomegaly, cardiac abnormalities</td> </tr> <tr> <td>Neurofibromatosis</td> <td>Caf&#233;-au-lait macules, axillary freckling, Lisch nodules</td> </tr> <tr> <td>Osteogenesis imperfecta</td> <td>Excess or atypical fractures, short stature, laxity of the skin and ligaments</td> </tr> <tr> <td>Sprengel deformity</td> <td>Elevated scapula</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101169 Version 4.0</div></div></div>"},"101170":{"type":"graphic_table","displayName":"Neuromuscular causes of scoliosis","title":"Clinical features of selected causes of neuromuscular scoliosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of selected causes of neuromuscular scoliosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Neuromuscular scoliosis</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Nonstructural</td> </tr> <tr> <td class=\"indent1\">Leg-length discrepancy</td> <td> <p>Asymmetric height of iliac crests</p> Scoliosis disappears if leg-length discrepancy is corrected by placing a block under the shorter leg</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Primary postural scoliosis</td> <td>Curvature flattens with forward bending, extension, or lying supine</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neuropathy</td> </tr> <tr> <td class=\"indent1\">Cerebral palsy</td> <td>Motor dysfunction (eg, spasticity, dyskinesia, ataxia, atonia)</td> </tr> <tr> <td class=\"indent1\">Closed (occult) spinal dysraphism (eg, tethered cord, split spinal cord malformation)</td> <td>Vascular, pigmentary, or other cutaneous lesions over the spine; progressive motor and sensory dysfunction; sphincteric dysfunction; pain in the lumbosacral region, perineum, and legs; progressive scoliosis</td> </tr> <tr> <td class=\"indent1\">Friedreich ataxia</td> <td>Neurologic dysfunction (eg, progressive ataxia, lower extremity weakness, loss of DTR), cardiomyopathy, diabetes mellitus</td> </tr> <tr> <td class=\"indent1\">Hereditary motor sensory neuropathy (Charcot-Marie-Tooth disease)</td> <td>Distal muscle weakness, pes cavus foot deformity, hammer toes, atrophy of intrinsic hand and foot muscles</td> </tr> <tr> <td class=\"indent1\">Myelomeningocele</td> <td>Impaired sensory and motor function below the level of the spinal column defect</td> </tr> <tr> <td class=\"indent1\">Poliomyelitis</td> <td>Weakness, hypotonia, decreased or absent DTR</td> </tr> <tr> <td class=\"indent1\">Spinal muscular atrophy type 3</td> <td>Diffuse symmetric proximal muscle weakness greater in the lower than upper limbs, decreased or absent DTR</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Syringomyelia</td> <td>Intrinsic wasting of hand muscles; progressive central cord deficits (loss of pain and temperature sensation in the distribution of one or several adjacent dermatomes)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Myopathy</td> </tr> <tr> <td class=\"indent1\">Duchenne muscular dystrophy</td> <td>Progressive muscle weakness that initially affects the proximal muscles of the lower extremities</td> </tr> <tr> <td class=\"indent1\">Facioscapulohumeral dystrophy</td> <td>Asymmetric muscle weakness of the facial, scapular, upper arm, lower leg, and abdominal muscles</td> </tr> <tr> <td class=\"indent1\">Limb-girdle muscular dystrophy</td> <td>Progressive weakness and muscle atrophy involving the shoulder girdle and/or the pelvic girdle</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Nemaline myopathy</td> <td>Weakness and hypotonia involving the muscles of the face, neck, trunk, and feet</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Trauma</strong></td> <td>History of spinal cord injury, vertebral trauma, extravertebral trauma (eg, thoracic surgery, severe burns of the trunk), or spinal irradiation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Tumors</td> </tr> <tr> <td class=\"indent1\">Vertebral (eg, osteoid osteoma, osteoblastoma)</td> <td>Progressive pain that is worse at night, unrelated to activity, and relieved by nonsteroidal antiinflammatory medications</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Spinal cord tumors</td> <td>Lumbosacral dimpling, back pain, sensory dysesthesia muscle weakness (especially of the iliopsoas), difficulty walking, sphincter dysfunction</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Rickets</td> <td>Bow legs, wide wrists, costochondral swelling</td> </tr> <tr> <td class=\"indent1\">Vertebral body infection</td> <td>Back pain, fever, tenderness with percussion, spasm of paraspinous muscles</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DTR: deep tendon reflexes.</div><div id=\"graphicVersion\">Graphic 101170 Version 2.0</div></div></div>"},"101180":{"type":"graphic_table","displayName":"Zanarini Rating Scale for Borderline Personality Disorder","title":"Zanarini Rating Scale for Borderline Personality Disorder","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Zanarini Rating Scale for Borderline Personality Disorder</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup span=\"2\" width=\"10%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"3\"><strong>The Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) by Mary C Zanarini, EdD is a brief clinician-administered interview to assess severity and change in BPD symptoms.</strong><br /> <strong>To score &ndash; count the number of yes's. A score of&nbsp;8 or more is indicative of a diagnosis of borderline personality disorder.</strong></td> </tr> <tr> <td class=\"indent1\">1. Have any of your closest relationships been troubled by a lot of arguments or repeated breakups?</td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\">2. Have you deliberately hurt yourself physically (eg, punched yourself, cut yourself, burned yourself)? How about made a suicide attempt?</td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\">3. Have you had at least two other problems with impulsivity (eg, eating binges and spending sprees, drinking too much and verbal outbursts)?</td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\">4. Have you been extremely moody?</td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\">5. Have you felt very angry a lot of the time? How about often acted in an angry or sarcastic manner?</td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\">6. Have you often been distrustful of other people?</td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\">7. Have you frequently felt unreal or as if things around you were unreal?</td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\">8. Have you chronically felt empty?</td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\">9. Have you often felt that you had no idea of who you are or that you have no identity?</td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> <tr> <td class=\"indent1\">10. Have you made desperate efforts to avoid feeling abandoned or being abandoned (eg, repeatedly called someone to reassure yourself that he or she still cared, begged them not to leave you, clung to them physically)?</td> <td><span class=\"primarybox_left\">&nbsp;</span>Yes</td> <td><span class=\"primarybox_left\">&nbsp;</span>No</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Zanarini MC, Zanarini Rating Scale for Borderline Personality Disorder, 2007: Jones &amp; Bartlett Learning, Burlington, MA. <a href=\"http://www.jblearning.com/\" target=\"_blank\">www.jblearning.com</a>. Reprinted with permission.</div><div id=\"graphicVersion\">Graphic 101180 Version 1.0</div></div></div>"},"101181":{"type":"graphic_table","displayName":"Causes of recurrent peptic ulcer disease","title":"Causes of recurrent peptic ulcer disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of recurrent peptic ulcer disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Persisting <em>H. pylori</em> infection</td> </tr> <tr> <td>Poor compliance with treatment</td> </tr> <tr> <td>Resistant organism</td> </tr> <tr> <td>Inadequate <em>H. pylori</em> regimen</td> </tr> <tr> <td class=\"sublist1_start\">Unrecognized <em>H. pylori</em> infection:</td> </tr> <tr> <td class=\"sublist1\">False negative <em>H. pylori</em> testing</td> </tr> <tr> <td class=\"sublist1\">Skipped or inadequate testing</td> </tr> <tr> <td class=\"subtitle1_single\">Ulcers related to nonsteroidal anti-inflammatory drugs (NSAIDs)</td> </tr> <tr> <td>Continued NSAID use</td> </tr> <tr> <td>Undiscovered NSAID use</td> </tr> <tr> <td>Poor response to co-therapy with a proton pump inhibitor (PPI) or histamine 2 receptor antagonist (H2RA)</td> </tr> <tr> <td class=\"subtitle1_single\">Other mechanisms</td> </tr> <tr> <td class=\"sublist1_start\">Hypersecretory states:</td> </tr> <tr> <td class=\"sublist1\">Gastrinoma</td> </tr> <tr> <td class=\"sublist1\">Antral G cell hyperfunction</td> </tr> <tr> <td class=\"sublist1\">Idiopathic hypersecretory duodenal ulcer</td> </tr> <tr> <td class=\"sublist1_start\">Co-therapies:</td> </tr> <tr> <td class=\"sublist1\">Glucocorticoids (especially when given with NSAIDs)</td> </tr> <tr> <td class=\"sublist1\">Cytotoxic drugs</td> </tr> <tr> <td class=\"sublist1\">Other drugs, such as methamphetamine or cocaine use</td> </tr> <tr> <td class=\"sublist1_start\">Uncommon causes:</td> </tr> <tr> <td class=\"sublist1\">Cancer</td> </tr> <tr> <td class=\"sublist1\">Crohn disease</td> </tr> <tr> <td class=\"sublist1\">Infections other than <em>H. pylori</em></td> </tr> <tr> <td class=\"sublist1\">Eosinophilic, inflammatory, infiltrative conditions</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101181 Version 1.0</div></div></div>"},"101200":{"type":"graphic_picture","displayName":"Great toe ischemic wound","title":"Great toe ischemic wound","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Great toe ischemic wound</div><div class=\"cntnt\"><img style=\"width:480px; height:640px;\" src=\"images/SURG/101200_Ischemia_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture depicts an ischemic wound on the medial aspect of the left great toe. Note the extension of the wound through the entire dermis, fibrotic tissue on the wound base, and the hyperkeratotic tissue about the wound edge. These findings are indicative of an ischemic wound, particularly given the location near a bony prominence at a location at risk for pressure ulceration.</div><div id=\"graphicVersion\">Graphic 101200 Version 2.0</div></div></div>"},"101201":{"type":"graphic_picture","displayName":"Nonhealing toe amputation wound","title":"Nonhealing toe amputation wound","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Nonhealing toe amputation wound</div><div class=\"cntnt\"><img style=\"width:640px; height:480px;\" src=\"images/SURG/101201_Ischemia2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture depicts an ischemic wound following amputation of the 2<SUP>nd</SUP>, 3<SUP>rd</SUP>, and 4<SUP>th</SUP> digits at the metatarsal-phalangeal joint level. A fibrotic wound base remains with little to no evidence of healing. There is no granulation tissue or epithelial ingrowth.</div><div id=\"graphicVersion\">Graphic 101201 Version 3.0</div></div></div>"},"101202":{"type":"graphic_picture","displayName":"Ischemic wound lateral foot","title":"Ischemic wound lateral foot","html":"<div class=\"graphic\"><div style=\"width: 498px\" class=\"figure\"><div class=\"ttl\">Ischemic wound lateral foot</div><div class=\"cntnt\"><img style=\"width:478px; height:640px;\" src=\"images/SURG/101202_Ischemia_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture depicts the clinical appearance of an ischemic wound on the lateral forefoot, specifically at&nbsp;the plantar aspect of the 5th metatarsal-phalangeal joint. Note the wound appearance of fibrotic tissue mixed with eschar in an area of increased pressure near a bony prominence.</div><div id=\"graphicVersion\">Graphic 101202 Version 2.0</div></div></div>"},"101203":{"type":"graphic_picture","displayName":"Ischemic wound lateral leg","title":"Ischemic wound lateral leg","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Ischemic wound lateral leg</div><div class=\"cntnt\"><img style=\"width:640px; height:480px;\" src=\"images/SURG/101203_Ischemia_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture depicts an ischemic wound on the lateral aspect of the leg near the lateral malleolus. Note that the wound extends through the entire dermis, with a mixture of fibrotic tissue and eschar at its base.</div><div id=\"graphicVersion\">Graphic 101203 Version 3.0</div></div></div>"},"101204":{"type":"graphic_picture","displayName":"Amputation stump wound breakdown","title":"Amputation stump wound breakdown","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Amputation stump wound breakdown</div><div class=\"cntnt\"><img style=\"width:480px; height:542px;\" src=\"images/SURG/101204_Ischemia_5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture depicts transmetatarsal amputation stump wound breakdown due to ischemia. Full-thickness wound dehiscence is seen medial and lateral with a fibrotic wound base and there is dependent rubor characteristic for ischemia of the dorsal and plantar amputation flaps.</div><div id=\"graphicVersion\">Graphic 101204 Version 2.0</div></div></div>"},"101205":{"type":"graphic_table","displayName":"VTd for multiple myeloma","title":"Bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone (VTd) induction therapy for initial treatment of patients with multiple myeloma<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bortezomib (Velcade), thalidomide (Thalomid), and dexamethasone (VTd) induction therapy for initial treatment of patients with multiple myeloma<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Cycle length:</strong> 28 days. </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1 divider_bottom\">Drug</td> <td class=\"subtitle1 divider_bottom\">Dose and route</td> <td class=\"subtitle1 divider_bottom\">Administration</td> <td class=\"subtitle1 divider_bottom\">Given on days</td> </tr> <tr> <td>Bortezomib*</td> <td>1.3 mg/m<sup>2</sup> subcutaneously (SC)</td> <td>Given as a single SC injection.</td> <td>Days 1, 8, 15, and 22<sup>[1,2]</sup></td> </tr> <tr> <td>Thalidomide<sup>&#182;</sup></td> <td>100 mg for first 14 days then 200 mg per day thereafter by mouth</td> <td>Take with water on an empty stomach at least one hour after the evening meal.</td> <td>Daily, days 1 through 21</td> </tr> <tr class=\"divider_bottom\"> <td>Dexamethasone<sup>&#916;</sup> (\"low dose\")</td> <td>40 mg by mouth</td> <td>Take with food (after meals or with food or milk) in the morning.</td> <td>Days 1, 8, 15, and 22<sup>[1,2]</sup></td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\"><strong>Emesis risk</strong></td> <td colspan=\"3\"> <ul> <li>MINIMAL TO LOW.</li> <li>Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Prophylaxis for infusion reactions</strong></td> <td colspan=\"3\"> <ul> <li>Routine premedication is not indicated. If a hypersensitivity reaction (not including local reactions) occurs with bortezomib or thalidomide, then neither drug should be readministered.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Antithrombotic prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Routine antithrombotic prophylaxis is warranted. Thromboembolism (grade 3 and 4) was reported in 3% of patients in a clinical trial receiving VTd despite antithrombotic prophylaxis.<sup>[2]</sup> In addition, reported risk of thromboembolism (grade 3 and 4) was 5% in the Td arm of this study.<sup>[2]</sup></li> <li>Refer to UpToDate topic on \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Infection prophylaxis</strong></td> <td colspan=\"3\"> <ul> <li>Bortezomib therapy may be associated with an increased risk of herpes zoster and infections not related to neutropenia. Antiviral prophylaxis (eg, acyclovir 400 mg orally twice a day) should be administered to all patients receiving VTd. Some clinicians also administer trimethoprim-sulfamethoxazole double strength once daily on Mondays, Wednesdays, and Fridays during treatment.<sup>[1,2]</sup> Primary prophylaxis with G-CSF is not indicated.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Vesicant/irritant properties</strong></td> <td colspan=\"3\"> <ul> <li>Bortezomib is an irritant.</li> <li>Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Dose adjustment for baseline liver or renal dysfunction</strong></td> <td colspan=\"3\"> <ul> <li><strong>Bortezomib:</strong> No dosage adjustment for bortezomib secondary to renal insufficiency is necessary. For patients undergoing hemodialysis, bortezomib should be administered after dialysis. Patients with moderate or severe hepatic impairment (serum bilirubin level &#62;1.5 times the upper limit of normal) should be started on bortezomib at a reduced dose of 0.7 mg/m<sup>2</sup> per injection during the first cycle, with further dose modifications based upon patient tolerance.<sup>[3]</sup> Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</li> <li><strong>Thalidomide:</strong> Dosage adjustment of thalidomide is not required for either preexisting renal or hepatic dysfunction.<sup>[4]</sup></li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Pregnancy warning</strong></td> <td colspan=\"3\"> <ul> <li>Thalidomide can result in severe, life-threatening human birth defects. Pregnancy testing is required within 24 hours prior to initiation of thalidomide therapy.<sup>[4]</sup></li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Assess CBC with differential, electrolytes, renal function, liver function, and M protein prior to starting each cycle. A CBC should also be performed prior to the dose of bortezomib on days 1, 8, 15, and 22.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for signs of neuropathy. Many clinicians provide a prophylactic bowel regimen for patients taking thalidomide.</li> </ul> </td> </tr> <tr> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for hypotension during therapy; adjustment of antihypertensives and/or administration of IV hydration may be needed.</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <ul class=\"decimal_heading\"> <li>Monitor for signs of rash, infection, or thrombotic event periodically.</li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle1_left\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\"><strong>Neuropathy</strong></td> <td colspan=\"3\"> <ul> <li>Dose adjustment guidelines for bortezomib in patients who develop peripheral neuropathy or neuropathic pain are available.<sup>[3]</sup></li> <li>Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\".</li> <li>Thalidomide should be discontinued or dose reduced if a patient develops paresthesias accompanied by pain, motor deficit, or interference with activities of daily living.</li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>Rash</strong></td> <td colspan=\"3\"> <ul> <li>Thalidomide has been associated with rashes including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). If a rash develops, thalidomide should be discontinued and the rash further evaluated. Thalidomide should not be administered again if the rash is exfoliative, purpuric, or bullous, or if SJS or TEN is suspected.<sup>[4]</sup></li> <li>Refer to UpToDate topic on \"Cutaneous complications of conventional chemotherapy agents\".</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Other nonhematological toxicity</strong></td> <td colspan=\"3\"> <ul> <li>For grade 3 or 4 nonhematologic toxicity other than neuropathy, bortezomib should be held. Once symptoms have resolved to grade 1 or baseline, bortezomib may be reinitiated with one dose level reduction (from 1.3 mg/m<sup>2</sup> to 1 mg/m<sup>2</sup>, or from 1 mg/m<sup>2</sup> to 0.7 mg/m<sup>2</sup>).<sup>[2,3]</sup></li> </ul> </td> </tr> <tr class=\"divider_top\"> <td class=\"highlight_gray_text\" style=\"font-size:1.2em;\" colspan=\"4\"><strong>If there is a change in body weight of at least 10%, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy, who should use independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</STRONG></div><div class=\"graphic_footnotes\">G-CSF: granulocyte-colony stimulating factor; CBC: complete blood count; IV: intravenous.<br />* SC administration is preferred due to a lower risk of neuropathy. If there are problems with SC administration such as anasarca or allergy, then bortezomib can be given intravenously as a rapid bolus over 3 to 5 seconds.<br />¶ In the United States, the use of thalidomide is subject to the THALOMID REMS program (formerly called the S.T.E.P.S. Program, www.THALOMIDREMS.com) developed in an attempt to minimize the potential for pregnancy among patients taking this medication and associated birth defects.<br />Δ These are the most commonly used doses/schedule of bortezomib, thalidomide, and dexamethasone in the VTd regimen. They are different than those described in the original report<SUP>[1]</SUP> due to subsequent data that show lower toxicity with similar efficacy.<SUP>[2]</SUP></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Rajkumar S. Am J Hematol 2014; 89:999.</LI>&#xD;&#xA;<LI>Cavo M, et al. Lancet 2010; 376:2075.</LI>&#xD;&#xA;<LI>Bortezomib injection. United States prescribing information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on January 26, 2015).</LI>&#xD;&#xA;<LI>Thalidomide. United States prescribing information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on January 26, 2015).</LI></OL></div><div id=\"graphicVersion\">Graphic 101205 Version 3.0</div></div></div>"},"101214":{"type":"graphic_table","displayName":"Chronic anterior knee pain in children and adolescents","title":"Chronic anterior knee pain* in children and skeletally immature adolescents: Causes and distinguishing features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Chronic anterior knee pain* in children and skeletally immature adolescents: Causes and distinguishing features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Historical features</td> <td class=\"subtitle1\">Common symptoms</td> <td class=\"subtitle1\">Key findings</td> <td class=\"subtitle1\">Additional comments</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Poorly localized pain</td> </tr> <tr> <td class=\"indent1\">Patellofemoral pain syndrome</td> <td> <ul> <li>History of overuse, often involves running with a change in training (eg, increased mileage or pace). </li> </ul> </td> <td> <ul> <li>Diffuse anterior, peripatellar pain. </li> <li>Knee may \"give way\". </li> <li>Pain increases with squatting, running (especially downhill), ascending or descending stairs, or arising after prolonged sitting. </li> </ul> </td> <td> <ul> <li>Tenderness under medial or lateral patella. </li> <li>Normal knee motion. </li> <li>Effusion rare. </li> <li>Positive special testing (eg, patellofemoral compression test). </li> <li>Vastus medialis obliquus atrophy and hamstring, iliopsoas, and gastrocnemius tightness common. </li> <li>Lower extremity malalignment often present, especially during a single leg squat. </li> </ul> </td> <td> <ul> <li>Most common condition seen in adolescents referred to sports medicine specialists. </li> <li>Knee effusion, abnormal knee motion, or ligamentous laxity require assessment for intra-articular damage. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Patellar subluxation</td> <td> <ul> <li>History of patella dislocation or hypermobility syndrome. </li> </ul> </td> <td> <ul> <li>Anterior or medial knee pain. </li> <li>Popping or clicking from superolateral portion of the patella with movement. </li> </ul> </td> <td> <ul> <li>Tenderness of the underside of the patella (patellar facets) and medial tenderness at the adductor tubercle. </li> <li>High-riding patella. </li> <li>Abnormal patellar tracking. </li> <li>Positive patellar apprehension test. </li> </ul> </td> <td> <ul> <li>Plain radiographs are indicated to assess for avulsion fractures. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Osteochondritis dissecans</td> <td> <ul> <li>History of acute injury or highly active patient with pain that worsens with exercise. </li> </ul> </td> <td> <ul> <li>Poorly localized pain with activity that may progress to stiffness, swelling, and mechanical symptoms of locking or catching. </li> </ul> </td> <td> <ul> <li>Tenderness over the medial femoral condyle in the flexed knee. </li> </ul> </td> <td> <ul> <li>Plain radiographs, including tunnel views of the knee, show crescent shaped lucency on the medial femoral condyle. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Chronic ACL injury&nbsp;</td> <td> <ul> <li>History of prior ACL injury.</li> </ul> </td> <td> <ul> <li>Anterior knee pain with swelling, shifting, and giving way.</li> </ul> </td> <td> <ul> <li>Ligamentous laxity on testing with anterior drawer, Lachman, and/or pivot shift testing.</li> <li>Knee effusion. </li> </ul> </td> <td> <ul> <li>Meniscal injury also present in as many as 90 percent of patients with chronic ACL injury.</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Referred hip pain</td> <td> <ul> <li>History of vague pain that may include the thigh. </li> <li>Depending upon etiology, pain may be worse with activity. </li> </ul> </td> <td> <ul> <li>Poorly localized knee pain. </li> </ul> </td> <td> <ul> <li>Normal knee examination. </li> <li>Limited range of motion at the hip. </li> </ul> </td> <td> <ul> <li>Plain radiographs of the hips, including a frog leg view should be obtained. </li> <li>Slipped capital femoral epiphysis requires emergent orthopedic consultation. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Referred back pain<br /> (L2/L3/L4 radiculopathy)</td> <td> <ul> <li>Anterior knee pain is associated with anterior thigh pain and back pain. </li> <li>Numbness, paresthesias, or other sensory changes may be reported. </li> <li>Incontinence suggests cauda equina syndrome. </li> </ul> </td> <td> <ul> <li>Anterior and medial knee pain associated with back pain that radiates into the medial foot. </li> </ul> </td> <td> <ul> <li>Normal knee examination. </li> <li>Weakness of hip flexion, knee extension, and hip adduction. </li> <li>Sensation may be reduced over the anterior thigh down to the medial aspect of the lower leg. </li> <li>A reduced knee reflex is common in the presence of moderate weakness. </li> </ul> </td> <td> <ul> <li>Rare in children. </li> <li>Plain radiographs and MRI of lumbar spine are indicated as is consultation with a pediatric neurologist or neurosurgeon, depending upon the findings. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Patellar stress fracture</td> <td> <ul> <li>Insidious onset of knee pain in highly active patients. </li> </ul> </td> <td> <ul> <li>Diffuse knee pain. </li> </ul> </td> <td> <ul> <li>Tenderness over patella at the fracture site. </li> </ul> </td> <td> <ul> <li>Plain radiograph may show normal bone for months. </li> <li>MRI best for establishing the diagnosis. </li> <li>High risk for nonunion. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Malignant tumors<br /> (eg, osteosarcoma, Ewing sarcoma, and leukemia)</td> <td> <ul> <li>Minor trauma may be incidental and lead to evaluation. </li> <li>Pain can begin as mild and worsen with time and with exercise. Pain may be intermittent, especially with Ewing sarcoma. </li> </ul> </td> <td> <ul> <li>Pain may or may not be well localized and is often worse at night. </li> <li>Fever may be present in patients with leukemia or Ewing sarcoma. </li> </ul> </td> <td> <ul> <li>Tender soft tissue mass on examination. </li> <li>Knee range of motion may be limited. </li> </ul> </td> <td> <ul> <li>Plain radiographs and blood studies (CBC with differential, CRP, ESR, serum alkaline phosphatase and lactate dehydrogenase) are indicated. </li> <li>Further evaluation depends upon initial findings. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Benign tumors</td> <td> <ul> <li>May come to light during evaluation for trauma. </li> </ul> </td> <td> <ul> <li>Usually asymptomatic, may cause vague pain. </li> </ul> </td> <td> <ul> <li>Tenderness at site of tumor sometimes present. </li> </ul> </td> <td> <ul> <li>Plain radiographs show benign tumors as an incidental finding. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Localized pain</td> </tr> <tr> <td class=\"indent1\">Osgood-Schlatter disease<br /> (tibial tuberosity apophyseal avulsion)</td> <td> <ul> <li>History of overuse, often with sports that involve jumping or cutting. </li> <li>Common during growth spurt. </li> <li>Pain increases with activity or direct pressure on the tibial tubercle and decreases with rest. </li> </ul> </td> <td> <ul> <li>Pain at tibial tubercle. </li> </ul> </td> <td> <ul> <li>Tenderness at tibial tubercle. </li> <li>Focal swelling and warmth directly over the apophysis. </li> <li>No effusion or ligamentous laxity. </li> </ul> </td> <td> <ul> <li>Imaging is not necessary unless the patient has atypical complaints (pain at night, pain that is unrelated to activity, acute onset of pain, associated systemic complaints) or pain that is not directly over the tibial tubercle. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Sinding-Larsen-Johansson disease<br /> (patellar apophyseal avulsion)</td> <td> <ul> <li>History of overuse, often with sports that involve jumping or cutting. </li> <li>Common during growth spurt. </li> <li>Pain increases with activity and decreases with rest. </li> </ul> </td> <td> <ul> <li>Pain at inferior patellar pole. </li> </ul> </td> <td> <ul> <li>Tenderness at inferior pole of patella. </li> <li>Focal swelling and warmth directly over the apophysis. </li> <li>No effusion or ligamentous laxity. </li> </ul> </td> <td> <ul> <li>Imaging if atypical complaints (eg, pain at night, unrelated to activity, unable to bear weight or take 4 steps, morning stiffness with \"gel phenomenon\" or associated with systemic complaints). </li> <li>Plain radiographs show open apophysis, often with fragmentation (also seen in normal patients as well). </li> <li>US shows open apophysis (often with fragmentation), patellar tendon thickening, and infrapatellar bursitis. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Patellar and quadriceps tendinitis</td> <td> <ul> <li>History of overuse, especially activities involving running and jumping. </li> <li>Gradual onset of pain that steadily increases over time as activities continue. </li> <li>Worse in knee that is opposite of the dominant hand, especially for sports such as baseball, basketball, fencing, or tennis. </li> </ul> </td> <td> <ul> <li>Pain with ballistic movements (eg, jumping, sprinting, cutting). </li> </ul> </td> <td> <ul> <li>Patella: Tenderness along tendon, superior and inferior to patella. </li> <li>Tendon may feel thick compared to contralateral side. </li> <li>Quadriceps: Focal tenderness between superior patella border and body of the quadriceps muscle. </li> <li>Pain with resisted knee flexion. </li> <li>Both: Quadriceps and hip flexor tightness often present. </li> </ul> </td> <td> <ul> <li>Patellar tendinitis more common than quadriceps tendinitis. </li> <li>Tendinitis is more common in children while a tendinopathy reflects a degenerative cascade that is more commonly seen in adults. </li> <li>Ultrasound can show characteristic tendon changes. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Fat pad impingement<br /> (Hoffa disease)</td> <td> <ul> <li>Pain worse with terminal extension, especially in dancers, gymnasts, jumping athletes (eg, basketball or volleyball), or swimmers. </li> </ul> </td> <td> <ul> <li>Vague achy pain deep to the patellar tendon which can be abrupt and sharp at specific angles of flexion or extension. </li> </ul> </td> <td> <ul> <li>Diffuse patellar and fat pad tenderness. </li> <li>Pain with knee extension against resistance. </li> <li>Pain at terminal extension of the bounce home test. </li> </ul> </td> <td> <ul> <li>Fat pad impingement may complicate patellar tendinitis, patellar fractures, or surgery. </li> <li>Infiltration of the fat pad with local anesthetic relieves the pain and can help differentiate impingement from other causes. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Bipartite and tripartite patella</td> <td> <ul> <li>History of strenuous activity. </li> </ul> </td> <td> <ul> <li>Lateral or superolateral patellar pain. </li> </ul> </td> <td> <ul> <li>Tenderness at the superolateral patella. </li> <li>Bony prominence at site of tenderness. </li> </ul> </td> <td> <ul> <li>Plain radiographs show anomaly. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Prepatellar bursitis</td> <td> <ul> <li>History of overuse, especially direct repetitive knee trauma (eg, wrestling) or single direct trauma to the anterior patella. </li> </ul> </td> <td> <ul> <li>Pain and swelling just below the patella. </li> </ul> </td> <td> <ul> <li>Swelling below distal patella tendon insertion and around tibial tubercle. </li> <li>Skin redness over the prepatellar bursa. </li> <li>Normal knee range of motion. </li> </ul> </td> <td> <ul> <li>Examination is typically sufficient to make the diagnosis. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">US: ultrasound; MRI: magnetic resonance imaging; ACL: anterior cruciate ligament; CBC: complete blood count; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate.<br />* Chronic knee pain refers to pain that has been present six weeks or longer.</div><div id=\"graphicVersion\">Graphic 101214 Version 6.0</div></div></div>"},"101234":{"type":"graphic_table","displayName":"Differential diagnosis of recurrent oral ulcerations","title":"Differential diagnosis of recurrent oral ulcerations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of recurrent oral ulcerations</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_single\">Rheumatologic diseases</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Systemic lupus erythematosus </li> <li>Reactive arthritis </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Gastrointestinal diseases</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Inflammatory bowel disease </li> <li>Celiac disease </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Autoinflammatory conditions</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Periodic fever, aphthous stomatitis, pharyngitis and adenitis (PFAPA) syndrome </li> <li>Hyperimmunoglobulinemia D syndrome</li> <li>A20 haploinsufficiency</li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Infections</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Herpes simplex virus </li> <li>Human immunodeficiency virus </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Dermatologic diseases </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Stevens-Johnson syndrome </li> <li>Pemphigoid </li> <li>Pemphigus </li> <li>Lichen planus </li> <li>Linear IgA bullous dermatosis </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Hematologic conditions</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Cyclic neutropenia </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Other</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Drugs including methotrexate, other chemotherapy and nicorandil </li> <li>Nutritional deficiencies such as vitamin B12, iron and folic acid </li> <li>Recurrent aphthous stomatitis </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Rheumatology. Ambrose NL, Haskard DO. Differential diagnosis and management of Beh&ccedil;et syndrome. Nat Rev Rheumatol 2013; 9:79. Copyright &copy; 2013. <a href=\"http://www.nature.com/nrrheum\" spellcheck=\"true\" target=\"_blank\">www.nature.com/nrrheum</a>.</div><div id=\"graphicVersion\">Graphic 101234 Version 2.0</div></div></div>"},"101236":{"type":"graphic_table","displayName":"Approach to the diagnosis of RCVS","title":"Summary of critical elements for the diagnosis of reversible cerebral vasoconstriction syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of critical elements for the diagnosis of reversible cerebral vasoconstriction syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>1. Recurrent acute, severe headaches, with or without additional neurologic signs and symptoms.</td> </tr> <tr> <td>2. Transfemoral angiography or indirect (CT or MR) angiography documenting segmental cerebral artery vasoconstriction.</td> </tr> <tr> <td>3. No evidence for aneurysmal subarachnoid hemorrhage.</td> </tr> <tr> <td>4. Normal or near-normal cerebrospinal fluid analysis results (total protein content &#60;80 mg/dL, white blood cell count &#60;10/mm<sup>3</sup>, normal glucose content).</td> </tr> <tr> <td>5. The diagnosis cannot be confirmed until reversibility of the angiographic abnormalities is documented within 12 weeks after onset or, if death occurs before the follow-up studies are completed, autopsy rules out conditions such as vasculitis, intracranial atherosclerosis, and aneurysmal subarachnoid hemorrhage, which can also manifest as headache and stroke.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RCVS: reversible cerebral vasoconstriction syndromes; CT: computed tomography; MR: magnetic resonance.</div><div class=\"graphic_reference\">From Annals of Internal Medicine, Calabrese LH, Dodick DW, Schwedt TJ, et al. Narrative review: Reversible cerebral vasoconstriction syndromes, Volume 146, Issue 1, Pages&nbsp;34-44. Copyright © 2007 American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 101236 Version 1.0</div></div></div>"},"101237":{"type":"graphic_figure","displayName":"Bipolar tubal sterilization","title":"Female sterilization: Bipolar electrosurgery method","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Female sterilization: Bipolar electrosurgery method</div><div class=\"cntnt\"><img style=\"width:422px; height:350px;\" src=\"images/OBGYN/101237_Bplr_tubal_sterilization.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 3-cm minimum zone of isthmic tube is desiccated with bipolar forceps. The paddles of the forceps extend across the tube onto the mesosalpinx.</div><div class=\"graphic_reference\">Reproduced with permission from: Memmel L, Gilliam M. Contraception. In: Danforth's Obstetrics and Gynecology, 10 Ed, Gibbs RS, Karlan BY, Haney AF, Nygaard I (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 101237 Version 2.0</div></div></div>"},"101246":{"type":"graphic_figure","displayName":"Shielding fetus from irradiation during surgery","title":"Shielding fetus from irradiation during surgery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Shielding fetus from irradiation during surgery</div><div class=\"cntnt\"><img style=\"width:375px; height:526px;\" src=\"images/SURG/101246_Shielding_fetus_from_irradiation_during_surgery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">During cholangiography, the fetus should be shielded by placing a lead apron on the lower abdomen of the patient. Because the biliary tree is in the upper abdomen, shielding the fetus in this way does not usually compromise the field of view necessary for proper imaging.</div><div id=\"graphicVersion\">Graphic 101246 Version 2.0</div></div></div>"},"101247":{"type":"graphic_table","displayName":"Contingency management survey: Favorite things","title":"Contingency management survey: Favorite things","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contingency management survey: Favorite things</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\">Client name____________________</td> <td class=\"subtitle1_left\">Date__________</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">We want to encourage our clients throughout their treatment and supervision episode. Please help us by identifying items that would serve as incentives to motivate you to make continued progress toward positive life goals.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">What is your:</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Favorite snack?____________________</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Favorite soda or juice?____________________</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Favorite candy bar?____________________</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Favorite sports team?____________________</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">Favorite clothing store?____________________</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">Favorite restaurant?____________________</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Which grocery store do you prefer?</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____Giant</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____Safeway</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____Super-fresh</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____Shoppers</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">_____Other:____________________</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Which drug store do you prefer?</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____CVS</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____Walgreens</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">_____Rite Aid</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Which variety store do you prefer?</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____Walmart</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____K-Mart</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">_____Target</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Which fast food restaurant do you prefer?</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____McDonalds</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____Wendy's</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____KFC</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____Burger King</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____Taco Bell</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"2\">_____Other:____________________</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Where would you like to go? (check those that apply)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____Science Center</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____Aquarium</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____ESPN Zone</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____Baltimore Zoo</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____Reginald Lewis Museum</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____National Great Blacks in Wax Museum</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____Movie theater</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____Restaurant (Which restaurant?____________________)</td> </tr> <tr> <td class=\"indent1\" colspan=\"2\">_____Other:____________________</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101247 Version 2.0</div></div></div>"},"101248":{"type":"graphic_table","displayName":"Patient-controlled analgesia regimens for opioid-naïve patients","title":"Patient controlled analgesia (PCA) regimens for opioid naïve adult patients: commonly-prescribed dose ranges","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient controlled analgesia (PCA) regimens for opioid naïve adult patients: commonly-prescribed dose ranges</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Concentration</td> <td class=\"subtitle1\">Initial loading and rescue loading dose range</td> <td class=\"subtitle1\">Demand (PCA) dose range</td> <td class=\"subtitle1\">Lockout interval</td> <td class=\"subtitle1\">Maximum in four hours</td> </tr> <tr> <td>Morphine</td> <td>1 mg/mL</td> <td>0.5 to 2.5 mg*</td> <td>0.5 to 2.5 mg</td> <td>5 to 10 minutes</td> <td>30 mg</td> </tr> <tr> <td>Hydromorphone</td> <td>0.2 mg/mL</td> <td>0.05 to 0.4 mg<sup>&#182;</sup></td> <td>0.05 to 0.4 mg</td> <td>5 to 10 minutes</td> <td>6 mg</td> </tr> <tr> <td>Fentanyl</td> <td>10 mcg/mL</td> <td>5 to 20 mcg<sup>&#916;</sup></td> <td>5 to 20 mcg</td> <td>4 to 10 minutes</td> <td>300 mcg</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Dosing should be individualized according to patient-specific factors, clinical situation, comorbidities, and concurrent medications. Lower doses and closer monitoring including continuous pulse oximetry and end-tidal carbon dioxide are recommended during the early post-operative period, in older adults, and in patients at elevated risk for respiratory depression, hypoxia, and/or opioid accumulation, eg, due to obstructive airway disease, sleep apnea, obesity, low body weight, frailty, renal and/or hepatic impairment, or use with other medications with sedating and/or respiratory depressant properties.</LI>&#xD;&#xA;<LI>Adjunctive medications for management of opioid-associated pruritus and nausea may be needed (eg, diphenhydramine, prochlorperazine). Refer to \"Management of acute perioperative pain\" topic for detail.</LI>&#xD;&#xA;<LI>The use of a continuous infusion (basal opioid infusion) is <STRONG>not </STRONG>recommended; such use should be limited to carefully selected patients who are opioid tolerant and/or receiving care in a critical care unit.</LI>&#xD;&#xA;<LI>PCA dose ranges and other detail shown in the table are based upon recommendations used at experienced centers; protocols will vary by institution. For additional detail, refer to the individual drug monographs provided by Lexicomp included with UpToDate.</LI></UL></div><div class=\"graphic_footnotes\">PCA: Patient-controlled analgesia.<br />* Morphine initial loading dose may be given incrementally in smaller divided doses every six minutes as needed. A single loading dose should not exceed 2.5 mg and total loading dose should not exceed 10 mg. A rescue loading dose may be repeated after eight hours if needed.<br />¶ Hydromorphone initial loading dose may be given incrementally in smaller divided doses every six minutes as needed. A single dose should not exceed 0.4 mg and total loading dose should not exceed 2 mg. A rescue loading dose may be repeated after eight hours if needed.<br />Δ Fentanyl initial loading dose may be given incrementally in smaller divided doses every six minutes as needed. A single loading dose should not exceed 20 mcg and total loading dose should not exceed 100 mcg. A rescue loading dose may be repeated after eight hours if needed.</div><div id=\"graphicVersion\">Graphic 101248 Version 4.0</div></div></div>"},"101252":{"type":"graphic_picture","displayName":"Erythema elevatum diutinum nodular","title":"Erythema elevatum diutinum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Erythema elevatum diutinum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101252_Erythm_elvtm_dtnm_ndlr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple nodules on the extensor surfaces of the arms.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101252 Version 1.0</div></div></div>"},"101253":{"type":"graphic_picture","displayName":"Erythema elevatum diutinum on arm","title":"Erythema elevatum diutinum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Erythema elevatum diutinum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101253_Erythm_elvtm_dtnm_arm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple erythematous plaques on the arm.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101253 Version 1.0</div></div></div>"},"101254":{"type":"graphic_figure","displayName":"Trends in all forms of tobacco use by youth","title":"Percentage of high school students who used tobacco in the preceding 30 days, by tobacco product, in the United States during 2011 to 2016","html":"<div class=\"graphic\"><div style=\"width: 793px\" class=\"figure\"><div class=\"ttl\">Percentage of high school students who used tobacco in the preceding 30 days, by tobacco product, in the United States during 2011 to 2016</div><div class=\"cntnt\"><img style=\"width:773px; height:389px;\" src=\"images/PEDS/101254_Trends_forms_tobacco_youth.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Estimated percentage of high school students who currently use any tobacco products,* any combustible tobacco products,<sup>&para;</sup> &ge;2 tobacco products,<sup>&Delta;</sup> and selected tobacco products - National Youth Tobacco Survey, United States, 2011 to 2016<sup>&loz;</sup><sup>&sect;</sup><sup>&yen;</sup>.</div><div class=\"graphic_footnotes\">* Any tobacco product use is defined as past 30-day use of electronic cigarettes, cigarettes, cigars, hookahs, smokeless tobacco, pipe tobacco and/or bidis.<br />¶ Any combustible tobacco use is defined as use of cigarettes, cigars, hookahs, pipe tobacco, and/or bidis on at least one day in the past 30 days.<br />Δ ≥2 tobacco product use is defined as past 30-day use of two or more of the following tobacco products: electronic cigarettes, cigarettes, cigars, hookahs, smokeless tobacco, pipe tobacco, and/or bidis.<br /><FONT class=lozenge>◊</FONT> From 2015 to 2016, a significant decrease in use of any tobacco product, any combustible tobacco product, ≥2 tobacco products, electronic cigarettes, and hookahs was observed (p&lt;0.05).<br />§ During 2011 to 2016, use of electronic cigarettes and hookahs exhibited a nonlinear increase (p&lt;0.05). Use of cigarettes, cigars, and smokeless tobacco exhibited a linear decrease (p&lt;0.05). Any combustible tobacco use, pipe tobacco, and bidis exhibited a nonlinear decrease (p&lt;0.05). There was a nonlinear change during this time in the use of ≥2 types of tobacco products (p&lt;0.05). No significant trend in current use of any tobacco product was observed during 2011 to 2016.<br />¥ Beginning in 2015, the definition of smokeless tobacco included chewing tobacco/snuff/dip, snus, and dissolvable tobacco because of limited sample sizes for individual products; this definition was applied across 2011 to 2016 for comparability purposes. In previous reports (National Youth Tobacco Survey 2014 and earlier) smokeless tobacco included only chewing tobacco/snuff/dip. Snus and dissolvable tobacco were reported as separate products.</div><div class=\"graphic_reference\">Reproduced from: Jamal A, Gentzke A, Hu S, et al. Tobacco Use Among Middle and High School Students &mdash; United States, 2011&ndash;2016. MMWR Morb Mortal Wkly Rep 2017; 66:601.</div><div id=\"graphicVersion\">Graphic 101254 Version 4.0</div></div></div>"},"101255":{"type":"graphic_diagnosticimage","displayName":"Duplex ultrasound of the carotid artery showing S curve","title":"Duplex ultrasound of the carotid artery showing extreme tortuosity (S curve)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Duplex ultrasound of the carotid artery showing extreme tortuosity (S curve)</div><div class=\"cntnt\"><img style=\"width:358px; height:318px;\" src=\"images/NEPH/101255_Dplx_ultrs_crtd_artry_S_crv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Duplex ultrasound (color power angio) of the carotid artery showing extreme tortuosity (S curve), which occurs in one-third of patients with fibromuscular dysplasia (FMD). The head is to the left, and feet are to the right.</div><div id=\"graphicVersion\">Graphic 101255 Version 1.0</div></div></div>"},"101256":{"type":"graphic_table","displayName":"T cell subsets 2","title":"T cell subsets","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">T cell subsets</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Designation</td> <td class=\"subtitle1\">Induced by</td> <td class=\"subtitle1\">Transcription factor</td> <td class=\"subtitle1\">Produces</td> </tr> <tr> <td>Th1</td> <td>IL-12</td> <td>T-beta</td> <td> <p>IFN-gamma</p> TNF-alpha</td> </tr> <tr> <td>Th2</td> <td>IL-4</td> <td>GATA-3</td> <td> <p>IL-4</p> <p>IL-5</p> <p>IL-6</p> IL-13</td> </tr> <tr> <td>Th3</td> <td> <p>IL-4</p> <p>IL-10</p> TGF-beta</td> <td>FoxP3</td> <td>TGF-beta</td> </tr> <tr> <td>Th9</td> <td> <p>IL-4</p> TGF-beta</td> <td> <p>GATA-3</p> <p>IRF-4</p> PU.1</td> <td>IL-9</td> </tr> <tr> <td>Th17</td> <td> <p>IL-1 beta</p> <p>IL-6</p> <p>IL-21</p> IL-23</td> <td>ROR-gammaT</td> <td>IL-17</td> </tr> <tr> <td>Th22</td> <td> <p>IL-6</p> <p>IL-12</p> <p>IL-23</p> TNF-alpha</td> <td>&nbsp;</td> <td>IL-22</td> </tr> <tr> <td>Treg</td> <td> <p>IL-2</p> TGF-beta</td> <td>FoxP3</td> <td> <p>IL-10</p> TGF-beta</td> </tr> <tr> <td>Tfh</td> <td> <p>IL-12</p> <p>IL-23</p> TGF-beta</td> <td>Bcl-6</td> <td> <p>IL-21</p> B cell help</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Th: T helper; IL: interleukin; IFN: interferon; TNF: tumor necrosis factor; GATA: GATA-binding protein (GATA is a deoxyribonucleic acid [DNA] sequence); TGF: transforming-growth factor; IRF: interferon regulatory factor; PU.1: an oncogene and transcription factor that binds to the PU-box, a purine-rich DNA sequence; ROR: regulator of reprogramming; Treg: regulatory T cell; Tfh: T follicular helper cell; Bcl: B cell lymphoma.</div><div id=\"graphicVersion\">Graphic 101256 Version 1.0</div></div></div>"},"101258":{"type":"graphic_picture","displayName":"Knee flexion testing","title":"Knee flexion testing","html":"<div class=\"graphic\"><div style=\"width: 865px\" class=\"figure\"><div class=\"ttl\">Knee flexion testing</div><div class=\"cntnt\"><img style=\"width:845px; height:663px;\" src=\"images/EM/101258_Knee_flexion_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Active knee flexion is assessed by having the prone patient flex the knee maximally, bringing the heel as close as possible to the gluteal fold. Flexion can be measured in degrees using a goniometer or by the minimum distance between the heels and the closest gluteal surface. </div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD.</div><div id=\"graphicVersion\">Graphic 101258 Version 1.0</div></div></div>"},"101261":{"type":"graphic_picture","displayName":"Nasal cannula for noninvasive ventilation in children","title":"Nasal cannula for noninvasive ventilation in children","html":"<div class=\"graphic\"><div style=\"width: 629px\" class=\"figure\"><div class=\"ttl\">Nasal cannula for noninvasive ventilation in children</div><div class=\"cntnt\"><img style=\"width:609px; height:405px;\" src=\"images/EM/101261_Nsl_cnnl_non_invs_vntl_chld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A nasal cannula with short prongs is often well tolerated in infants and young children. However, pressure leak through the mouth may limit its effectiveness.</div><div class=\"graphic_reference\">Courtesy of Joshua Nagler, MD.</div><div id=\"graphicVersion\">Graphic 101261 Version 3.0</div></div></div>"},"101262":{"type":"graphic_picture","displayName":"Nasal mask for noninvasive ventilation in children","title":"Nasal mask for noninvasive ventilation in children","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Nasal mask for noninvasive ventilation in children</div><div class=\"cntnt\"><img style=\"width:710px; height:520px;\" src=\"images/EM/101262_Nsl_msk_non_invs_vntlt_chld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Noninvasive ventilation with a nasal mask is frequently well tolerated in infants and children but may be less effective than a full face mask or helmet because of loss of pressure through the mouth.</div><div class=\"graphic_reference\">Courtesy of Joshua Nagler, MD.</div><div id=\"graphicVersion\">Graphic 101262 Version 3.0</div></div></div>"},"101263":{"type":"graphic_picture","displayName":"Full-face mask for noninvasive ventilation in children","title":"Full-face mask for noninvasive ventilation in children","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">Full-face mask for noninvasive ventilation in children</div><div class=\"cntnt\"><img style=\"width:617px; height:400px;\" src=\"images/EM/101263_Fll_msk_non_invsv_vntl_chld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A full-face mask provides a reliable means for delivering noninvasive ventilation (either continuous positive airway pressure [CPAP] or bilevel positive airway pressure [BPAP]) in children. However, infants and young children may become anxious or agitated when the mask is applied and may do better with a nasal cannula or nasal mask. </div><div class=\"graphic_reference\">Courtesy of Joshua Nagler, MD.</div><div id=\"graphicVersion\">Graphic 101263 Version 2.0</div></div></div>"},"101264":{"type":"graphic_picture","displayName":"Helmet for noninvasive ventilation in children","title":"Helmet for noninvasive ventilation in children","html":"<div class=\"graphic\"><div style=\"width: 935px\" class=\"figure\"><div class=\"ttl\">Helmet for noninvasive ventilation in children</div><div class=\"cntnt\"><img style=\"width:915px; height:341px;\" src=\"images/EM/101264_Hlmtnoinvsvvntchld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The helmet is secured by a \"baby-body\", which is worn under the pubic region as a pair of pants.<br />(B) The&nbsp; bidirectional safety valve is positioned on the cover of an opening to prevent asphyxia and to permit provider access to the patient's head.</div><div class=\"graphic_reference\">From: Codazzi D, Nacoti M, Passoni M, et al. Continuous positive airway pressure with modified helmet for treatment of hypoxemic acute respiratory failure in infants and a preschool population: a feasibility study. Pediatr Crit Care Med 2006;7:455. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2006 Society of Critical Care Medicine. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 101264 Version 5.0</div></div></div>"},"101265":{"type":"graphic_picture","displayName":"Inhaled medication delivery during noninvasive ventilation","title":"Inhaled medication delivery during noninvasive ventilation","html":"<div class=\"graphic\"><div style=\"width: 639px\" class=\"figure\"><div class=\"ttl\">Inhaled medication delivery during noninvasive ventilation</div><div class=\"cntnt\"><img style=\"width:619px; height:410px;\" src=\"images/EM/101265_Inhl_mdc_dlv_non_invsv_vntl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The adaptor for delivery of inhaled medication during noninvasive ventilation contains two ports. The arrow shows the reservoir for medication. The arrowhead identifies the port for attaching the aerosol generator.</div><div class=\"graphic_reference\">Courtesy of Joshua Nagler, MD.</div><div id=\"graphicVersion\">Graphic 101265 Version 2.0</div></div></div>"},"101267":{"type":"graphic_picture","displayName":"Cradle cap","title":"Cradle cap (seborrheic dermatitis of the scalp)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Cradle cap (seborrheic dermatitis of the scalp)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101267_Cradle_cap.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Yellowish greasy scales and diffuse erythema on the scalp of this infant with seborrheic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101267 Version 1.0</div></div></div>"},"101268":{"type":"graphic_picture","displayName":"Cradle cap dark skin","title":"Cradle cap (seborrheic dermatitis of the scalp)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Cradle cap (seborrheic dermatitis of the scalp)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101268_Cradle_cap_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Brownish greasy scales on the scalp of this infant with seborrheic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101268 Version 1.0</div></div></div>"},"101269":{"type":"graphic_picture","displayName":"Infantile seborrheic dermatitis face","title":"Infantile seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Infantile seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101269_Infntl_sbrrhc_drmtt_fc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, scaly plaques on the face and neck of this infant with seborrheic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101269 Version 1.0</div></div></div>"},"101270":{"type":"graphic_picture","displayName":"Infantile seborrheic dermatitis forehead","title":"Infantile seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Infantile seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101270_Infntl_sbrrhc_drmtt_frhd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous papules and plaques on the face of this infant with seborrheic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101270 Version 1.0</div></div></div>"},"101271":{"type":"graphic_picture","displayName":"Tinea capitis infant","title":"Tinea capitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tinea capitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101271_Tinea_capitis_infnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Slightly erythematous, scaly plaques with hair loss on the scalp of this infant with tinea capitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101271 Version 1.0</div></div></div>"},"101274":{"type":"graphic_algorithm","displayName":"PCNSL age less than 70","title":"Initial treatment of primary central nervous system lymphoma (PCNSL) in adults <70 years of age","html":"<div class=\"graphic\"><div style=\"width: 692px\" class=\"figure\"><div class=\"ttl\">Initial treatment of primary central nervous system lymphoma (PCNSL) in adults &lt;70 years of age</div><div class=\"cntnt\"><img style=\"width:672px; height:472px;\" src=\"images/NEURO/101274_PCNSL_age_less_than_70.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CR: complete response; HD/HCT: high-dose chemotherapy with autologous hematopoietic cell transplant; MTX: methotrexate; RTX: rituximab; WBRT: whole brain radiation therapy.<br />* Low functional status by itself should not exclude patients from a trial of aggressive therapy, as patients with PCNSL can improve rapidly with successful therapy.<br />&para; An estimated GFR &gt;30 is generally considered adequate for receipt of high-dose MTX, with appropriate dose reductions and precautions.<br />&Delta; Options include high-dose cytarabine, temozolomide; see UpToDate topic text for more details.<br /><span class=\"lozenge\">&loz;</span> Options include high-dose cytarabine with or without etoposide, temozolomide; see UpToDate topic text for more details.</div><div id=\"graphicVersion\">Graphic 101274 Version 2.0</div></div></div>"},"101275":{"type":"graphic_algorithm","displayName":"PCNSL older adults","title":"Initial treatment of primary central nervous system lymphoma (PCNSL) in older adults","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Initial treatment of primary central nervous system lymphoma (PCNSL) in older adults</div><div class=\"cntnt\"><img style=\"width:591px; height:377px;\" src=\"images/NEURO/101275_PCNSL_older_adults.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CR: complete response; ECOG: Eastern Cooperative Oncology Group; MTX: methotrexate; RTX: rituximab; WBRT: whole brain radiation therapy.<br />* Low functional status by itself should not exclude patients from a trial of aggressive therapy, as patients with PCNSL can improve rapidly with successful therapy.<br />¶ An estimated GFR &gt;30 is generally considered adequate for receipt of high-dose MTX, with appropriate dose reductions and precautions.<br />Δ Options include high-dose cytarabine, temozolomide; see UpToDate topic text for more details.<br /><FONT class=lozenge>◊</FONT> If renal function is inadequate for high-dose MTX.<br />§ TMZ or procarbazine.</div><div id=\"graphicVersion\">Graphic 101275 Version 2.0</div></div></div>"},"101276":{"type":"graphic_algorithm","displayName":"Diagnosis and management of secondary PPH","title":"Diagnosis and management of secondary postpartum hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 1202px\" class=\"figure\"><div class=\"ttl\">Diagnosis and management of secondary postpartum hemorrhage</div><div class=\"cntnt\"><img style=\"width:1182px; height:619px;\" src=\"images/OBGYN/101276_DXmgmtsecondaryPPHedit1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound examination in patients with secondary postpartum hemorrhage is often not definitive as there is considerable overlap between normal postpartum ultrasound findings and findings associated with secondary bleeding.&#xD;&#xA;<ol>&#xD;&#xA;    <li>Ultrasound findings are often nonspecific in endometritis. The uterus may have a thickened, heterogenous endometrium or show common normal postpartum findings, such as intracavitary debris, fluid, or gas. Infected retained placental tissue or a hematoma may be present.</li>&#xD;&#xA;    <li>Retained products of conception have a variable and sometimes nonspecific appearance on ultrasound. They often appear as a solid, echogenic intracavitary mass that extends to the endometrium. However, necrotic decidua and blood clots can mimic retained placental fragments. Color and spectral Doppler showing high-velocity, low-resistance arterial flow in the mass differentiates placental tissue from hematoma, but is not always present in the retained tissue. In the absence of a mass, increased vascularity in a thickened postpartum endometrium is also consistent with retained placental tissue. Rarely, a focal morbidly adherent placenta presents as secondary postpartum hemorrhage. Ultrasound findings include a mass that extends into or beyond the myometrium.</li>&#xD;&#xA;    <li>Bleeding diathesis and subinvolution have a similar ultrasound appearance. Ultrasound may show normal postpartum findings, such as intracavitary debris, fluid, or gas. An intracavitary hematoma may be present and appears as an echogenic mass, which can mimic the ultrasound appearance of retained products of conception. However, hematomas are not vascularized, whereas retained placenta may have vascular flow on Doppler. The uterus may be enlarged in subinvolution and hypoechoic tortuous vessels are seen along the inner third of the myometrium. Pulsed wave Doppler sonography shows increased peak systolic velocity with a low-resistance waveform along the inner third of the myometrium. In women with subinvolution and an intracavitary hematoma, low-resistance arterial flow within the myometrium at the placental implantation site should not be confused with low-resistance arterial flow in retained placental tissue. </li>&#xD;&#xA;    <li>AVM and pseudoaneurysm have characteristic features on ultrasound. Ultrasound findings of an AVM include multiple hypoechoic or anechoic serpentine spaces within the myometrium, with turbulent flow on color Doppler and high-velocity and low-resistance flow on spectral analysis. Subtle myometrial heterogeneity, a myometrial or endometrial mass, or prominent parametrial vessels may be observed. Ultrasound findings of a uterine artery pseudoaneurysm may include a hypoechoic intrauterine lesion, vascularity on color Doppler, and bidirectional systolic and diastolic flow with aliasing on spectral Doppler.</li>&#xD;&#xA;</ol></div><div class=\"graphic_footnotes\">CBC: complete blood count; hCG: human chorionic gonadotropin; AVM: arteriovenous malformation.<br />* In women with bleeding many weeks after delivery, a quantitative pregnancy test is useful for evaluating for choriocarcinoma, retained products of conception, or even a new pregnancy.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Kamaya A, Ro K, Benedetti NJ, et al. Imaging and diagnosis of postpartum complications: sonography and other imaging modalities. Ultrasound Q 2009; 25:151.</LI>&#xD;&#xA;<LI>Brown DL. Pelvic ultrasound in the postabortion and postpartum patient. Ultrasound Q 2005; 21:27.</LI>&#xD;&#xA;<LI>Di Salvo DN. Sonographic imaging of maternal complications of pregnancy. J Ultrasound Med 2003; 22:69.</LI>&#xD;&#xA;<LI>Laifer-Narin SL, Kwak E, Kim H, et al. Multimodality imaging of the postpartum or posttermination uterus: evaluation using ultrasound, computed tomography, and magnetic resonance imaging. Curr Probl Diagn Radiol 2014; 43:374.</LI></UL></div><div id=\"graphicVersion\">Graphic 101276 Version 4.0</div></div></div>"},"101277":{"type":"graphic_table","displayName":"Conditions associated with RCVS","title":"Conditions associated with reversible cerebral vasoconstriction syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with reversible cerebral vasoconstriction syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle2_single\">Pregnancy (\"Postpartum angiopathy\")</td> </tr> <tr> <td class=\"subtitle2_single\">Headache disorders</td> </tr> <tr> <td class=\"indent1\">Primary thunderclap headache</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Migraine</td> </tr> <tr> <td class=\"subtitle2_single\">Medications, drugs, and biologics</td> </tr> <tr> <td class=\"indent1\">Antimigraine agents (sumatriptan and other triptans, isometheptene, ergotamine tartrate, methylergonovine maleate)</td> </tr> <tr> <td class=\"indent1\">Cough and cold suppressants (phenylpropanolamine, pseudoephedrine)</td> </tr> <tr> <td class=\"indent1\">Diet pills (amphetamine derivatives, Hydroxycut)</td> </tr> <tr> <td class=\"indent1\">Antidepressants (selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors)</td> </tr> <tr> <td class=\"indent1\">Adrenergic agents (epinephrine, bromocriptine, lisuride)</td> </tr> <tr> <td class=\"indent1\">Illicit drugs (cocaine, ecstasy, marijuana, lysergic acid diethylamide)</td> </tr> <tr> <td class=\"indent1\">Chemotherapeutic agents (tacrolimus, cyclophosphamide)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Other (erythropoietin, indomethacin, intravenous immune globulin, interferon alpha, nicotine patches, red blood cell transfusions, licorice, ovarian stimulation, oral contraceptive pills)</td> </tr> <tr> <td class=\"subtitle2_single\">Miscellaneous</td> </tr> <tr> <td class=\"indent1\">Hypercalcemia, porphyria, pheochromocytoma, bronchial carcinoid tumor, unruptured saccular cerebral aneurysm, head trauma, spinal subdural hematoma, carotid endarterectomy, cervical artery dissection, neurosurgical procedures, carotid glomus tumor, tonsillectomy, neck surgery, high altitude, cerebral venous thrombosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Singhal AB, Bernstein RA. Postpartum angiopathy and other cerebral vasoconstriction syndromes. Neurocrit Care 2005; 3:91.</div><div id=\"graphicVersion\">Graphic 101277 Version 2.0</div></div></div>"},"101278":{"type":"graphic_table","displayName":"Intermediate- and long-term circulatory support outcomes","title":"Intermediate- and long-term mechanical circulatory support outcomes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Intermediate- and long-term mechanical circulatory support outcomes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">HeartMate II Study</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Device</td> <td class=\"subtitle1\">Indication</td> <td class=\"subtitle1\">Design</td> <td class=\"subtitle1\">Patient population</td> <td class=\"subtitle1\">Outcome</td> </tr> <tr class=\"divider_bottom\"> <td>REMATCH* 2001<sup>[1]</sup></td> <td class=\"centered\">129</td> <td>HeartMate XVE</td> <td>DT</td> <td>Prospective 1:1 HMXVE versus medical management</td> <td>Class IV x 60 days; VO<sub>2</sub> &#60;12 mL/kg/min; non-transplant candidate</td> <td>One- and two-year VAD survival of 52 and 23% versus 25 and 8% medical therapy</td> </tr> <tr class=\"divider_bottom\"> <td>INTrEPID<sup>&#182;</sup> 2007<sup>[2]</sup></td> <td class=\"centered\">55</td> <td>Novacor</td> <td>DT</td> <td>Prospective non-randomized</td> <td>Inotrope-dependent patients; non-transplant candidate</td> <td>One-year VAD survival 27 versus 11% in medical arm</td> </tr> <tr class=\"divider_bottom\"> <td>HeartMate II DT 2009<sup>[3]</sup></td> <td class=\"centered\">192</td> <td>HeartMate II versus <br /> HeartMate XVE</td> <td>DT</td> <td>Prospective randomized 2:1 HMII: HMXVE</td> <td>Same as REMATCH</td> <td>One- and two-year survival 68 and 58% HMII versus 55 and 24% HMXVE</td> </tr> <tr class=\"divider_bottom\"> <td>HeartMate II DT<sup>[4]</sup></td> <td class=\"centered\">414</td> <td>HeartMate II</td> <td>DT</td> <td>Mid trial versus early trial</td> <td>DT candidates</td> <td>One- and two-year survival 73 and 63% versus 68 and 58%</td> </tr> <tr class=\"divider_bottom\"> <td>HeartMate II 2007<sup>[5]</sup></td> <td class=\"centered\">133</td> <td>HeartMate II</td> <td>BTT</td> <td>Non-randomized</td> <td>Transplant candidates</td> <td>75% survival to transplant</td> </tr> <tr class=\"divider_bottom\"> <td>HeartMate II 2009<sup>[6]</sup></td> <td class=\"centered\">281</td> <td>HeartMate II</td> <td>BTT</td> <td>Non-randomized</td> <td>Transplant candidates</td> <td>Actuarial survival 73 and 72% at one year and 18 months; 79% transplanted, explanted, or alive on VAD at 18 months</td> </tr> <tr class=\"divider_bottom\"> <td>HeartMate II 2011<sup>[7]</sup></td> <td class=\"centered\">169</td> <td>HeartMate II</td> <td>BTT</td> <td>Post-FDA approval</td> <td>Transplant candidates</td> <td>91% transplanted, explanted, or ongoing at six months</td> </tr> <tr class=\"divider_bottom\"> <td>HeartWare<sup>[8]</sup></td> <td class=\"centered\">50</td> <td>HeartWare</td> <td>BTT</td> <td>Non-randomized</td> <td>Transplant candidates</td> <td>86% one-year survival</td> </tr> <tr> <td>ADVANCE<sup>&#916;</sup> 2012<sup>[9]</sup></td> <td class=\"centered\">137</td> <td>HeartWare</td> <td>BTT</td> <td>Non-randomized HW to LVAD registry controls (499)</td> <td>Transplant candidates</td> <td>92% survival to transplant or on device at six months, 90.6% one-year survival</td> </tr> <tr> <td>MOMENTUM 3<sup>&#9674;[10]</sup></td> <td class=\"centered\">294&nbsp;</td> <td>HearMate 3 versus<br /> HeartMate II&nbsp;</td> <td> <p>BTT and</p> <p>DT</p> </td> <td>Prospecitve randomized 1:1</td> <td>DT and transplant candidates</td> <td>Composite of survival free from disabling stroke or free from reoperation to replace or remove the device at 6 months was 86.2% for HeartMate&nbsp;3 and 76.8% for HeartMate II</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">DT: destination therapy; BTT: bridge to transplantation; VAD: ventricular assist device</div><div class=\"graphic_footnotes\">* REMATCH = Randomized Evaluation of Mehanical Assistance for Treatment of Heart failure<br />¶ INTrEPID = Investigation of Non-Transplant Eligible Patients who are Inotrope Dependent<br />Δ ADVANCE = Evaluation of HeartWare ventricular Assist Device for the Treatment of Advanced Heart Failure<br />◊ MOMENTUM&nbsp;3 Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 <br /></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001; 345:1435.</LI>&#xD;&#xA;<LI>Rogers JG, Butler J, Gass A, et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol 2007; 50:741.</LI>&#xD;&#xA;<LI>Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361:2241.</LI>&#xD;&#xA;<LI>Park SJ, Milano CA, Tatooles AJ, et al. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail 2012; 5:241.</LI>&#xD;&#xA;<LI>Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device in patients awaiting heart transplantation. N Engl J Med 2007; 357:885.</LI>&#xD;&#xA;<LI>Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009; 54:312.</LI>&#xD;&#xA;<LI>Starling RC, Naka Y, Boyle AJ, et al. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 2011; 57:1890.</LI>&#xD;&#xA;<LI>Strueber M, O'Driscoll G, Jansz P, et al. Multicenter evaluation of an intrapericardial left ventricular assist system. J Am Coll Cardiol 2011; 57:1375.</LI>&#xD;&#xA;<LI>Aaronson KD, Slaughter MS, Miller LW, et al. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. Circulation 2012; 125:3191.</LI>&#xD;&#xA;<LI>Mehra MR, Naka Y, Uriel N ET AL. A fully magnetically levitated circulatory pump for advanced heart failure. NEJM 2016 Nov 16.</LI></OL></div><div id=\"graphicVersion\">Graphic 101278 Version 3.0</div></div></div>"},"101281":{"type":"graphic_diagnosticimage","displayName":"Convexal SAH in patient with RCVS","title":"Convexal subarachnoid hemorrhage in a patient with reversible cerebral vasoconstriction syndrome","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Convexal subarachnoid hemorrhage in a patient with reversible cerebral vasoconstriction syndrome</div><div class=\"cntnt\"><img style=\"width:725px; height:338px;\" src=\"images/NEURO/101281_ConvexalSAHpatientRCVS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) CT scan of a 56-year-old man with severe headaches showing presence of superficial convexal SAH along bilateral posterior frontal lobes (arrows). <br />(B) Conventional angiogram performed a day later shows multiple vessel narrowings (arrows) involving the branches of the posterior and anterior cerebral arteries. <br />A repeat angiogram performed four weeks later showed restitution of normal arterial caliber (not shown).</div><div class=\"graphic_footnotes\">SAH: subarachnoid hemorrhage.</div><div class=\"graphic_reference\">From: Kumar S, Goddeau RP Jr, Selim MH, et al. Atraumatic convexal subarachnoid hemorrhage: Clinical presentation, imaging patterns, and etiologies. Neurology 2010; 74:893. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2010 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 101281 Version 2.0</div></div></div>"},"101287":{"type":"graphic_algorithm","displayName":"Management sharp object ingestion","title":"Algorithm for management of ingested sharp or pointed objects in children","html":"<div class=\"graphic\"><div style=\"width: 866px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of ingested sharp or pointed objects in children</div><div class=\"cntnt\"><img style=\"width:846px; height:380px;\" src=\"images/PEDS/101287_Mngmntshrpobjctingstn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computed tomography; MRI: magnetic resonance imaging; FB: foreign body.</div><div class=\"graphic_reference\">From: Kramer RE, Lerner DG, Lin T, et al. Management of ingested foreign bodies in children: A clinical report of the NASPGHAN Endoscopy Committee. J Pediatr Gastroenterol Nutr 2015; 60:562. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2015 ESPGHAN and NASPGHAN. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 101287 Version 3.0</div></div></div>"},"101288":{"type":"graphic_algorithm","displayName":"Management esophageal food impaction","title":"Algorithm for management of an esophageal food impaction","html":"<div class=\"graphic\"><div style=\"width: 509px\" class=\"figure\"><div class=\"ttl\">Algorithm for management of an esophageal food impaction</div><div class=\"cntnt\"><img style=\"width:489px; height:368px;\" src=\"images/PEDS/101288_Mngmntesphglfdimpct.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">EoE: eosinophilic esophagitis; FB: foreign body; PPI: proton pump inhibitor.</div><div class=\"graphic_reference\">From: Kramer RE, Lerner DG, Lin T, et al. Management of ingested foreign bodies in children: A clinical report of the NASPGHAN Endoscopy Committee. J Pediatr Gastroenterol Nutr 2015; 60:562. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2015 ESPGHAN and NASPGHAN. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 101288 Version 2.0</div></div></div>"},"101294":{"type":"graphic_figure","displayName":"Myeloid maturation arrest","title":"Myeloid compartments and maturation arrest","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Myeloid compartments and maturation arrest</div><div class=\"cntnt\"><img style=\"width:537px; height:352px;\" src=\"images/HEME/101294_Myeloid_maturation_arrest.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The absolute neutrophil count (ANC) determined from a standard CBC is only representative of the 5 percent of PMN in the vascular compartment (pink shading). The majority of functional PMN (bands and mature PMN, representing approximately 51 percent of total developing PMN) are in the maturation/storage pool in the bone marrow.&nbsp;In patients with an early myeloid arrest, the bone marrow reserve is depleted and there are no functional PMN available for delivery to the tissues. In contrast, when neutropenia occurs in the setting of late myeloid arrest or no arrest, mature PMN generally are available for fighting infection.</div><div class=\"graphic_footnotes\">PMN: polymorphonuclear neutrophils; CBC: complete blood count.</div><div id=\"graphicVersion\">Graphic 101294 Version 1.0</div></div></div>"},"101296":{"type":"graphic_table","displayName":"Neoadjuvant FOLFIRINOX in nonmetastatic pancreatic cancer","title":"Neoadjuvant FOLFIRINOX* in patients with locally advanced unresectable or borderline resectable pancreatic cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Neoadjuvant FOLFIRINOX* in patients with locally advanced unresectable or borderline resectable pancreatic cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Authors, year</td> <td class=\"subtitle1\">Number of patients</td> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Radiographic response rate</td> <td class=\"subtitle1\">Number of patients with subsequent resection</td> <td class=\"subtitle1\">R0 resections</td> <td class=\"subtitle1\">Median survival for resected patients (months)</td> </tr> <tr> <td>Conroy T, 2005</td> <td>11</td> <td>FOLFIRINOX</td> <td>3 of 11 (27%)</td> <td>0</td> <td>0</td> <td>&ndash;</td> </tr> <tr> <td>Peddi P, 2012</td> <td>19</td> <td>FOLFIRINOX then RT (n = 4)</td> <td>6 of 18<sup>&#916;</sup> (33%)</td> <td>8 of 23 (35%)</td> <td>Not reported</td> <td>Not reported</td> </tr> <tr> <td>Vasile E, 2012</td> <td>15</td> <td>FOLFIRINOX then CRT (n = 3)</td> <td>6 of 15 (40%)</td> <td>5 (33%)</td> <td>&ndash;</td> <td>30.1 (all 15 patients)</td> </tr> <tr> <td>Mahaseth H, 2013&nbsp;</td> <td>24</td> <td>FOLFIRINOX then CRT (n = 14)</td> <td>Not stated</td> <td>6 (25 percent)</td> <td>Not reported</td> <td>Not reported</td> </tr> <tr> <td>Hosein P, 2013<sup>&#182;</sup></td> <td>18</td> <td>FOLFIRINOX then CRT (n = 10)</td> <td>Not stated</td> <td>6 after CT, 3 after CRT (50%)</td> <td>8 of 9 (89%)</td> <td>Not reported</td> </tr> <tr> <td>Boone B, 2013</td> <td>13</td> <td>FOLFIRINOX then SBRT (n = 5)</td> <td>Not stated</td> <td>2 (15%)</td> <td>1 of 2 (50%)</td> <td>Not reported</td> </tr> <tr> <td>Christians K, 2014<sup>&#182;</sup></td> <td>18</td> <td>FOLFIRINOX then CRT</td> <td>Not stated</td> <td>12 (67%)</td> <td>12 of 12 (100%)</td> <td>7 of 12 alive at median 22 months after diagnosis</td> </tr> <tr> <td>Marthey L, 2015</td> <td>77</td> <td>FOLFIRINOX then RT (n = 24)</td> <td>22 of 77 (28%)</td> <td>28 (36%)</td> <td>25 of 28 (89%)</td> <td>24.9</td> </tr> <tr> <td>Ferrone C, 2015</td> <td>40</td> <td>FOLFIRINOX then CRT (n = 24)</td> <td>36 of 40 (90%)</td> <td>40 (100%)</td> <td>37 (92%)</td> <td>Approximately 32</td> </tr> <tr> <td>Blazer M, 2015</td> <td>43</td> <td>FOLFIRINOX then CRT (n = 23)</td> <td>9 of 40 (23%)<sup>&#167;</sup></td> <td>22 (51%)</td> <td>19 (86%)</td> <td>34.0</td> </tr> <tr> <td>Mellon E, 2015<sup>&#9674;</sup></td> <td>159</td> <td>FOLFIRINOX (n = 23), GTX (n = 94), Gem (n = 28), or Gem/Abrax (n = 8), then SBRT</td> <td>Not stated</td> <td>61 (38%)</td> <td>59 (96%)</td> <td>34.2</td> </tr> <tr> <td>Sadot E, 2015</td> <td>101</td> <td>FOLFIRINOX then CRT (n = 63)</td> <td>(29%)</td> <td>31 (31%)</td> <td>16 (55%)</td> <td>Not yet reached(median follow-up 12 months)</td> </tr> <tr> <td>Stein SM, 2016</td> <td>31</td> <td>FOLFIRINOX</td> <td>5 of 29 (17%)</td> <td>13 (42%)</td> <td>13 of 13 (100%)</td> <td>Not reported</td> </tr> <tr> <td>Kim S, 2016</td> <td>26</td> <td>FOLFIRINOX then RT (n = 4)</td> <td>13 of 26 (50%)</td> <td>26 of 26 (100%)</td> <td>24 of 92 (92%)</td> <td>Not yet reached (median follow-up 27.6 months)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">R0: complete; RT: radiation therapy; CRT: chemoradiotherapy; CT: computed tomography; SBRT: stereotactic body radiation therapy; GTX: gemcitabine plus docetaxel plus capecitabine; Gem: gemcitabine; Gem/Abrax: gemcitabine/nab-placitaxel.<br />* Short-term infusional fluorouracil plus leucovorin, irinotecan, and oxaliplatin.<br />¶ These series include patients treated with FOLFIRINOX for both unresectable or borderline resectable locally advanced pancreatic carcinoma.<br />Δ The 19<SUP>th</SUP> patient did not have imaging available after three cycles of chemotherapy.<br /><FONT class=lozenge>◊</FONT> Data not reported separately for each neoadjuvant chemotherapy regimen. However, of the 49 patients with locally advanced pancreatic cancer,&nbsp;5 responded sufficiently on imaging to undergo R0 resection after neoadjuvant therapy. All received FOLIRINOX.<br />§ Three patients died before restaging scans were completed.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Conroy T, Paillot B, François E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer – a Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005; 23:1228.</LI>&#xD;&#xA;<LI>Peddi PF, Lubner S, McWilliams R, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP 2012; 13:497.</LI>&#xD;&#xA;<LI>Vasile E, De Lio N, Cappelli C, et al. Neoadjuvant modified FOLFOXIRI in locally advanced pancreatic cancer. Ann Oncol 2012; 23 Suppl 9:ix241. Abstr 726P.</LI>&#xD;&#xA;<LI>Gunturu KS, Yao X, Cong X, et al. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Med Oncol 2013; 30:361.</LI>&#xD;&#xA;<LI>Hosein PJ, Macintyre J, Kawamura C, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline resectable locally advanced pancreatic adenocarcinoma. BMC Cancer 2012; 12:199.</LI>&#xD;&#xA;<LI>Boone BA, Steve J, Krasinskas AM, et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol 2013; 108:236.</LI>&#xD;&#xA;<LI>Christians KK, Tsai S, Mahmoud A, et al. <A href=\"http://www.ncbi.nlm.nih.gov/pubmed/24569947\" target=_blank>Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?</A> Oncologist 2014; 19:266.</LI>&#xD;&#xA;<LI>Marthey L, Sa-Cunha A, Blanc JF, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma. Results of an AGEO multicentric prospective observational cohort. Ann Oncol 2015; 22:295.</LI>&#xD;&#xA;<LI>Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 2015; 261:12.</LI>&#xD;&#xA;<LI>Blazer M, Wu C, Goldberg RM, et al. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol 2015; 22:1153.</LI>&#xD;&#xA;<LI>Mellon EA, Hoffe SE, Springett GM, et al. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol 2015; 54:979.</LI>&#xD;&#xA;<LI>Sadot E, Doussot A, O'Reilly EM, et al. FOLFIRINOX induction therapy for stage 3 pancreatic adenocarcinoma. Ann Surg Oncol 2015; 22:3512.</LI>&#xD;&#xA;<LI>Stein SM, James ES, Deng Y, et al. Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. Br J Cancer 2016; 114:737.</LI>&#xD;&#xA;<LI>Kim SS, Nakakura EK, Wang ZJ, et al. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? J Surg Oncol 2016; 114:587</LI></OL></div><div id=\"graphicVersion\">Graphic 101296 Version 6.0</div></div></div>"},"101297":{"type":"graphic_figure","displayName":"Pediatric obesity in US 2014","title":"Obesity in children and adolescents, United States, 2012-2014","html":"<div class=\"graphic\"><div style=\"width: 649px\" class=\"figure\"><div class=\"ttl\">Obesity in children and adolescents, United States, 2012-2014</div><div class=\"cntnt\"><img style=\"width:629px; height:688px;\" src=\"images/PEDS/101297_Pediatric_obesity_US_2012.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">BMI: body mass index.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Ogden CL, Carroll MD, Lawman HG, et al. Trends in Obesity Prevalence Among Children and Adolescents in the United States, 1988-1994 Through 2013-2014. JAMA 2016; 315:2292.</li>&#xD;&#xA;    <li>​Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014; 311:806.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 101297 Version 2.0</div></div></div>"},"101302":{"type":"graphic_diagnosticimage","displayName":"Galeazzi forearm fracture with DRUJ instability","title":"Galeazzi forearm fracture with DRUJ instability","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Galeazzi forearm fracture with DRUJ instability</div><div class=\"cntnt\"><img style=\"width:720px; height:519px;\" src=\"images/EM/101302_Glzz_frrm_frctr_DRUJ_instb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These radiographs show a Galeazzi fracture in an adult. The radial shaft fracture is obvious on both views (arrowhead on lateral view), as is the dramatic displacement of the distal ulna (arrow on lateral view), demonstrating complete disruption of the distal radioulnar joint (DRUJ).</div><div class=\"graphic_reference\">Courtesy of Nathaniel Nye, MD.</div><div id=\"graphicVersion\">Graphic 101302 Version 1.0</div></div></div>"},"101312":{"type":"graphic_figure","displayName":"Sinusitis antral puncture","title":"Sinusitis antral puncture","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Sinusitis antral puncture</div><div class=\"cntnt\"><img style=\"width:506px; height:453px;\" src=\"images/PEDS/101312_Sinusitis_antral_puncture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustration of antral puncture on coronal computed tomography image. A trocar is passed beneath the inferior turbinate, through the lateral nasal wall to reach the maxillary sinus antrum.</div><div class=\"graphic_reference\">Reprinted by permission of Edizioni Minerva Medica from Minerva Pediatrica 2015;67:357-68.</div><div id=\"graphicVersion\">Graphic 101312 Version 1.0</div></div></div>"},"101313":{"type":"graphic_diagnosticimage","displayName":"CT Pott puffy tumor","title":"Sagittal computed tomography demonstrating Pott puffy tumor","html":"<div class=\"graphic\"><div style=\"width: 750px\" class=\"figure\"><div class=\"ttl\">Sagittal computed tomography demonstrating Pott puffy tumor</div><div class=\"cntnt\"><img style=\"width:730px; height:739px;\" src=\"images/PEDS/101313_CT_pott_puffy_tumor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal computed tomography demonstrating subperiosteal abscess of the frontal bone (arrow) and soft tissue swelling if the forehead (Pott puffy tumor).</div><div id=\"graphicVersion\">Graphic 101313 Version 2.0</div></div></div>"},"101314":{"type":"graphic_table","displayName":"Indications for orthopedic referral for forearm fractures","title":"Indications for orthopedic referral for forearm fractures in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for orthopedic referral for forearm fractures in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">EMERGENT (&#60;1 hour)</td> <td class=\"subtitle1\">URGENT (&#60;24 hours)</td> <td class=\"subtitle1\">PRIORITY (24-72 hours)</td> </tr> <tr> <td>Arterial compromise (eg, severed artery)</td> <td>Ulnar shaft fracture with &#60;50% apposition or &#62;10 degrees angulation</td> <td>Isolated radial shaft fracture with any displacement</td> </tr> <tr> <td>Open fracture</td> <td>Forearm fracture with <strong>any</strong> DRUJ or PRUJ instability</td> <td>Both-bones fracture, even with minimal or no displacement</td> </tr> <tr> <td>&nbsp;</td> <td>Forearm fracture with peripheral nerve injury</td> <td>Isolated proximal third ulna fracture</td> </tr> <tr> <td>&nbsp;</td> <td>Both-bones fracture with displacement</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DRUJ: distal radioulnar joint; PRUJ: proximal radioulnar joint.<br />* The large majority of forearm fractures should be managed by orthopedic surgeons, in part because many are unstable and require surgical fixation. The injuries described here require more rapid orthopedic consultation.</div><div id=\"graphicVersion\">Graphic 101314 Version 1.0</div></div></div>"},"101316":{"type":"graphic_picture","displayName":"Functional brace for forearm fracture","title":"Functional brace for forearm fracture","html":"<div class=\"graphic\"><div style=\"width: 723px\" class=\"figure\"><div class=\"ttl\">Functional brace for forearm fracture</div><div class=\"cntnt\"><img style=\"width:703px; height:720px;\" src=\"images/EM/101316_Fnctnl_brc_frrm_frctr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following an initial period of full immobilization, a functional brace such as that pictured above is used to treat certain types of forearm fractures.</div><div class=\"graphic_reference\">Courtesy of Jennifer Aspinwall, MSOT, and Joshua Robertson, COTA.</div><div id=\"graphicVersion\">Graphic 101316 Version 2.0</div></div></div>"},"101318":{"type":"graphic_figure","displayName":"World prevalence of childhood overweight, 1960s to 1990s","title":"World prevalence of childhood overweight, 1960s to 1990s","html":"<div class=\"graphic\"><div style=\"width: 751px\" class=\"figure\"><div class=\"ttl\">World prevalence of childhood overweight, 1960s to 1990s</div><div class=\"cntnt\"><img style=\"width:731px; height:423px;\" src=\"images/PEDS/101318_Wrld_prv_chld_ovewt_1960_90.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prevalence of overweight or obesity, defined as body mass index ≥85th percentile for age and gender, using reference standards from the International Obesity Task Force (IOTF).</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 World Obesity Federation. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101318 Version 1.0</div></div></div>"},"101320":{"type":"graphic_picture","displayName":"Double sugar tong splint","title":"Double sugar tong splint","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Double sugar tong splint</div><div class=\"cntnt\"><img style=\"width:710px; height:544px;\" src=\"images/EM/101320_Double_sugar_tong_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A double sugar tong splint such as that pictured above is used to immobilize certain forearm fractures.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD and Nathaniel Nye, MD.</div><div id=\"graphicVersion\">Graphic 101320 Version 1.0</div></div></div>"},"101322":{"type":"graphic_figure","displayName":"World prevalence of childhood overweight, 2000s","title":"World prevalence of childhood overweight, 2000s","html":"<div class=\"graphic\"><div style=\"width: 751px\" class=\"figure\"><div class=\"ttl\">World prevalence of childhood overweight, 2000s</div><div class=\"cntnt\"><img style=\"width:731px; height:408px;\" src=\"images/PEDS/101322_Wrld_prvlnc_chld_ovrwt_2000.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Prevalence of overweight or obesity, defined as body mass index ≥85th percentile for age and gender, using reference standards from the International Obesity Task Force (IOTF). Data for most of the countries shown is from 2005 or later.*</div><div class=\"graphic_footnotes\">* Data from the late 1990s is used for Ethiopia, Iceland, Japan, Mali, Venezuela, and Zimbabwe.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2014 World Obesity Federation. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101322 Version 1.0</div></div></div>"},"101323":{"type":"graphic_picture","displayName":"Upper extremity cast loop","title":"Upper extremity cast loop","html":"<div class=\"graphic\"><div style=\"width: 729px\" class=\"figure\"><div class=\"ttl\">Upper extremity cast loop</div><div class=\"cntnt\"><img style=\"width:709px; height:732px;\" src=\"images/EM/101323_Upper_extremity_cst_loop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A loop of wire or plastic can be incorporated into an upper extremity cast and used to suspend the cast, as pictured above.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD and Nathaniel Nye, MD.</div><div id=\"graphicVersion\">Graphic 101323 Version 2.0</div></div></div>"},"101328":{"type":"graphic_picture","displayName":"Skin protection for noninvasive ventilation","title":"Skin protection for noninvasive ventilation","html":"<div class=\"graphic\"><div style=\"width: 702px\" class=\"figure\"><div class=\"ttl\">Skin protection for noninvasive ventilation</div><div class=\"cntnt\"><img style=\"width:682px; height:244px;\" src=\"images/EM/101328_Skn_prtct_no_invsv_vntlt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hydrocolloid dressing is placed beneath the noninvasive ventilation&nbsp;interface for skin protection (arrows).<br />(A) shows dressing in place before application of a nasal mask.<br />(B) Dressing can be seen beneath the oronasal mask.</div><div class=\"graphic_reference\">Courtesy of Joshua Nagler, MD.</div><div id=\"graphicVersion\">Graphic 101328 Version 3.0</div></div></div>"},"101329":{"type":"graphic_picture","displayName":"Cushioned face masks for noninvasive ventilation","title":"Cushioned face masks for noninvasive ventilation","html":"<div class=\"graphic\"><div style=\"width: 749px\" class=\"figure\"><div class=\"ttl\">Cushioned face masks for noninvasive ventilation</div><div class=\"cntnt\"><img style=\"width:729px; height:512px;\" src=\"images/EM/101329_Cshn_fc_msk_no_invsv_vntlt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Examples of masks with different cushions. The mask on the left (white) contains an air cushion. The mask on the right (blue) has a gel cushion.</div><div class=\"graphic_reference\">Courtesy of Joshua Nagler, MD.</div><div id=\"graphicVersion\">Graphic 101329 Version 2.0</div></div></div>"},"101330":{"type":"graphic_picture","displayName":"Affixing a noninvasive ventilation interface in a child","title":"Affixing a noninvasive ventilation interface in a child","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Affixing a noninvasive ventilation interface in a child</div><div class=\"cntnt\"><img style=\"width:376px; height:792px;\" src=\"images/PC/101330_Afx_no_invsv_vntl_infc_chld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) First the noninvasive ventilation&nbsp;interface is held in place manually.<br />(B) After the child has become comfortable, the straps can be secured.<br />(C) The noninvasive ventilation&nbsp;interface is held in place until the straps are in place.</div><div class=\"graphic_reference\">Courtesy of Joshua Nagler, MD.</div><div id=\"graphicVersion\">Graphic 101330 Version 2.0</div></div></div>"},"101331":{"type":"graphic_picture","displayName":"Head cap for noninvasive ventilation in an infant","title":"Head cap to support use of a face mask for noninvasive ventilation in an infant","html":"<div class=\"graphic\"><div style=\"width: 662px\" class=\"figure\"><div class=\"ttl\">Head cap to support use of a face mask for noninvasive ventilation in an infant</div><div class=\"cntnt\"><img style=\"width:642px; height:519px;\" src=\"images/EM/101331_Hd_cp_no_invsv_vntlt_infnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A head cap can provide a comfortable and more secure fit in infants receiving noninvasive ventilation using a face mask interface. </div><div class=\"graphic_reference\">Courtesy of Joshua Nagler, MD.</div><div id=\"graphicVersion\">Graphic 101331 Version 3.0</div></div></div>"},"101333":{"type":"graphic_picture","displayName":"Noninvasive ventilator display","title":"Noninvasive ventilator display","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Noninvasive ventilator display</div><div class=\"cntnt\"><img style=\"width:520px; height:738px;\" src=\"images/EM/101333_No_invsv_vntltr_dsply.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Display from a bilevel positive airway pressure machine. Settings for inspiratory positive airway pressure (IPAP) and back-up rate appear at the top lower left row of setting; expiratory positive airway pressure (EPAPA) and inspired oxygen (FiO<sub>2</sub>) are shown on the bottom lower left row.</div><div id=\"graphicVersion\">Graphic 101333 Version 2.0</div></div></div>"},"101334":{"type":"graphic_figure","displayName":"Pulmonary atresia with intact ventricular septum (PA/IVS)","title":"Pulmonary atresia with intact ventricular septum (PA/IVS)","html":"<div class=\"graphic\"><div style=\"width: 475px\" class=\"figure\"><div class=\"ttl\">Pulmonary atresia with intact ventricular septum (PA/IVS)</div><div class=\"cntnt\"><img style=\"width:455px; height:446px;\" src=\"images/PEDS/101334_Pulmonary_atresia_IVS.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 101334 Version 2.0</div></div></div>"},"101336":{"type":"graphic_picture","displayName":"Urticaria dark skin","title":"Urticaria","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Urticaria</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101336_Urticaria_drk_skn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A well-circumscribed plaque, slightly lighter-than-normal skin is visible on the neck of this patient with urticaria.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101336 Version 1.0</div></div></div>"},"101337":{"type":"graphic_picture","displayName":"Urticaria dark skin 2","title":"Urticaria","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Urticaria</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101337_Urticaria_dark_skin_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Large, well-circumscribed plaques on the chest of this patient with urticaria.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101337 Version 1.0</div></div></div>"},"101338":{"type":"graphic_figure","displayName":"Causes of death prevalent dialysis patients 2009 through 2011","title":"Causes of death in prevalent dialysis patients, 2009 through 2011","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Causes of death in prevalent dialysis patients, 2009 through 2011</div><div class=\"cntnt\"><img style=\"width:514px; height:530px;\" src=\"images/NEPH/101338_Cs_dth_prvln_dlys_2009_2011.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Incident and prevalent dialysis patients, 2009 through 2011.</div><div class=\"graphic_footnotes\">AMI: acute myocardial infarction; CHF: coronary heart failure; CVA: cardiovascular accident.</div><div class=\"graphic_reference\">Reproduced from: US Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD 2013.</div><div id=\"graphicVersion\">Graphic 101338 Version 1.0</div></div></div>"},"101339":{"type":"graphic_picture","displayName":"Henoch-Schönlein purpura dark skin","title":"Henoch-Schönlein purpura","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Henoch-Sch&ouml;nlein purpura</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101339_HnchSchnlnprprdrkskn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Purpuric lesions are clearly visible on the plantar surface but less obvious on the lower leg&nbsp;in this patient with Henoch-Schönlein purpura. </div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101339 Version 2.0</div></div></div>"},"101340":{"type":"graphic_figure","displayName":"HF adjusted rates of hospital admissions","title":"Adjusted rates of hospital admissions, by modality and diagnosis code type: Heart failure","html":"<div class=\"graphic\"><div style=\"width: 665px\" class=\"figure\"><div class=\"ttl\">Adjusted rates of hospital admissions, by modality and diagnosis code type: Heart failure</div><div class=\"cntnt\"><img style=\"width:645px; height:392px;\" src=\"images/NEPH/101340_HF_adjst_rts_hsptl_admssn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Period prevalent ESRD patients. Adjusted for age, gender, race, and primary diagnosis.</div><div class=\"graphic_footnotes\">CHF: coronary heart failure; ESRD: end-stage renal disease.</div><div class=\"graphic_reference\">Reproduced from: US Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD 2013.</div><div id=\"graphicVersion\">Graphic 101340 Version 1.0</div></div></div>"},"101341":{"type":"graphic_figure","displayName":"AMI adjusted rates of hospital admissions","title":"Adjusted rates of hospital admissions, by modality and diagnosis code type: Acute myocardial infarction","html":"<div class=\"graphic\"><div style=\"width: 821px\" class=\"figure\"><div class=\"ttl\">Adjusted rates of hospital admissions, by modality and diagnosis code type: Acute myocardial infarction</div><div class=\"cntnt\"><img style=\"width:801px; height:342px;\" src=\"images/NEPH/101341_AMI_adjst_rts_hsptl_admssn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Period prevalent dialysis patients. Adjusted for age, gender, race, and primary diagnosis.</div><div class=\"graphic_footnotes\">AMI: acute myocardial infarction.</div><div class=\"graphic_reference\">Reproduced from: US Renal Data System. USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, Bethesda, MD 2013.</div><div id=\"graphicVersion\">Graphic 101341 Version 1.0</div></div></div>"},"101342":{"type":"graphic_figure","displayName":"CVD burden in advancing CKD","title":"Cardiovascular disease burden in advancing chronic kidney disease","html":"<div class=\"graphic\"><div style=\"width: 922px\" class=\"figure\"><div class=\"ttl\">Cardiovascular disease burden in advancing chronic kidney disease</div><div class=\"cntnt\"><img style=\"width:902px; height:341px;\" src=\"images/NEPH/101342_CVD_burden_advanc_CKD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A conceptual framework of contributors to the cardiovascular disease burden in patients with advancing chronic kidney disease.</div><div class=\"graphic_footnotes\">CKD: chronic kidney disease; ESRD: end-stage renal disease.</div><div class=\"graphic_reference\">Reproduced from: Herzog CA, Shroff GR. Atherosclerotic versus nonatherosclerotic evaluation: The Ying and Yang of cardiovascular imaging in advanced chronic kidney disease. JACC Cardiovasc Imaging 2014; 7:729. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101342 Version 1.0</div></div></div>"},"101344":{"type":"graphic_diagnosticimage","displayName":"Retained products of conception causing secondary PPH","title":"Retained products of conception causing secondary PPH","html":"<div class=\"graphic\"><div style=\"width: 1093px\" class=\"figure\"><div class=\"ttl\">Retained products of conception causing secondary PPH</div><div class=\"cntnt\"><img style=\"width:1073px; height:436px;\" src=\"images/OBGYN/101344_RtnprdctcncpcsscndPPH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Transvaginal color Doppler shows an echogenic area with blood flow, consistent&nbsp;with retained products of conception. Spectral Doppler&nbsp;shows very high velocity (over 120 cm/sec).<br />(B) Angiogram shows early filling vein (arrow).&nbsp;The&nbsp;patient was treated with embolization prior to curettage&nbsp;because of the significant blood flow to the retained products.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 101344 Version 1.0</div></div></div>"},"101345":{"type":"graphic_diagnosticimage","displayName":"Blood clot in postpartum uterus","title":"Blood clot in postpartum uterus","html":"<div class=\"graphic\"><div style=\"width: 791px\" class=\"figure\"><div class=\"ttl\">Blood clot in postpartum uterus</div><div class=\"cntnt\"><img style=\"width:771px; height:294px;\" src=\"images/OBGYN/101345_Bloodclotpstprtmutrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with secondary postpartum bleeding.<br />(A) Transvaginal sonogram shows fluid in the endometrial cavity with some echogenic areas both anterior and posterior.<br />(B) Power Doppler image shows normal blood flow in the myometrium, no blood flow to these areas in the endometrium, which is consistent with either nonvascularized retained products of conception or blood clot; however, the appearance in this case is most suggestive of blood clot.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 101345 Version 1.0</div></div></div>"},"101346":{"type":"graphic_diagnosticimage","displayName":"Postpartum endometritis associated with bleeding","title":"Postpartum endometritis associated with bleeding","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Postpartum endometritis associated with bleeding</div><div class=\"cntnt\"><img style=\"width:725px; height:297px;\" src=\"images/OBGYN/101346_Pstprtmendmtrtassctbleed.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Postpartum patient with pain, bleeding, and fever.<br />(A) Transabdominal sagittal image of the uterus shows fluid within the endometrial cavity and a shaggy irregular appearance of the endometrium anteriorly.<br />(B) Power Doppler image shows no blood flow to this area of the&nbsp;endometrium, which rules out retained vascularized products of conception in this area. The patient was treated for endometritis and improved clinically.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 101346 Version 1.0</div></div></div>"},"101347":{"type":"graphic_diagnosticimage","displayName":"Vascularized retained products of conception with secondary PPH","title":"Vascularized retained products of conception with secondary postpartum hemorrhage","html":"<div class=\"graphic\"><div style=\"width: 749px\" class=\"figure\"><div class=\"ttl\">Vascularized retained products of conception with secondary postpartum hemorrhage</div><div class=\"cntnt\"><img style=\"width:729px; height:255px;\" src=\"images/OBGYN/101347_VsclrrtnprctcncpsndPPH.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Transvaginal image shows a heterogeneous mass (between caliper markers)&nbsp;in the endometrium&nbsp;of a patient with secondary postpartum hemorrhage.<br />(B) Transabdominal image shows a large amount of blood flow to this endometrial region. This combination of findings is consistent with vascularized retained products of conception.</div><div class=\"graphic_reference\">Courtesy of Deborah Levine, MD.</div><div id=\"graphicVersion\">Graphic 101347 Version 1.0</div></div></div>"},"101355":{"type":"graphic_picture","displayName":"Alumi-foam trigger finger splint","title":"Trigger finger splint","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">Trigger finger splint</div><div class=\"cntnt\"><img style=\"width:784px; height:584px;\" src=\"images/RHEUM/101355_Alm_fm_trggr_fngr_splnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Example of a simple splint for trigger finger that can be easily made using alumi-foam splinting strips. Measure from the proximal palm to the distal aspect of the middle phalanx, cut to length, trim and smooth sharp edges, and place a slight bend (about 10 degrees) under the MCP joint. Tape it to the finger and palm. This restricts flexion at the MCP joint but allows motion at the DIP joint.</div><div class=\"graphic_footnotes\">MCP: metacarpophalangeal; DIP: distal interphalangeal.</div><div class=\"graphic_reference\">Courtesy of Kevin deWeber, MD.</div><div id=\"graphicVersion\">Graphic 101355 Version 1.0</div></div></div>"},"101356":{"type":"graphic_picture","displayName":"Vitiligo macular lesion","title":"Vitiligo","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Vitiligo</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101356_Vitiligo_macular_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Depigmented macular lesions in a patient with vitiligo.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101356 Version 1.0</div></div></div>"},"101357":{"type":"graphic_table","displayName":"Clinical criteria and genetics of familial gastric CA syndromes","title":"Clinical criteria, recommended screening, and inherited alterations of familial gastric cancer syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical criteria, recommended screening, and inherited alterations of familial gastric cancer syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup><colgroup span=\"2\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Clinical criteria</td> <td class=\"subtitle1\">Genetic screening</td> <td class=\"subtitle1\">Alterations described</td> </tr> <tr> <td rowspan=\"2\"><strong>Hereditary diffuse gastric cancer</strong></td> <td> <p>Two or more cases of gastric cancer, one confirmed case of diffuse gastric cancer in someone younger than 50 years</p> <p>Three or more confirmed diffuse gastric cancer cases in first-degree or second-degree relatives, independent of age of onset</p> Diffuse gastric cancer before age 40 years without a family history</td> <td> <p>Sequencing of <em>CDH1</em> coding sequences</p> Multiplex ligation-dependent probe amplification (large <em>CDH1</em> rearrangements)</td> <td>Mutations throughout the <em>CDH1</em> gene and deletions mainly implicating flanking untranslated regions </td> </tr> <tr> <td>Personal or family history of diffuse gastric cancer and lobular breast cancer, one of which must be diagnosed before age 50 years</td> <td>Sequencing of <em>CTNNA1</em> coding sequences</td> <td>One germline truncating mutation in <em>CTNNA1</em></td> </tr> <tr> <td><strong>Gastric adenocarcinoma and proximal polyposis of the stomach</strong></td> <td> <p>Gastric polyps restricted to the body and fundus with no evidence of colorectal or duodenal polyposis</p> <p>More than 100 polyps carpeting the proximal stomach in the index case or more than 30 polyps in a first-degree relative of another case</p> <p>Mainly fundic gastric polyps, some with regions of dysplasia (or a family member with either dysplastic fundic gastric polyps or gastric adenocarcinoma)</p> <p>Autosomal dominant pattern of inheritance</p> Exclusions include other heritable gastric polyposis syndromes and use of proton pump inhibitors*</td> <td>No screening available</td> <td>No inherited mutations so far</td> </tr> <tr> <td><strong>Familial intestinal gastric cancer</strong></td> <td> <p>Two or more cases of gastric cancer in first-degree or second-degree relatives, with at least one confirmed case of intestinal histology in someone younger than 50 years</p> Three or more confirmed cases of intestinal gastric cancer in first-degree or second-degree relatives, independent of age</td> <td>No screening available</td> <td>No inherited mutations so far</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Proton pump inhibitors can induce a proximal polyposis of the stomach that may mimic a gastric adenocarcinoma. Patients taking these drugs should undergo a repeat endoscopy off-therapy to confirm the diagnosis of gastric adenocarcinoma versus proximal polyposis of the stomach.</div><div class=\"graphic_reference\">Reproduced from: Olivieria C, Pinhiero H, Figueiredo J, et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol 2015; 16:e60. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101357 Version 3.0</div></div></div>"},"101359":{"type":"graphic_picture","displayName":"Factitial dermatitis excoriated","title":"Factitial dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Factitial dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101359_Factitial_dermatitis_excrt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Excoriated lesions and postinflammatory hyperpigmentation in a patient with factitial dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101359 Version 1.0</div></div></div>"},"101364":{"type":"graphic_table","displayName":"Initial pharmacotherapy for RLS in adults","title":"Initial pharmacotherapy for chronic persistent restless legs syndrome (RLS) in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Initial pharmacotherapy for chronic persistent restless legs syndrome (RLS) in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Initial daily dose</td> <td class=\"subtitle1\">Minimum interval to assess effect before increasing dose</td> <td class=\"subtitle1\">Usual effective daily dose range*</td> <td class=\"subtitle1\">Metabolism and clearance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Dopamine agonists</td> </tr> <tr> <td class=\"indent1\">Pramipexole (IR)</td> <td>0.125 mg 2 to 3 hours before bedtime</td> <td>2 to 3 days</td> <td>0.25 to 0.5 mg</td> <td> <ul> <li>&#62;90% renally excreted as unchanged&nbsp;drug </li> <li>Use longer titration interval (ie, 14 days) in moderate to severe renal impairment and in older adults </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Ropinirole (IR)</td> <td>0.25 mg 1 to 3 hours before bedtime</td> <td>2 to 3 days</td> <td>2 to 4 mg</td> <td> <ul> <li>~90% metabolized, primarily by CYP1A2 </li> <li>Not studied in moderate to severe hepatic impairment; increased levels are likely </li> <li>Use with caution in severe renal impairment (maximum 3 mg daily in dialysis-dependent patients) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Rotigotine transdermal patch</td> <td>1 mg per 24 hour patch</td> <td>5 to 7 days</td> <td>2 to 3 mg per 24 hour patch</td> <td> <ul> <li>Hepatic metabolism (multiple substrates) and glucuronidation </li> <li>No dose adjustments&nbsp;recommended in renal or hepatic impairment&nbsp;for the dose ranges provided </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Alpha-2-delta calcium channel ligands</td> </tr> <tr> <td class=\"indent1\">Gabapentin (IR)</td> <td>100 to 300 mg 2 hours before bedtime</td> <td>5 to 7 days</td> <td>600 to 1800 mg in two divided doses (late afternoon and 2 hours before bedtime)</td> <td> <ul> <li>&#62;95% renally excreted as unchanged drug </li> <li>Dose adjustment is needed in renal impairment<sup>&#182;</sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Gabapentin enacarbil (ER)</td> <td>300 to 600 mg in early evening (eg, ~5 PM)</td> <td>No titration (doses &#8805;600 mg per day provided no added benefit)</td> <td>600 mg</td> <td> <ul> <li>&#62;95% renally excreted as unchanged drug </li> <li>Dose adjustment is needed in renal impairment<sup><span style=\"font-size: 13px;\">&#182;</span></sup> </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Pregabalin (IR)</td> <td>50 to 75 mg 1 to 3 hours before bedtime</td> <td>5 to 7 days</td> <td>150 to 450 mg</td> <td> <ul> <li>&#62;95% renally excreted as unchanged drug </li> <li>Dose adjustment is needed in renal impairment<sup><span style=\"font-size: 13px;\">&#182;</span></sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IR: immediate release; ER: extended release; US FDA: US Food and Drug Administration.<br />* Long-term use of dopaminergic drugs for RLS can result in augmentation. To&nbsp;decrease risk, use lowest effective dose&nbsp;and do not exceed&nbsp;upper dose range.&nbsp;Refer to UpToDate topic review for details.<br />¶ Specific dose adjustment recommendations for patients with impaired kidney function are provided in the Lexicomp drug specific monographs included within UpToDate.</div><div id=\"graphicVersion\">Graphic 101364 Version 5.0</div></div></div>"},"101369":{"type":"graphic_picture","displayName":"Glenohumeral internal rotation measurement","title":"Glenohumeral internal rotation measurement","html":"<div class=\"graphic\"><div style=\"width: 766px\" class=\"figure\"><div class=\"ttl\">Glenohumeral internal rotation measurement</div><div class=\"cntnt\"><img style=\"width:746px; height:540px;\" src=\"images/EM/101369_Glnhmrl_intrnl_rttn_msrmt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Internal rotation of the glenohumeral joint is measured with the shoulder abducted 90 degrees and the elbow flexed 90 degrees. Loss of internal rotation of 20 degrees or more compared to the non-throwing shoulder is generally considered abnormal.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 101369 Version 1.0</div></div></div>"},"101370":{"type":"graphic_picture","displayName":"Glenohumeral external rotation measurement","title":"Glenohumeral external rotation measurement","html":"<div class=\"graphic\"><div style=\"width: 793px\" class=\"figure\"><div class=\"ttl\">Glenohumeral external rotation measurement</div><div class=\"cntnt\"><img style=\"width:773px; height:531px;\" src=\"images/EM/101370_Glnhmrl_extrnl_rttn_msrmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Glenohumeral external rotation is measured with the shoulder abducted 90 degrees and the elbow flexed 90 degrees.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 101370 Version 1.0</div></div></div>"},"101371":{"type":"graphic_movie","displayName":"Glenohumeral rotation measurement","title":"Glenohumeral rotation measurement","html":"<div class=\"graphic normal\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Glenohumeral rotation measurement</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/101371_Glenohumrotatmeasurevid.mp4\" style=\"width:608px;height:352px\"></div><img style=\"width:612px; height:342px;\" src=\"images/EM/101371_Glenohumrotatmeasureimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Measurement of glenohumeral rotation is part of the assessment of symptomatic throwers. Significantly reduced internal rotation predisposes to injury.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 101371 Version 1.0</div></div></div>"},"101372":{"type":"graphic_diagnosticimage","displayName":"Proximal humeral epiphysiolysis","title":"Proximal humeral epiphysiolysis (little league shoulder)","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">Proximal humeral epiphysiolysis (little league shoulder)</div><div class=\"cntnt\"><img style=\"width:792px; height:375px;\" src=\"images/EM/101372_Prxml_hmrl_epphyslys.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The radiographs above show the affected (A)&nbsp;and unaffected (B)&nbsp;shoulders of a young pitcher with proximal humeral epiphysiolysis, or little league shoulder. Note the abnormally widened physis (arrow) of the affected shoulder.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 101372 Version 1.0</div></div></div>"},"101373":{"type":"graphic_picture","displayName":"Valgus stress test of elbow","title":"Valgus stress test of elbow","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Valgus stress test of elbow</div><div class=\"cntnt\"><img style=\"width:726px; height:572px;\" src=\"images/EM/101373_Vlgs_strss_tst_elbw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the patient's elbow passively flexed to about 30 degrees and their forearm in neutral position, the examiner applies a valgus stress to the elbow. A soft endpoint or palpable joint widening of 2 mm or more compared to the opposite, unaffected elbow marks a positive test.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 101373 Version 1.0</div></div></div>"},"101374":{"type":"graphic_movie","displayName":"Valgus stress test of elbow movie","title":"Valgus stress test of elbow movie","html":"<div class=\"graphic normal\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Valgus stress test of elbow movie</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/101374_Valgusstresstestelbwvid.mp4\" style=\"width:608px;height:352px\"></div><img style=\"width:612px; height:422px;\" src=\"images/EM/101374_Valgusstresstestelbwimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The valgus stress test is used to detect an ulnar collateral ligament injury of the elbow.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 101374 Version 1.0</div></div></div>"},"101376":{"type":"graphic_movie","displayName":"Moving stress test of elbow","title":"Moving stress test of elbow","html":"<div class=\"graphic normal\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Moving stress test of elbow</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/101376_Movingstresstestelbwvid.mp4\" style=\"width:608px;height:352px\"></div><img style=\"width:612px; height:402px;\" src=\"images/EM/101376_Movingstresstestelbwimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The moving stress test is used to help diagnose ulnar collateral ligament injury of the elbow. It is performed with the patient's upper extremity in a position that approximates the cocking phase of throwing.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 101376 Version 1.0</div></div></div>"},"101377":{"type":"graphic_algorithm","displayName":"Evaluation of goiter in adults without obstructive symptoms","title":"Evaluation of goiter in adults without obstructive symptoms","html":"<div class=\"graphic\"><div style=\"width: 821px\" class=\"figure\"><div class=\"ttl\">Evaluation of goiter in adults without obstructive symptoms</div><div class=\"cntnt\"><img style=\"width:801px; height:657px;\" src=\"images/ENDO/101377_Evl_gtr_wo_obstctv_symp_ed1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TSH: thyroid-stimulating hormone; T4: thyroxine; T3: triiodothyronine; TPO: thyroid peroxidase; TRAb: TSH-receptor antibodies.<br />* Focal areas of possible nodularity on thyroid scan (or exam) should be evaluated with ultrasound.<br />¶ We do not routinely obtain a thyroid ultrasound in patients with Hashimoto's thyroiditis. Ultrasound should be reserved for such patients with larger goiters, thyroid asymmetry, or a concern for thyroid nodularity.</div><div id=\"graphicVersion\">Graphic 101377 Version 3.0</div></div></div>"},"101378":{"type":"graphic_picture","displayName":"Moving stress test of elbow at 70 and 120 degrees","title":"Moving stress test of elbow at 70 and 120 degrees","html":"<div class=\"graphic\"><div style=\"width: 742px\" class=\"figure\"><div class=\"ttl\">Moving stress test of elbow at 70 and 120 degrees</div><div class=\"cntnt\"><img style=\"width:722px; height:323px;\" src=\"images/EM/101378_Mv_strss_tst_elbw_70_120_dg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the presence of an ulnar collateral ligament (UCL) injury, the moving stress test of the elbow typically elicits pain at the UCL with elbow flexed between 70 degrees (A)&nbsp;and 120 degrees (B).</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 101378 Version 1.0</div></div></div>"},"101380":{"type":"graphic_movie","displayName":"Milking maneuver for elbow UCL injury movie","title":"Milking maneuver for elbow UCL injury movie","html":"<div class=\"graphic normal\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Milking maneuver for elbow UCL injury movie</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/EM/101380_Milkingmaneuverelbowvid.mp4\" style=\"width:608px;height:352px\"></div><img style=\"width:612px; height:594px;\" src=\"images/EM/101380_Milkingmaneuverelbowimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The milking maneuver is used to help diagnose ulnar (or medial) collateral ligament injury of the elbow.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 101380 Version 1.0</div></div></div>"},"101381":{"type":"graphic_picture","displayName":"Xerosis dark skin","title":"Xerosis (dry skin)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Xerosis (dry skin)</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/101381_Xerosis_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reduced skin shininess and ashy appearance in this patient with extreme skin dryness.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101381 Version 1.0</div></div></div>"},"101382":{"type":"graphic_picture","displayName":"Postinflammatory hypopigmentation","title":"Postinflammatory hypopigmentation in a patient with psoriasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Postinflammatory hypopigmentation in a patient with psoriasis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101382_Pstnflmmtry_hyppgmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101382 Version 1.0</div></div></div>"},"101384":{"type":"graphic_diagnosticimage","displayName":"Bennett lesion of glenoid","title":"Bennett lesion of glenoid","html":"<div class=\"graphic\"><div style=\"width: 656px\" class=\"figure\"><div class=\"ttl\">Bennett lesion of glenoid</div><div class=\"cntnt\"><img style=\"width:636px; height:633px;\" src=\"images/EM/101384_Bennett_lesion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Bennett lesion, shown here in an&nbsp;MRI&nbsp;(arrow), is an abnormal mineralization that develops at the posteroinferior glenoid in throwing athletes.</div><div class=\"graphic_footnotes\">MRI: Magnetic resonance imaging</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 101384 Version 1.0</div></div></div>"},"101386":{"type":"graphic_picture","displayName":"Urine microscopy showing decoy cells","title":"Urine microscopy showing decoy cells","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urine microscopy showing decoy cells</div><div class=\"cntnt\"><img style=\"width:412px; height:235px;\" src=\"images/NEPH/101386_Urn_microscopy_show_dcy_cll.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Urine cytology sediment demonstrates three \"decoy\" cells, characterized by large viral nuclear inclusions that replace the normal chromatin (Papanicolaou stain). The nuclear inclusion is formed by dark, smudged material representing thousands of newly formed virions (V). Electron microscopy (insert) shows the contrast between the inclusion (V) and the darker surrounding chromatin.</div><div class=\"graphic_reference\">Courtesy of Cinthia Drachenberg, MD.</div><div id=\"graphicVersion\">Graphic 101386 Version 1.0</div></div></div>"},"101387":{"type":"graphic_diagnosticimage","displayName":"Olecranon stress fracture on MRI","title":"Olecranon stress fracture on magnetic resonance imaging","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Olecranon stress fracture on magnetic resonance imaging</div><div class=\"cntnt\"><img style=\"width:550px; height:548px;\" src=\"images/EM/101387_Olecranon_stress_fracture.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The MRI image above shows an olecranon stress fracture. Each arrow indicates one end of the fracture line.</div><div class=\"graphic_footnotes\">MRI: Magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 101387 Version 2.0</div></div></div>"},"101388":{"type":"graphic_table","displayName":"Hemodynamic values when RA pressure is increased","title":"Hemodynamic values on pulmonary artery catheter associated with the causes of an elevated right atrial pressure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hemodynamic values on pulmonary artery catheter associated with the causes of an elevated right atrial pressure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">RVp</td> <td class=\"subtitle1\">PAp</td> <td class=\"subtitle1\">CI</td> <td class=\"subtitle1\">SVR</td> <td class=\"subtitle1\">PAOP</td> </tr> <tr class=\"divider_bottom\"> <td><strong>RV pathology (eg, infarction, reduced contractility)</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;*</td> <td class=\"centered\">&#8596;/&#8595;</td> <td class=\"centered\">&#8596;/&#8593;</td> <td class=\"centered\">&#8596;/&#8593;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pulmonary arterial hypertension</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;*</td> <td class=\"centered\">&#8596;/&#8595;</td> <td class=\"centered\">&#8596;/&#8593;</td> <td class=\"centered\">&#8596;/&#8593;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pulmonic stenosis</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8596;</td> <td class=\"centered\">&#8596;</td> <td class=\"centered\">&#8596;</td> <td class=\"centered\">&#8596;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Left-to-right shunts</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8596;</td> <td class=\"centered\">&#8596;</td> <td class=\"centered\">&#8596;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Tricuspid stenosis</strong></td> <td class=\"centered\">&#8596;/&#8595;</td> <td class=\"centered\">&#8596;</td> <td class=\"centered\">&#8596;</td> <td class=\"centered\">&#8596;</td> <td class=\"centered\">&#8596;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Tricuspid regurgitation</strong></td> <td class=\"centered\">&#8596;</td> <td class=\"centered\">&#8596;</td> <td class=\"centered\">&#8596;</td> <td class=\"centered\">&#8596;</td> <td class=\"centered\">&#8596;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Tamponade/restrictive or constrictive cardiomyopathies</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8596;</td> <td class=\"centered\">&#8596;/&#8595;</td> <td class=\"centered\">&#8596;/&#8593;</td> <td class=\"centered\">&#8596;/&#8593;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>LV systolic heart failure</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8595;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> </tr> <tr> <td><strong>Hypervolemia</strong></td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8593;</td> <td class=\"centered\">&#8596;/&#8593;</td> <td class=\"centered\">&#8593;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RVp: RV pressure; PAp: pulmonary artery pressure; CI: cardiac index; SVR: systemic vascular resistance; PAOP: pulmonary artery occlusion pressure; RV: right ventricle; ↑: increased; ↔: normal; ↓: decreased; LV: left ventricle.<br />* In the setting of RV pathology, the elevation in PAp is mild. In contrast, the elevation in PAp is much greater in those with pulmonary arterial hypertension.</div><div id=\"graphicVersion\">Graphic 101388 Version 2.0</div></div></div>"},"101393":{"type":"graphic_diagnosticimage","displayName":"CTA showing focal aortic dissection","title":"Diagnosis and treatment of focal aortic dissection using CTA","html":"<div class=\"graphic\"><div style=\"width: 694px\" class=\"figure\"><div class=\"ttl\">Diagnosis and treatment of focal aortic dissection using CTA</div><div class=\"cntnt\"><img style=\"width:674px; height:476px;\" src=\"images/RADIOL/101393_CTA_shwng_fcl_artc_dssctn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CTA in the transverse plane through the mid thorax (A) shows a focal dissection of the aorta (arrow). Image B is a magnified view and shows a curvilinear accumulation of extraluminal contrast in the wall of the aorta (arrow). Image C is a sagittal reconstruction and shows a short focal dissection of the descending thoracic aorta (arrow). Image D is a magnified view showing localized dissection (arrow). Image E is a reconstruction of the aorta showing a stent in the descending thoracic aorta (arrow).</div><div class=\"graphic_footnotes\">CTA: computed tomography angiography.</div><div id=\"graphicVersion\">Graphic 101393 Version 1.0</div></div></div>"},"101394":{"type":"graphic_diagnosticimage","displayName":"CT of  penetrating ulcer of the aorta","title":"Penetrating atherosclerotic ulcer of the thoracic aorta on CT","html":"<div class=\"graphic\"><div style=\"width: 871px\" class=\"figure\"><div class=\"ttl\">Penetrating atherosclerotic ulcer of the thoracic aorta on CT</div><div class=\"cntnt\"><img style=\"width:851px; height:376px;\" src=\"images/RADIOL/101394_CT_penetrat_ulcr_art.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the descending thoracic aorta shows a penetrating ulcer extending into the wall of the aorta (arrow). Image B is a magnified view and shows the mouth of the ulcer, which then extends into and expands the wall of the aorta (arrowheads).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 101394 Version 1.0</div></div></div>"},"101395":{"type":"graphic_diagnosticimage","displayName":"CT of penetrating ulcer with mural hematoma","title":"Penetrating ulcer with mural hematoma on CT","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Penetrating ulcer with mural hematoma on CT</div><div class=\"cntnt\"><img style=\"width:541px; height:488px;\" src=\"images/RADIOL/101395_CT_pntrt_ulcer_mrl_hmtm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the arch of the aorta (A) shows a penetrating ulcer (arrowhead). Image B is a magnified view and shows a penetrating ulcer (arrowhead) and a small mural hematoma (arrow). Image C is a coronal reconstruction, magnified in D, and shows a focal penetrating ulcer (arrowhead), with a small mural hematoma (D, arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 101395 Version 1.0</div></div></div>"},"101396":{"type":"graphic_diagnosticimage","displayName":"CT aortic dissection complicating penetrating ulcer","title":"Aortic dissection complicating penetrating ulcer on CT","html":"<div class=\"graphic\"><div style=\"width: 953px\" class=\"figure\"><div class=\"ttl\">Aortic dissection complicating penetrating ulcer on CT</div><div class=\"cntnt\"><img style=\"width:933px; height:339px;\" src=\"images/RADIOL/101396_CT_artc_dssc_cmpl_pnt_ulcr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan performed five days following identification of a penetrating ulcer with hematoma (arrowhead) now shows an aortic dissection (arrow). Image B shows an intimal flap (arrows) involving the ascending aorta and hemopericardium (asterisk). Image C shows the intimal flap in the descending aorta (arrows).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 101396 Version 1.0</div></div></div>"},"101397":{"type":"graphic_diagnosticimage","displayName":"Wide mouth penetrating ulcer of aorta with rupture","title":"Penetrating ulcer with mural hematoma and aortic rupture","html":"<div class=\"graphic\"><div style=\"width: 943px\" class=\"figure\"><div class=\"ttl\">Penetrating ulcer with mural hematoma and aortic rupture</div><div class=\"cntnt\"><img style=\"width:923px; height:421px;\" src=\"images/RADIOL/101397_Wd_mth_pntrt_ulcr_art_rptr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A magnified view of the abdominal aorta (A) shows a wide mouthed penetrating ulcer (asterisk) with a mural hematoma (arrows). Image B shows a large high density mural hematoma (arrows), high density hematoma in the right psoas muscle (asterisk), and extension of the bleed into the surrounding soft tissues (arrowheads).</div><div id=\"graphicVersion\">Graphic 101397 Version 1.0</div></div></div>"},"101398":{"type":"graphic_picture","displayName":"Refractory ulcer disease","title":"Refractory ulcer disease","html":"<div class=\"graphic\"><div style=\"width: 510px\" class=\"figure\"><div class=\"ttl\">Refractory ulcer disease</div><div class=\"cntnt\"><img style=\"width:490px; height:438px;\" src=\"images/GAST/101398_Refractory_ulcer_disease.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refractory ulcer disease due to eosinophilic gastroenteritis. Note the nodularity caused by eosinophilic infiltration and the superficial ulceration.</div><div class=\"graphic_reference\">Courtesy of Dr. Nimish B. Vakil.</div><div id=\"graphicVersion\">Graphic 101398 Version 2.0</div></div></div>"},"101401":{"type":"graphic_table","displayName":"Evaluation and testing in myotonic dystrophy","title":"Clinical evaluations and tests for the diagnosis, surveillance, and management of patients with myotonic dystrophy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical evaluations and tests for the diagnosis, surveillance, and management of patients with myotonic dystrophy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Evaluation/Test</td> <td class=\"subtitle1\">Frequency</td> <td class=\"subtitle1\">Abnormal finding</td> <td class=\"subtitle1\">Management</td> </tr> <tr> <td>Genetic (diagnostic) testing</td> <td>Initial evaluation only to establish diagnosis</td> <td>Expanded CTG repeat (DM1) or CCTG repeat (DM2)</td> <td>Genetic counseling for individuals and families</td> </tr> <tr> <td>Cardiac evaluation: ECG, echocardiogram, Holter monitoring</td> <td>ECG at baseline and then annually; 24-hour ambulatory ECG monitoring if arrhythmias suspected clinically but not detected on standard ECG; echocardiography if symptoms or signs of myocardial dysfunction are present</td> <td>Cardiac conduction abnormalities (very common in DM1 and variably present in DM2); structural heart abnormalities</td> <td>Cardiology consultation and follow-up; may require advanced electrophysiological testing and possibly pacemaker or implantable cardioverter-defibrillator</td> </tr> <tr> <td>Ophthalmologic examination</td> <td>Baseline and then every two years</td> <td>Iridescent posterior subcapsular cataract</td> <td>May require cataract extraction</td> </tr> <tr> <td>Forced vital capacity</td> <td>Baseline and annually</td> <td>Downward trending</td> <td>Pulmonary medicine consultation</td> </tr> <tr> <td>Polysomnographic evaluation</td> <td>Indicated for evaluation of sleep complaints</td> <td>Obstructive sleep apnea</td> <td>Consult and follow-up with pulmonary medicine; consider NIPPV</td> </tr> <tr> <td>Swallowing assessment: Modified barium swallow</td> <td>Baseline (if symptomatic dysphagia) and annually or as needed</td> <td>Oropharyngeal dysphagia</td> <td>Assessment and follow-up by speech language pathologist and nutritionist</td> </tr> <tr> <td>Neuropsychologic evaluation for patients with congenital and childhood-onset DM1</td> <td>Baseline and as needed thereafter</td> <td>Learning disabilities; autism spectrum disorder; psychiatric symptoms</td> <td>Psychiatric/psychologic consultation for specific diagnosis and management of target symptoms; special education; social support; vocational skills training</td> </tr> <tr> <td>Fasting blood glucose and hemoglobin A1C</td> <td>Baseline and then annually</td> <td>Glucose intolerance or frank diabetes</td> <td>Treatment of diabetes if present</td> </tr> <tr> <td>Thyroid stimulating hormone</td> <td>Initial evaluation and every two to three years</td> <td>Elevated</td> <td>Endocrinology consultation for treatment of hypothyroidism if detected</td> </tr> <tr> <td>Creatine kinase*</td> <td>Initial evaluation</td> <td>Mild rise</td> <td>Expected; no action needed</td> </tr> <tr> <td>Electromyography*</td> <td>Initial evaluation</td> <td>Myotonia</td> <td>Expected; no action needed</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">DM1: myotonic dystrophy type 1; DM2: myotonic dystrophy type 2; ECG: electrocardiogram; NIPPV: noninvasive positive airway pressure ventilation.<br />* Creatine kinase levels and electromyography are often obtained in the diagnostic evaluation of the patient suspected of having a myopathy, but establishing the diagnosis of DM1 and DM2 per se depends upon genetic testing.</div><div id=\"graphicVersion\">Graphic 101401 Version 2.0</div></div></div>"},"101403":{"type":"graphic_figure","displayName":"Coronavirus phylogenetic tree","title":"Coronavirus phylogenetic tree","html":"<div class=\"graphic\"><div style=\"width: 848px\" class=\"figure\"><div class=\"ttl\">Coronavirus phylogenetic tree</div><div class=\"cntnt\"><img style=\"width:828px; height:866px;\" src=\"images/ID/101403_Coronavirus_phylogntc_tree.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Phylogenetic tree of 50 coronaviruses with partial nucleotide sequences of RNA-dependent RNA polymerase. The tree was constructed by the neighbor-joining method using MEGA 5.0. The scale bar indicates the estimated number of substitutions per 20 nucleotides.</div><div class=\"graphic_footnotes\">AntelopeCoV: sable antelope coronavirus; BCoV: bovine coronavirus; BdCoV HKU22: bottlenose dolphin coronavirus HKU22; BuCoV HKU11: bulbul coronavirus HKU11; BWCoV-SW1: beluga whale coronavirus SW1; CMCoV HKU21: common-moorhen coronavirus HKU21; DcCoV UAE-HKU23: dromedary camel coronavirus UAE-HKU23; ECoV: equine coronavirus; Erinaceous-CoV: betacoronavirus Erinaceus/VMC/DEU/2012; FIPV: feline infectious peritonitis virus; HCoV-229E: human coronavirus 229E; HCoV-HKU1: human coronavirus HKU1; HCoV-NL63: human coronavirus NL63; HCoV-OC43: human coronavirus OC43; Hi-BatCoV HKU10: <EM>Hipposideros</EM> bat coronavirus HKU10; IBV-partridge: avian infectious bronchitis virus partridge isolate; IBV-peafowl: avian infectious bronchitis virus peafowl isolate; KSA-CAMEL-363: KSA-CAMEL-363 isolate of Middle East respiratory syndrome coronavirus; MERS-CoV: Middle East respiratory syndrome coronavirus; MHV: murine hepatitis virus; Mi-BatCoV 1A: <EM>Miniopterus</EM> bat coronavirus 1A; Mi-BatCoV 1B: <EM>Miniopterus</EM> bat coronavirus 1B; Mi-BatCoV HKU7: <EM>Miniopterus</EM> bat coronavirus HKU7; Mi-BatCoV HKU8: <EM>Miniopterus</EM> bat coronavirus HKU8; MRCoV HKU18: magpie robin coronavirus HKU18; MunCoV HKU13: munia coronavirus HKU13; My-BatCoV HKU6: <EM>Myotis</EM> bat coronavirus HKU6; NeoCoV: coronavirus <EM>Neoromicia</EM>/PML-PHE1/RSA/2011; NHCoV HKU19: night heron coronavirus HKU19; PEDV: porcine epidemic diarrhea virus; PHEV: porcine hemagglutinating encephalomyelitis virus; Pi-BatCoV-HKU5: <EM>Pipistrellus</EM> bat coronavirus HKU5; PorCoV HKU15: porcine coronavirus HKU15; PRCV: porcine respiratory coronavirus; RbCoV HKU14: rabbit coronavirus HKU14; RCoV parker: rat coronavirus Parker; Rh-BatCoV HKU2:<EM> Rhinolophus </EM>bat coronavirus HKU2; Ro-BatCoV-HKU9: <EM>Rousettus</EM> bat coronavirus HKU9; Ro-BatCoV HKU10: <EM>Rousettus</EM> bat coronavirus HKU10; SARSCoV:&nbsp;severe acute respiratory syndrome&nbsp;coronavirus; SARSr-CiCoV: SARS-related palm civet coronavirus; SARSr-Rh-BatCoV HKU3: SARS-related <EM>Rhinolophus</EM> bat coronavirus HKU3; Sc-BatCoV 512: <EM>Scotophilus</EM> bat coronavirus 512; SpCoV HKU17: sparrow coronavirus HKU17; TCoV: turkey coronavirus; TGEV: transmissible gastroenteritis virus; ThCoV HKU12: thrush coronavirus HKU12; Ty-BatCoV-HKU4: <EM>Tylonycteris</EM> bat coronavirus HKU4; WECoV HKU16: white-eye coronavirus HKU16; WiCoV HKU20: wigeon coronavirus HKU20.</div><div class=\"graphic_reference\">From: Chan JF, Lau SK, To KK, et al. Middle East respiratory syndrome coronavirus: Another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 2015; 28:465. DOI: 10.1128/CMR.00102-14. Reproduced with permission from American Society for Microbiology. Copyright &copy; 2015.</div><div id=\"graphicVersion\">Graphic 101403 Version 1.0</div></div></div>"},"101404":{"type":"graphic_picture","displayName":"Dental abscess with parulis","title":"Dental abscess with parulis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dental abscess with parulis</div><div class=\"cntnt\"><img style=\"width:221px; height:188px;\" src=\"images/PEDS/101404_Dental_abscess_parulis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A parulis (arrow), also called a \"gum boil,\" is a soft, solitary papule located apical to an abscessed tooth. It occurs at the exit point of the draining fistulous tract.</div><div id=\"graphicVersion\">Graphic 101404 Version 1.0</div></div></div>"},"101405":{"type":"graphic_figure","displayName":"Biceps femoris","title":"Biceps femoris","html":"<div class=\"graphic\"><div style=\"width: 744px\" class=\"figure\"><div class=\"ttl\">Biceps femoris</div><div class=\"cntnt\"><img style=\"width:724px; height:754px;\" src=\"images/EM/101405_Biceps_femoris.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>. &nbsp;</div><div id=\"graphicVersion\">Graphic 101405 Version 2.0</div></div></div>"},"101406":{"type":"graphic_figure","displayName":"Semimembranosus","title":"Semimembranosus","html":"<div class=\"graphic\"><div style=\"width: 655px\" class=\"figure\"><div class=\"ttl\">Semimembranosus</div><div class=\"cntnt\"><img style=\"width:635px; height:757px;\" src=\"images/EM/101406_Semimembranosus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A spellcheck=true href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 101406 Version 2.0</div></div></div>"},"101407":{"type":"graphic_figure","displayName":"Semitendinosus","title":"Semitendinosus","html":"<div class=\"graphic\"><div style=\"width: 679px\" class=\"figure\"><div class=\"ttl\">Semitendinosus</div><div class=\"cntnt\"><img style=\"width:659px; height:802px;\" src=\"images/EM/101407_Semitendinosus.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists. Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 101407 Version 2.0</div></div></div>"},"101409":{"type":"graphic_picture","displayName":"Histopathology pulmonary capillaritis","title":"Histopathology of pulmonary capillaritis","html":"<div class=\"graphic\"><div style=\"width: 514px\" class=\"figure\"><div class=\"ttl\">Histopathology of pulmonary capillaritis</div><div class=\"cntnt\"><img style=\"width:494px; height:342px;\" src=\"images/PULM/101409_Histo_pulm_capillaritis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lung histopathology from a patient with pulmonary capillaritis causing diffuse alveolar hemorrhage. Note the alveolar septal infiltration by neutrophils, which stream along the septal capillaries (arrow). Red cells admixed with neutrophils are seen leaking from the affected septa, resulting in marked accumulation within alveolar spaces (star). Nuclear fragmentation of neutrophils is present within the septa but not in alveolar space (Hematoxylin-eosin; magnification: x400).</div><div class=\"graphic_reference\">Reprinted with permission of the American Thoracic Society. Copyright &copy; 2015 American Thoracic Society. Jennings CA, King TE Jr, Tuder R, et al. Diffuse alveolar hemorrhage with underlying isolated, pauciimmune pulmonary capillaritis. Am J Respir Crit Care Med 1997; 155:1101. The American Journal of Respiratory and Critical Care Medicine is an official journal of the American Thoracic Society.</div><div id=\"graphicVersion\">Graphic 101409 Version 1.0</div></div></div>"},"101412":{"type":"graphic_figure","displayName":"Side-to-end coloanal anastomosis","title":"Side-to-end coloanal anastomosis","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Side-to-end coloanal anastomosis</div><div class=\"cntnt\"><img style=\"width:486px; height:484px;\" src=\"images/SURG/101412_Side_to_end_coloanal_anastomosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A side-to-end anastomosis is created by joining the side of the distal colon to the end of the rectum or anus, in the shape of the letter \"T.\"</div><div id=\"graphicVersion\">Graphic 101412 Version 2.0</div></div></div>"},"101413":{"type":"graphic_table","displayName":"Infections with MAHA and thrombocytopenia","title":"Infections associated with microangiopathic hemolytic anemia and thrombocytopenia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Infections associated with microangiopathic hemolytic anemia and thrombocytopenia</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1\">Pathogens</td> <td class=\"subtitle1\">Examples</td> </tr> <tr> <td>Bacteria</td> <td>Gram positives,&nbsp;Rickettsiae, <em>Borrelia</em>, <em>Brucella</em>, <em>Chlamydia</em>, <em>Clostridium difficile</em>, <em>Ehrlichia</em>, <em>Legionella</em>, <em>Leptospira</em>, Mycobacteria, Rocky Mountain spotted fever</td> </tr> <tr> <td>Viruses</td> <td><em>Cytomegalovirus</em>, hepatitis viruses, HIV, Influenza A, Parvovirus B19, <em>Varicella zoster</em>, HHV6, EBV, Dengue, Coxsackie virus, noroviruses</td> </tr> <tr> <td>Fungi</td> <td><em>Aspergillus</em>, <em>Blastomyces</em>, <em>Candida albicans</em>, <em>Cryptococcus neoformans</em></td> </tr> <tr> <td>RBC parasites</td> <td><em>Babesia</em>, malaria</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on thrombotic microangiopathies and individual organisms for further details of diagnosis and management.</div><div class=\"graphic_footnotes\">MAHA: microangiopathic hemolytic anemia; HIV: human immunodeficiency virus; HHV6: human herpesvirus 6; EBV: Epstein-Barr virus; RBC: red blood cell.</div><div class=\"graphic_reference\">Adapted from: <br />1.&nbsp;&nbsp;&nbsp;&nbsp; Booth KK, Terrell DR, Vesely SK, George JN. Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol 2011; 86:743.<br />2.&nbsp;&nbsp;&nbsp;&nbsp; Nester CM, Barbour T, de Cordoba SR, et al. Atypical aHUS: State of the art. Mol Immunol 2015; 67:31.</div><div id=\"graphicVersion\">Graphic 101413 Version 3.0</div></div></div>"},"101415":{"type":"graphic_picture","displayName":"Erythema elevatum diutinum histopathology","title":"Erythema elevatum diutinum","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">Erythema elevatum diutinum</div><div class=\"cntnt\"><img style=\"width:783px; height:439px;\" src=\"images/DERM/101415_Erythm_elvtm_dtnm_hstpthlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse mixed dermal inflammation.</div><div class=\"graphic_reference\">Courtesy of Omar Sangueza, MD.</div><div id=\"graphicVersion\">Graphic 101415 Version 3.0</div></div></div>"},"101416":{"type":"graphic_picture","displayName":"Erythema elevatum diutinum histopathology 2","title":"Erythema elevatum diutinum","html":"<div class=\"graphic\"><div style=\"width: 802px\" class=\"figure\"><div class=\"ttl\">Erythema elevatum diutinum</div><div class=\"cntnt\"><img style=\"width:782px; height:437px;\" src=\"images/DERM/101416_Erythm_elvtm_dtnm_hstpthl_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse mixed dermal inflammation composed of lymphocytes, histiocytes, neutrophils with leukocytoclasis, and few eosinophils. Areas of vascular damage with fibrinogen necrosis, vascular wall infiltration with neutrophils, and red blood cell extravasation consistent with leukocytoclastic vasculitis are also noted.</div><div class=\"graphic_reference\">Courtesy of Omar Sangueza, MD.</div><div id=\"graphicVersion\">Graphic 101416 Version 3.0</div></div></div>"},"101417":{"type":"graphic_picture","displayName":"Glucocorticoid injection in pes anserinus pain syndrome","title":"Glucocorticoid injection in pes anserinus pain syndrome","html":"<div class=\"graphic\"><div style=\"width: 801px\" class=\"figure\"><div class=\"ttl\">Glucocorticoid injection in pes anserinus pain syndrome</div><div class=\"cntnt\"><img style=\"width:781px; height:579px;\" src=\"images/RHEUM/101417_Glccrt_injct_ps_ans_pn_synd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simulated injection of the anserine bursa. The injection site is best determined by following the tendinous posteromedial border of thigh (gracilis and semitendinosus), with the knee in semiflexion, to the tibia, where a mark is placed (pes anserinus insertion). The knee is then brought into extension and the needle is inserted vertically, 3 cm proximal to the mark. An area about 3 cm in&nbsp;diameter is then injected, moving the needle back and forth, adjacent to periosteum (likely intrabursal), from the single initial entry. We use a 40 mg methylprednisolone mixed with 4 mL of lidocaine 2% without epinephrine in a 22-gauge needle and a 10 mL syringe.</div><div id=\"graphicVersion\">Graphic 101417 Version 3.0</div></div></div>"},"101423":{"type":"graphic_algorithm","displayName":"Diagnostic approach to anemia in the newborn","title":"Diagnostic approach to anemia in the newborn","html":"<div class=\"graphic\"><div style=\"width: 652px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to anemia in the newborn</div><div class=\"cntnt\"><img style=\"width:632px; height:676px;\" src=\"images/PEDS/101423_Diag_appr_anemia_newborn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HGB: hemoglobin; RBC: red blood cell; DAT: direct antiglobulin test; MCV: mean corpuscular volume; DIC: disseminated intravascular coagulation; PK: pyruvate kinase; G6PD: glucose-6-phosphate dehydrogenase; CMV: cytomegalovirus; HSV: herpes simplex virus.</div><div class=\"graphic_reference\">Reproduced from: Gallagher PG. The neonatal erythrocyte and its disorders. In: Nathan and Oski's Hematology and Oncology of Infancy and Childhood, 8th Ed, Orkin SH, Fisher DE, Look AT, et al (Eds), WB Saunders, Philadelphia 2015. p.52. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101423 Version 1.0</div></div></div>"},"101426":{"type":"graphic_figure","displayName":"Nasolacrimal duct massage","title":"Technique for nasolacrimal duct (NLD) massage in infants and children with congenital NLD obstruction (dacryostenosis)","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Technique for nasolacrimal duct (NLD) massage in infants and children with congenital NLD obstruction (dacryostenosis)</div><div class=\"cntnt\"><img style=\"width:528px; height:316px;\" src=\"images/PEDS/101426_Nasolacrimal_duct_massage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The index finger is placed over the superior aspect of the nasolacrimal sac and moderate pressure is applied downward. <br />(B) Downward pressure causes rupture of the membranous obstruction at the bottom of the nasolacrimal duct.</div><div id=\"graphicVersion\">Graphic 101426 Version 1.0</div></div></div>"},"101428":{"type":"graphic_table","displayName":"Risk factors for airway complications with extubation","title":"Risk factors for airway complications with extubation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for airway complications with extubation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Preexisting airway difficulties</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Difficult mask ventilation at induction </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Difficult tracheal intubation at induction </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>History of difficult airway management </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Obesity and/or obstructive sleep apnea </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Increased risk for aspiration of gastric contents </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Perioperative airway deterioration</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Surgical factors (anatomical distortion, hemorrhage, hematoma, edema) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Nonsurgical factors (dependent edema due to positioning, airway trauma from prior airway management, aggressive fluid management) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Restricted airway access</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Halo fixation </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Mandibulomaxillary fixation </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Surgical implants </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cervical collar </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Large head/neck dressings </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Popat M, Mitchell V, Dravid R, et al. Difficult Airway Society Guidelines for the management of tracheal extubation. Anaesthesia 2012; 67:318.</div><div id=\"graphicVersion\">Graphic 101428 Version 3.0</div></div></div>"},"101432":{"type":"graphic_diagnosticimage","displayName":"Ulnar collateral ligament elbow avulsion fracture","title":"Avulsion fracture of the ulnar collateral ligament of the elbow","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Avulsion fracture of the ulnar collateral ligament of the elbow</div><div class=\"cntnt\"><img style=\"width:534px; height:784px;\" src=\"images/EM/101432_Ulnr_cllt_lgm_elb_avlsn_frc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This plain radiograph shows an avulsion fracture (arrows) involving the distal ulnar collateral ligament in a skeletally immature thrower.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 101432 Version 2.0</div></div></div>"},"101433":{"type":"graphic_diagnosticimage","displayName":"Ulnar neuropathy at elbow MRI","title":"Ulnar neuropathy at elbow on MRI","html":"<div class=\"graphic\"><div style=\"width: 506px\" class=\"figure\"><div class=\"ttl\">Ulnar neuropathy at elbow on MRI</div><div class=\"cntnt\"><img style=\"width:486px; height:475px;\" src=\"images/EM/101433_Ulnr_nrpthy_elbw_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The MRI image above shows an inflamed, edematous ulnar nerve (arrow) at the elbow.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 101433 Version 1.0</div></div></div>"},"101434":{"type":"graphic_diagnosticimage","displayName":"Osteochondral defect capitellum MRI","title":"Osteochondral defect of the capitellum on MRI","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Osteochondral defect of the capitellum on MRI</div><div class=\"cntnt\"><img style=\"width:320px; height:320px;\" src=\"images/EM/101434_Ostchndrl_dfct_cptllm_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The MRI image above shows an osteochondral defect (between arrows) of the capitellum, the most common site. These injuries occur most often in adolescent throwers.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 101434 Version 2.0</div></div></div>"},"101435":{"type":"graphic_picture","displayName":"Upper extremity carrying angle","title":"Upper extremity carrying angle","html":"<div class=\"graphic\"><div style=\"width: 709px\" class=\"figure\"><div class=\"ttl\">Upper extremity carrying angle</div><div class=\"cntnt\"><img style=\"width:689px; height:792px;\" src=\"images/EM/101435_Upper_extrem_carry_angle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A normal carrying angle is approximately 5 to 10 degrees in males and 10 to 15 degrees in females. Abnormal angles suggest underlying pathology in some throwers.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD.</div><div id=\"graphicVersion\">Graphic 101435 Version 1.0</div></div></div>"},"101439":{"type":"graphic_waveform","displayName":"EPS tracings polymorphic VT response to procainamide","title":"Electrophysiology study (EPS) tracings showing polymorphic ventricular tachycardia (VT) and the response to procainamide","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Electrophysiology study (EPS) tracings showing polymorphic ventricular tachycardia (VT) and the&nbsp;response to procainamide</div><div class=\"cntnt\"><img style=\"width:526px; height:528px;\" src=\"images/CARD/101439_VT_response_procainamide.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Programmed electrical stimulation in the electrophysiology laboratory in a patient with remote myocardial infarction who was resuscitated from cardiac arrest.&nbsp; The top recording shows stimulation in the baseline state (no antiarrhythmic medication) (three ventricular extrastimuli, the third extrastimulus does not capture) during a drive cycle of 400 milliseconds (150 beats per minute) which&nbsp;induces only nonsustained polymorphic VT.&nbsp; Repeat programmed stimulation with&nbsp;two extrastimuli &nbsp;at progressively increasing doses of intravenous procainamide, 15 and 30 mg/kg, as shown in the middle and bottom recordings, results in induction of monomorphic sustained VT, cycle lengths 240 and 280 milliseconds (250 and 214 beats per minute), respectively.</div><div class=\"graphic_footnotes\">RVA: right ventricular apex; RVOT: right ventricular outflow tract.</div><div id=\"graphicVersion\">Graphic 101439 Version 1.0</div></div></div>"},"101441":{"type":"graphic_picture","displayName":"Striae rubra","title":"Striae distensae (stretch marks)","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">Striae distensae (stretch marks)</div><div class=\"cntnt\"><img style=\"width:784px; height:393px;\" src=\"images/DERM/101441_Striae_rubra.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous linear plaques on the abdomen consistent with the striae rubra form of striae distensae.</div><div id=\"graphicVersion\">Graphic 101441 Version 1.0</div></div></div>"},"101442":{"type":"graphic_picture","displayName":"Striae rubra on thigh","title":"Striae distensae (stretch marks)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Striae distensae (stretch marks)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101442_Striae_rubra_thigh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous, linear, atrophic plaques on the thigh.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101442 Version 1.0</div></div></div>"},"101443":{"type":"graphic_picture","displayName":"Striae alba","title":"Striae distensae (stretch marks)","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Striae distensae (stretch marks)</div><div class=\"cntnt\"><img style=\"width:562px; height:782px;\" src=\"images/DERM/101443_Striae_alba.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hypopigmented, linear, atrophic plaques on the buttocks.</div><div id=\"graphicVersion\">Graphic 101443 Version 1.0</div></div></div>"},"101444":{"type":"graphic_picture","displayName":"Striae alba on upper extremity","title":"Striae distensae (stretch marks)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Striae distensae (stretch marks)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101444_Striae_alba_up_extrmty.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple hypopigmented, linear, atrophic plaques on the shoulder and upper arm.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101444 Version 1.0</div></div></div>"},"101445":{"type":"graphic_picture","displayName":"Post-pregnancy striae distensae","title":"Striae distensae (stretch marks)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Striae distensae (stretch marks)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101445_Pst_prgnncy_str_dstns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Striae distensae on the abdomen after pregnancy.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101445 Version 1.0</div></div></div>"},"101446":{"type":"graphic_picture","displayName":"Post-pregnancy striae distensae on abdomen","title":"Striae distensae (stretch marks)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Striae distensae (stretch marks)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101446_Pst_prgnncy_str_dstn_abdmn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Post-pregnancy striae distensae on the abdomen.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101446 Version 1.0</div></div></div>"},"101447":{"type":"graphic_picture","displayName":"Striae distensae pulsed dye laser","title":"Treatment of striae distensae with a 595 nm pulsed dye laser","html":"<div class=\"graphic\"><div style=\"width: 915px\" class=\"figure\"><div class=\"ttl\">Treatment of striae distensae with a 595 nm pulsed dye laser</div><div class=\"cntnt\"><img style=\"width:895px; height:343px;\" src=\"images/DERM/101447_Striae_dstns_plsd_dye_laser.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Striae distensae beore (A) and after (B) pulsed dye laser treatment.</div><div id=\"graphicVersion\">Graphic 101447 Version 1.0</div></div></div>"},"101448":{"type":"graphic_picture","displayName":"Striae distensae nonablative fractional laser","title":"Treatment of striae distensae with a nonablative fractional laser","html":"<div class=\"graphic\"><div style=\"width: 845px\" class=\"figure\"><div class=\"ttl\">Treatment of striae distensae with a nonablative fractional laser</div><div class=\"cntnt\"><img style=\"width:825px; height:506px;\" src=\"images/DERM/101448_Str_dstns_nnbltv_frctnl_lsr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Striae disensae before (A) and after (B) nonablative fractional resurfacing.</div><div id=\"graphicVersion\">Graphic 101448 Version 1.0</div></div></div>"},"101449":{"type":"graphic_picture","displayName":"Striae distensae nonablative fractional laser therapy on breast","title":"Treatment of striae distensae with a nonablative fractional laser","html":"<div class=\"graphic\"><div style=\"width: 814px\" class=\"figure\"><div class=\"ttl\">Treatment of striae distensae with a nonablative fractional laser</div><div class=\"cntnt\"><img style=\"width:794px; height:522px;\" src=\"images/DERM/101449_Str_dst_nnbl_frct_thr_brst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Striae alba before (A) and after (B) nonablative fractional resurfacing. Note the advancing striae at the edge of the treated area (B).</div><div class=\"graphic_reference\">Courtesy of Nuno Os&oacute;rio, MD.</div><div id=\"graphicVersion\">Graphic 101449 Version 1.0</div></div></div>"},"101453":{"type":"graphic_table","displayName":"Conditions associated with striae distensae","title":"Conditions associated with striae distensae","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions associated with striae distensae</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">General</td> </tr> <tr> <td class=\"indent1\">Family history (genetic)</td> </tr> <tr> <td class=\"indent1\">Obesity</td> </tr> <tr> <td class=\"indent1\">Sudden weight gain or loss</td> </tr> <tr> <td class=\"indent1\">Bodybuilding exercise</td> </tr> <tr> <td class=\"indent1\">Smoking</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Adolescents during or after growth spurt</td> </tr> <tr> <td class=\"subtitle1_single\">Medical conditions</td> </tr> <tr> <td class=\"indent1\">Marfan syndrome</td> </tr> <tr> <td class=\"indent1\">Cushing's syndrome</td> </tr> <tr> <td class=\"indent1\">Anorexia nervosa</td> </tr> <tr> <td class=\"indent1\">Typhoid fever</td> </tr> <tr> <td class=\"indent1\">Rheumatic fever</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Chronic liver disease</td> </tr> <tr> <td class=\"subtitle1_single\">Medications</td> </tr> <tr> <td class=\"indent1\">Systemic and topical corticosteroids</td> </tr> <tr> <td class=\"indent1\">Human immunodeficiency virus (HIV) therapy</td> </tr> <tr> <td class=\"indent1\">Chemotherapy</td> </tr> <tr> <td class=\"indent1\">Tuberculosis therapy</td> </tr> <tr> <td class=\"indent1\">Contraceptives</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Neuroleptics</td> </tr> <tr> <td class=\"subtitle1_single\">Surgery</td> </tr> <tr> <td class=\"indent1\">Breast augmentation</td> </tr> <tr> <td class=\"indent1\">Tissue expanders</td> </tr> <tr> <td class=\"indent1\">Tension-requiring skin sutures</td> </tr> <tr> <td class=\"indent1\">Organ transplantation</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cardiac surgery</td> </tr> <tr> <td class=\"subtitle1_single\">Pregnancy</td> </tr> <tr> <td class=\"indent1\">Family history</td> </tr> <tr> <td class=\"indent1\">Younger age</td> </tr> <tr> <td class=\"indent1\">Higher birthweight</td> </tr> <tr> <td class=\"indent1\">Increased gestational age</td> </tr> <tr> <td class=\"indent1\">Weight gained</td> </tr> <tr> <td class=\"indent1\">Pre-pregnancy body mass index (BMI)</td> </tr> <tr> <td class=\"indent1\">Lack of chronic diseases</td> </tr> <tr> <td class=\"indent1\">Polyhydramnios</td> </tr> <tr> <td class=\"indent1\">Pre-pregnancy presence of breast striae (but not thigh striae)</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Prepared with information from the following sources:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Cho S, Park ES, Lee DH, et al. Clinical features and risk factors for striae distensae in Korean adolescents. J Eur Acad Dermatol Venerol 2006; 20:1108.</li>&#xD;&#xA;    <li>Davey CM. Factors associated with the occurrence of striae gravidarum. J Obstet Gynaecol Br Commonw 1972; 79:1113.</li>&#xD;&#xA;    <li>Kasielska-Trojan A, Sobczak M, Antoszewski B. Risk factors of striae gravidarum. Int J Cosmet Sci 2015; 37:236.</li>&#xD;&#xA;    <li>Chan WY, Akhtar S, Phipps AR. Striae distensae in tissue-expanded skin in the upper arm. Ann Plast Surg 2006; 57:240.</li>&#xD;&#xA;    <li>Tsuji T, Sawabe M. Hyperpigmentation in striae distensae after bleomycin treatment. J Am Acad Dermatol 1993; 28:503.</li>&#xD;&#xA;    <li>Di Lernia V, Bonci A, Cattania M, et al. Striae distensae (rubrae) in monozygotic twins. Pediatr Dermatol 2001; 18:261.</li>&#xD;&#xA;    <li>Kharb S, Gundgurthi A, Dutta MK, et al. Striae atrophicans: a mimic to Cushing's cutaneous striae. Indian J Endocrinol Metab 2012; 16 Suppl 1:S123.</li>&#xD;&#xA;    <li>Rogalski C, Haustein UF, Glander HJ, et al. Extensive striae distensae as a result of topical corticosteroid therapy in psoriasis vulgaris. Acta Derm Venereol 2003; 83:54.</li>&#xD;&#xA;    <li>Pinkus H, Keech MK, Mehregan AH. Histopathology of striae distensae, with special reference to striae and wound healing in the Marfan syndrome. J Invest Dermatol 1966; 46:283.</li>&#xD;&#xA;    <li>Gupta M. Medroxyprogesterone acetate (Depo Provera) injection. Development of striae. Br J Fam Plann 2000; 26:104.</li>&#xD;&#xA;    <li>Strumia R. Skin signs in anorexia nervosa. Dermatoendocrinol 2009; 1:268.</li>&#xD;&#xA;    <li>Rolleston JD. Striae atrophicae following rheumatic fever. Proc R Soc Med 1932; 25:803.</li>&#xD;&#xA;    <li>Keramidas E, Rodopoulou S. Striae distensae after subfascial breast augmentation. Aesthet Plast Surg 2008; 32:377.</li>&#xD;&#xA;    <li>Ono T, Matsunaga W, Yoshimura K. Striae distensae after tension-requiring skin sutures. J Dermatol 1991; 18:47.</li>&#xD;&#xA;    <li>Euvrard S, Kanitakis J, Cochat P, et al. Skin diseases in children with organ transplants. J Am Acad Dermatol 2001; 44:932.</li>&#xD;&#xA;    <li>Goggin N, Enright F, Costigan C, et al. Striae and acne following cardiac surgery in a child. Br J Dermatol 1999; 140:734.</li>&#xD;&#xA;    <li>Darvay A, Acland K, Lynn W, et al. Striae formation in two HIV-positive persons receiving protease inhibitors. J Am Acad Dermatol 1999; 41:467.</li>&#xD;&#xA;    <li>Choe SW, Yoon YH, Seo SJ, et al. A case of edematous striae distensae by corticosteroid and generalized edema in nephrotic syndrome. Korean J Dermatol 2004; 42:1238.</li>&#xD;&#xA;    <li>Hofer W. Striae cutis atrophica following INH medication. Z Haut Geschlechtskr 1967; 42:603.</li>&#xD;&#xA;    <li>Hinson J, Shumway M, Chen J, et al. Cutaneous striae in neuroleptic treatment. Ann Clin Psychiatry 1992; 4:221.</li>&#xD;&#xA;    <li>Basak P, Dhar S, Kanwar AJ. Involvement of the legs in idiopathic striae distensae - a case report. Indian J Dermatol 1989; 34:21.</li>&#xD;&#xA;    <li>Rolleston JD, Goodall EW. Two cases of striae atrophica following typhoid fever. Proc R Soc Med 1931; 25:213.</li>&#xD;&#xA;    <li>Shafir R, Gur E. Re: striae distensae of augmented breasts after oral contraceptives. Ann Plast Surg 1999; 43:220.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 101453 Version 1.0</div></div></div>"},"101454":{"type":"graphic_picture","displayName":"Linear focal elastosis","title":"Linear focal elastosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Linear focal elastosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101454_Linear_focal_elastosis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Linear, yellowish plaques horizontally arranged on the lower back.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101454 Version 1.0</div></div></div>"},"101457":{"type":"graphic_picture","displayName":"Diaper dermatitis mild","title":"Diaper dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Diaper dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:520px;\" src=\"images/DERM/101457_Dpr_dermatitis_mld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Limited erythema and scattered erythematous papules are present in the diaper area of this child with mild diaper dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101457 Version 1.0</div></div></div>"},"101460":{"type":"graphic_picture","displayName":"Diaper dermatitis candidal","title":"Candidal diaper dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Candidal diaper dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101460_Diaper_drmtts_cnddl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sharply demarcated red plaques involving the skin folds (with satellite pustules) are present in this infant with candidal diaper dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101460 Version 1.0</div></div></div>"},"101461":{"type":"graphic_figure","displayName":"Development of DS-AML","title":"Stepwise development of acute myeloid leukemia in Down syndrome","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Stepwise development of acute myeloid leukemia in Down syndrome</div><div class=\"cntnt\"><img style=\"width:560px; height:394px;\" src=\"images/HEME/101461_Development_DS_AML.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><em>GATA1</em> mutations in prenatal hematopoietic cells with trisomy 21 result in transient myeloproliferative disorder (TMD). After apparent resolution of TMD, additional mutations cooperating with mutant <em>GATA1</em> result in transformation to myelodysplastic syndrome and AML in a subset.</div><div class=\"graphic_footnotes\">DS: Down syndrome; AML: acute myeloid leukemia; TMD: transient myeloproliferative disorder.</div><div id=\"graphicVersion\">Graphic 101461 Version 1.0</div></div></div>"},"101462":{"type":"graphic_picture","displayName":"Bullous impetigo diaper area","title":"Bullous impetigo","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Bullous impetigo</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101462_Bullous_impetigo_dpr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bullous impetigo of the diaper area presenting with superficial erosions with a collarette of scale.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101462 Version 1.0</div></div></div>"},"101485":{"type":"graphic_figure","displayName":"Causes of stridor by location","title":"Causes of stridor in children by location","html":"<div class=\"graphic\"><div style=\"width: 894px\" class=\"figure\"><div class=\"ttl\">Causes of stridor in children by location</div><div class=\"cntnt\"><img style=\"width:874px; height:670px;\" src=\"images/PEDS/101485_Causes_stridor_location.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Acute or subacute onset.</div><div id=\"graphicVersion\">Graphic 101485 Version 1.0</div></div></div>"},"101492":{"type":"graphic_picture","displayName":"Chronic actinic dermatitis","title":"Chronic actinic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Chronic actinic dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101492_Chronic_actinic_drmtt_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse infiltrated erythema, scaling, and fissures on the face of this patient with chronic actinic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101492 Version 1.0</div></div></div>"},"101493":{"type":"graphic_table","displayName":"Causes of mediastinal lymphadenopathy","title":"Causes of mediastinal lymphadenopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of mediastinal lymphadenopathy</div><div class=\"cntnt\"><table class=\"container\" cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Malignant causes</td> </tr> <tr> <td class=\"indent1\">Lymphoma and other lymphoid neoplasms&nbsp;(eg, Hodgkin and non-Hodgkin lymphoma, Castleman's disease, multiple myeloma, Angioimmunoblastic T cell lymphoma)</td> </tr> <tr> <td class=\"indent1\">Leukemia (eg, acute lymphoblastic leukemia)</td> </tr> <tr> <td class=\"indent1\">Metastatic cancer (eg, lung, esophagus, gastrointestinal, breast)</td> </tr> <tr> <td class=\"indent1\">Lymphangitis carcinomatosis</td> </tr> <tr> <td class=\"indent1\">Kaposi sarcoma</td> </tr> <tr> <td class=\"indent1\">Lymphosarcoma</td> </tr> <tr> <td class=\"indent1\">Non malignant lymphoid disorders (eg, lymphoid histiocytosis)</td> </tr> </tbody> </table> </td> <td class=\"container\"> <table cellspacing=\"0\"> <tbody> <tr> <td class=\"subtitle1_single\">Benign</td> </tr> <tr> <td class=\"subtitle2_single\">Infectious</td> </tr> <tr> <td class=\"indent1\">Mycobacterial disease &ndash; M. tuberculosis, atypical mycobacterium</td> </tr> <tr> <td class=\"indent1\">Fungal infection &ndash; histoplasmosis, coccidioidomycosis</td> </tr> <tr> <td class=\"indent1\">Infectious mononucleosis (Epstein Barr virus)</td> </tr> <tr> <td class=\"indent1\">Human immune deficiency virus</td> </tr> <tr> <td class=\"indent1\">Pulmonary anthrax (Bacillus anthracis)</td> </tr> <tr> <td class=\"indent1\">Bacterial abscess (eg, actinomycosis)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tularemia (Francisella tularensis)</td> </tr> <tr> <td class=\"subtitle2_single\">Inflammatory</td> </tr> <tr> <td class=\"indent1\">Sarcoidosis</td> </tr> <tr> <td class=\"indent1\">Rheumatoid arthritis</td> </tr> <tr> <td class=\"indent1\">Systemic sclerosis</td> </tr> <tr> <td class=\"indent1\">Systemic lupus erythematosus</td> </tr> <tr> <td class=\"indent1\">Whipple's disease</td> </tr> <tr> <td class=\"indent1\">Cystic fibrosis</td> </tr> <tr> <td class=\"indent1\">Hypersensitivity pneumonitis</td> </tr> <tr> <td class=\"indent1\">Pneumoconiosis (coal, beryllium, silica, asbestos)</td> </tr> <tr> <td class=\"indent1\">Lymphomatoid granulomatosis</td> </tr> <tr> <td class=\"indent1\">Rosai-Dorfman disease</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Amyloidosis</td> </tr> <tr> <td class=\"subtitle2_single\">Reactive</td> </tr> <tr> <td class=\"indent1\">Local infection (eg, pneumonia, pharyngitis)</td> </tr> <tr> <td class=\"indent1\">Pulmonary edema</td> </tr> <tr> <td class=\"indent1\">Mediastinal hematoma</td> </tr> </tbody> </table> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The most common causes of bilateral hilar adenopathy include sarcoidosis and lymphoma. Other less common causes include pulmonary edema and rheumatologic lung disorders such as rheumatoid arthritis. Many of the other listed disorders cause asymmetric enlargement of mediastinal lymph nodes.</div><div id=\"graphicVersion\">Graphic 101493 Version 1.0</div></div></div>"},"101494":{"type":"graphic_picture","displayName":"Chronic actinic dermatitis dark skin","title":"Chronic actinic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Chronic actinic dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101494_Chrnc_actnc_drmtts_drk_skn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The skin on photoexposed areas appears erythematous and lichenified in this patient with chronic actinic dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101494 Version 1.0</div></div></div>"},"101496":{"type":"graphic_diagnosticimage","displayName":"Calcinosis cutis in scleroderma on radiograph","title":"Calcinosis cutis in scleroderma on radiograph","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">Calcinosis cutis in scleroderma on radiograph</div><div class=\"cntnt\"><img style=\"width:792px; height:476px;\" src=\"images/DERM/101496_Clcns_cts_sclrdrm_rdgrph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Calcification involving the periarticular soft tissues of the extremity.</div><div id=\"graphicVersion\">Graphic 101496 Version 1.0</div></div></div>"},"101497":{"type":"graphic_picture","displayName":"Calciphylaxis purpura","title":"Calciphylaxis","html":"<div class=\"graphic\"><div style=\"width: 875px\" class=\"figure\"><div class=\"ttl\">Calciphylaxis</div><div class=\"cntnt\"><img style=\"width:855px; height:292px;\" src=\"images/DERM/101497_Calciphylaxis_purpura.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retiform purpura with bullae and ulceration on the legs.</div><div id=\"graphicVersion\">Graphic 101497 Version 1.0</div></div></div>"},"101498":{"type":"graphic_picture","displayName":"Idiopathic calcification of the scrotum","title":"Idiopathic calcification of the scrotum","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Idiopathic calcification of the scrotum</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/101498_Idiopathic_clcfct_scrtm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple firm nodules on the scrotum.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101498 Version 1.0</div></div></div>"},"101499":{"type":"graphic_picture","displayName":"Calcinosis cutis on finger","title":"Calcinosis cutis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Calcinosis cutis</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/101499_Calcinosis_cutis_fngr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">White papules, chalk-like exudate, and ulceration on the finger secondary to calcinosis cutis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101499 Version 1.0</div></div></div>"},"101500":{"type":"graphic_picture","displayName":"Calcinosis cutis on elbow","title":"Calcinosis cutis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Calcinosis cutis</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/101500_Calcinosis_cutis_elbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small white papules on the elbow.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101500 Version 1.0</div></div></div>"},"101501":{"type":"graphic_picture","displayName":"Calcinosis cutis on hand","title":"Calcinosis cutis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Calcinosis cutis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101501_Calcinosis_cutis_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nodule with chalk-white exudate at the base of the thumb.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101501 Version 1.0</div></div></div>"},"101502":{"type":"graphic_picture","displayName":"Calcinosis cutis multiple nodules","title":"Calcinosis cutis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Calcinosis cutis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101502_Clcns_cts_mltpl_ndl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple firm nodules on the upper extremities.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101502 Version 1.0</div></div></div>"},"101503":{"type":"graphic_picture","displayName":"Idiopathic calcification of the scrotum 2","title":"Idiopathic calcification of the scrotum","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Idiopathic calcification of the scrotum</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101503_Idpthc_clcfc_scrtm_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple firm nodules on the scrotum.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101503 Version 1.0</div></div></div>"},"101505":{"type":"graphic_picture","displayName":"Diaper dermatitis severe","title":"Diaper dermatitis (nappy rash)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Diaper dermatitis (nappy rash)</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101505_Diaperdrmttssvr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Severe diaper dermatitis with diffuse erythema and large, eroded areas.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101505 Version 3.0</div></div></div>"},"101506":{"type":"graphic_picture","displayName":"Diaper dermatitis nodules","title":"Diaper dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Diaper dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101506_Diaper_drmtts_ndl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive erythema, scaling, and nodules in the diaper area of this child with severe diaper dermatitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101506 Version 1.0</div></div></div>"},"101508":{"type":"graphic_picture","displayName":"Pseudoverrucous papules and nodules","title":"Vulvar pseudoverrucous papules and nodules","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Vulvar pseudoverrucous papules and nodules</div><div class=\"cntnt\"><img style=\"width:648px; height:486px;\" src=\"images/DERM/101508_Pseudovrrcspapulesnodules.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple shiny, white-gray, wart-like papules and nodules, sometimes partly confluent and crescent-shaped, involving the vulva and the surrounding erythematous skin.</div><div class=\"graphic_reference\">From: Garrido-Ruiz MC, Rosales B, Luis Rodr&iacute;guez-Peralto J. Vulvar pseudoverrucous papules and nodules secondary to a urethral--vaginal fistula. Am J Dermatopathol 2011; 33:410. DOI: <a href=\"http://journals.lww.com/amjdermatopathology/Abstract/2011/06000/Vulvar_Pseudoverrucous_Papules_and_Nodules.16.aspx\" target=\"_blank\">10.1097/DAD.0b013e3181ee5378</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2011 International Society of Dermatopathology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 101508 Version 2.0</div></div></div>"},"101526":{"type":"graphic_table","displayName":"Noncongenital causes of stridor in children","title":"Noncongenital causes of stridor in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Noncongenital causes of stridor in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"14%\"></colgroup><colgroup span=\"8\" width=\"6%\"></colgroup><colgroup width=\"38%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Cause</td> <td class=\"subtitle1\" colspan=\"5\">Typical age of presentation</td> <td class=\"subtitle1\" rowspan=\"2\">Inspiratory stridor</td> <td class=\"subtitle1\" rowspan=\"2\">Expiratory stridor*</td> <td class=\"subtitle1\" rowspan=\"2\">Fever/toxic</td> <td class=\"subtitle1\" rowspan=\"2\">Other characteristics</td> </tr> <tr> <td class=\"subtitle2\">Neonate</td> <td class=\"subtitle2\">Infants and toddlers<br /> (6 to 24 months)</td> <td class=\"subtitle2\">Pre-school<br /> (3 to 5 years)</td> <td class=\"subtitle2\">School-aged</td> <td class=\"subtitle2\">Adolescents</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Acute onset</td> </tr> <tr> <td class=\"indent1\">Foreign body aspiration<sup>&#182;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;</td> <td class=\"centered\">&nbsp;</td> <td>A history of a witnessed choking episode is common, but the acute symptoms often resolve and may not be immediately recalled by the caregiver.</td> </tr> <tr> <td class=\"indent1\">Airway burn&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X&nbsp;</td> <td class=\"centered\">X&nbsp;</td> <td class=\"centered\">X&nbsp;</td> <td class=\"centered\">X&nbsp;</td> <td class=\"centered\">+&nbsp;</td> <td class=\"centered\">+/&ndash;&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Due to thermal injury or caustic ingestion.&nbsp;</td> </tr> <tr> <td class=\"indent1\">Bacterial tracheitis<sup>&#916;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X&nbsp;</td> <td class=\"centered\">X&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;&nbsp;&nbsp;</td> <td class=\"centered\">+&nbsp;</td> <td>Among the most common airway emergencies requiring PICU admission. Most patients have prodromal symptoms of viral URI.&nbsp;</td> </tr> <tr> <td class=\"indent1\">Anaphylaxis</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Often associated with hives, choking, vomiting, and/or wheezing.</td> </tr> <tr> <td class=\"indent1\">Epiglottitis</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Subacute or intermittent onset</td> </tr> <tr> <td class=\"indent1\">Laryngotracheitis (croup)<sup>&#916;</sup></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+/&ndash;</td> <td>URI symptoms, fever, cough, hoarseness.</td> </tr> <tr> <td class=\"indent1\">Spasmodic croup</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Mild URI symptoms may be present.</td> </tr> <tr> <td class=\"indent1\">Retropharyngeal abscess&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td>Sore throat progressing to fever, dysphagia, and&nbsp;muffled \"hot&nbsp;potato\" voice.&nbsp;</td> </tr> <tr> <td class=\"indent1\">Peritonsillar abscess</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td>Usually preceded by tonsillitis or pharyngitis (eg, streptococcal), with muffled voice.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"10\">Chronic or recurrent</td> </tr> <tr> <td class=\"indent1\">Congenital anomalies<sup>&#9674;</sup>&nbsp;</td> <td class=\"centered\">X&nbsp;</td> <td class=\"centered\">&nbsp;X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+/&ndash;&nbsp;</td> <td class=\"centered\">+/&ndash;&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Vocal cord dysfunction<sup>&#916;</sup></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">+</td> <td class=\"centered\">+/&ndash;&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>May be congenital, iatrogenic, or acquired (idiopathic or neurologic). Children with bilateral vocal cord paralysis typically present with stridor and respiratory insufficiency, and may have normal voice/cry.&nbsp; </td> </tr> <tr> <td class=\"indent1\">Recurrent respiratory papillomatosis&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X&nbsp;</td> <td class=\"centered\">X&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+</td> <td class=\"centered\">&nbsp;+/&ndash;</td> <td class=\"centered\">&nbsp;</td> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">Typically presents with chronic or progressive stridor, hoarseness of voice or weak cry, choking episodes, and cough,&nbsp;with wheezing if trachea is also involved. In some cases, upper airway obstruction may be life-threatening and may be the presenting symptom.</span></td> </tr> <tr> <td class=\"indent1\"><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">Hypocalcemic laryngeal spasm</span>&nbsp;</td> <td class=\"centered\">X&nbsp;</td> <td class=\"centered\">&nbsp;X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">+/&ndash;&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td><span style=\"font-size: 11pt; font-family: 'Calibri','sans-serif';\">May be caused by severe hypocalcemia from any cause (eg, calcipenic rickets). The associated stridor can be chronic or intermittent but also may present with acute severe onset.</span>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Tumor&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X&nbsp;</td> <td class=\"centered\">X&nbsp;</td> <td class=\"centered\">X&nbsp;</td> <td class=\"centered\">X&nbsp;</td> <td class=\"centered\">+/&ndash;&nbsp;</td> <td class=\"centered\">+/&ndash;&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td>Airway compression usually is extrinsic. Stridor symptoms depend on location of compression.&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">+: usually present; +/-: may or may not be present; PICU: pediatric intensive care unit; URI: upper respiratory tract infection.<br />* Any obstructive process that leads to a fixed airway narrowing will produce both inspiratory and expiratory noise.<br />¶ Foreign body aspiration can occur in any age group, but is most common in toddlers and pre-school aged children. <br />Δ&nbsp;Onset either acute or subacute/gradual.&nbsp;<br />◊ Congenital anomalies that cause stridor include laryngomalacia, tracheomalacia, subglottic stenosis, bronchogenic cysts, laryngeal malformations, hemangiomas, and vascular rings. These are outlined in a separate table.</div><div id=\"graphicVersion\">Graphic 101526 Version 5.0</div></div></div>"},"101527":{"type":"graphic_picture","displayName":"Atopic dermatitis diaper area","title":"Atopic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Atopic dermatitis</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/101527_Atpc_dermatitis_dpr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In infants, atopic dermatitis characteristically spares the diaper area.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101527 Version 1.0</div></div></div>"},"101528":{"type":"graphic_picture","displayName":"Congenital syphilis","title":"Congenital syphilis​","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Congenital syphilis​</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101528_Congenital_syphilis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scaly eruption with a few superficial erosions in the diaper area of this infant with congenital syphilis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101528 Version 1.0</div></div></div>"},"101536":{"type":"graphic_picture","displayName":"Knee in extension (knee bursitis)","title":"Knee in extension (knee bursae)","html":"<div class=\"graphic\"><div style=\"width: 689px\" class=\"figure\"><div class=\"ttl\">Knee in extension (knee bursae)</div><div class=\"cntnt\"><img style=\"width:669px; height:584px;\" src=\"images/RHEUM/101536_Knee_extnsn_knee_bursitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Knee in extension. Markers indicate the position of the anserine enthesis (distal marker), the mid-portion of the tibial (medial) collateral ligament (middle marker), and the tendons of the gracilis and semitendinosus in the distal thigh (proximal marker).</div><div class=\"graphic_reference\">Courtesy of Juan Canoso, MD.</div><div id=\"graphicVersion\">Graphic 101536 Version 3.0</div></div></div>"},"101537":{"type":"graphic_picture","displayName":"Knee at 90 degrees flexion (knee bursitis)","title":"Knee at 90 degrees flexion (knee bursae)","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Knee at 90 degrees flexion (knee bursae)</div><div class=\"cntnt\"><img style=\"width:584px; height:740px;\" src=\"images/RHEUM/101537_Knee_90_dgr_flxn_knee_brsts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Knee at 90 degrees flexion. Note the larger area in which previously colinear markers have spread. Left lower marker, pes anserinus enthesis; left upper marker, mid portion of tibial collateral ligament; right marker, gracilis and semitendinosus tendons in the distal thigh.</div><div class=\"graphic_reference\">Courtesy of Juan Canoso, MD.</div><div id=\"graphicVersion\">Graphic 101537 Version 3.0</div></div></div>"},"101543":{"type":"graphic_table","displayName":"Medical history in the child with anemia","title":"The medical history in the child with anemia: Elements associated with specific causes of childhood anemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The medical history in the child with anemia: Elements associated with specific causes of childhood anemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Patient characteristics</strong></td> <td>Age: <ul class=\"decimal_heading\"> <li>In neonates and young infants, immune hemolytic disease, infection, and hereditary disorders are most common </li> <li>Anemia detected at three to six months of age suggests a hemoglobinopathy </li> <li>Nutritional iron deficiency is an unlikely cause of anemia before the age of six months in term infants </li> <li>In older children, acquired causes of anemia are more likely, particularly iron deficiency anemia (dietary or due to blood loss) </li> </ul> </td> </tr> <tr> <td>Sex: <ul class=\"decimal_heading\"> <li>Some inherited causes of anemia are X-linked (eg, G6PD deficiency and X-linked sideroblastic anemia), and occur most commonly in males </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Race/ethnicity: <ul class=\"decimal_heading\"> <li>Hemoglobin S and C are most commonly seen in black and Hispanic populations </li> <li>Thalassemia syndromes are more common in individuals of Mediterranean and Southeast Asian descent </li> <li>G6PD deficiency is more common among Sephardic Jews, Filipinos, Greeks, Sardinians, Kurds, and black populations </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Symptoms</strong></td> <td> <ul> <li>Changes in urine color, scleral icterus, or jaundice suggest a hemolytic disorder </li> <li>Bloody stools, hematemesis, severe epistaxis, or severe menstrual bleeding suggest anemia from blood loss and/or iron deficiency </li> <li>Infectious symptoms (eg, fevers, cough) suggest an infectious etiology of anemia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>History of anemia</strong></td> <td> <ul> <li>Prior episodes of anemia suggest an inherited disorder </li> <li>Anemia in a patient with previously documented normal CBC suggests an acquired etiology </li> <li>Hyperbilirubinemia in the newborn period suggests a hemolytic etiology; microcytosis at birth suggests chronic intrauterine blood loss or thalassemia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Underlying medical conditions</strong></td> <td> <ul> <li>Underlying renal disease, malignancy, or inflammatory/autoimmune disorders may be associated with anemia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Drugs and toxin exposure</strong></td> <td> <ul> <li>Anemia following exposure to oxidant drugs or fava beans suggests G6PD deficiency </li> <li>Exposure to paint, home renovations, or use of imported or glazed ceramics suggest lead toxicity </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Family history</strong></td> <td> <ul> <li>Family members with jaundice, gallstones, or splenomegaly suggests an inherited hemolytic anemia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Dietary history</strong></td> <td>In infants and young children, iron deficiency is suggested by the following: <ul class=\"decimal_heading\"> <li>Use of low iron formula </li> <li>Introduction of unmodified cow's milk before the age of one year </li> <li>Excessive milk intake (&#62;24 ounces per day) </li> <li>Poor intake of iron-rich foods (meats or fortified infant cereal) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Travel history</strong></td> <td> <ul> <li>Travel to/from areas of endemic infection suggests infectious etiology such as malaria or tuberculosis </li> </ul> </td> </tr> <tr> <td><strong>Developmental history</strong></td> <td> <ul> <li>Developmental delay is associated with iron deficiency, vitamin B12/folic acid deficiency, and Fanconi anemia </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CBC: complete blood count; G6PD: glucose-6-phosphate dehydrogenase.</div><div id=\"graphicVersion\">Graphic 101543 Version 1.0</div></div></div>"},"101544":{"type":"graphic_table","displayName":"HGB, HCT, and MCV values in children","title":"Normal values for hemoglobin, hematocrit, and mean corpuscular volume in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal values for hemoglobin, hematocrit, and mean corpuscular volume in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"10\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\" colspan=\"3\">Age</td> <td class=\"subtitle1\" colspan=\"2\">Hemoglobin (g/dL)</td> <td class=\"subtitle1\" colspan=\"2\">Hematocrit (%)</td> <td class=\"subtitle1\" colspan=\"3\">MCV (fL)</td> </tr> <tr> <td class=\"subtitle2\">50<sup>th</sup> percentile</td> <td class=\"subtitle2\">Lower limit*</td> <td class=\"subtitle2\">50<sup>th</sup> percentile</td> <td class=\"subtitle2\">Lower limit*</td> <td class=\"subtitle2\">50<sup>th</sup> percentile</td> <td class=\"subtitle2\">Lower limit*</td> <td class=\"subtitle2\">Upper limit*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">1 year<sup>&#182;</sup></td> <td colspan=\"2\">Caucasian</td> <td class=\"centered\">12.5</td> <td class=\"centered\">11</td> <td class=\"centered\">37</td> <td class=\"centered\">32</td> <td class=\"centered\">80</td> <td class=\"centered\">71</td> <td class=\"centered\">89</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">African American</td> <td class=\"centered\">12</td> <td class=\"centered\">11</td> <td class=\"centered\">36</td> <td class=\"centered\">31</td> <td class=\"centered\">77</td> <td class=\"centered\">63</td> <td class=\"centered\">88</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">2 to 3 years</td> <td colspan=\"2\">Caucasian</td> <td class=\"centered\">12.6</td> <td class=\"centered\">11</td> <td class=\"centered\">37</td> <td class=\"centered\">33</td> <td class=\"centered\">82</td> <td class=\"centered\">74</td> <td class=\"centered\">89</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">African American</td> <td class=\"centered\">12</td> <td class=\"centered\">11</td> <td class=\"centered\">36</td> <td class=\"centered\">32</td> <td class=\"centered\">80</td> <td class=\"centered\">64</td> <td class=\"centered\">89</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">4 to 6 years</td> <td colspan=\"2\">Caucasian</td> <td class=\"centered\">12.9</td> <td class=\"centered\">11.7</td> <td class=\"centered\">38</td> <td class=\"centered\">34</td> <td class=\"centered\">84</td> <td class=\"centered\">77</td> <td class=\"centered\">91</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">African American</td> <td class=\"centered\">12.5</td> <td class=\"centered\">11</td> <td class=\"centered\">37</td> <td class=\"centered\">33</td> <td class=\"centered\">83</td> <td class=\"centered\">67</td> <td class=\"centered\">91</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">7 to 10 years</td> <td colspan=\"2\">Caucasian</td> <td class=\"centered\">13.5</td> <td class=\"centered\">12</td> <td class=\"centered\">40</td> <td class=\"centered\">35</td> <td class=\"centered\">85</td> <td class=\"centered\">78</td> <td class=\"centered\">91</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">African American</td> <td class=\"centered\">12.7</td> <td class=\"centered\">11.2</td> <td class=\"centered\">38</td> <td class=\"centered\">34</td> <td class=\"centered\">84</td> <td class=\"centered\">72</td> <td class=\"centered\">92</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">11 to 14 years</td> <td rowspan=\"2\">Caucasian</td> <td>Female</td> <td class=\"centered\">13.7</td> <td class=\"centered\">12.3</td> <td class=\"centered\">40</td> <td class=\"centered\">36</td> <td class=\"centered\">87</td> <td class=\"centered\">80</td> <td class=\"centered\">94</td> </tr> <tr> <td>Male</td> <td class=\"centered\">14.3</td> <td class=\"centered\">12.6</td> <td class=\"centered\">42</td> <td class=\"centered\">36</td> <td class=\"centered\">87</td> <td class=\"centered\">80</td> <td class=\"centered\">94</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">African American</td> <td>Female</td> <td class=\"centered\">12.9</td> <td class=\"centered\">10.6</td> <td class=\"centered\">38</td> <td class=\"centered\">33</td> <td class=\"centered\">86</td> <td class=\"centered\">71</td> <td class=\"centered\">95</td> </tr> <tr class=\"divider_bottom\"> <td>Male</td> <td class=\"centered\">13.6</td> <td class=\"centered\">11.8</td> <td class=\"centered\">40</td> <td class=\"centered\">35</td> <td class=\"centered\">86</td> <td class=\"centered\">73</td> <td class=\"centered\">95</td> </tr> <tr> <td rowspan=\"4\">15 to 18 years</td> <td rowspan=\"2\">Caucasian</td> <td>Female</td> <td class=\"centered\">13.7</td> <td class=\"centered\">11.5</td> <td class=\"centered\">40</td> <td class=\"centered\">34</td> <td class=\"centered\">89</td> <td class=\"centered\">81</td> <td class=\"centered\">96</td> </tr> <tr> <td>Male</td> <td class=\"centered\">15.4</td> <td class=\"centered\">13.7</td> <td class=\"centered\">46</td> <td class=\"centered\">40</td> <td class=\"centered\">89</td> <td class=\"centered\">81</td> <td class=\"centered\">96</td> </tr> <tr> <td rowspan=\"2\">African American</td> <td>Female</td> <td class=\"centered\">12.8</td> <td class=\"centered\">10.7</td> <td class=\"centered\">38</td> <td class=\"centered\">32</td> <td class=\"centered\">87</td> <td class=\"centered\">71</td> <td class=\"centered\">96</td> </tr> <tr> <td>Male</td> <td class=\"centered\">14.9</td> <td class=\"centered\">12.9</td> <td class=\"centered\">44</td> <td class=\"centered\">38</td> <td class=\"centered\">87</td> <td class=\"centered\">75</td> <td class=\"centered\">96</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MCV: mean corpuscular volume; fL: femtoliter; AAP: American Academy of Pediatrics.<br />* Lower limits are defined as the 2.5<SUP>th</SUP> percentile for all values, except hemoglobin levels at&nbsp;one and&nbsp;two to&nbsp;three years, which are based upon recommendations from the AAP. Upper limits are defined as the 97.5<SUP>th</SUP> percentile for all values. <br />¶ Normal values for hemoglobin, hematocrit, and MCV change dramatically during the first year of life. Refer to UpToDate topic on the approach to the child with anemia for a discussion of normal values in infants &lt;1 year old.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Brugnara C, Oski FA, Nathan DG. Diagnostic approach to the anemic patient. In: Nathan and Oski's Hematology and Oncology of Infancy and Childhood, 8th ed, Orkin SH, Fisher DE, Ginsburg D, et al (Eds), WB Saunders, Philadelphia 2015. p.293.</LI>&#xD;&#xA;<LI>Cembrowski GS, Chan J, Cheng C. NHANES 1999-2000 data used to create comprehensive health-associated race-, sex- and age-stratified pediatric reference intervals for the Coulter MAXM. Laboratory Hematol 2004; 10:245.</LI>&#xD;&#xA;<LI>Baker RD, Greer FR, Committee on Nutrition American Academy of Pediatrics. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). Pediatrics 2010; 126:1040.</LI></OL></div><div id=\"graphicVersion\">Graphic 101544 Version 4.0</div></div></div>"},"101546":{"type":"graphic_algorithm","displayName":"Algorithm for anemia in children with other cell lines affected","title":"Diagnostic approach to the child with anemia and abnormalities of other cell lines","html":"<div class=\"graphic\"><div style=\"width: 694px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to the child with anemia and abnormalities of other cell lines</div><div class=\"cntnt\"><img style=\"width:674px; height:682px;\" src=\"images/PEDS/101546_Diag_child_anemia_abnormal.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HGB: hemoglobin; HUS: hemolytic uremic syndrome; TTP: thrombotic thrombocytopenic purpura; DIC: disseminated intravascular coagulation; PMNs: polymorphonuclear cells; TIBC: total iron binding capacity; LDH: lactate dehydrogenase; DAT: direct antiglobulin test; WBC: white blood cell; PLT: platelets.<br />* Hemoglobin levels vary considerably by age, race, and sex; when diagnosing anemia, hemoglobin values should be compared with age-, race-, and sex-adjusted norms. Mild anemia occurring at six to nine weeks of life is consistent with \"physiologic anemia\" and is not pathologic. Falsely elevated hemoglobin values may occur when measured using capillary samples (eg, finger or heel sticks), particularly when using microhematocrit measurements. Spurious results may also occur with automated counters in the presence of lipemia, hemolysis, leukocytosis, or high immunoglobulin levels.<br />¶ Findings on blood smear may suggest an underlying etiology of anemia, but they are generally not diagnostic. Further confirmatory testing should be performed to confirm the diagnosis.<br />Δ Selected testing is based upon review of the patient's history and examination of the peripheral blood smear.<br /><FONT class=lozenge>◊</FONT> In children with mild microcytic anemia with thrombocytosis and a dietary history that is suggestive of iron deficiency, serum iron studies (ie, ferritin, iron, and TIBC levels) are generally not necessary. In these children, a therapeutic trial of iron can be used to confirm the diagnosis.</div><div class=\"graphic_reference\"><EM>References: </EM>&#xD;&#xA;<OL>&#xD;&#xA;<LI><EM>Brugnara C, Oski FA, Nathan DG. Diagnostic approach to the anemic patient. In: Nathan and Oski's Hematology and Oncology of Infancy and Childhood, 8th ed, Orkin SH, Fisher DE, Ginsburg D, et al (Eds), WB Saunders, Philadelphia 2015. p.293.</EM></LI>&#xD;&#xA;<LI><EM>Rapaport SI. Diagnosis of anemia. In: Introduction to hematology, JB Lippincott, Philadelphia 1987. p.15.</EM></LI></OL></div><div id=\"graphicVersion\">Graphic 101546 Version 3.0</div></div></div>"},"101548":{"type":"graphic_algorithm","displayName":"Algorithm for anemia in children based on MCV","title":"Diagnostic approach to isolated anemia in children: Morphologic classification","html":"<div class=\"graphic\"><div style=\"width: 1152px\" class=\"figure\"><div class=\"ttl\">Diagnostic approach to isolated anemia in children: Morphologic classification</div><div class=\"cntnt\"><img style=\"width:1132px; height:972px;\" src=\"images/PEDS/101548_Anemia_based_MCV_child.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HGB: hemoglobin; RBC: red blood cell; MCV: mean corpuscular volume; HU: hydroxyurea; RDW: red cell distribution width; TIBC: total iron binding capacity; TEC: transient erythroblastopenia of childhood; G6PD: glucose-6-phosphate dehydrogenase; HUS: hemolytic uremic syndrome; TTP: thrombotic thrombocytopenic purpura; DIC: disseminated intravascular coagulation; DAT: direct antiglobulin test; PMNs: polymorphonuclear cells; LDH: lactate dehydrogenase.<br />* Hemoglobin levels vary considerably by age, race, and sex; when diagnosing anemia, hemoglobin values should be compared with age-, race-, and sex-adjusted norms. Mild anemia occurring at six to nine weeks of life is consistent with \"physiologic anemia\" and is not pathologic. Falsely elevated hemoglobin values may occur when measured using capillary samples (eg, finger or heel \"sticks\"), particularly when using microhematocrit measurements. Spurious results may also occur with automated counters in the presence of lipemia, hemolysis, leukocytosis, or high immunoglobulin levels.<br />¶ The RDW can be helpful in differentiating thalassemia from iron deficiency. High RDW is typical of iron deficiency whereas the RDW is usually normal in patients with thalassemia (though elevated RDW can occur).<br />Δ Anemia of chronic disease typically presents as a normocytic anemia, but can have low MCV.<br /><FONT class=lozenge>◊</FONT> Selected testing is based upon review of the patient's history and examination of the peripheral blood smear.<br />§ In children with mild microcytic anemia and dietary history that is suggestive of iron deficiency, serum iron studies (ie, ferritin, iron, and TIBC levels) are generally not necessary. In these children, a therapeutic trial of iron can be used to confirm the diagnosis.<br />¥ Evidence of hemolysis includes jaundice, indirect hyperbilirubinemia, elevated lactate dehydrogenase, and/or&nbsp;decreased haptoglobin.<br />‡ Findings on blood smear may suggest an underlying etiology of anemia but they are generally not diagnostic. Further confirmatory testing should be carried out to confirm the diagnosis.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Brugnara C, Oski FA, Nathan DG. Diagnostic approach to the anemic patient. In: Nathan and Oski's Hematology and Oncology of Infancy and Childhood, 8th ed, Orkin SH, Fisher DE, Ginsburg D, et al (Eds), WB Saunders, Philadelphia 2015. p.293.</LI>&#xD;&#xA;<LI>Rapaport SI. Diagnosis of anemia. In: Introduction to hematology, JB Lippincott, Philadelphia 1987. p.15.</LI></OL></div><div id=\"graphicVersion\">Graphic 101548 Version 4.0</div></div></div>"},"101551":{"type":"graphic_table","displayName":"Classification of MEN2","title":"Classification of multiple endocrine neoplasia type 2","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of multiple endocrine neoplasia type 2</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Type 2A</td> </tr> <tr> <td class=\"indent1\">MEN2A classical (medullary thyroid cancer, pheochromocytoma, primary hyperparathyroidism)</td> </tr> <tr> <td class=\"indent1\">MEN2A with cutaneous lichen amyloidosis</td> </tr> <tr> <td class=\"indent1\">MEN2A with Hirschsprung disease</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Familial medullary cancer without pheochromocytoma or parathyroid hyperplasia</td> </tr> <tr> <td class=\"subtitle1_single\">Type 2B</td> </tr> <tr> <td class=\"indent1\">Medullary thyroid cancer</td> </tr> <tr> <td class=\"indent1\">Pheochromocytoma</td> </tr> <tr> <td class=\"sublist2_start\">Other</td> </tr> <tr> <td class=\"sublist2\">Mucosal neuromas</td> </tr> <tr> <td class=\"sublist2\">Intestinal ganglioneuromas</td> </tr> <tr> <td class=\"sublist2\">Marfanoid habitus</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MEN2A: multiple endocrine neoplasia type 2A.</div><div id=\"graphicVersion\">Graphic 101551 Version 4.0</div></div></div>"},"101554":{"type":"graphic_algorithm","displayName":"Algorithm for congenital nasolacrimal duct obstruction","title":"Overview of the management of congenital nasolacrimal duct obstruction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Overview of the management of congenital nasolacrimal duct obstruction</div><div class=\"cntnt\"><img style=\"width:396px; height:452px;\" src=\"images/PEDS/101554_Mngmntnslcrmldctobstrctn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Lacrimal sac massage is performed by applying moderate pressure over the lacrimal sac in a downward direction for 2 to 3 seconds. Caregivers are instructed to perform this maneuver two to three times per day until symptoms resolve.<br />¶ If recurrent symptoms occur after the age of six months, referral to an ophthalmologist is warranted.<br />Δ Anisometric amblyopia occurs in approximately 10% of patients with congenital nasolacrimal duct obstruction.<br /><FONT class=lozenge>◊</FONT> Lacrimal duct probing is typically performed in the office with local anesthesia in infants 6 to 10 months of age, whereas it is generally performed in the operating room under general anesthesia in children &gt;12 months old. Nasolacrimal duct intubation, balloon dacryoplasty, dacryocystorhinostomy, and conjunctivodacryocystorhinostomy are performed in the operating room under general anesthesia. Refer to UpToDate topic on nasolacrimal duct obstruction in children for details of surgical management.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>&Ouml;rge FH, Boente CS. The lacrimal system. Pediatr Clin North Am 2014; 61:529.</li>&#xD;&#xA;    <li>Olitsky SE. Update on congenital nasolacrimal duct obstruction. Int Ophthalmol Clin 2014; 54:1.</li>&#xD;&#xA;    <li>Schnall BM. Pediatric nasolacrimal duct obstruction. Curr Opin Ophthalmol 2013; 24:421.</li>&#xD;&#xA;    <li>Pediatric Eye Disease Investigator Group. A randomized trial comparing the cost-effectiveness of 2 approaches for treating unilateral nasolacrimal duct obstruction. Arch Ophthalmol 2012; 130:1525.</li>&#xD;&#xA;    <li>Piotrowski JT, Diehl NN, Mohney BG. Neonatal dacryostenosis as a risk factor for anisometropia. Arch Ophthalmol 2010; 128:1166.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 101554 Version 3.0</div></div></div>"},"101561":{"type":"graphic_picture","displayName":"The three prepatellar bursae","title":"The three prepatellar bursae","html":"<div class=\"graphic\"><div style=\"width: 701px\" class=\"figure\"><div class=\"ttl\">The three prepatellar bursae</div><div class=\"cntnt\"><img style=\"width:681px; height:472px;\" src=\"images/RHEUM/101561_three_prptllr_brs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Subcutaneous.<br />(B) Subfascial.<br />(C) Intertendinous.</div><div class=\"graphic_reference\">Reproduced with permission from: Dye SF, Campagna-Pinto D, Dye CC, et al. Soft-tissue anatomy anterior to the human patella. J Bone Joint Surg Am 2003; 85-A:1012. Copyright &copy; 2003 The Journal of Bone and Joint Surgery, Inc. <a href=\"http://jbjs.org/\" spellcheck=\"true\" target=\"_blank\">http://jbjs.org/</a>.</div><div id=\"graphicVersion\">Graphic 101561 Version 2.0</div></div></div>"},"101562":{"type":"graphic_algorithm","displayName":"Approach to acute lumbosacral radiculopathy","title":"Approach to acute lumbosacral radiculopathy","html":"<div class=\"graphic\"><div style=\"width: 954px\" class=\"figure\"><div class=\"ttl\">Approach to acute lumbosacral radiculopathy</div><div class=\"cntnt\"><img style=\"width:934px; height:772px;\" src=\"images/NEURO/101562_Appr_acute_lmbscrl_rdclpthy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm applies to the evaluation and management of acute (within four weeks of onset) lumbosacral radiculopathy. The objectives of treatment are to ameliorate pain (symptomatic treatment), and to address the specific underlying process (mechanism-specific treatment) if necessary. Neoplastic or infectious etiologies of radiculopathy require prompt mechanism-specific treatment. Though rare, cauda equina syndrome represents a true surgical emergency where decompression should be performed within 24 hours, and within 12 hours if possible. With radiculopathy caused by disc herniation or foraminal stenosis, symptomatic treatment is used during the acute period. However, mechanism-specific treatment is indicated if there is progressive neurologic compromise and/or persistent symptoms that are unresponsive to time and conservative measures.</div><div class=\"graphic_footnotes\">NSAID: nonsteroidal anti-inflammatory drugs.</div><div id=\"graphicVersion\">Graphic 101562 Version 2.0</div></div></div>"},"101563":{"type":"graphic_table","displayName":"Summary of anesthesia machine checkout recommendations","title":"American Society of Anesthesiologists Summary of Anesthesia Machine Checkout Recommendations","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">American Society of Anesthesiologists Summary of Anesthesia Machine Checkout Recommendations</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Item to be completed</td> <td class=\"subtitle1\">Responsible party</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">To be completed daily</td> </tr> <tr> <td class=\"indent1\">Item #1: Verify that auxiliary oxygen cylinder and self-inflating manual ventilation device are available and functioning</td> <td>Provider and technician</td> </tr> <tr> <td class=\"indent1\">Item #2: Verify that patient suction is adequate to clear the airway</td> <td>Provider and technician</td> </tr> <tr> <td class=\"indent1\">Item #3: Turn on anesthesia delivery system and confirm that&nbsp;AC power is available</td> <td>Provider or technician</td> </tr> <tr> <td class=\"indent1\">Item #4: Verify availability of required monitors, including alarms</td> <td>Provider or technician</td> </tr> <tr> <td class=\"indent1\">Item #5: Verify that pressure is adequate on the spare oxygen cylinder mounted on the anesthesia machine</td> <td>Provider and technician</td> </tr> <tr> <td class=\"indent1\">Item #6: Verify that the piped gas pressures are &#8805;50 psig</td> <td>Provider and technician</td> </tr> <tr> <td class=\"indent1\">Item #7: Verify that vaporizers are adequately filled and, if applicable, that the filler ports are tightly closed</td> <td>Provider or technician</td> </tr> <tr> <td class=\"indent1\">Item #8: Verify that there are no leaks in the gas supply lines between the flowmeters and the common gas outlet</td> <td>Provider or technician</td> </tr> <tr> <td class=\"indent1\">Item #9: Test scavenging system function</td> <td>Provider or technician</td> </tr> <tr> <td class=\"indent1\">Item #10: Calibrate, or verify calibration of, the oxygen monitor, and check the low oxygen alarm</td> <td>Provider or technician</td> </tr> <tr> <td class=\"indent1\">Item #11: Verify that carbon dioxide absorbent is not exhausted</td> <td>Provider or technician</td> </tr> <tr> <td class=\"indent1\">Item #12: Breathing system pressure and leak testing</td> <td>Provider and technician</td> </tr> <tr> <td class=\"indent1\">Item #13: Verify that gas flows properly through the breathing circuit during both inspiration and exhalation</td> <td>Provider and technician</td> </tr> <tr> <td class=\"indent1\">Item #14: Document completion of checkout procedures</td> <td>Provider and technician</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Item #15: Confirm ventilator settings and evaluate readiness to deliver anesthesia care <strong>(anesthesia time out)</strong></td> <td>Provider</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">To be completed prior to each procedure</td> </tr> <tr> <td class=\"indent1\">Item #2: Verify that patient suction is adequate to clear the airway</td> <td>Provider and technician</td> </tr> <tr> <td class=\"indent1\">Item #4: Verify availability of required monitors, including alarms</td> <td>Provider or technician</td> </tr> <tr> <td class=\"indent1\">Item #7: Verify that vaporizers are adequately filled and, if applicable, that the filler ports are tightly closed</td> <td>Provider</td> </tr> <tr> <td class=\"indent1\">Item #11: Verify that carbon dioxide absorbent is not exhausted</td> <td>Provider or technician</td> </tr> <tr> <td class=\"indent1\">Item #12: Breathing system pressure and leak testing</td> <td>Provider and technician</td> </tr> <tr> <td class=\"indent1\">Item #13: Verify that gas flows properly through the breathing circuit during both inspiration and exhalation</td> <td>Provider and technician</td> </tr> <tr> <td class=\"indent1\">Item #14: Document completion of checkout procedures</td> <td>Provider and technician</td> </tr> <tr> <td class=\"indent1\">Item #15: Confirm ventilator settings and evaluate readiness to deliver anesthesia care <strong>(anesthesia time out)</strong></td> <td>Provider</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">AC: alternating current; psig: pounds per square inch gauge.</div><div class=\"graphic_reference\">Reproduced with permission from: Riutort KT, Eisenkraft JB. The Anesthesia Workstation and Delivery Systems for Inhaled Anesthetics. In: Clinical Anesthesia, 7th ed, Barash PG, Cullen BF, Stoelting RK, et al. (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 101563 Version 4.0</div></div></div>"},"101565":{"type":"graphic_figure","displayName":"McCall culdoplasty technique, abdominal view","title":"McCall culdoplasty technique, abdominal view","html":"<div class=\"graphic\"><div style=\"width: 579px\" class=\"figure\"><div class=\"ttl\">McCall culdoplasty technique, abdominal view</div><div class=\"cntnt\"><img style=\"width:559px; height:784px;\" src=\"images/OBGYN/101565_Mccll_cldplsty_tchnq_abdmnl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Abdominal view of McCall culdoplasty sutures.</div><div class=\"graphic_reference\">Courtesy of Drs. Jasmine Tan-Kim and Shawn Menefee.</div><div id=\"graphicVersion\">Graphic 101565 Version 2.0</div></div></div>"},"101566":{"type":"graphic_figure","displayName":"Moschcowitz culdoplasty, abdominal view","title":"Moschcowitz culdoplasty, abdominal view","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Moschcowitz culdoplasty, abdominal view</div><div class=\"cntnt\"><img style=\"width:558px; height:784px;\" src=\"images/OBGYN/101566_Moschcowitz_cldplsty_abdmnl.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drs. Jasmine Tan-Kim and Shawn Menefee.</div><div id=\"graphicVersion\">Graphic 101566 Version 1.0</div></div></div>"},"101567":{"type":"graphic_picture","displayName":"Halban culdoplasty, abdominal view","title":"Halban culdoplasty, abdominal view","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Halban culdoplasty, abdominal view</div><div class=\"cntnt\"><img style=\"width:582px; height:784px;\" src=\"images/OBGYN/101567_Halban_culdoplasty_abdomina.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drs. Jasmine Tan-Kim and Shawn Menefee.</div><div id=\"graphicVersion\">Graphic 101567 Version 1.0</div></div></div>"},"101571":{"type":"graphic_picture","displayName":"Sinus tract drainage site in left ischio-rectal fossa","title":"Sinus tract drainage site in left ischio-rectal fossa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sinus tract drainage site in left ischio-rectal fossa</div><div class=\"cntnt\"><img style=\"width:444px; height:667px;\" src=\"images/OBGYN/101571_Sns_trct_drng_sch_rctl_fss.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drs. Emanuel Trabuco and John Gebhart.</div><div id=\"graphicVersion\">Graphic 101571 Version 1.0</div></div></div>"},"101572":{"type":"graphic_picture","displayName":"Granulation tissue surrounding exposed Gore-Tex suture","title":"Granulation tissue surrounding exposed Gore-Tex suture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Granulation tissue surrounding exposed Gore-Tex suture</div><div class=\"cntnt\"><img style=\"width:446px; height:674px;\" src=\"images/OBGYN/101572_Grnl_tss_srrn_exps_gr_tx.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Drs. Emanuel Trabuco and John Gebhart.</div><div id=\"graphicVersion\">Graphic 101572 Version 1.0</div></div></div>"},"101573":{"type":"graphic_picture","displayName":"Sinus tract from transvaginal Gore-Tex suture","title":"Sinus tract from transvaginal Gore-Tex suture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Sinus tract from transvaginal Gore-Tex suture</div><div class=\"cntnt\"><img style=\"width:446px; height:672px;\" src=\"images/OBGYN/101573_Sns_trct_trnsvgl_Gr_tex_str.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Probe passed from peri-rectal drainage site into the vagina demonstrating fistula tract created by Gore-Tex suture.</div><div class=\"graphic_reference\">Courtesy of Drs. Emanuel Trabuco and John Gebhart.</div><div id=\"graphicVersion\">Graphic 101573 Version 1.0</div></div></div>"},"101574":{"type":"graphic_picture","displayName":"Vaginal sinus tract from Gore-Tex suture","title":"Vaginal sinus tract from Gore-Tex suture","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vaginal sinus tract from Gore-Tex suture</div><div class=\"cntnt\"><img style=\"width:366px; height:551px;\" src=\"images/OBGYN/101574_Vgnl_sns_trct_gore_tex_str.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Blunt probe emerging in vagina from peri-rectal sinus tract caused by Gore-Tex suture.</div><div class=\"graphic_reference\">Courtesy of Drs. Emanuel Trabuco and John Gebhart.</div><div id=\"graphicVersion\">Graphic 101574 Version 1.0</div></div></div>"},"101575":{"type":"graphic_picture","displayName":"Debridement of vaginal sinus tract","title":"Debridement of vaginal sinus tract​","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Debridement of vaginal sinus tract​</div><div class=\"cntnt\"><img style=\"width:368px; height:552px;\" src=\"images/OBGYN/101575_Dbrdmnt_vgnl_sns_trct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Debridement of sinus tract extending from vagina to peri-rectal skin to aid in healing.</div><div class=\"graphic_reference\">Courtesy of Drs. Emanuel Trabuco and John Gebhart.</div><div id=\"graphicVersion\">Graphic 101575 Version 1.0</div></div></div>"},"101576":{"type":"graphic_picture","displayName":"Excised Gore-Tex suture and indurated tissue","title":"Excised Gore-Tex suture and indurated tissue","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Excised Gore-Tex suture and indurated tissue</div><div class=\"cntnt\"><img style=\"width:712px; height:391px;\" src=\"images/OBGYN/101576_Excs_gore_tex_str_indrt_tss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Gore-Tex sutures and indurated tissue removed from sinus tract between vagina and ischio-rectal fossa.</div><div class=\"graphic_reference\">Courtesy of Drs. Emanuel Trabuco and John Gebhart.</div><div id=\"graphicVersion\">Graphic 101576 Version 1.0</div></div></div>"},"101578":{"type":"graphic_diagnosticimage","displayName":"Imaging of penetrating ulcer with hematoma","title":"Pentrating ulcer with hematoma on radiography and CT scan","html":"<div class=\"graphic\"><div style=\"width: 884px\" class=\"figure\"><div class=\"ttl\">Pentrating ulcer with hematoma on radiography and CT scan</div><div class=\"cntnt\"><img style=\"width:864px; height:393px;\" src=\"images/RADIOL/101578_Imag_penetrat_ulcr_hmtm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A frontal chest radiograph (A) shows an enlarged aortic knob (arrow) and a prominent aorto-pulmonary window (arrowhead). A computed tomography scan (B) through the aortic arch shows a penetrating ulcer with a mural hematoma (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 101578 Version 3.0</div></div></div>"},"101579":{"type":"graphic_diagnosticimage","displayName":"CT of focal aortic dissection","title":"Focal aortic dissection on CT scan","html":"<div class=\"graphic\"><div style=\"width: 890px\" class=\"figure\"><div class=\"ttl\">Focal aortic dissection on CT scan</div><div class=\"cntnt\"><img style=\"width:870px; height:349px;\" src=\"images/RADIOL/101579_CT_focal_aortic_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the upper abdomen shows a focal dissection (arrowhead) and a small mural hematoma (arrow). Small bilateral pleural effusions are present (asterisks). Image B is a magnified view and shows focal dissection (arrowhead) and the mural hematoma (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 101579 Version 2.0</div></div></div>"},"101580":{"type":"graphic_diagnosticimage","displayName":"CT of aortic ulcer","title":"Aortic ulcer on CT scan","html":"<div class=\"graphic\"><div style=\"width: 827px\" class=\"figure\"><div class=\"ttl\">Aortic ulcer on CT scan</div><div class=\"cntnt\"><img style=\"width:807px; height:418px;\" src=\"images/RADIOL/101580_CT_aortic_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the mid chest shows an aortic ulcer (arrow) with a wide mouth (arrowhead). Bilateral pleural effusions are present (asterisks). Image B is a magnified view and shows an aortic ulcer (arrow) with a wide mouth (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 101580 Version 2.0</div></div></div>"},"101582":{"type":"graphic_table","displayName":"Basic rehabilitation program for adductor muscle strain","title":"Basic rehabilitation program for adductor muscle strain","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic rehabilitation program for adductor muscle strain</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Phase I (acute): From time of injury to up to five days depending on severity</td> </tr> <tr> <td class=\"subtitle2_single\">Acute care:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">RICE (rest, ice, compression, elevation) for first 48 hours; ice can be applied as often as every hour for 10 to 20 minutes for pain relief; Acetaminophen or topical or oral NSAIDs for pain relief if needed.</td> </tr> <tr> <td class=\"subtitle2_single\">Massage:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gentle soft tissue techniques; avoid deep tissue, cross friction, or other vigorous techniques.</td> </tr> <tr> <td class=\"subtitle2_single\">Compression:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">A compression sleeve or elastic wrap may limit swelling and increase comfort during and after exercise. Some athletic trainers prefer adductor taping techniques during activity.</td> </tr> <tr> <td class=\"subtitle2_single\">Hip passive range of motion in pain-free range:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hip abduction and external rotation are limited by pain. Passive hip movement may be performed gently by PT. PT may recommend easy home exercises. Patient should not extend motion beyond point of mild pain (2/10); excess motion may disrupt healing. Gentle static stretching within a pain-free range once or twice daily - usually a maximum of 3 stretches for 15 to 30 seconds for each stretch - may be performed. </td> </tr> <tr> <td class=\"subtitle2_single\">Isometric adductor contractions:</td> </tr> <tr> <td class=\"indent1\">Begin with submaximal isometric contractions for 15 to 30 seconds with knees bent. Gradually progress to contraction with knees straight, and then to maximal isometric contraction, when this can be done pain free. Performed to relieve pain and allow a flexible scar to form. Not for strengthening at this stage.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Light resistance exercises performed in non weight-bearing position without added load (all <strong>except</strong> abduction/adduction). Exercises should be pain-free. Example: side-lying bridge with physio ball squeezed between knees, 3 sets of 30 second holds on each side.</td> </tr> <tr> <td class=\"subtitle2_single\">General exercises:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Strength exercises for trunk, upper extremities, and contralateral lower extremity that do not cause pain in injured adductors; flexibility exercises as indicated for uninjured muscles; balance board using bilateral stance to improve proprioception - building up to 1 minute with eyes open, and progressing to 1 minute with eyes closed.</td> </tr> <tr> <td class=\"subtitle2_single\">Ultrasound and electrotherapy:</td> </tr> <tr> <td class=\"indent1\">The author uses these modalities with the goal of promoting early healing. No high quality evidence supporting these techniques is available.</td> </tr> <tr> <td class=\"indent1\">Progress to Phase II when athlete can perform concentric adduction against gravity without pain, signs of inflammation have decreased, and minimal or no pain present at rest (some pain with adduction, abduction stretch, and palpation will persist).</td> </tr> <tr> <td class=\"subtitle1_single\">Phase II (subacute): From 72 hours up to 6 weeks post injury depending on severity</td> </tr> <tr> <td class=\"subtitle2_single\">Mobility and flexibility:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Range of hip motion exercises is increased to the point of mild pain only. Motion exercises should not cause significant pain. Specific Soft Tissue Mobilization (SSTM) and Myofascial release performed by an experienced therapist may be added.</td> </tr> <tr> <td class=\"subtitle2_single\">Adductor stretches:</td> </tr> <tr> <td class=\"indent1\">May use static stretch or proprioceptive neuromuscular facilitation (PNF) techniques. Avoid pain and increase range of motion gradually.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Continue general flexibility exercises as indicated.</td> </tr> <tr> <td class=\"subtitle2_single\">Adductor-specific strength exercises:</td> </tr> <tr> <td class=\"indent1\">Concentric adduction against gravity - build up to 3 sets of 10 to 12 repetitions.</td> </tr> <tr> <td class=\"indent1\">Single leg stance - 3 sets of 30 seconds.</td> </tr> <tr> <td class=\"indent1\">When basic strength exercises can be performed without pain, add standing exercises against resistance, Sumo squats, and lunges. Standing concentric/eccentric adductor exercises against resistance (eg, elastic band, weight column); start with light resistance; gradually build to 3 sets of 10 to 12 repetitions. Maintain strength of uninjured adductors.</td> </tr> <tr> <td class=\"indent2\">Sumo squats: Start with 1 set of 6 repetitions; gradually build to 3 sets of 12 repetitions.</td> </tr> <tr> <td class=\"indent2\">Unilateral lunges: Start with 1 set of 8 to 10 repetitions, and gradually build to 3 sets of 10 to 12 repetitions.</td> </tr> <tr> <td class=\"indent2\">When basic adductor strength exercises are performed without pain, introduce sliding board exercises: Unilateral adduction on sliding board moving in frontal plane: perform under control with arms holding stationary object for support; start with 1 set of 6 to 8 repetitions, and gradually build to 3 sets of 10 to 12 repetitions.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Bilateral adduction on sliding board moving in frontal plane: Perform under control with arms holding stationary object for support; start with 1 set of 6 to 8 repetitions and gradually build to 3 sets of 10 to 12 repetitions.</td> </tr> <tr> <td class=\"subtitle2_single\">General conditioning:</td> </tr> <tr> <td class=\"indent1\">May begin stationary cycling or swimming. Start with 10 to 15 minutes and build to 30 minutes. Begin cycling with no resistance; may gradually add light resistance, provided no pain. Backstroke, freestyle, and butterfly okay; avoid breaststroke, flip (tumble) turns, and diving.</td> </tr> <tr> <td class=\"indent1\">With mild injuries, jogging may be permitted provided it is pain-free.</td> </tr> <tr> <td class=\"indent1\">Progress to Phase III when range of motion for injured lower extremity is equal to uninvolved side and strength of injured adductors (tested with hand dynamometer/cuff) at least 75 percent of ipsilateral abductors. Experienced clinicians may determine preparedness for Phase III based on examination, but some objective assessment demonstrating adequate strength in the affected lower extremity should be performed.</td> </tr> <tr> <td class=\"subtitle1_single\">Phase III (preparation for return to sport): From 6 weeks up to 1 year post injury</td> </tr> <tr> <td class=\"indent1\">Continue SSTM in more functional positions.</td> </tr> <tr> <td class=\"indent1\">Continue stretching exercises as indicated.</td> </tr> <tr> <td class=\"indent1\">Perform select Phase II strength exercises (eg, standing adductor exercises, Sumo squats, slide board) with appropriate but gradual increases in load and volume.</td> </tr> <tr> <td class=\"indent1\">Lunges in all planes: Start with 1 set of 10 to 12 repetitions and build to at least 3 sets (volume needed for full rehabilitation varies by sport).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Begin sport-specific training: Participants in sports involving change of direction (eg, soccer, rugby, basketball, tennis) perform shuttle runs and cutting exercises involving frequent and sudden changes in direction; participants in sports involving kicking begin kicking exercises.</td> </tr> <tr> <td class=\"subtitle2_single\">Exercises for skaters:</td> </tr> <tr> <td class=\"indent2\">Resisted strides using cable column or elastic band (to simulate skating).</td> </tr> <tr> <td class=\"indent2\">On ice, kneeling adductor pull-togethers.</td> </tr> <tr> <td class=\"indent1\">Assess sport biomechanics and correct or modify technique (eg, ice skating) as necessary. </td> </tr> <tr> <td class=\"indent1\">Progress to full sport when adduction strength at least 90% of ipsilateral abduction strength (tested using dynamometer or cuff) and equal to contralateral adduction strength. Running must be without a limp, even when executing a sharp change of direction, and push-off force should be equal with each extremity.</td> </tr> <tr> <td class=\"indent1\">Evaluation of the athlete's kinetic chain and all intrinsic as well as extrinsic factors should be evaluated and addressed to prevent recurrence.</td> </tr> <tr> <td class=\"indent1\">Important warning: The pace of each stage of rehabilitation for any injury should be determined according to the injury, the athlete's overall needs and goals, and to the healing response. In particular, although the rehabilitation exercises used may be similar, tendon injuries heal more slowly than isolated muscle injuries, and older athletes heal more slowly than younger ones.</td> </tr> <tr> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101582 Version 1.0</div></div></div>"},"101583":{"type":"graphic_table","displayName":"Subtypes of calcinosis cutis","title":"Subtypes of calcinosis cutis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Subtypes of calcinosis cutis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Subtype</td> <td class=\"subtitle1\">Etiology</td> <td class=\"subtitle1\">Common clinical findings</td> <td class=\"subtitle1\">Associated manifestations</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"14\"><strong>Dystrophic</strong></td> <td>Systemic sclerosis</td> <td>Firm papules, plaques or nodules usually on the hands, feet, or extremities, often in sites of minor trauma</td> <td>Limited SSc: Cutaneous sclerosis primarily involving hands and distal forearms CREST: Raynaud phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia</td> </tr> <tr> <td>Dermatomyositis</td> <td>Firm papules, plaques or nodules on the extremities (particularly elbows, knees, shoulders, and buttocks), often in sites of repeated trauma; deposits may be intracutaneous, subcutaneous, fascial, or intramuscular</td> <td>Gottron papules, heliotrope eruption, poikiloderma, periungual capillary changes, proximal muscle weakness</td> </tr> <tr> <td>Systemic lupus erythematosus</td> <td>Often an asymptomatic incidental radiologic finding; often buttocks and extremities</td> <td>Manifestations of systemic lupus erythematosus</td> </tr> <tr> <td>Pancreatic enzyme panniculitis</td> <td>Painful subcutaneous nodules, often on pretibial skin with ulceration; may drain an oily substance</td> <td>Manifestations of pancreatic disease, particularly pancreatitis or pancreatic adenocarcinoma</td> </tr> <tr> <td>Subcutaneous fat necrosis of the newborn</td> <td>Erythematous nodules and plaques, especially on cheeks, back, buttocks, and extremities</td> <td>Risk of hypercalcemia</td> </tr> <tr> <td>Lupus panniculitis</td> <td>Firm subcutaneous nodules on the head, proximal extremities, or trunk</td> <td>Systemic lupus erythematosus may or may not be present</td> </tr> <tr> <td>Porphyria cutanea tarda</td> <td>Firm plaques within sites of cutaneous sclerosis that may exhibit ulceration or transepidermal elimination of calcium; usually on head, neck, or dorsal hands</td> <td>Photosensitivity, skin fragility, blistering, sclerodermoid changes</td> </tr> <tr> <td>Pseudoxanthoma elasticum</td> <td>Clinically evident calcification rare; if occurs, may exhibit papules or nodules extruding calcium</td> <td>Yellowish papules in flexural areas, angioid streaks, cardiovascular abnormalities</td> </tr> <tr> <td>Werner syndrome</td> <td>Painful soft tisue calcification with ulceration, usually involving Achilles tendon and knee or elbow tendons</td> <td>Premature aging, scleroderma-like skin changes</td> </tr> <tr> <td>Ehlers-Danlos syndromes</td> <td>Calcified spheroids, focal subcutaneous calcification, calcification within molluscoid pseudotumors</td> <td>Connective tissue abnormalities (eg, skin hyperextensibility, joint hypermobility, tissue fragility)</td> </tr> <tr> <td>Cutaneous neoplasms</td> <td>Most common in pilomatricomas; sometimes only noted histologically</td> <td>N/A</td> </tr> <tr> <td>Trauma</td> <td>Firm, whitish papules or subcutaneous nodules</td> <td>History of injury to involved area; may precede calicifcation by years</td> </tr> <tr> <td>Onchocerciasis</td> <td>Subcutaneous nodules (onchocercomas) that may calcify over time</td> <td>Ocular changes, pruritus, papular eruptions, hypopigmentation</td> </tr> <tr class=\"divider_bottom\"> <td>Cysticercosis</td> <td>Papulonodules</td> <td>Seizures, headache, nausea, vomiting if neurologic involvement</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Metastatic</strong></td> <td>Chronic renal failure</td> <td>Firm nodules, particularly at periarticular sites</td> <td>Often normal serum calcium and increased serum phosphate</td> </tr> <tr> <td>Hypervitaminosis D</td> <td>Periarticular calcification</td> <td>Symptoms of hypercalcemia and hypercalciuria (weakness, lethargy, headache, nausea, polyuria)</td> </tr> <tr> <td>Albright hereditary osteodystrophy</td> <td>Symmetric cutaneous ossification</td> <td>Pseudohypoparathyroidism, intellectual disability, obesity</td> </tr> <tr class=\"divider_bottom\"> <td>Malignancy</td> <td>Firm, whitish papules or subcutaneous nodules</td> <td>Signs or symptoms of a bone-destroying malignancy</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>Idiopathic</strong></td> <td>Idiopathic calcification of the scrotum</td> <td>Firm, white subcutaneous nodules on the scrotum</td> <td>N/A</td> </tr> <tr> <td>Subepidermal calcified nodule</td> <td>Solitary hard, white papules usually on the head, neck, or upper extremities; less frequently, multiple nodules occur</td> <td>N/A</td> </tr> <tr class=\"divider_bottom\"> <td>Tumoral calcinosis</td> <td>Large calcium deposits around major joints (eg, hips, shoulders, elbows, knees)</td> <td>Some patients have hyperphosphatemia</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Iatrogenic</strong></td> <td>Iatrogenic</td> <td>Firm papules, nodules, or plaques</td> <td>History of intravenous therapy or other medical procedure</td> </tr> <tr> <td><strong>Calciphylaxis</strong></td> <td>Calciphylaxis</td> <td>Painful retiform purpura, stellate ulcers, particularly in areas with high adiposity (eg, buttocks, thighs)</td> <td>End-stage renal disease</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101583 Version 1.0</div></div></div>"},"101585":{"type":"graphic_table","displayName":"MMR contraindications and precautions","title":"Contraindications and precautions for MMR and MMRV vaccine*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications and precautions for MMR and MMRV vaccine*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Contraindications</td> </tr> <tr> <td class=\"indent1\">Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component</td> </tr> <tr> <td class=\"indent1\">Pregnancy or possibility of pregnancy within 4 weeks</td> </tr> <tr> <td class=\"sublist2_start\">Immunosuppression</td> </tr> <tr> <td class=\"indent2\">Primary or acquired immunodeficiency (eg, cellular immunodeficiencies, hypogammaglobulinemia, dysgammaglobulinemia, AIDS and HIV infection with severe immunosuppression<sup>&#182;</sup>)</td> </tr> <tr> <td class=\"indent2\">Blood dyscrasia, leukemia, lymphoma, malignant neoplasms affecting the bone marrow or lymphatic system</td> </tr> <tr> <td class=\"indent2\">Long-term immunosuppressive therapy; for corticosteroids: &#8805;2 weeks of prednisone 20 mg per day or 2 mg/kg per day or equivalent</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">History of congenital or hereditary immunodeficiency in a parent or sibling, unless the immune competence of the vaccine recipient has been substantiated clinically or verified by a laboratory</td> </tr> <tr> <td class=\"subtitle1_single\">Precautions<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Receipt of antibody-containing blood product within past 3 to 11 months<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">History of thrombocytopenia or thrombocytopenic purpura</td> </tr> <tr> <td class=\"indent1\">Need for tuberculosis testing<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Moderate or severe illness with or without fever (ie, illness more severe than upper respiratory infection, otitis media, gastroenteritis)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">For MMRV only: Personal history of seizures or seizures in sibling or parent</td> </tr> <tr> <td class=\"subtitle1_single\">Conditions commonly misperceived as contraindications that are not contraindications to MMR or MMRV</td> </tr> <tr> <td class=\"indent1\">Egg allergy</td> </tr> <tr> <td class=\"indent1\">HIV infection without severe immune compromise<sup>&#182;</sup> is not a contraindication to MMR, but is a contraindication to MMRV</td> </tr> <tr> <td class=\"indent1\">Positive tuberculin skin test</td> </tr> <tr> <td class=\"indent1\">Simultaneous tuberculosis testing (either TST or IGRA)<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent1\">Breastfeeding</td> </tr> <tr> <td class=\"indent1\">Pregnant contact</td> </tr> <tr> <td class=\"indent1\">Child-bearing age, but not trying to become pregnant</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Immune deficient family member or household contact</td> </tr> <tr> <td class=\"subtitle1_single\">Conditions commonly misperceived as contraindications that are not contraindications to any vaccine</td> </tr> <tr> <td class=\"indent1\">Mild acute illness with or without fever (eg, upper respiratory infection, otitis media, gastroenteritis)</td> </tr> <tr> <td class=\"indent1\">Mild-to-moderate local reaction (eg, swelling, redness, soreness) after previous dose</td> </tr> <tr> <td class=\"indent1\">Low-grade or moderate fever after previous dose</td> </tr> <tr> <td class=\"indent1\">Current antimicrobial therapy<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent1\">Convalescent phase of illness</td> </tr> <tr> <td class=\"indent1\">Preterm birth (except for hepatitis B vaccine in infants who weigh &#60;2000 g and whose mother is hepatitis B surface antigen negative at the time of birth)</td> </tr> <tr> <td class=\"indent1\">Recent exposure to infectious disease</td> </tr> <tr> <td class=\"indent1\">History of penicillin allergy, other nonvaccine allergies, relatives with allergies, or receiving allergen extract immunotherapy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MMR: measles, mumps, rubella combination vaccine; MMRV: measles, mumps, rubella, varicella combination vaccine; AIDS: acquired immunodeficiency syndrome; HIV: human immunodeficiency virus; TST: tuberculin skin test; IGRA: interferon gamma release assay.<br />* MMR and varicella vaccines can be administered on the same day. If not administered on the same day, they should be separated by ≥28 days.<br />¶ Refer to UpToDate topic on measles, mumps, and rubella vaccines for definition of severe immunosuppression in HIV infection.<br />Δ Precautions should be reviewed with respect to potential benefits and risks. If the benefit of vaccination is believed to outweigh the risk, the vaccine should be administered; if the risk from the vaccine is believed to outweigh the benefit, the vaccine should not be administered.<br /><FONT class=lozenge>◊</FONT> The specific interval depends upon the product. Refer to UpToDate topic on measles, mumps, and rubella vaccines for children for details.<br />§ Measles vaccination may suppress temporarily tuberculin reactivity. Measles-containing vaccine can be administered on the same day or 4 to 6 weeks after tuberculin skin testing. The effect of live virus vaccination on IGRA is uncertain. Pending additional information, the Advisory Committee on Immunization Practices suggests that IGRA testing be performed on the same day or 4 to 6 weeks after administration of MMR.<br />¥ Antiviral drugs active against herpes viruses (eg, acyclovir, valacyclovir) may interfere with varicella-containing vaccines and should be discontinued ≥24 hours before administration of varicella vaccines and avoided for 14 days after vaccination.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: Summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.</LI>&#xD;&#xA;<LI>Kroger AT, Duchin J, Vázquez M. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at: <A spellcheck=true href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</A>. Accessed on April 28, 2017.</LI></OL></div><div id=\"graphicVersion\">Graphic 101585 Version 3.0</div></div></div>"},"101586":{"type":"graphic_figure","displayName":"Measles epidemiology US","title":"Number of measles cases – United States, 1962 to 2011","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Number of measles cases – United States, 1962 to 2011</div><div class=\"cntnt\"><img style=\"width:700px; height:380px;\" src=\"images/PEDS/101586_Measles_epidemiology_US.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Measles data provided were reported voluntarily to the Centers for Disease Control and Prevention from state health departments.</div><div class=\"graphic_reference\">Reproduced from: McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: Summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.</div><div id=\"graphicVersion\">Graphic 101586 Version 3.0</div></div></div>"},"101587":{"type":"graphic_table","displayName":"MMR and MMRV storage requirements","title":"Storage requirements for measles, mumps, and rubella (MMR) and measles, mumps, rubella, and varicella (MMRV) vaccines*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Storage requirements for measles, mumps, and rubella (MMR) and measles, mumps, rubella, and varicella (MMRV) vaccines*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Form</td> <td class=\"subtitle1\">MMR vaccine</td> <td class=\"subtitle1\">MMRV vaccine</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Lyophilized form</td> <td>Vaccine should be shipped and stored at -50 to +8&#176;C (-58 to +46&#176;F) to maintain potency.</td> <td>Vaccine should be shipped at -50 to -15&#176;C (-58 to +5&#176;F).</td> </tr> <tr class=\"divider_bottom\"> <td>Do not use dry ice because this may subject the vaccine to temperatures colder than -50&#176;C (-58&#176;F).</td> <td>Do not use dry ice because temperatures below -50&#176;C (-58&#176;F) might reduce potency.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Reconstituted form</td> <td>Use reconstituted vaccine as soon as possible or store at 2 to 8&#176;C (36 to 46&#176;F) for up to 8 hours.</td> <td>Use reconstituted vaccine as soon as possible or store at room temperature for up to 30 minutes.</td> </tr> <tr class=\"divider_bottom\"> <td>Discard if not used.</td> <td>Discard if not used.</td> </tr> <tr> <td rowspan=\"2\">Diluent</td> <td>Store at room temperature 20 to 25&#176;C (68 to 77&#176;F) or in a refrigerator 2 to 8&#176;C (36 to 46&#176;F).</td> <td>Store at room temperature 20 to 25&#176;C (68 to 77&#176;F) or in a refrigerator 2 to 8&#176;C (36 to 46&#176;F).</td> </tr> <tr> <td>Do not freeze.</td> <td>Do not freeze.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Vaccine viruses can be inactivated by light and should always be stored in a dark place.</div><div class=\"graphic_reference\">Reproduced from: McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: Summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.</div><div id=\"graphicVersion\">Graphic 101587 Version 2.0</div></div></div>"},"101588":{"type":"graphic_diagnosticimage","displayName":"CT of necrotizing fasciitis","title":"Necrotizing fasciitis on CT","html":"<div class=\"graphic\"><div style=\"width: 812px\" class=\"figure\"><div class=\"ttl\">Necrotizing fasciitis on CT</div><div class=\"cntnt\"><img style=\"width:792px; height:475px;\" src=\"images/RADIOL/101588_CT_necrotizing_fasciitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT scan through the mid thighs (A) shows necrosis of the right vastus lateralis muscle (arrowheads) with spread to the medial aspect of the thigh (arrow). The normal left vastus lateralis (asterisk) is shown in contrast. Image B is a coronal reconstruction and shows the cranio-caudal extent of the necrosis (arrowheads).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 101588 Version 1.0</div></div></div>"},"101589":{"type":"graphic_table","displayName":"MMR seroconversion and effectiveness","title":"Summary of immune response (seroconversion), vaccine effectiveness, and duration of immunity for the measles, rubella, and mumps component of the measles, mumps, rubella combination vaccine*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of immune response (seroconversion), vaccine effectiveness, and duration of immunity for the measles, rubella, and mumps component of the measles, mumps, rubella combination vaccine*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Disease</td> <td class=\"subtitle1\" rowspan=\"2\">Seroconversion after 1 dose<br /> Median % (range)</td> <td class=\"subtitle1\" colspan=\"2\">Vaccine effectiveness<br /> Median % (range)</td> <td class=\"subtitle1\" colspan=\"2\">Duration of immunity</td> </tr> <tr> <td class=\"subtitle2\">1 dose</td> <td class=\"subtitle2\">2 doses</td> <td class=\"subtitle2\">1 dose</td> <td class=\"subtitle2\">2 doses</td> </tr> <tr> <td>Measles</td> <td class=\"centered\">96 (84 to 100)</td> <td class=\"centered\">93 (39&nbsp;to 100)</td> <td class=\"centered\">97 (67&nbsp;to 100)</td> <td class=\"centered\">&#8805;11 years</td> <td class=\"centered\">&#8805;15 years</td> </tr> <tr> <td>Rubella</td> <td class=\"centered\">99 (95&nbsp;to 100)</td> <td class=\"centered\">97 (94&nbsp;to 100)</td> <td class=\"centered\">NA</td> <td class=\"centered\">&#8805;16 years</td> <td class=\"centered\">&#8805;15 years</td> </tr> <tr> <td>Mumps</td> <td class=\"centered\">94 (89&nbsp;to 97)</td> <td class=\"centered\">78 (49&nbsp;to 92)</td> <td class=\"centered\">88 (66&nbsp;to 95)</td> <td class=\"centered\">&#8805;10 years</td> <td class=\"centered\">&#8805;15 years</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: not applicable.<br />* Data were obtained from multiple studies describing immune response (seroconversion), vaccine effectiveness, and duration of immunity for the measles, rubella, and mumps component of the measles, mumps, rubella, combination vaccine.</div><div class=\"graphic_reference\">Reproduced from: McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: Summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.</div><div id=\"graphicVersion\">Graphic 101589 Version 2.0</div></div></div>"},"101590":{"type":"graphic_figure","displayName":"Mumps epidemiology US","title":"Number of mumps cases – United States 1968 to 2011","html":"<div class=\"graphic\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Number of mumps cases – United States 1968 to 2011</div><div class=\"cntnt\"><img style=\"width:704px; height:460px;\" src=\"images/PEDS/101590_Mumps_epidemiology_US.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mumps data provided were reported voluntarily to Centers for Disease Control and Prevention from state health departments.</div><div class=\"graphic_reference\">Reproduced from: McLean HQ, Fiebelkorn AP, Temte JL, et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: Summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:1.</div><div id=\"graphicVersion\">Graphic 101590 Version 3.0</div></div></div>"},"101591":{"type":"graphic_table","displayName":"MMR catch-up schedule","title":"Catch-up schedule for measles, mumps, and rubella immunization for children in the United States*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Catch-up schedule for measles, mumps, and rubella immunization for children in the United States*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Current age</td> <td class=\"subtitle1\">Number of previous doses</td> <td class=\"subtitle1\">Number and timing of doses for catch-up if using</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">&#8805;12 months to 4 years</td> <td> <p>0 doses of MMR</p> 0 doses of varicella</td> <td> <p>First dose of MMR and first dose of varicella now<sup>&#182;</sup></p> Second dose of MMR and second dose of varicella<sup>&#182;</sup> at 4 to 6 years of age<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td> <p>0 doses of MMR</p> 1 dose of varicella</td> <td> <p>First dose of MMR now or as soon as possible at least 28 days after first dose of varicella vaccine</p> Second dose of MMR and second dose of varicella vaccine<sup>&#182;</sup> at 4 to 6 years<sup>&#916;</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">&#8805;4 years and &#60;13 years</td> <td> <p>0 doses of MMR</p> 0 doses of varicella</td> <td> <p>First dose of MMR and first dose of varicella now<sup>&#182;</sup></p> Second dose of MMR in &#8805;28 days and second dose of varicella in &#8805;3 months, <strong>or</strong> MMRV in &#8805;3 months</td> </tr> <tr> <td> <p>0 doses of MMR</p> 1 dose of varicella</td> <td> <p>First MMR now (if &#8805;28 days after first dose of varicella vaccine) and MMRV in &#8805;28 days (if &#8805;3 months after first varicella), <strong>or</strong></p> <p>MMRV now (if &#8805;3 months after first varicella) and MMR &#8805;28 days later, <strong>or</strong></p> First MMR now (if &#8805;28 days after first dose of varicella vaccine); second MMR in &#8805;28 days, and varicella &#8805;3 months after first varicella</td> </tr> <tr class=\"divider_bottom\"> <td> <p>1 dose of MMR</p> 0 doses of varicella</td> <td> <p>MMRV now (if &#8805;28 days after first dose of varicella vaccine) and varicella vaccine &#8805;3 months later, <strong>or</strong></p> <p>MMR and varicella now (if &#8805;28 days after first MMR) and varicella in &#8805;3 months, <strong>or</strong></p> Varicella now (if &#8805;28 days after first MMR) and MMRV in &#8805;3 months</td> </tr> <tr> <td rowspan=\"3\">&#62;13 years</td> <td> <p>0 doses of MMR</p> 0 doses of varicella</td> <td>MMR and varicella now and MMR and varicella in &#8805;28 days</td> </tr> <tr> <td> <p>0 doses of MMR</p> 1 dose of varicella</td> <td>MMR and varicella now (if &#8805;28 days after first dose of varicella) and MMR in &#8805;28 days</td> </tr> <tr> <td> <p>1 dose of MMR</p> 0 doses of varicella</td> <td>MMR and varicella now (if &#8805;28 days after first MMR) and varicella in &#8805;28 days</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MMR: measles, mumps, rubella combination vaccine; MMRV: measles, mumps, rubella, varicella combination vaccine; ACIP: Advisory Committee on Immunization Practices.<br />* This catch-up schedule is for children who have no plans for upcoming international travel. For children who are planning to travel internationally, refer to UpToDate topic on immunizations for travel.<br />&para; Either separate injections of MMR and varicella or MMRV may be used depending upon parental preference; for the first dose of MMR and varicella in children 12 through 47 months of age whose parents do not have a preference, the ACIP prefers separate injections of MMR and varicella vaccine. For the second dose at any age (15 months through 12 years), the ACIP prefers MMRV.<br />&Delta; The ACIP recommends that the second doses of MMR and varicella be administered at 4 to 6 years of age. However, the second dose of MMR may be administered as early as 28 days after the first dose; doses of varicella-containing vaccines should be separated by &ge;3 months for children &lt;13 years and &ge;28 days for children &ge;13 years. However, for children 12 months through 12 years, if the second dose is administered at least 28 days after the first dose, the second dose does not need to be repeated.</div><div id=\"graphicVersion\">Graphic 101591 Version 1.0</div></div></div>"},"101592":{"type":"graphic_diagnosticimage","displayName":"Angiography pseudoaneurysm internal carotid artery intervention","title":"Pseudoaneurysm of the internal carotid artery with subsequent stent placement","html":"<div class=\"graphic\"><div style=\"width: 859px\" class=\"figure\"><div class=\"ttl\">Pseudoaneurysm of the internal carotid artery with subsequent stent placement</div><div class=\"cntnt\"><img style=\"width:839px; height:378px;\" src=\"images/RADIOL/101592_Ang_psdnr_intr_crtd_artr_in.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An internal carotid angiogram (A) shows a focal dissection (arrow) in the cervical portion of the carotid artery. An angiogram performed two years later (B) shows a pseudoaneurysm at the previous site of dissection (arrow). Image C shows stent placement (arrowheads) across the mouth of the pseudoaneurysm. Six months later (D), an angiogram shows resolution of the pseudoaneurysm (arrowhead).</div><div class=\"graphic_reference\">Courtesy of Thanh Nguyen, MD.</div><div id=\"graphicVersion\">Graphic 101592 Version 1.0</div></div></div>"},"101597":{"type":"graphic_picture","displayName":"Anserine bursa","title":"Anserine bursa","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Anserine bursa</div><div class=\"cntnt\"><img style=\"width:416px; height:602px;\" src=\"images/RHEUM/101597_Anserine_bursa_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The bursa has been filled with blue gelatin. S (brownish) is sartorius muscle, SN (white branching structure) is saphenous nerve. There is ample bursal room for an anterior sliding of pes anserinus when the knee is brought from flexion&nbsp;into extension.</div><div class=\"graphic_reference\">Reproduced with permission from: Lee JH, Kim KJ, Jeong YG, et al. Pes anserinus and anserine bursa: anatomical study. Anat Cell Biol. 2014; 47:127. Copyright &copy; 2014 Anatomy &amp; Cell Biology.</div><div id=\"graphicVersion\">Graphic 101597 Version 1.0</div></div></div>"},"101598":{"type":"graphic_picture","displayName":"Perianal streptococcal dermatitis","title":"Perianal streptococcal dermatitis","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Perianal streptococcal dermatitis</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/101598_Perianal_strptcccl_drmtt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intense perianal erythema with well-defined margins characterizes perianal infection from group A <em>Streptococcus pyogenes</em>.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101598 Version 1.0</div></div></div>"},"101600":{"type":"graphic_picture","displayName":"Scabies infant diaper area","title":"Scabies","html":"<div class=\"graphic\"><div style=\"width: 880px\" class=\"figure\"><div class=\"ttl\">Scabies</div><div class=\"cntnt\"><img style=\"width:860px; height:558px;\" src=\"images/DERM/101600_Scbs_infnt_dpr_area.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A papular erythematous eruption in the diaper area of a one-year-old baby.</div><div class=\"graphic_reference\">Reproduced with permission from: Diepgen TL, Yihune G, et al. Dermatology Online Atlas. Published online at: <a href=\"http://www.dermis.net/\" spellcheck=\"true\" target=\"_blank\">www.dermis.net</a>. Copyright &copy; 1996-2015 DermIS. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101600 Version 1.0</div></div></div>"},"101603":{"type":"graphic_table","displayName":"More specific IHC and molecular markers for SFT DDX","title":"Entities in the differential diagnosis of solitary fibrous tumor for which there are specific diagnostic immunohistochemical and/or molecular markers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Entities in the differential diagnosis of solitary fibrous tumor for which there are specific diagnostic immunohistochemical and/or molecular markers</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"6\">Immunohistochemical markers</td> <td class=\"subtitle1\" rowspan=\"2\">Diagnostic molecular alterations</td> </tr> <tr> <td class=\"subtitle2\">Tumor type</td> <td class=\"subtitle2\">STAT6</td> <td class=\"subtitle2\"> <p>MDM2/</p> <p>CDK4</p> </td> <td class=\"subtitle2\">MUC4</td> <td class=\"subtitle2\">DOG1</td> <td class=\"subtitle2\">Beta-catenin (nuclear)</td> <td class=\"subtitle2\">TLE1</td> </tr> <tr> <td>SFT</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;/+</td> <td><em>NAB2-STAT6</em> fusion</td> </tr> <tr> <td>Synovial sarcoma</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td><em>SS18</em> rearrangement</td> </tr> <tr> <td>LGFMS</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td><em>FUS</em> rearrangement</td> </tr> <tr> <td>WD/DDLPS</td> <td class=\"centered\">&ndash;/+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td>12q14~15 amplification</td> </tr> <tr> <td>Fibromatosis</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td><em>CTNNB1</em> mutations</td> </tr> <tr> <td>GIST</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td><em>KIT, PDGFRA</em> mutations</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SFT: solitary fibrous tumor; LGFMS: low-grade fibromyxoid sarcoma; WD/DDPS: well-differentiated/de-differentiated liposarcoma; GIST: gastrointestinal stromal tumor.</div><div id=\"graphicVersion\">Graphic 101603 Version 1.0</div></div></div>"},"101604":{"type":"graphic_diagnosticimage","displayName":"Aortitis in GCA on MR angiography","title":"Aortitis in GCA on MR angiography","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortitis in GCA on MR angiography</div><div class=\"cntnt\"><img style=\"width:360px; height:766px;\" src=\"images/RHEUM/101604_Aortitis_GCA_MR_angiography.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Parasagittal MR angiography image of the aorta demonstrates diffuse thickening and peripheral enhancement of the aortic wall along the aortic arch, the descending aorta, and the proximal abdominal aorta in a patient with biopsy-proved GCA.<br />(B) High-resolution, axial-delayed MR angiography image of the aorta shows thickening and enhancement of the aortic wall.</div><div class=\"graphic_footnotes\">GCA: giant cell (temporal) arteritis; MR: magnetic resonance.</div><div class=\"graphic_reference\">Courtesy of William Docken, MD.</div><div id=\"graphicVersion\">Graphic 101604 Version 3.0</div></div></div>"},"101605":{"type":"graphic_diagnosticimage","displayName":"MRA of the aorta and great vessels in GCA","title":"MRA of the aorta and great vessels in GCA","html":"<div class=\"graphic\"><div style=\"width: 772px\" class=\"figure\"><div class=\"ttl\">MRA of the aorta and great vessels in GCA</div><div class=\"cntnt\"><img style=\"width:752px; height:827px;\" src=\"images/RHEUM/101605_MRA_art_grt_vssl_GCA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stenosis of the proximal and distal right subclavian artertery in a patient with large vessel giant cell arteritis. The right axillary artery is completely occluded; the right brachial artery is reconstituted via collateral channels. The distal left subclavian artery is severely stenosed.</div><div class=\"graphic_footnotes\">MRA: magnetic resonance angiogram; GCA: giant cell arteritis.</div><div class=\"graphic_reference\">Courtesy of William Docken, MD.</div><div id=\"graphicVersion\">Graphic 101605 Version 2.0</div></div></div>"},"101606":{"type":"graphic_diagnosticimage","displayName":"Histopathology of idiopathic aortitis","title":"Histopathology of the ascending aorta in idiopathic aortitis","html":"<div class=\"graphic\"><div style=\"width: 873px\" class=\"figure\"><div class=\"ttl\">Histopathology of the ascending aorta in idiopathic aortitis</div><div class=\"cntnt\"><img style=\"width:853px; height:591px;\" src=\"images/RHEUM/101606_Histopathology_idpthc_artts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is a chronic inflammatory infiltrate in the media with lymphocytes, macrophages, and occasional multinucleated giant cells, associated with areas of medial necrosis. The adventitia shows chronic inflammation and fibrosis.</div><div class=\"graphic_reference\">Courtesy of William Docken, MD.</div><div id=\"graphicVersion\">Graphic 101606 Version 1.0</div></div></div>"},"101607":{"type":"graphic_diagnosticimage","displayName":"High-power view of histopathology in idiopathic aortitis","title":"High-power view of histopathology in idiopathic aortitis","html":"<div class=\"graphic\"><div style=\"width: 938px\" class=\"figure\"><div class=\"ttl\">High-power view of histopathology in idiopathic aortitis</div><div class=\"cntnt\"><img style=\"width:918px; height:687px;\" src=\"images/RHEUM/101607_Hgh_pwr_hstpthlg_idpth_artt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view demonstrates giant cells in the media.</div><div class=\"graphic_reference\">Courtesy of William Docken, MD.</div><div id=\"graphicVersion\">Graphic 101607 Version 1.0</div></div></div>"},"101608":{"type":"graphic_algorithm","displayName":"Management of extracranial carotid artery aneurysm","title":"Management of extracranial carotid artery aneurysm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Management of extracranial carotid artery aneurysm</div><div class=\"cntnt\"><img style=\"width:402px; height:370px;\" src=\"images/SURG/101608_Mngm_extrcr_crtd_artry_anry.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TIA: transient ischemic attack.<br />* Imaging every six months after diagnosis, then if stable, annual surveillance.<br />&para; Open repair preferred for: Most true aneurysms, infected aneurysm, ruptured aneurysm. Endovascular repair may be preferred for: Pseudoaneurysm, distal internal carotid artery, prior neck surgery.</div><div id=\"graphicVersion\">Graphic 101608 Version 2.0</div></div></div>"},"101610":{"type":"graphic_table","displayName":"Basic rehabilitation program for low risk tibial stress fracture","title":"Basic rehabilitation program for low risk tibial stress fracture","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic rehabilitation program for low risk tibial stress fracture</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Phase 1: Cross training: Typical duration 2 weeks</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Wear long air splint continuously while standing and during cross training, but not needed for sleep </li> <li>Apply ice to fracture site 2-3 times daily for 10 to 20 minutes; may repeat if swelling increases and after training sessions </li> <li>Calcium 1500 mg and vitamin D 800 IU supplementation daily throughout rehabilitation</li> <li>45 minutes stationary cycle daily </li> <li>Heel raises, toe raises, and squats with weight every other day: 25 to 30 percent of body weight is used for three sets of 15 repetitions for each exercise </li> <li>Advance to Phase 2 when patient can jog 50 steps with no pain in a long air splint </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Phase 2: Initiation of weight bearing exercise: Typical duration 2 weeks</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Perform all weight bearing activity in&nbsp;long air splint </li> <li>Every other day, run 400 m/walk 400 m for eight laps (lap = 400 m) on a soft track; perform three sessions </li> <li>Next, run 500 m/walk 300 m for eight laps; perform three sessions, one session&nbsp;every other day <ul> <li>Continue progression, performing three sessions at each level, as follows: run 600 m/walk 200 m; run 700 m/walk 100 m; total of eight laps for each session, one session every other day&nbsp; </li> </ul> </li> <li>45 minutes stationary cycle on alternate (non-running) days </li> <li>Apply ice after activity as above&nbsp; </li> <li>Perform weight exercises as described in Phase 1 on non-running days </li> <li>Advance to Phase 3 when patient can complete 8 laps of 700M run/100 M walk without limp or pain </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Phase 3: Initiation of protected training: Typical duration 2 weeks</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Perform all weight bearing activity in long air splint </li> <li>45 minutes stationary cycle on alternate days </li> <li>Run 2 miles (3.2 km) every other day for three sessions </li> <li>Run 2.5 miles (4 km) every other day for four sessions </li> <li>Continue strength exercises as described in Phase 1 on non-running days&nbsp; </li> <li>Apply ice after activity as above </li> <li>Advance to Phase 4 if running for Phase 3 is completed without limp or pain; fracture site is non-tender; and, patient is able to hop 10 times and to jog without limp with air splint off </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Phase 4: Weaning from long air splint: Typical duration 2 to 3 weeks</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Begin running 2.5 miles (4 km) every other day <ul> <li>Run without splint on first day and with splint on second day; thereafter, alternate splint use every other day </li> </ul> </li> <li>Continue strength exercises as described in Phase 1 </li> <li>Advance to Phase 5 when pain free on all run days without splint </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Phase 5: Progressive training: Typical duration 4 weeks</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Increase run duration by five minutes after two workouts at each level; no air splint </li> <li>Five runs per week during weeks 9 and 10 </li> <li>Six runs per week during weeks 11 and 12 </li> <li>When tolerating 40 continuous minutes of running without significant pain, resume normal training </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Protocol guidelines</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>If patient has problems at any stage of rehabilitation, move back one level for an additional week and then try to advance </li> <li>Continue all training for the first 12 weeks on a soft, level surface, the softer the better </li> <li>Evaluate patient in the office every two weeks for evidence of healing and signs of injury until they reach phase 5 </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Karl B. Fields, MD.</div><div id=\"graphicVersion\">Graphic 101610 Version 2.0</div></div></div>"},"101611":{"type":"graphic_table","displayName":"Basic rehabilitation program low risk fibular stress fracture","title":"Basic rehabilitation program for low risk fibular stress fracture","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic rehabilitation program for low risk fibular stress fracture</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Phase 1: Cross training and symptomatic treatment: Typical duration 1 week:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Wear long air splint for stress fracture of proximal and middle third of fibula; short air splint may suffice for distal fibula </li> <li>Wear air splint continuously while awake; remove for sleep </li> <li>Apply ice to fracture site two to three times daily for 10 to 20 minutes for as long as swelling persists; may apply after activity</li> <li>Calcium 1500 mg and vitamin D 800 IU supplementation daily throughout rehabilitation</li> <li>Cross train with stationary cycling or swimming as tolerated up to 45 minutes daily </li> <li>Perform heel raises, toe raises, and squats with weight every other day: 25 to 30% of body weight is used for three sets of 15 repetitions for each exercise </li> <li>Progress to Phase 2 if able to jog, while wearing air splint, without limp or pain </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Phase 2: Initiation of weight bearing activity; Typical duration 3 weeks:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Use air splint for all activity </li> <li>Begin walk/run program: 4 minutes run/1 minute walk for 20 minutes during week 1; 4&nbsp;sessions per week maximum </li> <li>Cross train on stationary cycle to complete 45 minutes total training daily </li> <li>During week 2 increase total walk/run to 25 minutes during each session with 5 sessions per week maximum </li> <li>During week 3 increase total walk/run time to 30 minutes during a session with 6 sessions per week maximum </li> <li>Continue weight exercises as in Phase 1 on&nbsp;non-running days </li> <li>Apply ice to fracture site for 10 to 20 minutes after each training session </li> <li>Progress to Phase 3 if able to run continuously, without air splint, for 10 minutes without limp or pain. Patient may use a compression sleeve or taping if this makes running more comfortable, but if the patient is unable to run without an air splint because of pain, the patient should continue Phase 2 for an additional week. </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Phase 3: Weaning from air splint: Typical duration 2 weeks:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Week 1 &ndash; Begin advanced walk/run program: <ul> <li>Start by running 10 minutes then walking 2 minutes for 22 minutes total (one session); perform one session each day for 2 days </li> <li>Progress to running 12 minutes and walking 2 minutes for total of 26 minutes (one session); perform one session each day for 2 days </li> <li>Progress to running 15 minutes and walking 2 minutes for 32 minutes total (one session); perform one session each day for 2 days. Rest one day. </li> </ul> </li> <li>Week 2 - Perform 3 sessions (one session per day) of 25 minutes of continuous running, followed by 3 sessions (one session per day) of 30 minutes of continuous running </li> <li>If progressive running is tolerated without limp or pain, patient may progress gradually&nbsp;to normal training </li> <li>Apply ice to fracture site for 10 to 20 minutes after each training session </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Courtesy of Karl B. Fields, MD.</div><div id=\"graphicVersion\">Graphic 101611 Version 2.0</div></div></div>"},"101616":{"type":"graphic_figure","displayName":"Tissue damage","title":"Relationship between tissue damage and tissue destruction","html":"<div class=\"graphic\"><div style=\"width: 474px\" class=\"figure\"><div class=\"ttl\">Relationship between tissue damage and tissue destruction</div><div class=\"cntnt\"><img style=\"width:454px; height:354px;\" src=\"images/PULM/101616_Tissue_damage.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graph represents the relationship between the degree of tissue damage and tissue destruction during electrocautery.&nbsp;As damage worsens, the rate of destruction slows.</div><div class=\"graphic_reference\">Reproduced with permission from: Davison JM, Zamah NM. Electrosurgery: principles, biologic effects and results in female reproductive surgery. In: Glob libr women's med, 2008. Copyright &copy; 2008 The Global Library of Women's Medicine.</div><div id=\"graphicVersion\">Graphic 101616 Version 1.0</div></div></div>"},"101617":{"type":"graphic_picture","displayName":"Longitudinal melanonychia dermoscopy","title":"Dermoscopic image of longitudinal melanonychia","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of longitudinal melanonychia</div><div class=\"cntnt\"><img style=\"width:582px; height:780px;\" src=\"images/DERM/101617_Lngtdnl_mlnnych_drmscpy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Longitudinal melanonychia bands in a dark-skinned individual presenting as multiple lines on a gray background.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101617 Version 1.0</div></div></div>"},"101618":{"type":"graphic_picture","displayName":"Frictional melanonychia dermoscopy","title":"Dermoscopic image of frictional melanonychia","html":"<div class=\"graphic\"><div style=\"width: 777px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of frictional melanonychia</div><div class=\"cntnt\"><img style=\"width:757px; height:558px;\" src=\"images/DERM/101618_Frictional_melanonychia_drmscpy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Frictional (trauma-induced) melanonychia showing a gray background with blood spots.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101618 Version 1.0</div></div></div>"},"101619":{"type":"graphic_picture","displayName":"Nail matrix nevus dermoscopy","title":"Dermoscopic image of a nail matrix nevus","html":"<div class=\"graphic\"><div style=\"width: 778px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a nail matrix nevus</div><div class=\"cntnt\"><img style=\"width:758px; height:556px;\" src=\"images/DERM/101619_Nail_matrix_nevus_dermoscop.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A nail matrix nevus typically presents as multiple regular hyperpigmented lines with a brown background.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101619 Version 1.0</div></div></div>"},"101620":{"type":"graphic_picture","displayName":"Traction alopecia - traction folliculitis","title":"Traction alopecia","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">Traction alopecia</div><div class=\"cntnt\"><img style=\"width:783px; height:701px;\" src=\"images/DERM/101620_Trctn_alpc_trctn_fllclt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early traction alopecia with follicular pustules (traction folliculitis).</div><div class=\"graphic_reference\">Reproduced from: Mirmirani P, Khumalo NP. Traction alopecia: How to translate study data for public education--closing the KAP gap? Dermatol Clin 2014; 32:153. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101620 Version 1.0</div></div></div>"},"101621":{"type":"graphic_picture","displayName":"Marginal traction alopecia from braids","title":"Traction alopecia","html":"<div class=\"graphic\"><div style=\"width: 628px\" class=\"figure\"><div class=\"ttl\">Traction alopecia</div><div class=\"cntnt\"><img style=\"width:608px; height:672px;\" src=\"images/DERM/101621_Margin_traction_alpc_braid.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marginal traction alopecia from chronic use of braids.</div><div class=\"graphic_reference\">Courtesy of Nonhlanhla P Khumalo, MBChB, FCDerm, PhD, and Paradi Mirmirani, MD.</div><div id=\"graphicVersion\">Graphic 101621 Version 1.0</div></div></div>"},"101622":{"type":"graphic_picture","displayName":"Traction alopecia with fringe sign","title":"Traction alopecia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Traction alopecia</div><div class=\"cntnt\"><img style=\"width:417px; height:596px;\" src=\"images/DERM/101622_Tract_alopecia_fringe_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Marginal traction alopecia with a fringe of finer hair at the hairline (fringe sign).</div><div class=\"graphic_reference\">Courtesy of Nonhlanhla P Khumalo, MBChB, FCDerm, PhD, and Paradi Mirmirani, MD.</div><div id=\"graphicVersion\">Graphic 101622 Version 1.0</div></div></div>"},"101623":{"type":"graphic_picture","displayName":"Hair casts","title":"Hair casts","html":"<div class=\"graphic\"><div style=\"width: 802px\" class=\"figure\"><div class=\"ttl\">Hair casts</div><div class=\"cntnt\"><img style=\"width:782px; height:586px;\" src=\"images/DERM/101623_Hair_casts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple movable, white collections of scale surrounding hair shafts.</div><div class=\"graphic_reference\">Courtesy of Nonhlanhla P Khumalo, MBChB, FCDerm, PhD, and Paradi Mirmirani, MD.</div><div id=\"graphicVersion\">Graphic 101623 Version 3.0</div></div></div>"},"101624":{"type":"graphic_picture","displayName":"Traction alopecia from hair weave","title":"Traction alopecia","html":"<div class=\"graphic\"><div style=\"width: 671px\" class=\"figure\"><div class=\"ttl\">Traction alopecia</div><div class=\"cntnt\"><img style=\"width:651px; height:786px;\" src=\"images/DERM/101624_Traction_alopecia_hair_weav.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Occipital traction alopecia secondary to hair extensions (hair weave). The patient's own hair is in the horizontal cornrow braids attached to the scalp. The hair extensions are sewn onto the braids. Traction alopecia is evident between the braids.</div><div class=\"graphic_reference\">Courtesy of Nonhlanhla P Khumalo, MBChB, FCDerm, PhD, and Paradi Mirmirani, MD.</div><div id=\"graphicVersion\">Graphic 101624 Version 1.0</div></div></div>"},"101625":{"type":"graphic_picture","displayName":"Traction alopecia from hair weave in horseshoe pattern","title":"Traction alopecia","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Traction alopecia</div><div class=\"cntnt\"><img style=\"width:549px; height:455px;\" src=\"images/DERM/101625_Trctn_alpc_hr_wv_hrssh_pttr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hair loss in a curved or \"horseshoe\" pattern secondary to placement of a hair weave.</div><div class=\"graphic_reference\">Reproduced from: Mirmirani P, Khumalo NP. Traction alopecia: How to translate study data for public education--closing the KAP gap? Dermatol Clin 2014; 32:153. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101625 Version 1.0</div></div></div>"},"101626":{"type":"graphic_picture","displayName":"Traction alopecia histopathology","title":"Traction alopecia","html":"<div class=\"graphic\"><div style=\"width: 836px\" class=\"figure\"><div class=\"ttl\">Traction alopecia</div><div class=\"cntnt\"><img style=\"width:816px; height:712px;\" src=\"images/DERM/101626_Traction_alopecia_hstpthlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Horizontal sectioning of a 4 mm punch biopsy, hematoxylin and eosin 10x. Vellus hairs (arrows), retained sebaceous glands, and fibrotic tracts (circle) are characteristic findings of late-stage traction alopecia.</div><div class=\"graphic_reference\">Courtesy of Nonhlanhla P Khumalo, MBChB, FCDerm, PhD, and Paradi Mirmirani, MD.</div><div id=\"graphicVersion\">Graphic 101626 Version 1.0</div></div></div>"},"101627":{"type":"graphic_picture","displayName":"Alopecia areata ophiasis pattern","title":"Alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 512px\" class=\"figure\"><div class=\"ttl\">Alopecia areata</div><div class=\"cntnt\"><img style=\"width:492px; height:396px;\" src=\"images/DERM/101627_Alopecia_areata_ophiasis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Alopecia areata in a band-like distribution on the posterior scalp (ophiasis pattern).</div><div class=\"graphic_reference\">Courtesy of Nonhlanhla P Khumalo, MBChB, FCDerm, PhD, and Paradi Mirmirani, MD.</div><div id=\"graphicVersion\">Graphic 101627 Version 1.0</div></div></div>"},"101628":{"type":"graphic_picture","displayName":"Frontal fibrosing alopecia on scalp","title":"Frontal fibrosing alopecia","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Frontal fibrosing alopecia</div><div class=\"cntnt\"><img style=\"width:378px; height:552px;\" src=\"images/DERM/101628_Frntl_fbrsng_alopecia_scalp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loss of hair along the frontal and temporal hairline in a band-like pattern.</div><div class=\"graphic_reference\">Courtesy of Nonhlanhla P Khumalo, MBChB, FCDerm, PhD, and Paradi Mirmirani, MD.</div><div id=\"graphicVersion\">Graphic 101628 Version 1.0</div></div></div>"},"101630":{"type":"graphic_picture","displayName":"Tinea capitis with hair loss","title":"Tinea capitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tinea capitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101630_Tineacapitishrlss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hair loss and scale on the scalp of a child with tinea capitis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101630 Version 2.0</div></div></div>"},"101639":{"type":"graphic_picture","displayName":"Nail melanoma dermoscopy 3","title":"Dermoscopic image of nail melanoma in situ","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of nail melanoma in situ</div><div class=\"cntnt\"><img style=\"width:648px; height:784px;\" src=\"images/DERM/101639_Nail_melanoma_dermoscopy_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Melanoma in situ of the nail presenting as a homogeneous brown band.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101639 Version 1.0</div></div></div>"},"101640":{"type":"graphic_picture","displayName":"Nail nevus dermoscopy","title":"Dermoscopic image of a nail nevus","html":"<div class=\"graphic\"><div style=\"width: 777px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a nail nevus</div><div class=\"cntnt\"><img style=\"width:757px; height:566px;\" src=\"images/DERM/101640_Nail_nevus_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nail matrix nevus in a child presenting as brown background pigmentation with numerous black dots corresponding to melanin granules.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101640 Version 1.0</div></div></div>"},"101642":{"type":"graphic_picture","displayName":"Nail plate free edge dermoscopy","title":"Nail matrix nevus: Dermoscopic image of the nail plate free edge","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Nail matrix nevus: Dermoscopic image of the nail plate free edge</div><div class=\"cntnt\"><img style=\"width:586px; height:780px;\" src=\"images/DERM/101642_Na_plt_free_edg_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The examination of the nail plate free edge shows a pigmented band in the ventral portion of the nail plate, indicating that the nevus is located in the distal matrix.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101642 Version 1.0</div></div></div>"},"101643":{"type":"graphic_picture","displayName":"Nail plate free edge dermoscopy child","title":"Nail matrix nevus: Dermoscopy of the nail plate free edge","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Nail matrix nevus: Dermoscopy of the nail plate free edge</div><div class=\"cntnt\"><img style=\"width:584px; height:782px;\" src=\"images/DERM/101643_Nl_plt_fr_edg_drmscpy_chld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nail matrix nevus in a small child: The nail plate is thin and the exact location of the pigmented band in the nail plate cannot be established.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101643 Version 1.0</div></div></div>"},"101644":{"type":"graphic_picture","displayName":"Micro-Hutchinson sign dermoscopy","title":"Nail matrix congenital nevus","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Nail matrix congenital nevus</div><div class=\"cntnt\"><img style=\"width:584px; height:782px;\" src=\"images/DERM/101644_Micro_hutchinson_sgn_drmscp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nail matrix congenital nevus in a child: Note the micro-Hutchinson sign on the nail fold.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101644 Version 1.0</div></div></div>"},"101647":{"type":"graphic_picture","displayName":"Micro-Hutchinson sign dark skin","title":"Longitudinal melanonychia with micro-Hutchinson sign","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Longitudinal melanonychia with micro-Hutchinson sign</div><div class=\"cntnt\"><img style=\"width:586px; height:784px;\" src=\"images/DERM/101647_Micro_htchns_sign_dark_skin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Micro-Hutchinson sign associated with a light brown longitudinal band in a dark-skinned patient. Also note&nbsp;nail plate surface abnormalities in correspondence&nbsp;with the band. Histopathologic examination of this lesion revealed melanocytic activation typical of physiologic longitudinal melanonychia seen in individuals with darker skin types.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101647 Version 3.0</div></div></div>"},"101650":{"type":"graphic_picture","displayName":"Hyponychium dermoscopy child","title":"Nail matrix nevus with periungual pigmentation in a child","html":"<div class=\"graphic\"><div style=\"width: 779px\" class=\"figure\"><div class=\"ttl\">Nail matrix nevus with periungual pigmentation in a child</div><div class=\"cntnt\"><img style=\"width:759px; height:558px;\" src=\"images/DERM/101650_Hyponychium_dermoscopy_chld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dermoscopy of the hyponychium shows a brushy linear pattern across the skin marks.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101650 Version 2.0</div></div></div>"},"101651":{"type":"graphic_picture","displayName":"Intraoperative dermoscopy","title":"Nail matrix lentigo: Intraoperative dermoscopy","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Nail matrix lentigo: Intraoperative dermoscopy</div><div class=\"cntnt\"><img style=\"width:584px; height:782px;\" src=\"images/DERM/101651_Intraoperative_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dermoscopy shows regular longitudinal brown lines. Histopathology was consistent with lentigo.</div><div class=\"graphic_reference\">Courtesy of Martin Zaiac, MD.</div><div id=\"graphicVersion\">Graphic 101651 Version 2.0</div></div></div>"},"101652":{"type":"graphic_picture","displayName":"Intraoperative dermoscopy 2","title":"Melanoma in situ of the nail matrix: Intraoperative dermoscopy","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Melanoma in situ of the nail matrix: Intraoperative dermoscopy</div><div class=\"cntnt\"><img style=\"width:586px; height:784px;\" src=\"images/DERM/101652_Intraoperative_dermoscopy_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dermoscopy shows irregular longitudinal brown lines and blotches. Pathology was consistent with melanoma in situ.</div><div class=\"graphic_reference\">Courtesy of Martin Zaiac, MD.</div><div id=\"graphicVersion\">Graphic 101652 Version 2.0</div></div></div>"},"101653":{"type":"graphic_picture","displayName":"Drug-induced melanonychia dermoscopy","title":"Dermoscopic image of drug-induced melanonychia","html":"<div class=\"graphic\"><div style=\"width: 888px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of drug-induced melanonychia</div><div class=\"cntnt\"><img style=\"width:868px; height:505px;\" src=\"images/DERM/101653_Drg_indcd_mlnnych_drmscpy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Melanonychia in a patient undergoing chemotherapy. <br />(A) Multiple pigmented bands are present in several nails.<br />(B) Dermoscopy shows a homogeneous gray background.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101653 Version 1.0</div></div></div>"},"101654":{"type":"graphic_picture","displayName":"Fungal melanonychia","title":"Clinical and dermoscopic image of fungal melanonychia","html":"<div class=\"graphic\"><div style=\"width: 816px\" class=\"figure\"><div class=\"ttl\">Clinical and dermoscopic image of fungal melanonychia</div><div class=\"cntnt\"><img style=\"width:796px; height:455px;\" src=\"images/DERM/101654_Fungal_melanonychia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Fungal melanonychia presenting as a diffuse, dark brown nail pigmentation.<br />(B) Dermoscopy shows multicolored pigmentation with yellow strikes.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101654 Version 3.0</div></div></div>"},"101655":{"type":"graphic_picture","displayName":"Nail matrix nevus child dermoscopy","title":"Dermoscopic image of a nail matrix nevus in a child","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a nail matrix nevus in a child</div><div class=\"cntnt\"><img style=\"width:581px; height:783px;\" src=\"images/DERM/101655_Nail_mtrx_nvs_chld_drmscpy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dermoscopy shows a brown background and irregular lines. Note leukonychia due to trauma.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101655 Version 1.0</div></div></div>"},"101657":{"type":"graphic_picture","displayName":"Onychopapilloma dermoscopy","title":"Dermoscopic image of onychopapilloma","html":"<div class=\"graphic\"><div style=\"width: 875px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of onychopapilloma</div><div class=\"cntnt\"><img style=\"width:855px; height:573px;\" src=\"images/DERM/101657_Onychopapilloma_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A brown homogeneous band is visible in the nail.<br />(B) Free edge dermoscopy shows a keratotic subungual mass.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101657 Version 1.0</div></div></div>"},"101658":{"type":"graphic_picture","displayName":"Subungual hematoma dermoscopy","title":"Dermoscopic image of subungual hematoma​","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of subungual hematoma​</div><div class=\"cntnt\"><img style=\"width:584px; height:782px;\" src=\"images/DERM/101658_Subungual_hmtm_drmscpy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Homogeneous purple-black nail pigmentation with characteristic peripheral fading of pigment.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101658 Version 1.0</div></div></div>"},"101659":{"type":"graphic_picture","displayName":"Nail amelanotic melanoma dermoscopy","title":"Dermoscopic image of amelanotic melanoma of the nail bed","html":"<div class=\"graphic\"><div style=\"width: 778px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of amelanotic melanoma of the nail bed</div><div class=\"cntnt\"><img style=\"width:758px; height:567px;\" src=\"images/DERM/101659_Nail_amlntc_mlnm_drmscpy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Amelanotic melanoma of the nail bed showing linear irregular vessels and milky red areas on dermoscopy.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101659 Version 1.0</div></div></div>"},"101660":{"type":"graphic_picture","displayName":"Nail matrix nevus child","title":"Dermoscopic image of a nail matrix nevus","html":"<div class=\"graphic\"><div style=\"width: 777px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of a nail matrix nevus</div><div class=\"cntnt\"><img style=\"width:757px; height:564px;\" src=\"images/DERM/101660_Nail_matrix_nevus_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In children, nail matrix nevi may present as a brown/black band with irregular lines of different color and thickness. This pattern is suspicious for melanoma in adults.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101660 Version 1.0</div></div></div>"},"101663":{"type":"graphic_algorithm","displayName":"Evaluation of suspected trigeminal neuralgia","title":"Evaluation of suspected trigeminal neuralgia","html":"<div class=\"graphic\"><div style=\"width: 792px\" class=\"figure\"><div class=\"ttl\">Evaluation of suspected trigeminal neuralgia</div><div class=\"cntnt\"><img style=\"width:772px; height:572px;\" src=\"images/NEURO/101663_Eval_susp_trgmnal_neuralgia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TN: trigeminal neuralgia.</div><div id=\"graphicVersion\">Graphic 101663 Version 1.0</div></div></div>"},"101667":{"type":"graphic_table","displayName":"Criteria for histological grading of colorectal adenocarcinomas","title":"Criteria for histological grading of colorectal adenocarcinomas","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for histological grading of colorectal adenocarcinomas</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Criterion</td> <td class=\"subtitle1\">Differentiation category</td> <td class=\"subtitle1\">Numerical grade*</td> <td class=\"subtitle1\">Descriptive grade</td> </tr> <tr> <td>&#62;95% with gland formation</td> <td>Well differentiated</td> <td>1</td> <td>Low</td> </tr> <tr> <td>50 to 90% with gland formation</td> <td>Moderately differentiated</td> <td>2</td> <td>Low</td> </tr> <tr> <td>&#62;0 to 49% with gland formation</td> <td>Poorly differentiated</td> <td>3</td> <td>High</td> </tr> <tr> <td>High level of microsatellite instability<sup>&#182;</sup></td> <td>Variable</td> <td>Variable</td> <td>Low</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* The category \"undifferentiated carcinoma\" (grade 4) is reserved for carcinomas with no gland formation, mucin production, or neuroendocrine, squamous, or sarcomatoid differentiation.<br />¶ MSI-H.</div><div class=\"graphic_reference\">Reprinted from World Health Organization Classification of Tumours of the Digestive System, 4th ed, Hamilton SR, Bosman FT, Boffetta P, et al., Criteria for histological grading of colorectal adenocarcinomas, p.138, Copyright &copy; 2010 World Health Organization.</div><div id=\"graphicVersion\">Graphic 101667 Version 1.0</div></div></div>"},"101671":{"type":"graphic_diagnosticimage","displayName":"Histopathology of PACNS","title":"Histopathologic findings of primary angiitis of the CNS","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">Histopathologic findings of primary angiitis of the CNS</div><div class=\"cntnt\"><img style=\"width:783px; height:624px;\" src=\"images/RHEUM/101671_Histopathology_PACNS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathologic findings of a patient with primary angiitis of the central nervous system (PACNS). Granulomatous changes are present in the vessel wall.</div><div class=\"graphic_reference\">Reproduced from: Hajj-Ali RA, Langford CA. Primary angiitis of the central nervous system. In: Kelley's Textbook of Rheumatology, 9th ed, Firestein GS, Budd RC, Gabriel SE, et al (Eds), Saunders, Philadelphia 2013. Vol 2, p.1519. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101671 Version 2.0</div></div></div>"},"101679":{"type":"graphic_figure","displayName":"Proximal aortic dissection ","title":"Proximal aortic dissection","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Proximal aortic dissection</div><div class=\"cntnt\"><img style=\"width:521px; height:317px;\" src=\"images/SURG/101679_Proximal_aortic_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mechanisms of aortic regurgitation in ascending aortic dissection may include:<br />(A) Dilation of the aortic root <br />(B) Asymmetric cusp coaptation<br />(C) Disruption of aortic annulus</div><div class=\"graphic_reference\">Original figure modified for this publication. Isselbacher EM, Eagle KA, Desanctis RW. Diseases of the aorta. In: Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 5th ed, Mendelsohn ME (Ed), Philadelphia: Saunders, 1997. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101679 Version 1.0</div></div></div>"},"101681":{"type":"graphic_algorithm","displayName":"Lab evaluation: Persistent neonatal hypoglycemia","title":"Diagnostic testing for persistent neonatal hypoglycemia","html":"<div class=\"graphic\"><div style=\"width: 684px\" class=\"figure\"><div class=\"ttl\">Diagnostic testing for persistent neonatal hypoglycemia</div><div class=\"cntnt\"><img style=\"width:664px; height:286px;\" src=\"images/PEDS/101681_Lb_pstnt_nntl_hypglycm_edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Initial diagnostic testing for persistent neonatal hypoglycemia (low glucose concentrations that persist beyond 48 hours of life) differentiates major etiologic categories of hypoglycemia based on laboratory testing (bicarbonate, beta-hydroxybutyrate, and free fatty acid) from a critical sample (obtained when the plasma glucose level is &lt;50 mg/dL [2.8 mmol/L]). Additional specific testing (eg, plasma insulin, C-peptide, and carnitine and acyl-carnitine levels) using a critical sample is used to confirm the diagnosis of the underlying cause of hypoglycemia.</div><div class=\"graphic_footnotes\">HCO<sub>3</sub>: bicarbonate; BOHB: beta-hydroxybutyrate; FFA: free fatty acid; GH: growth hormone.</div><div class=\"graphic_reference\">Original figure modified for this publication. Thornton PS, Stanley CA, De Leon DD, et al. Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children. J Pediatr 2015. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101681 Version 2.0</div></div></div>"},"101682":{"type":"graphic_table","displayName":"Risk factors for OHSS","title":"Risk factors for OHSS","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for OHSS</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Risk factors present at baseline: Before gonadotropin administration</td> </tr> <tr> <td class=\"indent1\">Previous OHSS</td> </tr> <tr> <td class=\"indent1\">PCOS</td> </tr> <tr> <td class=\"indent1\">Potential markers:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Basal serum anti-m&#252;llerian hormone &#62;3.3 ng/mL </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Antral follicle count &#62;8 </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Single nucleotide polymorphisms (SNPs) in genes involved in follicular growth (<em>BMP15</em>)</td> </tr> <tr> <td class=\"subtitle1_single\">Risk factors related to ovarian response</td> </tr> <tr> <td class=\"indent1\">Multiple follicles &#62;20 follicles larger than 10 mm</td> </tr> <tr> <td class=\"indent1\">High or rapidly rising serum estradiol concentration (&#62;3500 pg/mL [12,850 pmol/L] in COH)</td> </tr> <tr> <td class=\"indent1\">High number of oocytes retrieved</td> </tr> <tr> <td class=\"indent1\">hCG given for luteal phase supplementation</td> </tr> <tr> <td class=\"indent1\">Elevated serum/follicular fluid VEGF levels</td> </tr> <tr> <td class=\"indent1\">Pregnancy (increase in endogenous hCG)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OHSS: ovarian hyperstimulation syndrome;&nbsp;PCOS: polycystic ovary syndrome; BMP: bone morphogenetic protein; COH: controlled ovarian hyperstimulation;&nbsp;hCG: human chorionic gonadotropin; VEGF: vascular endothelial growth factor.</div><div class=\"graphic_reference\">Adapted from: Fiedler K, Ezcurra D. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): The need for individualized not standardized treatment. Reprod Biol Endocrinol 2012; 10:32.</div><div id=\"graphicVersion\">Graphic 101682 Version 2.0</div></div></div>"},"101683":{"type":"graphic_table","displayName":"Warfarin initiation nomogram","title":"Warfarin initiation nomogram","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Warfarin initiation nomogram</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Day</td> <td class=\"subtitle1\">INR</td> <td class=\"subtitle1\">Warfarin dose (mg)</td> </tr> <tr class=\"divider_bottom centered\"> <td>1</td> <td>&nbsp;</td> <td>5</td> </tr> <tr class=\"divider_bottom centered\"> <td>2</td> <td>&nbsp;</td> <td>5</td> </tr> <tr class=\"centered\"> <td class=\"divider_bottom\" rowspan=\"4\">3</td> <td>&#60;1.5</td> <td>10</td> </tr> <tr class=\"centered\"> <td>1.5-1.9</td> <td>5</td> </tr> <tr class=\"centered\"> <td>2-3</td> <td>2.5</td> </tr> <tr class=\"divider_bottom centered\"> <td>&#62;3</td> <td>0</td> </tr> <tr class=\"centered\"> <td class=\"divider_bottom\" rowspan=\"4\">4</td> <td>&#60;1.5</td> <td>10</td> </tr> <tr class=\"centered\"> <td>1.5-1.9</td> <td>7.5</td> </tr> <tr class=\"centered\"> <td>2-3</td> <td>5</td> </tr> <tr class=\"divider_bottom centered\"> <td>&#62;3</td> <td>0</td> </tr> <tr class=\"centered\"> <td class=\"divider_bottom\" rowspan=\"3\">5</td> <td>&#60;2</td> <td>10</td> </tr> <tr class=\"centered\"> <td>2-3</td> <td>5</td> </tr> <tr class=\"divider_bottom centered\"> <td>&#62;3</td> <td>0</td> </tr> <tr class=\"centered\"> <td rowspan=\"4\">6</td> <td>&#60;1.5</td> <td>12.5</td> </tr> <tr class=\"centered\"> <td>1.5-1.9</td> <td>10</td> </tr> <tr class=\"centered\"> <td>2-3</td> <td>7.5</td> </tr> <tr class=\"centered\"> <td>&#62;3</td> <td>0</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This nomogram applies to warfarin initial dosing in an otherwise healthy adult without comorbidities that could affect warfarin metabolism. Evidence to support this nomogram was derived in a young, mostly male population with venous thromboembolism. Lower initial dosing may be appropriate for individuals who are frail, elderly, or malnourished; who have liver or kidney disease or heart failure; or who are receiving a medication known to increase warfarin sensitivity. Higher initial dosing may be appropriate for individuals who were previously receiving warfarin and had higher dose requirements. Refer to UpToDate topics on the use of warfarin and specific clinical indications for further details.</div><div class=\"graphic_footnotes\">INR: international normalized ratio.</div><div class=\"graphic_reference\">From Annals of Internal Medicine, Kovacs MJ, Rodger M, Anderson DR, et al, Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial, Volume 138, Issue 9, Pages 714-9. Copyright &copy; 2003 American College of Physicians. All Rights Reserved. Reprinted with the permission of American College of Physicians, Inc.</div><div id=\"graphicVersion\">Graphic 101683 Version 3.0</div></div></div>"},"101685":{"type":"graphic_table","displayName":"Drugs implicated in DITMA","title":"Drugs implicated in drug-induced thrombotic microangiopathy (DITMA)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Drugs implicated in drug-induced thrombotic microangiopathy (DITMA)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"60%\"></colgroup><colgroup span=\"2\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug</td> <td class=\"subtitle1\" colspan=\"2\">Mechanism</td> </tr> <tr> <td class=\"subtitle2\">Immune</td> <td class=\"subtitle2\">Toxic</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Leg cramps, other minor symptoms, malaria</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Quinine</td> <td class=\"centered\">X</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Cancer therapy</td> </tr> <tr> <td class=\"indent1\">Bevacizumab</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Bortezomib</td> <td class=\"centered\"><span class=\"subtitle1\"></span>X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Carfilzomib</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Gemcitabine</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Mitomycin</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Oxaliplatin</td> <td class=\"centered\">X</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Pentostatin</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Sunitinib</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Antibiotic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trimethoprim-sulfamethoxazole</td> <td class=\"centered\">X</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Immunosuppressive therapy</td> </tr> <tr> <td class=\"indent1\">Cyclosporine</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Interferon</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Sirolimus</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tacrolimus</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Drugs of abuse</td> </tr> <tr> <td class=\"indent1\">Cocaine</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Ecstasy (MDMA, also known as Molly)</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Oxymorphone extended release (Opana ER)</td> <td>&nbsp;</td> <td class=\"centered\">X</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The listed drugs are those that may most commonly cause DITMA. Published reports often described these syndromes as TTP or HUS. Some drugs that have been commonly reported to be associated with DITMA, such as clopidogrel, do not describe evidence supporting a definite or probable causal association. The presentation and prognosis differ between immune-mediated and toxicity-mediated DITMA. Refer to UpToDate topics on DITMA for details of evaluation and management.</div><div class=\"graphic_footnotes\">DITMA: drug-induced thrombotic microangiopathy; TMA: thrombotic microangiopathy; TTP: thrombotic thrombocytopenic purpura; HUS: hemolytic uremic syndrome. </div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Al-Nouri ZL, Reese JA, Terrell DR, et al. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood 2015; 125:616.</li>&#xD;&#xA;    <li>Reese JA, Bougie DW, Curtis BR, et al. Drug-induced thrombotic microangiopathy: Experience of the Oklahoma registry and the BloodCenter of Wisconsin. Am J of Hematol 2015; 90:406.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 101685 Version 4.0</div></div></div>"},"101695":{"type":"graphic_table","displayName":"Age-adjusted incidence of stroke/transient ischemic attack","title":"Age-adjusted incidence of stroke/transient ischemic attack","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Age-adjusted incidence of stroke/transient ischemic attack</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age (years)</td> <td class=\"subtitle1\">White men*</td> <td class=\"subtitle1\">White women*</td> <td class=\"subtitle1\">Black men*</td> <td class=\"subtitle1\">Black women*</td> </tr> <tr class=\"centered\"> <td>45 to 54</td> <td>2.4</td> <td>2.4</td> <td>9.7</td> <td>7.2</td> </tr> <tr class=\"centered\"> <td>55 to 64</td> <td>6.1</td> <td>4.8</td> <td>13.1</td> <td>10.0</td> </tr> <tr class=\"centered\"> <td>65 to 74</td> <td>12.2</td> <td>9.9</td> <td>16.2</td> <td>15.0</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Age-adjusted incidence of stroke/transient ischemic attack by race and sex, ages 45 to 74 years, Atherosclerosis Risk in Communities study cohort, 1987 to 2001.</div><div class=\"graphic_footnotes\">* Per 1000 persons per&nbsp;year.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>National Heart, Lung, and Blood Institute. Incidence and prevalence: 2006 chart book on cardiovascular and lung disease. National Institutes of Health, 2006. </LI>&#xD;&#xA;<LI>Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update:&nbsp;A report from the American Heart Association. Circulation 2014; 129:e28.</LI></OL></div><div id=\"graphicVersion\">Graphic 101695 Version 1.0</div></div></div>"},"101697":{"type":"graphic_table","displayName":"Awareness, treatment, and control of high blood pressure","title":"Awareness, treatment, and control of high blood pressure","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Awareness, treatment, and control of high blood pressure</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">NH white males*</td> <td class=\"subtitle1\">NH white females*</td> <td class=\"subtitle1\">NH black males*</td> <td class=\"subtitle1\">NH black females*</td> <td class=\"subtitle1\">Mexican-American males*</td> <td class=\"subtitle1\">Mexican-American females*</td> </tr> <tr> <td><strong>Awareness</strong></td> <td class=\"centered\">79.4</td> <td class=\"centered\">84.0</td> <td class=\"centered\">80.0</td> <td class=\"centered\">87.8</td> <td class=\"centered\">66.4</td> <td class=\"centered\">75.5</td> </tr> <tr> <td><strong>Treatment</strong></td> <td class=\"centered\">72.3</td> <td class=\"centered\">79.1</td> <td class=\"centered\">68.8</td> <td class=\"centered\">80.4</td> <td class=\"centered\">58.2</td> <td class=\"centered\">70.2</td> </tr> <tr> <td><strong>Controlled</strong></td> <td class=\"centered\">53.0</td> <td class=\"centered\">56.8</td> <td class=\"centered\">40.3</td> <td class=\"centered\">52.7</td> <td class=\"centered\">36.2</td> <td class=\"centered\">42.8</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Extent of awareness, treatment, and control of high blood pressure by race/ethnicity and sex (National Health and Nutrition Examination Survey: 2007-2010).</div><div class=\"graphic_footnotes\">NH: non-Hispanic.<br />* Percent of population with hypertension.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>National Heart, Lung, and Blood Institute.</li>&#xD;&#xA;    <li>National Center for Health Statics.</li>&#xD;&#xA;    <li>Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update: A report from the American Heart Association. Circulation 2014; 129:e28.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 101697 Version 1.0</div></div></div>"},"101700":{"type":"graphic_diagnosticimage","displayName":"Imaging perforated esophageal carcinoma","title":"Esophageal carcinoma perforating into the lung on imaging","html":"<div class=\"graphic\"><div style=\"width: 800px\" class=\"figure\"><div class=\"ttl\">Esophageal carcinoma perforating into the lung on imaging</div><div class=\"cntnt\"><img style=\"width:780px; height:512px;\" src=\"images/RADIOL/101700_Img_prfrt_esphgl_crcnm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An axial CT through the lung apices shows a proximal esophageal carcinoma (arrow). Two weeks later (image B), there is a focal perforation into the right lung apex (arrow) with formation of a cavity in the lung (arrowhead). Image C is a PET-CT scan that shows hyper metabolic activity in the esophagus (arrow) and the lung cavity (arrowhead). Image D is a gastrograffin swallow that shows the perforation (arrow) and the cavity (arrowhead).</div><div class=\"graphic_footnotes\">CT: computed tomography; PET: positron emission tomography.</div><div id=\"graphicVersion\">Graphic 101700 Version 1.0</div></div></div>"},"101701":{"type":"graphic_diagnosticimage","displayName":"Imaging complications of perforated esophageal carcinoma","title":"Complications of perforating esophageal carcinoma on imaging","html":"<div class=\"graphic\"><div style=\"width: 817px\" class=\"figure\"><div class=\"ttl\">Complications of perforating esophageal carcinoma on imaging</div><div class=\"cntnt\"><img style=\"width:797px; height:391px;\" src=\"images/RADIOL/101701_Img_cmplct_prfrt_esph_crcnm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A chest radiograph shows extensive right upper lobe pneumonia (asterisk) following perforation. Image B is a coronal reconstruction of a chest CT and shows a cavitating and necrotizing right upper lobe pneumonia (arrowheads). Image C is an angiogram of the supreme intercostal artery performed for hemoptysis and shows hyperemia in the region of the tumor (between arrows). Image D is an angiogram of the right bronchial artery and shows an abnormal cluster of vessels (arrow). The bronchial artery was successfully embolized.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 101701 Version 1.0</div></div></div>"},"101702":{"type":"graphic_diagnosticimage","displayName":"Palliative care and aspiration","title":"Carcinoma of esophagus complicated by TE fistula on barium swallow and CT","html":"<div class=\"graphic\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Carcinoma of esophagus complicated by TE fistula on barium swallow and CT</div><div class=\"cntnt\"><img style=\"width:688px; height:430px;\" src=\"images/RADIOL/101702_Img_TE_fistula_esphgl_crcnm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A barium swallow (A) in a patient with esophageal carcinoma and an esophageal stent (dashed arrow) shows a fistulous tract (arrow head) from the esophagus (e) to the trachea (t) and spillage of the contrast into the left mainstem bronchus (arrow). Image B is a sagittal reconstruction of a chest CT and shows an air-filled fistulous tract (arrow) between the esophagus (e) and trachea (t).</div><div class=\"graphic_footnotes\">TE: tracheo-esophageal; CT: Computed tomography.</div><div id=\"graphicVersion\">Graphic 101702 Version 1.0</div></div></div>"},"101703":{"type":"graphic_algorithm","displayName":"Management of OHSS","title":"Management of OHSS","html":"<div class=\"graphic\"><div style=\"width: 806px\" class=\"figure\"><div class=\"ttl\">Management of OHSS</div><div class=\"cntnt\"><img style=\"width:786px; height:1150px;\" src=\"images/ENDO/101703_Management_of_OHSS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">OHSS: ovarian hyperstimulation syndrome; NSAID: nonsteroidal anti-inflammatory drug; CBC: complete blood count; TVUS: transvaginal ultrasound; Hct: hematocrit; WBC: white blood cells; BUN: blood urea nitrogen; hCG: human chorionic gonadotropin; IV: intravenous; OB-GYN: obstetrics and gynecology.</div><div id=\"graphicVersion\">Graphic 101703 Version 4.0</div></div></div>"},"101704":{"type":"graphic_figure","displayName":"Effect of proteinuria and BP on GFR in pediatric CKD","title":"Effect of proteinuria and elevated blood pressure on the progression of pediatric chronic kidney disease","html":"<div class=\"graphic\"><div style=\"width: 905px\" class=\"figure\"><div class=\"ttl\">Effect of proteinuria and elevated blood pressure on the progression of pediatric chronic kidney disease</div><div class=\"cntnt\"><img style=\"width:885px; height:631px;\" src=\"images/PEDS/101704_EftprtnrBPGFRpdtrcCKD.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The effect of baseline urine protein-to-creatinine ratio (Up/c) and BP status (elevated [greater than the 90th percentile] versus normal blood pressure) on glomerular filtration rate (GFR) changes (mL/min per 1.73 m<sup>2</sup> per year) for 522 children with nonglomerular chronic kidney disease prospectively followed in the CKiD study.</div><div class=\"graphic_footnotes\">CKD: chronic kidney disease; BP: blood pressure; CKiD: Chronic Kidney Disease in Children.</div><div class=\"graphic_reference\">Reproduced with permission from: Fathallah-Shaykh SA, Flynn JT, Pierce CB, et al. Progression of pediatric CKD of nonglomerular origin in the CKiD cohort. Clin J Am Soc Nephrol 2015; 10:571. Copyright &copy; 2015 American Society of Nephrology.</div><div id=\"graphicVersion\">Graphic 101704 Version 2.0</div></div></div>"},"101761":{"type":"graphic_algorithm","displayName":"Algorithm acquired TTP","title":"Algorithm acquired TTP","html":"<div class=\"graphic\"><div style=\"width: 566px\" class=\"figure\"><div class=\"ttl\">Algorithm acquired TTP</div><div class=\"cntnt\"><img style=\"width:546px; height:712px;\" src=\"images/HEME/101761_Algorithm_acquired_TTP.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to UpToDate topics on TTP for details of the evaluation; the criteria for confidence in the diagnosis of TTP (which is based on clinical criteria rather than solely on ADAMTS13 activity); the timing of central venous catheter removal (typically, five to seven days); and the dosing of glucocorticoids and rituximab. </div><div class=\"graphic_footnotes\">TTP: thrombotic thrombocytopenic purpura; PEX: therapeutic plasma exchange;&nbsp;TMA: thrombotic microangiopathy.<br />* Glucocorticoids are given to all patients based on the potential benefits in reducing inhibitor production. A typical dose for a patient who is awake and alert without neurologic abnormalities is 1 mg/kg per day orally; for a more seriously affected patient, intravenous methylprednisolone at a dose of 125 mg two to four times daily&nbsp;may be appropriate.<br />¶&nbsp;Rituximab is used as part of initial therapy unless there is a contraindication. This is based on emerging evidence that rituximab may reduce the risks of exacerbation and relapse and may hasten the response to therapy.&nbsp;&nbsp;<br />​</div><div id=\"graphicVersion\">Graphic 101761 Version 4.0</div></div></div>"},"101764":{"type":"graphic_figure","displayName":"Onlay patch (Bricker procedure)","title":"Onlay patch (Bricker procedure)","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">Onlay patch (Bricker procedure)</div><div class=\"cntnt\"><img style=\"width:500px; height:539px;\" src=\"images/SURG/101764_Onlay_patch_Bricker.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Colonic onlay patch (Bricker procedure) for repair of rectovaginal fistula. After colostomy, the proximal end of bypassed colon is brought down to&nbsp;cover the rectal defect as an onlay patch (panel A). After healing of the fistula, bowel continuity is restored by reversing the colostomy (panel B).</div><div class=\"graphic_reference\">Modified from: Lowry AC, Hoexter B.&nbsp;Benign anorectal: Rectovaginal fistulas. In: The ASCRS Textbook of Colon and Rectal Surgery, 1st ed,&nbsp;Beck DE, Wolf BG, Fleshman JW, et al (Eds), Springer 2007.</div><div id=\"graphicVersion\">Graphic 101764 Version 1.0</div></div></div>"},"101768":{"type":"graphic_figure","displayName":"Progressive vaccinia","title":"Progressive vaccinia","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Progressive vaccinia</div><div class=\"cntnt\"><img style=\"width:480px; height:224px;\" src=\"images/ID/101768_Progressive_vaccinia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Progressive vaccinia over the course of two months.</div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention (CDC). Progressive vaccinia in a military smallpox vaccinee - United States, 2009. MMWR Morb Mortal Wkly Rep 2009; 58:532.</div><div id=\"graphicVersion\">Graphic 101768 Version 1.0</div></div></div>"},"101775":{"type":"graphic_picture","displayName":"Nail lentigo dermoscopy","title":"Dermoscopic image of nail lentigo","html":"<div class=\"graphic\"><div style=\"width: 778px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of nail lentigo</div><div class=\"cntnt\"><img style=\"width:758px; height:560px;\" src=\"images/DERM/101775_Nail_lentigo_dermoscopy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dermoscopy shows brown band with irregular lines.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101775 Version 1.0</div></div></div>"},"101776":{"type":"graphic_picture","displayName":"Nail melanoma in situ dermoscopy","title":"Dermoscopic image of nail matrix melanoma","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of nail matrix melanoma</div><div class=\"cntnt\"><img style=\"width:586px; height:784px;\" src=\"images/DERM/101776_Nl_mlnm_situ_drmscpy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Melanoma in situ of the nail matrix presenting as multiple lines of irregular color with a brown/black background.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101776 Version 1.0</div></div></div>"},"101777":{"type":"graphic_picture","displayName":"Hyponychium Hutchinson sign dermoscopy","title":"Dermoscopic image of the Hutchinson sign of the hyponychium","html":"<div class=\"graphic\"><div style=\"width: 777px\" class=\"figure\"><div class=\"ttl\">Dermoscopic image of the Hutchinson sign of the hyponychium</div><div class=\"cntnt\"><img style=\"width:757px; height:566px;\" src=\"images/DERM/101777_Hypnychm_htchnsn_sgn_drms.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nail matrix melanoma with the Hutchinson sign. The dermoscopic examination of the hyponychium shows a parallel ridge pattern typical of melanoma of palms and soles.</div><div class=\"graphic_reference\">Courtesy of Antonella Tosti, MD.</div><div id=\"graphicVersion\">Graphic 101777 Version 1.0</div></div></div>"},"101782":{"type":"graphic_picture","displayName":"Tenosynovial giant cell tumor","title":"Tenosynovial giant cell tumor","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tenosynovial giant cell tumor</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/RHEUM/101782_Gnt_cll_tmr_tndn_shth.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tenosynovial giant cell tumor on a patient's finger.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101782 Version 2.0</div></div></div>"},"101783":{"type":"graphic_figure","displayName":"Common femoral arterial access for REBOA (male)","title":"Common femoral arterial access for REBOA (male)","html":"<div class=\"graphic\"><div style=\"width: 551px\" class=\"figure\"><div class=\"ttl\">Common femoral arterial access for REBOA (male)</div><div class=\"cntnt\"><img style=\"width:531px; height:679px;\" src=\"images/SURG/101783_CommonfemoralarterialaccessforREBOA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The illustration depicts transfemoral occlusion of Aortic Zone I with a balloon catheter advanced over a wire within the thoracic aorta.</div><div id=\"graphicVersion\">Graphic 101783 Version 2.0</div></div></div>"},"101784":{"type":"graphic_picture","displayName":"Coda balloon inflation","title":"Coda balloon inflation","html":"<div class=\"graphic\"><div style=\"width: 495px\" class=\"figure\"><div class=\"ttl\">Coda balloon inflation</div><div class=\"cntnt\"><img style=\"width:475px; height:352px;\" src=\"images/SURG/101784_Coda_blln_infltn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A pelvic binder was placed in the emergency department because of hemodynamic instability in the setting of a pelvic fracture. The patient transiently responded to blood product resuscitation but then became hypotensive again. An aortic occlusion balloon (Cook Coda) was inserted through a right femoral arterial access sheath and inflated to support hemodynamics in the operating room until external pelvic fixation and&nbsp;&nbsp;preperitoneal pelvic packing could be accomplished to control the pelvic hemorrhage. </div><div id=\"graphicVersion\">Graphic 101784 Version 1.0</div></div></div>"},"101785":{"type":"graphic_diagnosticimage","displayName":"Aortic zone III balloon inflation","title":"Aortic zone III balloon inflation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Aortic zone III balloon inflation</div><div class=\"cntnt\"><img style=\"width:275px; height:270px;\" src=\"images/SURG/101785_Artc_zn_III_blln_inflt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The portable fluoroscopy image demonstrates an aortic occlusion&nbsp;balloon inflated in Zone III.</div><div id=\"graphicVersion\">Graphic 101785 Version 1.0</div></div></div>"},"101787":{"type":"graphic_figure","displayName":"Anatomy of the tonsils","title":"Anatomy of the tonsils","html":"<div class=\"graphic\"><div style=\"width: 555px\" class=\"figure\"><div class=\"ttl\">Anatomy of the tonsils</div><div class=\"cntnt\"><img style=\"width:535px; height:350px;\" src=\"images/PC/101787_Tonsils_in_pharynx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Waldeyer's ring is the ring of lymphoid tissue in the pharynx formed by the palatine tonsils, pharyngeal tonsils, tubal tonsils, and lingual tonsils.</div><div id=\"graphicVersion\">Graphic 101787 Version 3.0</div></div></div>"},"101799":{"type":"graphic_diagnosticimage","displayName":"Typical neuroimaging features of RCVS","title":"Typical neuroimaging features of reversible cerebral vasoconstriction syndrome","html":"<div class=\"graphic\"><div style=\"width: 726px\" class=\"figure\"><div class=\"ttl\">Typical neuroimaging features of reversible cerebral vasoconstriction syndrome</div><div class=\"cntnt\"><img style=\"width:706px; height:542px;\" src=\"images/NEURO/101799_Typcl_neuroimag_ftr_RCVS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Head CT angiogram: sagittal, maximum-intensity projection image showing the classic \"sausage on a string\" appearance of both anterior cerebral arteries.<br />(B) Head CT: axial image showing subarachnoid hemorrhage overlying the right frontal lobe (arrow).<br />(C) Brain MRI: axial FLAIR image in the same patient showing the right frontal subarachnoid hemorrhage (arrow) as well as multiple dot-shaped hyperintensities (arrowhead) within the sulci of both hemispheres, suggesting the presence of dilated cortical surface arteries.<br />(D) Brain MRI: axial FLAIR image showing the posterior-predominant crescentic hyperintense signal in the cortical-subcortical regions (dashed arrow). Corresponding DWI and SWI (not shown) were normal. These findings suggest the presence of brain edema as described in the posterior reversible leukoencephalopathy syndrome.<br />(E) Brain MRI: axial DWI showing ischemic lesions (short arrows) in the bilateral \"watershed\" regions of the middle and posterior cerebral arteries.<br />(F) Head CT scan: axial image showing a left frontal parenchymal hemorrhage.</div><div class=\"graphic_footnotes\">RCVS: reversible cerebral vasoconstriction syndrome; FLAIR: fluid-attenuated inversion recovery; DWI: diffusion-weighted image; SWI: susceptibility-weighted image.</div><div class=\"graphic_reference\">Reproduced with permission from: Singhal AB, Hajj-Ali RA, Topcuoglu MA, et al. Reversible cerebral vasoconstriction syndromes: Analysis of 139 cases. Arch Neurol 2011; 68:1005. Copyright &copy; 2011 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101799 Version 3.0</div></div></div>"},"101802":{"type":"graphic_table","displayName":"CMV syndromes in infants and children","title":"Clinical manifestations, treatment, and outcome of CMV infections in infants, children, and adolescents","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical manifestations, treatment, and outcome of CMV infections in infants, children, and adolescents</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"4\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Congenital infection</td> <td class=\"subtitle1\">Early postnatal infection</td> <td class=\"subtitle1\">Infection in immunocompetent children and adolescents</td> <td class=\"subtitle1\">Infection in immunocompromised children and adolescents</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Clinical manifestations</strong></td> <td> <p>At birth, 90% of cases are asymptomatic.</p> Clinical and laboratory findings include: <ul class=\"decimal_heading\"> <li>Petechiae </li> <li>Jaundice at birth </li> <li>Hepatosplenomegaly </li> <li>Petechial rash </li> <li>Small size for gestational age </li> <li>Thrombocytopenia </li> <li>Microcephaly </li> <li>Intracranial calcifications </li> <li>Polymicrogyria </li> <li>Ventriculomegaly </li> <li>Sensorineural hearing loss </li> <li>Chorioretinitis </li> <li>Seizures </li> </ul> </td> <td> <p><strong>Term infants:</strong> Most infants are asymptomatic.</p> Clinical and laboratory findings are usually transient and include: <ul class=\"decimal_heading\"> <li>Fever </li> <li>Hepatosplenomegaly </li> <li>Mild pneumonitis </li> <li>Abnormal blood counts </li> <li>Abnormal liver function tests </li> </ul> <p><strong>Premature and VLBW infants:</strong> Infection can be severe and life-threatening.</p> Clinical and laboratory manifestations include: <ul class=\"decimal_heading\"> <li>Sepsis-like syndrome </li> <li>Hepatosplenomegaly </li> <li>Pneumonitis </li> <li>Hepatitis</li> <li>NEC </li> <li>Abnormal blood counts </li> </ul> </td> <td> <p>Most children are asymptomatic.</p> Clinical and laboratory findings include: <ul class=\"decimal_heading\"> <li>Fever </li> <li>Fatigue </li> <li>Pharyngitis </li> <li>Mononucleosis-like syndrome </li> <li>Adenopathy </li> <li>Hepatitis </li> <li>Headache </li> <li>Abdominal pain </li> <li>Diarrhea </li> <li>Arthralgias </li> <li>Rash </li> <li>Lymphocytosis or lymphopenia </li> <li>Thrombocytopenia </li> <li>Abnormal liver function tests </li> <li>Negative monospot test </li> </ul> </td> <td> <p>Infection can be severe and life-threatening.</p> Clinical and laboratory findings include: <ul class=\"decimal_heading\"> <li>Fever </li> <li>Malaise </li> <li>Leukopenia </li> <li>Hepatitis </li> <li>Pneumonitis </li> <li>Colitis </li> <li>Graft loss (in patients with organ transplant) </li> <li>Myocarditis </li> <li>Retinitis </li> <li>Encephalitis/encephalopathy (especially in patients with HIV) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Treatment</strong></td> <td> <p>Asymptomatic infants do not require antiviral treatment.</p> Ganciclovir or valganciclovir for symptomatic infections.*</td> <td> <p>Most term infants and asymptomatic preterm infants do not require antiviral treatment.</p> Ganciclovir or valganciclovir for severe symptomatic infections in premature infants.*</td> <td> <p>Antiviral treatment is generally not indicated.</p> Supportive care with hydration and fever control.</td> <td>Ganciclovir or valganciclovir<sup>&#182;</sup></td> </tr> <tr> <td><strong>Outcome</strong></td> <td> <p>Overall mortality rate is 4 to 8%.</p> <p>Mortality rate with severe fulminant disease is as high as 30%.</p> Long-term sequelae include hearing loss, cerebral palsy, intellectual disability, vision impairment, and seizures.</td> <td> <p><strong>Term infants:</strong> No permanent sequelae</p> <p><strong>Premature and VLBW infants:</strong> Mortality rate with symptomatic infection is 5 to 10%.</p> There does not appear to be increased risk of hearing loss, cerebral palsy, or other&nbsp;neurodevelopmental disability; however, long-term&nbsp;outcomes are&nbsp;not clearly understood. </td> <td>No permanent sequelae</td> <td>High risk of morbidity and mortality; depends in part on the underlying condition.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; VLBW: very low birth weight; NEC: necrotizing enterocolitis; IV: intravenously.<br />* For treatment of congenital and severe early postnatal CMV infections, the dose of ganciclovir is 6 mg/kg per dose administered intravenously every 12 hours. The dose of valganciclovir is 16 mg/kg per dose of commercially available suspension administered orally every 12 hours. Doses of both medications must be adjusted in renal insufficiency. These dosing regimens have not been studied in infants &lt;32 weeks gestation. Refer to UpToDate topics on congenital CMV infection for details regarding monitoring and duration of therapy.<br />¶ For treatment of CMV infections in immunocompromised children, the induction dose of ganciclovir is 5 mg/kg per dose IV every 12 hours for two to three weeks, depending upon the clinical and virologic response. Maintenance dosing is provided for high-risk patients (including bone marrow transplant recipients, patients with AIDS, or those in whom prolonged immunosuppression is anticipated). Maintenance therapy usually consists of a single daily dose of ganciclovir IV at 5 mg/kg administered every other day or five days a week. Valganciclovir, 15 mg/kg per dose of commercially available suspension orally every 12 hours, may be used for maintenance therapy in patients who are able to tolerate and absorb oral medication. Doses of both medications must be adjusted in renal insufficiency. Refer to UpToDate topic on acquired CMV infection in infants, children, and adolescents for details on antiviral therapy.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Harrison GJ. Cytomegalovirus. In: Feigin and Cherry's Textbook of Pediatric Infectious Diseases, 7th ed, Cherry JD, Harrison GJ, Kaplan SL, et al (Eds), Elsevier Saunders, Philadelphia 2014. p.1969.</LI>&#xD;&#xA;<LI>Kimberlin DW, Jester PM, Sánchez PJ, et al. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med 2015; 372:933. </LI>&#xD;&#xA;<LI>American Academy of Pediatrics. Cytomegalovirus infection. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.317. </LI></OL></div><div id=\"graphicVersion\">Graphic 101802 Version 3.0</div></div></div>"},"101808":{"type":"graphic_diagnosticimage","displayName":"Radiographic progression of lumbar spine in a patient with AS","title":"Radiographic progression of lumbar spine in a patient with ankylosing spondylitis","html":"<div class=\"graphic\"><div style=\"width: 827px\" class=\"figure\"><div class=\"ttl\">Radiographic progression of lumbar spine in a patient with ankylosing spondylitis</div><div class=\"cntnt\"><img style=\"width:807px; height:626px;\" src=\"images/RHEUM/101808_Rdgrp_prgr_lmbr_spn_AS_ptnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radiographic progression of the spine of an AS patient from 2008 to 2013.</div><div class=\"graphic_footnotes\">AS: ankylosing spondylitis.</div><div class=\"graphic_reference\">Courtesy of Xenofon Baraliakos, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universit&auml;t, Herne, Germany.</div><div id=\"graphicVersion\">Graphic 101808 Version 1.0</div></div></div>"},"101809":{"type":"graphic_table","displayName":"Distinguishing features: Primary and secondary pediatric HTN","title":"Distinguishing clinical features between primary (essential) and secondary pediatric hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Distinguishing clinical features between primary (essential) and secondary pediatric hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical features</td> <td class=\"subtitle1\">Primary HTN</td> <td class=\"subtitle1\">Secondary HTN</td> </tr> <tr> <td colspan=\"3\">Age:</td> </tr> <tr> <td class=\"indent1\">Prepubertal</td> <td>&nbsp;</td> <td>Secondary HTN&nbsp;&nbsp;is more likely in younger children, especially those&nbsp;less than six years of age.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Postpubertal</td> <td>Older children and adolescents are more likely to have primary HTN.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Diastolic HTN*</td> <td>&nbsp;</td> <td>Diastolic HTN is more likely to be associated with secondary HTN.</td> </tr> <tr class=\"divider_bottom\"> <td>Nocturnal HTN*</td> <td>&nbsp;</td> <td>Nocturnal HTN is more likely to be associated with secondary HTN.</td> </tr> <tr class=\"divider_bottom\"> <td>Overweight/obesity</td> <td>Overweight or obese children/adolescents are more likely to have primary HTN.</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Family history of HTN</td> <td>Children with a positive family history of primary&nbsp;HTN are more likely to have primary HTN.</td> <td>Family history may be positive in some cases of secondary&nbsp;HTN due to a monogenic cause (eg, autosomal dominant polycystic kidney disease).</td> </tr> <tr> <td>Symptoms of underlying disorder</td> <td>Patients with primary HTN are typically asymptomatic.</td> <td>Patients with secondary HTN often have other symptoms related to the underlying cause (eg, headache, sweating, and tachycardia due to catecholamine excess in patients with pheochromocytoma).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HTN: hypertension; ABPM: ambulatory blood pressure monitoring.<br />* Nocturnal and diastolic hypertension are usually detected by ABPM.</div><div id=\"graphicVersion\">Graphic 101809 Version 2.0</div></div></div>"},"101813":{"type":"graphic_table","displayName":"Choice of ART agents based upon specific clinical scenarios","title":"Choice of antiretroviral agents based upon specific clinical scenarios in adults and adolescent patients*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Choice of antiretroviral agents based upon specific clinical scenarios in adults and adolescent patients*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"20%\"></colgroup><colgroup span=\"2\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient or regimen characteristics</td> <td class=\"subtitle1\">Clinical scenario</td> <td class=\"subtitle1\">Consideration(s)</td> <td class=\"subtitle1\">Rationale/comments</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\"><strong>Pre-ART characteristics</strong></td> <td>CD4 count &#60;200 cells/microL</td> <td><strong>Avoid the following regimens:</strong> <ul class=\"decimal_heading\"> <li>RPV-based regimens </li> <li>DRV-r plus RAL </li> </ul> </td> <td>Higher rate of virologic failure observed in those with low pre-treatment CD4 cell count.</td> </tr> <tr> <td>HIV RNA &#8805;100,000 copies/mL</td> <td><strong>Avoid the following regimens:</strong> <ul class=\"decimal_heading\"> <li>RPV-based regimens </li> <li>ABC/3TC with EFV or ATV-r </li> <li>DRV-r plus RAL </li> </ul> </td> <td>Higher rates of virologic failure observed in those with high pre-treatment HIV RNA.</td> </tr> <tr> <td>HLA-B*5701-positive</td> <td><strong>Do not use ABC-containing regimens.</strong></td> <td>Abacavir hypersensitivity, a potentially fatal reaction, is highly associated with positivity for the HLA-B*5701 allele.</td> </tr> <tr class=\"divider_bottom\"> <td>Must treat before HIV drug resistance results are&nbsp;available (eg, in&nbsp;a person with acute HIV or when rapid initiation of ART is warranted)</td> <td> <p><strong>Avoid NNRTI-based regimens.</strong></p> <p>Recommend ART regimens:</p> <ul> <li>​DRV (DRV-r or DRV/c)&nbsp;plus TAF/FTC or TDF/FTC </li> <li>DTG plus TAF/FTC or TDF/FTC </li> </ul> </td> <td> <p>Transmitted mutations conferring NNRTI resistance are more likely than mutations associated with PI or INSTI resistance.</p> <p>&nbsp;</p> Resistance to DRV-r and DTG emerges slowly; transmitted resistance to DRV is rare and transmitted resistance to DTG has not been reported to date.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>ART specific characteristics</strong></td> <td>One pill once daily regimen desired</td> <td>ART options include: <ul class=\"decimal_heading\"> <li>DTG/ABC/3TC (if HLA-B*5701-negative) </li> <li>EFV/FTC/TDF </li> <li>EVG/c/FTC/TAF </li> <li>EVG/c/FTC/TDF (if eGFR is &#8805;70 mL/min/1.73 m<sup>2</sup>) </li> <li>RPV/FTC/TAF </li> <li>RPV/FTC/TDF </li> </ul> </td> <td> <p>Available as fixed-dose combination tablets.</p> <p>&nbsp;</p> <p>Avoid RPV-based regimens if HIV RNA &#8805;100,00 copies/mL and/or CD4 count &#60;200 cell/microL.</p> <p>&nbsp;</p> <p>Since RPV-containing single-pill regimens are smaller in size than other single-pill regimens, they may be considered for eligible patients when a person has difficulty swallowing a larger pill.</p> <p>&nbsp;</p> <p>Refer to the topic on selecting an antiretroviral regimen for a discussion of which regimen to use in the setting of specific comorbid conditions (eg, reduced kidney function, chronic HBV infection).&nbsp;</p> </td> </tr> <tr> <td>Food effects<br /> &nbsp;<br /> </td> <td>Regimens that can be taken without regard to food: <ul class=\"decimal_heading\"> <li>RAL- or DTG-based regimen </li> </ul> <p>&nbsp;</p> <p>Regimens that should be taken on an empty stomach:</p> <ul class=\"decimal_heading\"> <li>EFV-based regimens </li> </ul> <p>&nbsp;</p> <p>Regimens that should be taken with food:&nbsp;</p> <ul class=\"decimal_heading\"> <li>ATV-r or ATV/c-based regimens </li> <li>DRV-r or DRV/c-based regimens </li> <li>EVG/c/FTC/TAF </li> <li>EVG/c/FTC/TDF </li> <li>RPV-based regimens </li> </ul> </td> <td> <p>Oral bioavailability of these regimens is not significantly affected by food.</p> <p>&nbsp;</p> <p>Taking EFV-based regimens with food increases EFV absorption and may increase CNS side effects.</p> <p>&nbsp;</p> <p>Food improves absorption of the listed regimens.</p> <p>&nbsp;</p> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"11\"><strong>Presence of other conditions</strong></td> <td>Chronic kidney disease (defined as eGFR &#60;60 mL/min/1.73 m<sup>2</sup>)</td> <td> <p><strong>Avoid TDF.</strong></p> <p>Use ABC or TAF.</p> <ul> <li>ABC may be used if HLA-B*5701-negative. If HIV RNA &#8805;100,000 copies/mL, do not use ABC/3TC plus (EFV or ATV-r). </li> <li>TAF may be used if eGFR &#8805;30 mL/min/1.73 m<sup>2</sup>.&nbsp;&nbsp; </li> </ul> <p>Options when ABC or TAF cannot be used:<sup>&#182;</sup></p> <ul> <li>DRV (DRV-r or DRV/c)&nbsp;plus 3TC; </li> <li>DTG&nbsp;plus DRV (DRV-r or DRV/c) </li> </ul> <p>&nbsp;</p> <p><strong>Avoid ATV if possible.</strong></p> </td> <td> <p>TDF has been associated with renal tubulopathy.</p> <p>Higher rates of renal dysfunction reported in patients using TDF in conjunction with RTV-containing regimens.</p> <p>ATV has been associated with chronic kidney disease in some observational studies.</p> <p>TAF has less impact on renal function and lower rates of proteinuria than TDF.</p> <p>ABC has not been associated with renal dysfunction.</p> Specific dose adjustment recommendations for use in patients with reduced renal function are provided in the Lexicomp individual drug monographs within UpToDate.</td> </tr> <tr> <td>Liver disease with cirrhosis</td> <td>Some ARVs are contraindicated or may require dosage modification in patients with Child-Pugh class B or C disease.</td> <td>Patients with cirrhosis should be carefully evaluated by an expert in advanced liver disease.</td> </tr> <tr> <td>Osteoporosis</td> <td> <p><strong>Avoid TDF.</strong></p> <p>Use TAF/FTC or ABC/3TC (only if HLA-B*5701-negative).</p> <p>If HIV RNA &#8805;100,000 copies/mL, do not use ABC/3TC&nbsp;with EFV or ATV-r.</p> </td> <td> <p>TDF is associated with decreases in bone mineral density along with renal tubulopathy, urine phosphate wasting, and osteomalacia.</p> TAF and ABC are associated with smaller declines in bone mineral density than TDF.</td> </tr> <tr> <td>Psychiatric illnesses</td> <td> <p><strong>Avoid EFV- and RPV-based regimens if possible.</strong></p> <p>Patients on INSTI-based regimens with preexisting psychiatric conditions should be closely monitored.</p> </td> <td> <p>EFV and RPV can exacerbate psychiatric symptoms and may be associated with suicidality.</p> <p>INSTIs have been associated with adverse neuropsychiatric effects in some retrospective cohort studies and case series.</p> </td> </tr> <tr> <td>HIV-associated dementia (HAD)</td> <td> <p><strong>Avoid EFV-based regimens if possible.</strong></p> Favor DRV-based or DTG-based regimen.</td> <td> <p>EFV neuropsychiatric effects may confound assessment of the effect of ART on improvement of symptoms associated with HAD.</p> Theoretical CNS penetration advantage.</td> </tr> <tr> <td>Opioid replacement therapy required</td> <td> <p><strong>If patient receiving methadone, avoid EFV-based regimen if possible.</strong></p> If EFV is used, an increase in methadone dose may be necessary.</td> <td>EFV reduces methadone concentrations and may lead to withdrawal symptoms.</td> </tr> <tr> <td>High cardiac risk</td> <td> <p>DTG-, RAL-, or RPV-based regimens may be advantageous in this setting.&nbsp;</p> <p><strong>Avoid ABC- and LPV/r-based regimens if possible.</strong></p> <p>If a boosted PI is the desired option, an ATV-based regimen may have advantages over a DRV-based regimen.</p> </td> <td> <p>Increased cardiovascular risk in some studies.</p> <p>Observational cohort studies reported an association between some PIs (DRV, IDV, FPV, and LPV/r) and an increased risk of cardiovascular events, while this has not been seen with ATV.</p> </td> </tr> <tr> <td>Cardiac QTc interval prolongation</td> <td><strong>Avoid EFV- or RPV-based regimens if taking other medications with known risk of torsades de pointes or in patients at higher risk of torsades de pointes.</strong></td> <td>High EFV or RPV concentrations may cause QT prolongation.</td> </tr> <tr> <td>Hyperlipidemia</td> <td><strong>The following ARV drug classes or drugs have been associated with deleterious effects on lipids:</strong> <ul class=\"decimal_heading\"> <li>PI-r or PI/c </li> <li>EFV </li> <li>EVG/c </li> </ul> </td> <td>TDF has been associated with greater beneficial lipid effects compared with ABC or TAF.</td> </tr> <tr> <td>Patients with history of poor adherence to ARV or inconsistent engagement in care</td> <td>Administer dual-NRTI plus boosted PI- or DTG-based regimens.</td> <td>These regimens have a high genetic barrier to resistance.</td> </tr> <tr class=\"divider_bottom\"> <td>Pregnancy</td> <td colspan=\"2\">Refer to the UpToDate topics on antiretroviral therapy in HIV-infected pregnant women.</td> </tr> <tr> <td rowspan=\"3\"><strong>Presence of co-infections</strong></td> <td>HBV infection</td> <td> <p>Use tenofovir-based regimen whenever possible.</p> <p>Refer to the UpToDate topic on treatment of chronic HBV in HIV-infected patients for management of patients unable to take TAF or TDF.</p> </td> <td> <p>TDF, TAF, FTC, and 3TC are active against both HIV and HBV. However, 3TC- or FTC-associated HBV mutations can emerge rapidly when these drugs are used without another HBV-active agent.</p> </td> </tr> <tr> <td>HCV treatment required</td> <td colspan=\"2\">Use TAF/FTC or ABC/3TC plus DTG or RAL; for other regimens, refer to the&nbsp;UpToDate topic on HIV/HCV coinfection.</td> </tr> <tr> <td>Treating TB infection with rifamycins</td> <td> <p><strong>TAF is not recommended with any rifamycin-containing regimen.&nbsp;</strong></p> <p>If rifampin is used:</p> <ul class=\"decimal_heading\"> <li>EFV-based regimens are preferred </li> <li>If RAL is used, increase RAL dose to 800 mg twice per day </li> <li>If DTG is used, use DTG at 50 mg dose twice per day </li> </ul> If using a PI-based regimen, rifabutin should be used in place of rifampin in the TB regimen.</td> <td> <ul> <li>Rifamycins may significantly reduce TAF exposure.&nbsp; </li> <li>Rifampin is a strong inducer of CYP3A, UGT1A1 (glucuronidation) enzymes, and P-glycoprotein efflux causing significant decrease in concentrations of PI, INSTI, and RPV. </li> <li>Rifampin has a less significant effect on EFV concentration than on other NNRTIs, PIs, and INSTIs. </li> <li>Rifabutin is a less potent inducer of drug metabolism and should be considered for patients receiving non-EFV-based regimens. </li> </ul> Drug interactions should be carefully analyzed in patients requiring rifamycin treatment with HIV ARV therapy; this may be done by use of the Lexi-Interact program included within UpToDate.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">ARV abbreviations separated by \"/\" (eg, TAF/FTC) are available in single-tablet coformulations.</div><div class=\"graphic_footnotes\">3TC: lamivudine; ABC: abacavir; ART: antiretroviral therapy; ATV: atazanavir; ATV-r: ritonavir-boosted atazanavir; ARV: antiretroviral; c: cobicistat; CKD: chronic kidney disease; CNS: central nervous system; DRV: darunavir; DRV-r: ritonavir-boosted darunavir; DTG: dolutegravir; eGFR: estimated glomerular filtration rate; EFV: efavirenz; EVG: elvitegravir; EVG/COBI/TDF/FTC: elvitegravir/cobicistat/tenofovir/emtricitabine; FDA: US Food and Drug Administration; FPV: fosamprenavir;&nbsp;FTC: emtricitabine; HAD: HIV-associated dementia; HBV: hepatitis B virus; HCV: hepatitis C virus; IDV: indinavir; INSTI: integrase strand transfer inhibitor; LPV/r: ritonavir-boosted lopinavir; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; PI-r: ritonavir-boosted protease inhibitor; RAL: raltegravir; RPV: rilpivirine; RTV: ritonavir; TAF: tenofovir-alafenamide; TB: tuberculosis;&nbsp;TDF: tenofovir disoproxil fumarate.<br />*&nbsp;This table is intended to guide the initial choice of regimen. When more than one scenario applies to a patient, clinicians should review the ART choices for each relevant scenario and select the most appropriate regimen. For specific dosing recommendations, refer to the individual Lexicomp drug monographs available in UpToDate. Refer to the UpToDate topic on selecting antiretroviral regimens for treatment-naïve HIV-infected patients for more detailed discussions.<br />¶&nbsp;There are limited data with regimens that do not contain tenofovir or abacavir. Regimens other than those listed in the table include RAL (twice daily) plus DRV-r, or LPV/r plus 3TC; some experts prefer these regimens since they have been specifically evaluated in clinical trials. However, we prefer regimens such as pharmacologically boosted DRV plus DTG, or pharmacologically boosted DRV plus 3TC, since these regimens would be expected to be equally effective, are easier to administer (eg, once versus twice daily), and are better tolerated (eg, DRV-r versus LPV/r ). If RAL plus DRV-r is used, the combination should be avoided in patients with a CD4 count &lt;200 cells/microL and/or an HIV RNA ≥100,000 copies/mL. See the topic that discusses choosing an antiretroviral regimen in treatment-naïve patients for more information on these regimens.</div><div class=\"graphic_reference\">Adapted from: Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at: <A href=\"https://aidsinfo.nih.gov/guidelines\" target=_blank>https://aidsinfo.nih.gov/guidelines</A> (Accessed on October 17, 2017).</div><div id=\"graphicVersion\">Graphic 101813 Version 4.0</div></div></div>"},"101816":{"type":"graphic_figure","displayName":"Map Mansonella perstans","title":"Endemic areas of <em>Mansonella perstans</em> infection","html":"<div class=\"graphic\"><div style=\"width: 766px\" class=\"figure\"><div class=\"ttl\">Endemic areas of <em>Mansonella perstans</em> infection</div><div class=\"cntnt\"><img style=\"width:746px; height:426px;\" src=\"images/ID/101816_Map_mansonella_prstn.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Institute of Tropical Medicine in Antwerp, Belgium. Illustrated Lecture Notes on Tropical Medicine. Copyright &copy; 2013 Institute of Tropical Medicine in Antwerp, Belgium.</div><div id=\"graphicVersion\">Graphic 101816 Version 1.0</div></div></div>"},"101817":{"type":"graphic_figure","displayName":"Map Mansonella streptocerca","title":"Endemic areas of <em>Mansonella streptocerca</em> infection","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Endemic areas of <em>Mansonella streptocerca</em> infection</div><div class=\"cntnt\"><img style=\"width:505px; height:612px;\" src=\"images/ID/101817_Map_mansonella_streptocerca.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Institute of Tropical Medicine in Antwerp, Belgium. Illustrated Lecture Notes on Tropical Medicine. Copyright &copy; 2013 Institute of Tropical Medicine in Antwerp, Belgium.</div><div id=\"graphicVersion\">Graphic 101817 Version 1.0</div></div></div>"},"101819":{"type":"graphic_table","displayName":"Eurofever clinical diagnostic classification criteria","title":"The Eurofever clinical diagnostic/classification criteria*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Eurofever clinical diagnostic/classification criteria*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"5%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"5%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"5%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">FMF</td> <td class=\"subtitle1\" colspan=\"2\">MKD</td> <td class=\"subtitle1\" colspan=\"2\">CAPS</td> <td class=\"subtitle1\" colspan=\"2\">TRAPS</td> </tr> <tr> <td class=\"subtitle2_left\">Presence</td> <td class=\"subtitle2_left centered\">Score</td> <td class=\"subtitle2_left\">Presence</td> <td class=\"subtitle2_left centered\">Score</td> <td class=\"subtitle2_left\">Presence</td> <td class=\"subtitle2_left centered\">Score</td> <td class=\"subtitle2_left\">Presence</td> <td class=\"subtitle2_left centered\">Score</td> </tr> <tr> <td class=\"indent1\">Duration of episodes &#60;2 days</td> <td class=\"centered\">9</td> <td class=\"indent1\">Age at onset &#60;2 years</td> <td class=\"centered\">10</td> <td class=\"indent1\">Urticarial rash</td> <td class=\"centered\">25</td> <td class=\"indent1\">Periorbital edema</td> <td class=\"centered\">27</td> </tr> <tr> <td class=\"indent1\">Chest pain</td> <td class=\"centered\">13</td> <td class=\"indent1\">Aphthous stomatitis</td> <td class=\"centered\">11</td> <td class=\"indent1\">Neurosensorial hearing loss</td> <td class=\"centered\">25</td> <td class=\"indent1\">Duration of episodes &#62;6 days</td> <td class=\"centered\">19</td> </tr> <tr> <td class=\"indent1\">Abdominal pain</td> <td class=\"centered\">9</td> <td class=\"indent1\">Generalized enlargement of lymph nodes or splenomegaly</td> <td class=\"centered\">8</td> <td class=\"indent1\">Conjunctivitis</td> <td class=\"centered\">10</td> <td class=\"indent1\">Migratory rash<sup>&#182;</sup></td> <td class=\"centered\">18</td> </tr> <tr> <td class=\"indent1\">Eastern Mediterranean<sup>&#916;</sup> ethnicity</td> <td class=\"centered\">22</td> <td class=\"indent1\">Painful lymph nodes</td> <td class=\"centered\">13</td> <td class=\"divider_bottom\" rowspan=\"3\" colspan=\"2\">&nbsp;</td> <td class=\"indent1\">Myalgia</td> <td class=\"centered\">6</td> </tr> <tr> <td class=\"indent1\">North Mediterranean<sup>&#916;</sup> ethnicity</td> <td class=\"centered\">7</td> <td class=\"indent1\">Diarrhea (sometimes/often)</td> <td class=\"centered\">20</td> <td class=\"indent1\">Relatives affected</td> <td class=\"centered\">7</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">&nbsp;</td> <td class=\"indent1\">Diarrhea (always)</td> <td class=\"centered\">37</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Absence</td> <td class=\"subtitle2_left\" colspan=\"2\">Absence</td> <td class=\"subtitle2_left\" colspan=\"2\">Absence</td> <td class=\"subtitle2_left\" colspan=\"2\">Absence</td> </tr> <tr> <td class=\"indent1\">Aphthous stomatitis</td> <td class=\"centered\">9</td> <td class=\"indent1\">Chest pain</td> <td class=\"centered\">11</td> <td class=\"indent1\">Exudative pharyngitis</td> <td class=\"centered\">25</td> <td class=\"indent1\">Vomiting</td> <td class=\"centered\">14</td> </tr> <tr> <td class=\"indent1\">Urticarial rash</td> <td class=\"centered\">15</td> <td class=\"divider_bottom\" rowspan=\"3\" colspan=\"2\">&nbsp;</td> <td class=\"indent1\">Abdominal pain</td> <td class=\"centered\">15</td> <td class=\"indent1\">Aphthous stomatitis</td> <td class=\"centered\">15</td> </tr> <tr> <td class=\"indent1\">Enlarged cervical lymph nodes</td> <td class=\"centered\">10</td> <td class=\"divider_bottom\" rowspan=\"2\" colspan=\"2\">&nbsp;</td> <td class=\"divider_bottom\" rowspan=\"2\" colspan=\"2\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Duration of episodes &#62;6 days</td> <td class=\"centered\">13</td> </tr> <tr> <td><strong>Cut-off</strong></td> <td class=\"centered\"><strong>&#8805;60</strong></td> <td><strong>Cut-off</strong></td> <td class=\"centered\"><strong>&#8805;42</strong></td> <td><strong>Cut-off</strong></td> <td class=\"centered\"><strong>&#8805;52</strong></td> <td><strong>Cut-off</strong></td> <td class=\"centered\"><strong>&#8805;43</strong></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FMF: familial Mediterranean fever; MKD: mevalonate kinase deficiency; CAPS: cryopyrin-associated periodic syndromes; TRAPS: receptor-associated periodic fever syndromes.<br />* The clinical features should be related to the typical fever episodes (ie, exclusion of intercurrent infection or other comorbidities).<br />&para; Centrifugal migratory, erythematous patches most typically overlying a local area of myalgia, usually on the limbs or trunk.<br />&Delta; Eastern Mediterranean: Turkish, Armenian, non-Ashkenazi Jewish. North Mediterranean: Italian, Spanish, Greek.</div><div class=\"graphic_reference\">From: Federici S, Sormani MP, Ozen S, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis 2015; 74:799. Reproduced with permission from BMJ Publishing Group, Ltd. Copyright &copy; 2015.</div><div id=\"graphicVersion\">Graphic 101819 Version 2.0</div></div></div>"},"101823":{"type":"graphic_algorithm","displayName":"A practical approach for determining the cause of hyponatremia","title":"A practical approach for determining the cause of hyponatremia","html":"<div class=\"graphic\"><div style=\"width: 1155px\" class=\"figure\"><div class=\"ttl\">A practical approach for determining the cause of hyponatremia</div><div class=\"cntnt\"><img style=\"width:1135px; height:1966px;\" src=\"images/NEPH/101823_Apprdetermincausehypntrm.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IVIG: intravenous immune globulin; TURP: transurethral resection of the prostate; BP: blood pressure; ACTH: adrenocorticotropic hormone; ADH: antidiuretic hormone; TSH: thyroid-stimulating hormone; SIADH: syndrome of inappropriate antidiuretic hormone secretion.<br />* A simple and convenient correction of the serum sodium for hyperglycemia is as follows: Add 2 mEq/L to the serum sodium for every 100 mg/dL of serum glucose above the normal value.<br />¶ Impaired water excretion in renal failure occurs if there is severe impairment in glomerular filtration rate. Patients with mild-to-moderate impairment in glomerular filtration rate are typically able to excrete water loads. The measured plasma osmolality may be high in patients with renal failure because of high urea concentrations. However, urea is an ineffective osmole, and such patients have hypotonic hyponatremia even if the plasma osmolality is normal.<br />Δ Thiazide-induced hyponatremia may be protracted. An extensive evaluation for other etiologies can be delayed for several weeks in mildly hyponatremic patients.<br /><FONT class=lozenge>◊</FONT> If the serum sodium is 125 mEq/L or less, we do not give isotonic saline. In such patients, the evaluation can be delayed until the sodium is slowly raised to higher levels.<br />§ Although patients with hyponatremia due to heart failure or cirrhosis will usually have edema that is clinically apparent, hypovolemia may not always be apparent by clinical exam. Thus, in a patient who appears to be euvolemic but whose urine chemistries are consistent with hypovolemia, infusion of isotonic saline (eg, 1 liter over one hour) can be helpful.</div><div id=\"graphicVersion\">Graphic 101823 Version 4.0</div></div></div>"},"101831":{"type":"graphic_figure","displayName":"Serum creatinine frequency above normal range","title":"Relative and absolute frequencies of serum creatinine levels greater than the upper limit of the normal laboratory range","html":"<div class=\"graphic\"><div style=\"width: 608px\" class=\"figure\"><div class=\"ttl\">Relative and absolute frequencies of serum creatinine levels greater than the upper limit of the normal laboratory range</div><div class=\"cntnt\"><img style=\"width:588px; height:358px;\" src=\"images/NEPH/101831_Serum_creat_freq_above_norm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relative and absolute frequencies of serum creatinine levels greater than the upper limit of the normal laboratory range (men &gt;1.2 mg/dL; women &gt;0.9 mg/dL) in residents aged 20 to 60 years of two coastal villages by categories of duration of work on coastal sugarcane or cotton plantations.</div><div class=\"graphic_footnotes\">SCr: serum creatinine.</div><div class=\"graphic_reference\">Reproduced from: Peraza S, Wesseling C, Aragon A, et al. Decreased kidney function among agricultural workers in El Salvador. Am J Kidney Dis 2012; 59:531. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101831 Version 1.0</div></div></div>"},"101832":{"type":"graphic_figure","displayName":"Mechanism of action of heparins and fondaparinux","title":"Heparin/fondaparinux mechanism of action","html":"<div class=\"graphic\"><div style=\"width: 569px\" class=\"figure\"><div class=\"ttl\">Heparin/fondaparinux mechanism of action</div><div class=\"cntnt\"><img style=\"width:549px; height:690px;\" src=\"images/HEME/101832_Heparin_graphic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic representation of anticoagulant mechanisms. Heparins bind to antithrombin (AT) and induce a conformational change that makes AT an efficient inactivator of coagulation factors. Unfractionated heparin inhibits thrombin (factor IIa) by forming a ternary complex. The inhibitory effect of LMW heparins on thrombin is variable, with longer products such as tinzaparin having greater inhibition than the shorter products such as enoxaparin. All heparins and fondaparinux efficiently inactivate factor Xa. Refer to UpToDate topics on use of heparins and fondaparinux for details.</div><div class=\"graphic_footnotes\">LMW: low molecular weight; AT: antithrombin (formerly called AT III).</div><div id=\"graphicVersion\">Graphic 101832 Version 4.0</div></div></div>"},"101833":{"type":"graphic_table","displayName":"Patient-Determined Disease Steps","title":"Patient-Determined Disease Steps (PDDS) in multiple sclerosis*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Patient-Determined Disease Steps (PDDS) in multiple sclerosis*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td class=\"centered\">0</td> <td><strong>Normal:</strong> I may have some mild symptoms, mostly sensory, due to MS, but they do not limit my activity. If I do have an attack, I return to normal when the attack has passed.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">1</td> <td><strong>Mild disability:</strong> I have some noticeable symptoms from my MS, but they are minor and have only a small effect on my lifestyle.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">2</td> <td><strong>Moderate disability:</strong> I don't have any limitations in my walking ability. However, I do have significant problems due to MS that limit daily activities in other ways.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">3</td> <td><strong>Gait disability:</strong> MS does interfere with my activities, especially my walking. I can work a full day, but athletic or physically demanding activities are more difficult than they used to be. I usually don't need a cane or other assistance to walk, but I might need some assistance during an attack.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">4</td> <td><strong>Early cane:</strong> I use a cane or a single crutch or some other form of support (such as touching a wall or leaning on someone's arm) for walking all the time or part of the time, especially when walking outside. I think I can walk 25 feet in 20 seconds without a cane or crutch. I always need some assistance (cane or crutch) if I want to walk as far as three blocks.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">5</td> <td><strong>Late cane:</strong> To be able to walk 25 feet, I have to have a cane, crutch, or someone to hold onto. I can get around the house or other buildings by holding onto furniture or touching the walls for support. I may use a scooter or wheelchair if I want to go greater distances.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">6</td> <td><strong>Bilateral support:</strong> To be able to walk as far as 25 feet I must have two canes or crutches or a walker. I may use a scooter or wheelchair for longer distances.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">7</td> <td><strong>Wheelchair/scooter:</strong> My main form of mobility is a wheelchair. I may be able to stand and/or take one or two steps, but I can't walk 25 feet, even with crutches or a walker.</td> </tr> <tr> <td class=\"centered\">8</td> <td><strong>Bedridden:</strong> Unable to sit in a wheelchair for more than one hour.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">MS: multiple sclerosis.<br />* This non-copyrighted scale is an expanded version of Disease Steps introduced by Hohol et al<sup>[1,2]</sup>.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology 1995; 45:251.</li>&#xD;&#xA;    <li>Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler 1999; 5:349.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Kister I, Chamot E, Salter AR, et al. Disability in multiple sclerosis: a reference for patients and clinicians. Neurology 2013; 80:1018. DOI: <a href=\"http://www.neurology.org/content/80/11/1018.abstract\" target=\"_blank\">10.1212/WNL.0b013e3182872855</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2013 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 101833 Version 1.0</div></div></div>"},"101835":{"type":"graphic_diagnosticimage","displayName":"Substernal goiter CT coronal view","title":"Substernal goiter: Appearance on CT, coronal view","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">Substernal goiter: Appearance on CT, coronal view</div><div class=\"cntnt\"><img style=\"width:600px; height:660px;\" src=\"images/ENDO/101835_Substernal_goitr_CT_coronal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT with contrast showing substernal goiter extending below the brachiocephalic vessels with displacement and narrowing of the tracheal lumen.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 101835 Version 1.0</div></div></div>"},"101836":{"type":"graphic_diagnosticimage","displayName":"Substernal goiter CT axial view","title":"Substernal goiter: Appearance on CT, axial view","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Substernal goiter: Appearance on CT, axial view</div><div class=\"cntnt\"><img style=\"width:532px; height:512px;\" src=\"images/ENDO/101836_Substernal_goiter_CT_axial.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CT with contrast showing substernal goiter with displacement and narrowing of the tracheal lumen and the esophagus.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 101836 Version 1.0</div></div></div>"},"101837":{"type":"graphic_figure","displayName":"Manometry of neonatal nonnutritive and nutritive sucking","title":"Manometry of neonatal nonnutritive and nutritive sucking","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Manometry of neonatal nonnutritive and nutritive sucking</div><div class=\"cntnt\"><img style=\"width:527px; height:747px;\" src=\"images/PEDS/101837_Mnmt_nntl_no_ntrt_ntrtv_sck.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Manometric testing demonstrating nonnutritive sucking and nutritive sucking patterns.<br />(A) Nonnutritive sucking pattern is characterized by the presence of several oral sucks, accompanied by a solitary fully propagated pharyngeal swallow (arrowhead), associated with UES relaxation, esophageal body peristalsis, and LES relaxation. The black arrows represent anterograde propagation of the swallow&nbsp;from pharynx to stomach.<br />(B) Nutritive sucking pattern is characterized by the presence of pharyngeal bursting pattern (dashed arrow) followed by multiple propagated swallows as the infant moves the bolus through the esophagus before propagation into the stomach. These swallows are associated with UES relaxation, esophageal body peristalsis, and LES relaxation. The black arrows represent anterograde propagation from pharynx to stomach.</div><div class=\"graphic_footnotes\">UES: upper esophageal sphincter; PE: proximal esophagus; ME: mid-esophagus; DE: distal esophagus; LES: lower esophageal sphincter.</div><div id=\"graphicVersion\">Graphic 101837 Version 2.0</div></div></div>"},"101839":{"type":"graphic_table","displayName":"Comparison of features of proctitis","title":"Comparison of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"19%\"></colgroup><colgroup span=\"3\" width=\"27%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Characteristics</td> <td class=\"subtitle1\">Ulcerative proctitis</td> <td class=\"subtitle1\">Chronic radiation proctopathy</td> <td class=\"subtitle1\">Diversion proctitis</td> </tr> <tr class=\"divider_bottom\"> <td>Shared clinical features</td> <td colspan=\"3\">Rectal bleeding, diarrhea, urgency, tenesmus, incontinence, pelvic pain</td> </tr> <tr class=\"divider_bottom\"> <td>Disease-specific clinical features</td> <td>Risk of proximal extension of inflammation; ulcerative proctitis improves after fecal diversion</td> <td>Excessive bleeding; inflammation persists even after fecal diversion</td> <td>Bloody mucus discharge; inflammation resolves after reestablishment of GI continuity</td> </tr> <tr class=\"divider_bottom\"> <td>Shared endoscopic features</td> <td colspan=\"3\">Edema, erythema, friability, ulcer, granularity, exudates</td> </tr> <tr class=\"divider_bottom\"> <td>Disease-specific endoscopic features</td> <td>Sharp demarcation of diseased and non-diseased segments of distal large bowel; inflammatory polyps</td> <td>Angiectasia or arteriovenous malformation-like lesions</td> <td>Anal or distal rectal stricture, bleeding induced by endoscopic air insufflation; \"cat scratch\"</td> </tr> <tr class=\"divider_bottom\"> <td>Shared histologic features</td> <td colspan=\"3\">There are no definite shared histologic features</td> </tr> <tr class=\"divider_bottom\"> <td>Disease-specific histologic features</td> <td>Prominent basal lymphoplasmacytosis</td> <td>Dilated, tortuous capillaries have prominent endothelial cell nuclei and are surrounded by a cuff of hyalinized lamina propria</td> <td>Follicular lymphoid hyperplasia</td> </tr> <tr> <td>Other histologic features</td> <td>Epithelial injury from mucin depletion, cryptitis, crypt abscess, erosion and ulceration; crypt distortion; Paneth cell metaplasia; hypertrophy of muscularis mucosae in some cases</td> <td>Variable degree of epithelial injury, crypt distortion, erosion and ulceration; sclerosis of submucosal arteries, the presence of atypical stellate fibroblasts, and secondary chronic ischemic changes such as crypt atrophy and Paneth cell metaplasia</td> <td>Diffuse mild acute inflammation, and a lymphoplasmacytic infiltrate most dense in the upper mucosa; may show mucin depletion, cryptitis, crypt abscess, crypt atrophy, and Paneth cell metaplasia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GI: gastrointestinal.</div><div class=\"graphic_reference\">From: Wu XR, Liu XL, Katz S, Shen B. Pathogenesis, diagnosis, and management of ulcerative proctitis, chronic radiation proctopathy, and diversion proctitis. Inflamm Bowel Dis 2015; 21:703. DOI: <a href=\"http://journals.lww.com/ibdjournal/Abstract/2015/03000/Pathogenesis,_Diagnosis,_and_Management_of.23.aspx\" target=\"_blank\">10.1097/MIB.0000000000000227</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2015 Crohn's and Colitis Foundation of America, Inc. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 101839 Version 1.0</div></div></div>"},"101840":{"type":"graphic_picture","displayName":"Stricture complicating diversion colitis","title":"Stricture complicating diversion colitis","html":"<div class=\"graphic\"><div style=\"width: 712px\" class=\"figure\"><div class=\"ttl\">Stricture complicating diversion colitis</div><div class=\"cntnt\"><img style=\"width:692px; height:562px;\" src=\"images/GAST/101840_Tight_strictur_divert_bowel.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tight stricture in the diverted bowel.<br />(A) Tight anastomotic stricture prior to balloon dilation.<br />(B) Post-balloon dilatation with trauma.<br />(C) Tight anastomotic stricture prior to needle-knife stricturotomy.<br />(D) Post-needle-knife stricturotomy.</div><div class=\"graphic_reference\">From: Sinh P, Shen B. Endoscopic evaluation of surgically altered bowel in patients with inflammatory bowel diseases. Inflamm Bowel Dis 2015; 21:1459. DOI: <a href=\"http://journals.lww.com/ibdjournal/Abstract/2015/06000/Endoscopic_Evaluation_of_Surgically_Altered_Bowel.27.aspx\" target=\"_blank\">10.1097/MIB.0000000000000357</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2015 Crohn's and Colitis Foundation of America, Inc. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 101840 Version 1.0</div></div></div>"},"101841":{"type":"graphic_algorithm","displayName":"Diagnosis of burn wound infection and sepsis","title":"Diagnosis of burn wound infection and sepsis","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Diagnosis of burn wound infection and sepsis</div><div class=\"cntnt\"><img style=\"width:504px; height:552px;\" src=\"images/SURG/101841_Brn_wnd_infctn_sps.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Temp: temperature; WBC: white blood cell.<br />* The accuracy of histopathology depends on the capabilities of the institution. For institutions without appropriate expertise, positive qualitative cultures from wound culture may be sufficient.</div><div id=\"graphicVersion\">Graphic 101841 Version 3.0</div></div></div>"},"101843":{"type":"graphic_figure","displayName":"Tibiofibular unions and the interosseous membrane (right leg)","title":"Tibiofibular unions and the interosseous membrane (right leg)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tibiofibular unions and the interosseous membrane (right leg)</div><div class=\"cntnt\"><img style=\"width:358px; height:831px;\" src=\"images/EM/101843_Tbfbl_un_intrs_mbrn_rght_lg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tibiofibular syndesmosis is comprised of four ligamentous structures: the anterior tibiofibular ligament (ATiFL), the posterior tibiofibular ligament (PTiFL), the transverse ligament, and the interosseous membrane (IOM). The ATiFL and IOM are shown in the picture above.</div><div class=\"graphic_reference\">Originally published in: Sobotta Atlas der Anatomie des Menschen, 22. Auflage, Band 1, Band 2; M&uuml;nchen: Elsevier/Urban &amp; Fischer &copy; 2006. The English translation was undertaken by Lippincott Williams &amp; Wilkins and published in: Anatomy: A Regional Atlas of the Human Body, 6th ed, Clemente CD (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101843 Version 1.0</div></div></div>"},"101857":{"type":"graphic_picture","displayName":"Cervical lymphadenopathy in tinea capitis","title":"Cervical lymphadenopathy in tinea capitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Cervical lymphadenopathy in tinea capitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101857_Crvcl_lymphdnp_tnea_cpt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101857 Version 1.0</div></div></div>"},"101858":{"type":"graphic_picture","displayName":"Tinea capitis scaly patch","title":"Tinea capitis","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Tinea capitis</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/101858_Tinea_cpts_scly_ptch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Scaly patch with hair loss on the posterior scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101858 Version 1.0</div></div></div>"},"101859":{"type":"graphic_picture","displayName":"Tinea capitis multiple sites","title":"Tinea capitis","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Tinea capitis</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/101859_Tinea_cpts_mltpl_sts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple scaly macules and patches on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101859 Version 1.0</div></div></div>"},"101860":{"type":"graphic_picture","displayName":"Tinea capitis diffuse","title":"Tinea capitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tinea capitis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101860_Tinea_capitis_diffuse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse scaling on the scalp and mild hair loss.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101860 Version 1.0</div></div></div>"},"101861":{"type":"graphic_picture","displayName":"Favus","title":"Favus","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Favus</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101861_Favus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive scale, hair loss, and cup-shaped crusts (scutula) on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101861 Version 1.0</div></div></div>"},"101863":{"type":"graphic_algorithm","displayName":"Evaluation for acute HCV in a patient with acute hepatitis","title":"Evaluation for acute HCV infection in a patient with acute hepatitis","html":"<div class=\"graphic\"><div style=\"width: 722px\" class=\"figure\"><div class=\"ttl\">Evaluation for acute HCV infection in a patient with acute hepatitis</div><div class=\"cntnt\"><img style=\"width:702px; height:524px;\" src=\"images/ID/101863_Eval_acute_HCV_hepatitis.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HCV: hepatitis C virus; PCR: polymerase chain reaction; Ab: antibody</div><div id=\"graphicVersion\">Graphic 101863 Version 1.0</div></div></div>"},"101864":{"type":"graphic_algorithm","displayName":"Evaluation for acute HCV in a patient with recent exposure","title":"Evaluation for acute HCV in a patient with recent exposure","html":"<div class=\"graphic\"><div style=\"width: 686px\" class=\"figure\"><div class=\"ttl\">Evaluation for acute HCV in a patient with recent exposure</div><div class=\"cntnt\"><img style=\"width:666px; height:682px;\" src=\"images/ID/101864_Eval_acute_HCV_recent_expos.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">HCV: hepatitis C virus; Ab: antibody</div><div class=\"graphic_footnotes\">This algorithm represents one approach to the diagnosis of acute HCV infection following a known exposure to HCV.&nbsp;After evaluating the baseline HCV RNA and&nbsp;antibody levels, repeat testing intervals over the next six months depend, in part,&nbsp;on how soon detection of infection is desired. Aminotransferases can also be checked&nbsp;as well, and new elevations in these levels&nbsp;would be a trigger to recheck HCV RNA sooner if not already detectable. </div><div id=\"graphicVersion\">Graphic 101864 Version 1.0</div></div></div>"},"101868":{"type":"graphic_figure","displayName":"Urinary tract dilation classification system","title":"Urinary tract dilation classification system for pediatric hydronephrosis","html":"<div class=\"graphic\"><div style=\"width: 922px\" class=\"figure\"><div class=\"ttl\">Urinary tract dilation classification system for pediatric hydronephrosis</div><div class=\"cntnt\"><img style=\"width:902px; height:1150px;\" src=\"images/PEDS/101868_UTD_classification_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Urinary Tract Dilation (UTD) Classification System describes the appearance of the urinary tract based on antenatal and postnatal presentation. The antenatal presentation (left column) is divided into normal, A1, and A2-3, and measurements between 16 and 27 weeks and ≥28 weeks gestation. A normal urinary tract is one with no urinary tract abnormalities and anterior posterior renal pelvic diameter (APRPD) measuring less than 4 mm between 16 and 27 weeks gestation and less than 7 mm ≥28 weeks gestation. A1 describes a normal urinary tract with 4 to &lt;7 mm pelvic dilation at 16 to 27 weeks gestation or 7 to &lt;10 mm ≥28 weeks gestation with or without central calyceal dilation. UTD A2-3 is for fetuses if there is APRPD ≥7 mm between 16 and 27 weeks gestation or ≥10 mm ≥28 weeks gestation, peripheral calyceal dilation, ureteral dilation, renal parenchymal, or bladder abnormalities. The postnatal presentation (right column) is divided into normal, P1, P2, and P3. Measurements are more reliable if taken 48 hours after birth or later. A normal urinary tract is one with no urinary tract abnormalities and APRPD &lt;10 mm. P1 describes a normal urinary tract with APRPD 10 to &lt;15 mm and/or central calyceal dilation. P2 describes APRPD ≥15 mm or peripheral calyceal dilation. P3 describes additional ureteral dilation, abnormal renal echogenicity or cysts, or bladder abnormalities regardless of APRPD measurement.</div><div class=\"graphic_reference\">Pediatric Radiology, Multidisciplinary consensus on the classification of antenatal and postnatal urinary tract dilation (UTD classification system), Vol. 45, 2015, p. 787, Chow JS, Darge K, © Springer-Verlag Berlin Heidelberg 2015. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 101868 Version 4.0</div></div></div>"},"101869":{"type":"graphic_table","displayName":"Contraindications and precautions for hepatitis B vaccines","title":"Contraindications and precautions for hepatitis B vaccines","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications and precautions for hepatitis B vaccines</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Contraindications</td> </tr> <tr> <td class=\"indent1\">Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component (eg, yeast)</td> </tr> <tr> <td class=\"subtitle1_single\">Precautions</td> </tr> <tr> <td class=\"indent1\">Infant weighing &#60;2 kg (4.4 pounds)*</td> </tr> <tr> <td class=\"indent1\">Moderate or severe illness with or without fever (ie, illness more severe than upper respiratory infection, otitis media, gastroenteritis)</td> </tr> <tr> <td class=\"subtitle1_single\">Conditions commonly misperceived as contraindications that are not contraindications to hepatitis B vaccine</td> </tr> <tr> <td class=\"indent1\">Pregnancy</td> </tr> <tr> <td class=\"indent1\">Autoimmune disease (eg, systemic lupus erythematosus, rheumatoid arthritis)</td> </tr> <tr> <td class=\"subtitle1_single\">Conditions commonly misperceived as contraindications that are not contraindications to any vaccine</td> </tr> <tr> <td class=\"indent1\">Mild acute illness with or without fever (eg, upper respiratory infection, otitis media, gastroenteritis)</td> </tr> <tr> <td class=\"indent1\">Mild-to-moderate local reaction (eg, swelling, redness, soreness) after previous dose</td> </tr> <tr> <td class=\"indent1\">Low-grade or moderate fever after previous dose</td> </tr> <tr> <td class=\"indent1\">Current antimicrobial therapy</td> </tr> <tr> <td class=\"indent1\">Convalescent phase of illness</td> </tr> <tr> <td class=\"indent1\">Recent exposure to infectious disease</td> </tr> <tr> <td class=\"indent1\">History of penicillin allergy, other nonvaccine allergies, relatives with allergies, or receiving allergen extract immunotherapy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HBsAg: hepatitis B surface antigen.<br />*Hepatitis B vaccination should be deferred for infants weighing &lt;2 kg (4.4 pounds) if the mother is documented to be HBsAg-negative at the time of the infant's birth. Vaccination can begin when the infant is one month old or at hospital discharge. For infants born to HBsAg-positive women, hepatitis B immune globulin and hepatitis B vaccine should be administered within 12 hours after birth, regardless of weight.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018; 67:1.</LI>&#xD;&#xA;<LI>Kroger AT, Duchin J, Vázquez M. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at: <A spellcheck=true href=\"http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</A>. Accessed on May 9, 2017.</LI></OL></div><div id=\"graphicVersion\">Graphic 101869 Version 3.0</div></div></div>"},"101870":{"type":"graphic_figure","displayName":"Incidence HBV US","title":"Reported acute hepatitis B incidence,* by age group and year – United States, 1990-2004","html":"<div class=\"graphic\"><div style=\"width: 606px\" class=\"figure\"><div class=\"ttl\">Reported acute hepatitis B incidence,* by age group and year – United States, 1990-2004</div><div class=\"cntnt\"><img style=\"width:586px; height:386px;\" src=\"images/PEDS/101870_IncidenceHBVUS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Per 100,000 population.</div><div class=\"graphic_reference\">Reproduced from: Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: Immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54:1.</div><div id=\"graphicVersion\">Graphic 101870 Version 3.0</div></div></div>"},"101871":{"type":"graphic_table","displayName":"Interpretation follow-up serology HBV exposed infant","title":"Interpretation of postvaccination serologic testing for infants born to HBsAg-positive women*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interpretation of&nbsp;postvaccination serologic testing for infants born to HBsAg-positive women*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">HBsAg</td> <td class=\"subtitle1\">Anti-HBs</td> <td class=\"subtitle1\">Interpretation</td> <td class=\"subtitle1\">Action</td> </tr> <tr> <td>Positive</td> <td>&#8805;10 mIU/mL</td> <td rowspan=\"3\">Infected with HBV</td> <td rowspan=\"3\">Refer for appropriate follow-up including medical evaluation for chronic liver disease.</td> </tr> <tr> <td>Positive</td> <td>&#60;10 mIU/mL</td> </tr> <tr> <td>Positive</td> <td>Not reported</td> </tr> <tr> <td>Negative</td> <td>&#8805;10 mIU/mL</td> <td>Protected against HBV</td> <td>NA</td> </tr> <tr> <td>Negative</td> <td>&#60;10 mIU/mL</td> <td>Susceptible to HBV</td> <td> <p><span style=\"color: black;\">Provide an additional dose of HepB vaccine and obtain HBsAg and anti-HBs one to two months later.<sup>&#182;</sup></span></p> <p><span style=\"color: black;\"><sup></sup>If anti-HBs remains &#60;10 mIU/mL, administer two additional doses of HepB vaccine (at least eight weeks apart) to complete the second series and obtain HBsAg and anti-HBs one to two months later.</span></p> </td> </tr> <tr> <td>Negative</td> <td>Not reported</td> <td rowspan=\"4\">Indeterminate</td> <td rowspan=\"4\">Repeat serologic testing.</td> </tr> <tr> <td>Not reported</td> <td>&#8805;10 mIU/mL</td> </tr> <tr> <td>Not reported</td> <td>&#60;10 mIU/mL</td> </tr> <tr> <td>Not reported</td> <td>Not reported</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; anti-HBs: antibody to HBsAg; mIU: milli-international units; NA: not applicable; HepB: hepatitis B vaccine.<br />* Postvaccination serology (HBsAg and anti-HBs)&nbsp;should be obtained after completion of the HepB vaccine series, usually at 9 to 12 months of age or one to two months after the last dose of HepB vaccine if immunization is delayed.&nbsp;<br />¶ This is the preferred regimen. As an alternative, depending upon clinical circumstances or family preference, infants may be revaccinated with a second complete three-dose series (at 0, 1 to 2, and 6 months), followed by serologic testing (HBsAg and anti-HBs) one to two months after the final dose. Refer to UpToDate content on HBV immunization in infants for additional information. </div><div class=\"graphic_reference\">Adapted from: Centers for Disease Control and Prevention (CDC). Postvaccination serologic testing results for infants aged ≤24 months exposed to hepatitis B virus at birth: United States, 2008-2011. MMWR Morb Mortal Wkly Rep 2012; 61:768 <SPAN style=\"COLOR: black\">with additional data from Schillie S, Vellozzi C, Reingold A, et al. Prevention of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018; 67:1</SPAN><SPAN style=\"COLOR: black\">.</SPAN></div><div id=\"graphicVersion\">Graphic 101871 Version 3.0</div></div></div>"},"101872":{"type":"graphic_figure","displayName":"Risk of chronic hepatitis B virus carriage by age of infection","title":"Risk of chronic hepatitis B virus carriage by age of infection","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Risk of chronic&nbsp;hepatitis B virus&nbsp;carriage by age of infection</div><div class=\"cntnt\"><img style=\"width:576px; height:338px;\" src=\"images/PEDS/101872_RskchrncHBVageacqs.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Centers for Disease Control and Prevention. Hepatitis B. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13<SUP>th</SUP> ed, Hamborsky J, Kroger A, Wolfe S, (Eds). Public Health Foundation, Washington, DC 2015.</div><div id=\"graphicVersion\">Graphic 101872 Version 3.0</div></div></div>"},"101873":{"type":"graphic_figure","displayName":"Classification of palatomaxillary defects","title":"Classification of palatomaxillary defects","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Classification of palatomaxillary defects</div><div class=\"cntnt\"><img style=\"width:525px; height:708px;\" src=\"images/ONC/101873_Classification_of_palatomaxillary_defects.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Modified from: Okay DJ,&nbsp;Genden E, Buchbinder D, Urken M. Prosthodontic guidelines for surgical reconstruction of the maxilla: A classification system of defects. J Prosthet Dent 2001; 86:352.</div><div id=\"graphicVersion\">Graphic 101873 Version 1.0</div></div></div>"},"101875":{"type":"graphic_table","displayName":"Oral progestin-only regimens","title":"Suggested oral progestin/progesterone-only regimens for the acute management of anovulatory uterine bleeding and maintenance therapy after acute bleeding is controlled*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested oral progestin/progesterone-only regimens for the acute management of anovulatory uterine bleeding and maintenance therapy after acute bleeding is controlled*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody class=\"subtitle1\"> <tr> <td class=\"subtitle1\" colspan=\"2\">Preferred regimen for acute management</td> </tr> <tr> <td>Norethindrone acetate</td> <td>5 or 10 mg orally nightly<sup>&#182;</sup> until bleeding stops and anemia resolves</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Preferred maintenance regimens<sup>&#916;</sup></td> </tr> <tr> <td>Oral micronized progesterone</td> <td>200 mg orally nightly for the first 12 days of each calendar month (if not allergic to peanuts)<sup>&#9674;</sup></td> </tr> <tr> <td>Norethindrone acetate</td> <td>5&nbsp;mg orally nightly for the first 5 to 10 days<sup>&#916;</sup> of each calendar month<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Alternative maintenance regimen​​​​​​​​​​​​​​​​​</td> </tr> <tr> <td>Medroxyprogesterone acetate</td> <td>10 mg orally nightly for the first 10 days of each calendar month<sup>&#9674;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* For patients who do not desire contraception. <br />¶ May be administered up to four times per day if acute bleeding is severe. <br />Δ We suggest taking oral progesterone on the first 5 to 12 days of each calendar month because it is easier for adolescents to remember than other regimens.<br />◊ Discontinue if menstrual bleeding occurs while taking oral progesterone.</div><div id=\"graphicVersion\">Graphic 101875 Version 4.0</div></div></div>"},"101881":{"type":"graphic_algorithm","displayName":"Management of abdominal compartment syndrome and open abdomen","title":"Management of abdominal compartment syndrome and open abdomen","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Management of abdominal compartment syndrome and open abdomen</div><div class=\"cntnt\"><img style=\"width:487px; height:610px;\" src=\"images/SURG/101881_Abdm_cmprt_snd_opn_abd.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IAP: intra-abdominal pressure; OR: operating room.<br />* Severe injury, severe burns, liver transplantation, prolonged open surgery, massive resuscitation.<br />¶ For at-risk patients, bladder pressure measurements are obtained every&nbsp;four to&nbsp;six hours.<br />Δ Abdominal decompression can be considered in the absence of other obvious causes of organ dysfunction.<br /><FONT class=lozenge>◊</FONT> Bladder pressure should be rechecked for new clinical findings (eg, abdominal tension, organ dysfunction).</div><div id=\"graphicVersion\">Graphic 101881 Version 3.0</div></div></div>"},"101882":{"type":"graphic_algorithm","displayName":"Failed primary hemodialysis arteriovenous access","title":"Failed primary hemodialysis arteriovenous access","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Failed primary hemodialysis arteriovenous access</div><div class=\"cntnt\"><img style=\"width:350px; height:514px;\" src=\"images/SURG/101882_Fl_prm_hmdlys_artrvn_acs.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AV: arteriovenous.<br />* Failed primary AV fistula or AV graft. AV grafts should be evaluated with the first instance of graft failure.<br />¶ Central catheters for hemodialysis are an access of last resort.<br />Δ AV graft is typically placed in the upper arm and depends on the status of the axillosubclavian veins.</div><div id=\"graphicVersion\">Graphic 101882 Version 2.0</div></div></div>"},"101883":{"type":"graphic_table","displayName":"Functional classification of myelomeningocele","title":"Functional classification and ambulatory capacity of children with myelomeningocele (spina bifida)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Functional classification and ambulatory capacity of children with myelomeningocele (spina bifida)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Neurologic level of lesion</td> <td class=\"subtitle1\">Prevalence</td> <td class=\"subtitle1\">Ambulatory capacity</td> <td class=\"subtitle1\">Functional mobility scale*</td> </tr> <tr> <td><strong>Thoracic/high lumbar</strong></td> <td>L3 or above</td> <td>30%</td> <td> <ul> <li>Require HKAFO or RGO for ambulation </li> <li>70 to 99% require wheelchair for mobility in adulthood </li> </ul> </td> <td>1,1,1</td> </tr> <tr> <td><strong>Low lumbar</strong></td> <td>L3 to L5</td> <td>30%</td> <td> <ul> <li>Require AFOs and crutches for ambulation </li> <li>80 to 95% maintain community ambulation in adulthood </li> </ul> </td> <td>3,3,1</td> </tr> <tr> <td><strong>High sacral</strong></td> <td>S1 to S3</td> <td>30%</td> <td> <ul> <li>Require AFOs for ambulation </li> <li>94 to 100% maintain community ambulation in adulthood </li> </ul> </td> <td>6,6,6</td> </tr> <tr> <td><strong>Low sacral</strong></td> <td>S3 to S5</td> <td>5 to 10%</td> <td> <ul> <li>Ambulate without braces or support </li> <li>94 to 100% maintain community ambulation in adulthood </li> </ul> </td> <td>6,6,6</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HKAFO: hip-knee-ankle-foot orthosis; RGO: reciprocating gait orthosis; AFO: ankle-foot orthosis.<br />* The functional mobility scale is a tool that rates the child's ability on a scale of 1 to 6 (1 = uses wheelchair; 6 = independent on all surfaces) for walking three distances: 5 meters, 50 meters, and 500 meters. Refer to UpToDate topic on orthopedic issues in myelomeningocele for further details.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Swank M, Dias LS. Walking ability in spina bifida patients: a model for predicting future ambulatory status based on sitting balance and motor level. J Pediatr Orthop 1994; 14:715. </li>&#xD;&#xA;    <li>Kerr GH, Harvey A, Rodda J, et al. The functional mobility score. J Pediatr Orthop 2004; 24:514.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 101883 Version 1.0</div></div></div>"},"101888":{"type":"graphic_picture","displayName":"Tubal titanium clip","title":"Titanium clip for female sterilization","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Titanium clip for female sterilization</div><div class=\"cntnt\"><img style=\"width:129px; height:159px;\" src=\"images/OBGYN/101888_Tbl_ttnm_clp.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Image provided by CooperSurgical, Inc. The Filshie Tubal Ligation System is a registered trademark of Utah Medical, Inc.</div><div id=\"graphicVersion\">Graphic 101888 Version 1.0</div></div></div>"},"101890":{"type":"graphic_figure","displayName":"Tubal titanium clip placement","title":"Placement of titanium clip for female sterilization","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Placement of titanium clip for female sterilization</div><div class=\"cntnt\"><img style=\"width:712px; height:559px;\" src=\"images/OBGYN/101890_Tbl_ttnm_clp_plcm.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Peterson HB, Pollack AE, Warshaw JS. Tubal Sterilization. In: Te Linde's Operative Gynecology, 10th Ed, Rock JA, Jones III HW, Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 101890 Version 1.0</div></div></div>"},"101892":{"type":"graphic_diagnosticimage","displayName":"Mixed-type IPMN","title":"Mixed-type intraductal papillary mucinous neoplasm of the pancreas","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Mixed-type intraductal papillary mucinous neoplasm of the pancreas</div><div class=\"cntnt\"><img style=\"width:282px; height:212px;\" src=\"images/GAST/101892_Mixed_type_IPMN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Magnetic resonance cholangiopancreatography revealing mixed-type intraductal papillary mucinous neoplasm. There are multiple dilated branch ducts and a moderately dilated main pancreatic duct in the pancreatic body region.</div><div class=\"graphic_reference\">Courtesy of Kevin McGrath, MD.</div><div id=\"graphicVersion\">Graphic 101892 Version 1.0</div></div></div>"},"101893":{"type":"graphic_table","displayName":"Wound management dressing guide","title":"Wound management dressing guide","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Wound management dressing guide</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Type of tissue in the wound</td> <td class=\"subtitle1\" rowspan=\"2\">Therapeutic goal</td> <td class=\"subtitle1\" rowspan=\"2\">Role of dressing</td> <td class=\"subtitle1\" colspan=\"3\">Treatment options</td> </tr> <tr> <td class=\"subtitle2\">Wound bed preparation</td> <td class=\"subtitle2\">Primary dressing</td> <td class=\"subtitle2\">Secondary dressing</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Necrotic, black, dry </li> </ul> </td> <td> <ul> <li>Remove devitalized tissue </li> <li>Do not attempt debridement if vascular insufficiency suspected </li> <li>Keep dry and refer for vascular assessment </li> </ul> </td> <td> <ul> <li>Hydration of wound bed </li> <li>Promote autolytic debridement </li> </ul> </td> <td> <ul> <li>Surgical or mechanical debridement </li> </ul> </td> <td> <ul> <li>Hydrogel </li> <li>Honey </li> </ul> </td> <td> <ul> <li>Polyurethane film dressing </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Sloughy, yellow, brown, black or grey </li> <li>Dry to low exudate </li> </ul> </td> <td> <ul> <li>Remove slough </li> <li>Provide clean wound bed for granulation tissue </li> </ul> </td> <td> <ul> <li>Rehydrate wound bed </li> <li>Control moisture balance </li> <li>Promote autolytic debridement </li> </ul> </td> <td> <ul> <li>Surgical or mechanical debridement if appropriate </li> <li>Wound cleansing (consider antiseptic wound cleansing solution) </li> </ul> </td> <td> <ul> <li>Hydrogel </li> <li>Honey </li> </ul> </td> <td> <ul> <li>Polyurethane film dressing </li> <li>Low adherent (silicone) dressing </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Sloughy, yellow, brown, black or grey </li> <li>Moderate to high exudate </li> </ul> </td> <td> <ul> <li>Remove slough </li> <li>Provide clean wound bed for granulation tissue </li> <li>Exudate management </li> </ul> </td> <td> <ul> <li>Absorb excess fluid </li> <li>Protect periwound skin to prevent maceration </li> <li>Promote autolytic debridement </li> </ul> </td> <td> <ul> <li>Surgical or mechanical debridement if appropriate </li> <li>Wound cleansing (consider antiseptic wound cleansing solution) </li> <li>Consider barrier products </li> </ul> </td> <td> <ul> <li>Absorbent dressing (alginate/CMC/foam) </li> <li>For deep wounds, use cavity strips, rope or ribbon versions </li> </ul> </td> <td> <ul> <li>Retention bandage or polyurethane film dressing </li> </ul> </td> </tr> <tr> <td class=\"divider_bottom\"> <ul> <li>Granulating, clean, red </li> <li>Dry to low exudate </li> </ul> </td> <td class=\"divider_bottom\"> <ul> <li>Promote granulation </li> <li>Provide healthy wound bed for epithelialization </li> </ul> </td> <td class=\"divider_bottom\"> <ul> <li>Maintain moisture balance </li> <li>Protect new tissue growth </li> </ul> </td> <td class=\"divider_bottom\"> <ul> <li>Wound cleansing </li> </ul> </td> <td class=\"divider_bottom\"> <ul> <li>Hydrogel </li> <li>Low adherent (silicone) dressing </li> <li>For deep wounds use cavity strips, rope or ribbon versions </li> </ul> </td> <td rowspan=\"4\"> <ul> <li>Pad and/or retention bandage </li> <li>Avoid bandages that may cause occlusion and maceration </li> <li>Tapes should be used with caution due to allergy potential and secondary complications </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Granulating, clean, red </li> <li>Moderate to high exudate </li> </ul> </td> <td> <ul> <li>Exudate management </li> <li>Provide healthy wound bed for epithelialization </li> </ul> </td> <td> <ul> <li>Maintain moisture balance </li> <li>Protect new tissue growth </li> </ul> </td> <td> <ul> <li>Wound cleansing </li> <li>Consider barrier products </li> </ul> </td> <td> <ul> <li>Absorbent dressing (alginate/CMC/foam) </li> <li>Low adherent (silicone) dressing </li> <li>For deep wounds, use cavity strips, rope or ribbon versions </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Epithelializing, red, pink </li> <li>No to low exudate </li> </ul> </td> <td> <ul> <li>Promote epithelialization and wound maturation (contraction) </li> </ul> </td> <td> <ul> <li>Protect new tissue growth </li> </ul> </td> <td>&nbsp;</td> <td> <ul> <li>Hydrocolloid (thin) </li> <li>Polyurethane film dressing </li> <li>Low adherent (silicone) dressing </li> </ul> </td> </tr> <tr> <td> <ul> <li>Infected </li> <li>Low to high exudate </li> </ul> </td> <td> <ul> <li>Reduce bacterial load </li> <li>Exudate management </li> <li>Odor control </li> </ul> </td> <td> <ul> <li>Antimicrobial action </li> <li>Moist wound healing </li> <li>Odor absorption </li> </ul> </td> <td> <ul> <li>Wound cleansing (consider antiseptic wound cleansing solution) </li> <li>Consider barrier products </li> </ul> </td> <td> <ul> <li>Antimicrobial dressing </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The purpose of this table is to provide guidance about appropriate dressings and should be used in conjunction with clinical judgement and local protocols. Where wounds contain mixed tissue types, it is important to consider the predominant factors affecting healing and address accordingly. Where infection is suspected, it is important to regularly inspect the wound and to change the dressing frequently. Wound dressings should be used in combination with appropriate wound bed preparation, systemic antibiotic therapy, pressure offloading, and diabetic control.</div><div class=\"graphic_footnotes\">CMC: carboxymethyl cellulose.</div><div class=\"graphic_reference\">Reproduced with permission from: McCardle J, Chadwick P, Edmonds M, et al. International Best Practice Guidelines: Wound Management in Diabetic Foot Ulcers. Wounds International, 2013. Copyright &copy; 2013 Schofield Healthcare Media LTD. Available from: <a href=\"http://www.woundsinternational.com/\" target=\"_blank\">www.woundsinternational.com</a>.</div><div id=\"graphicVersion\">Graphic 101893 Version 2.0</div></div></div>"},"101897":{"type":"graphic_table","displayName":"The transgender five Ps of sexual history","title":"The transgender five P's: Partners, prevention of pregnancy, protection from STIs, practices, and past history of STIs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The transgender five P's: Partners, prevention of pregnancy, protection from STIs, practices, and past history of STIs</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody sizcache=\"157\" sizset=\"36\"> <tr sizcache=\"156\" sizset=\"36\"> <td class=\"subtitle1_single\">Partners</td> </tr> <tr sizcache=\"156\" sizset=\"37\"> <td>Do you have sex with men, women, or both? Are any of them transgender?</td> </tr> <tr sizcache=\"156\" sizset=\"38\"> <td>In the past&nbsp;two months, how many partners have you had sex with?</td> </tr> <tr sizcache=\"156\" sizset=\"39\"> <td>In the past 12 months, how many partners have you had sex with?</td> </tr> <tr sizcache=\"156\" sizset=\"40\"> <td>Is it possible that any of your sex partners in the past 12 months had sex with someone else while they were still in a sexual relationship with you?</td> </tr> <tr sizcache=\"156\" sizset=\"41\"> <td class=\"subtitle1_single\">Prevention of pregnancy</td> </tr> <tr sizcache=\"156\" sizset=\"42\"> <td>What are you doing to prevent pregnancy?</td> </tr> <tr sizcache=\"156\" sizset=\"43\"> <td class=\"subtitle1_single\">Protection from STIs</td> </tr> <tr sizcache=\"156\" sizset=\"44\"> <td>What do you do to protect yourself from STIs and HIV?</td> </tr> <tr sizcache=\"156\" sizset=\"45\"> <td class=\"subtitle1_single\">Practices</td> </tr> <tr sizcache=\"156\" sizset=\"46\"> <td>To understand your risks for STIs, I need to understand the kind of sex you have had recently.</td> </tr> <tr sizcache=\"156\" sizset=\"47\"> <td>Have you had vaginal sex, meaning \"penis-in-vagina\" sex?*</td> </tr> <tr sizcache=\"156\" sizset=\"48\"> <td class=\"sublist1_start\">If yes:</td> </tr> <tr sizcache=\"156\" sizset=\"49\"> <td class=\"sublist1\">Do you use condoms: never, sometimes, or always?</td> </tr> <tr sizcache=\"156\" sizset=\"50\"> <td>Have you had anal sex, meaning \"penis-in-rectum/anus\" sex?</td> </tr> <tr sizcache=\"156\" sizset=\"51\"> <td class=\"sublist1_start\">If yes:</td> </tr> <tr sizcache=\"156\" sizset=\"52\"> <td class=\"sublist1\">Do you use condoms: never, sometimes, or always?</td> </tr> <tr sizcache=\"156\" sizset=\"53\"> <td>Have you had oral sex, meaning \"mouth-on-penis/vagina\"?</td> </tr> <tr sizcache=\"156\" sizset=\"54\"> <td>For condom answers:</td> </tr> <tr sizcache=\"156\" sizset=\"55\"> <td class=\"sublist1\">If never:</td> </tr> <tr sizcache=\"156\" sizset=\"56\"> <td class=\"sublist2\">Why do&nbsp;you not use condoms?</td> </tr> <tr sizcache=\"156\" sizset=\"57\"> <td class=\"sublist1\">If sometimes:</td> </tr> <tr sizcache=\"156\" sizset=\"58\"> <td class=\"sublist2\">In what situations (or with whom) do you not use condoms?</td> </tr> <tr sizcache=\"156\" sizset=\"59\"> <td class=\"subtitle1_single\">Past history of STIs</td> </tr> <tr sizcache=\"156\" sizset=\"60\"> <td>Have you ever had an STI?</td> </tr> <tr sizcache=\"156\" sizset=\"61\"> <td>Have any of your partners had an STI?</td> </tr> <tr sizcache=\"156\" sizset=\"62\"> <td class=\"subtitle1_single\">Additional questions to identify HIV and viral hepatitis risk:</td> </tr> <tr sizcache=\"156\" sizset=\"63\"> <td>Have you or any of your partners ever injected drugs?</td> </tr> <tr sizcache=\"156\" sizset=\"64\"> <td>Have you or any of your partners exchanged money or drugs for sex?</td> </tr> <tr sizcache=\"156\" sizset=\"65\"> <td>Is there anything else about your sexual practices that I need to know about?</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">STI: sexually transmitted infection; HIV: human immunodeficiency virus.<br />* Some transgender men (female to male) do not use the term \"vagina\" and may prefer to refer to the vagina as \"front hole.\" It is generally best for the provider to ask patients what their preferred term for their genitals is.</div><div class=\"graphic_reference\">Adapted from: Workowski KA, Berman SM. Sexually transmitted diseases guidelines, 2010. MMWR Recomm Rep 2010; 59 (No.RR-12): 3.</div><div id=\"graphicVersion\">Graphic 101897 Version 2.0</div></div></div>"},"101898":{"type":"graphic_table","displayName":"WHC and clinical description","title":"West Haven criteria for hepatic encephalopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">West Haven&nbsp;criteria for hepatic encephalopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"11%\"></colgroup><colgroup span=\"3\" width=\"26%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">WHC including MHE</td> <td class=\"subtitle1\">ISHEN</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Suggested operative criteria</td> <td class=\"subtitle1\">Comment</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\" colspan=\"2\">Unimpaired</td> <td> <ul> <li>No encephalopathy at all, no history of HE </li> </ul> </td> <td>Tested and proved to be normal</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Minimal</td> <td class=\"centered\" style=\"vertical-align: middle;\" rowspan=\"2\">Covert</td> <td> <ul> <li>Psychometric or neuropsychological alterations of tests exploring psychomotor speed/executive functions or neurophysiological alterations without clinical evidence of mental change </li> </ul> </td> <td>Abnormal results of established psychometric or neuropsychological tests without clinical manifestations</td> <td> <p>No universal criteria for diagnosis</p> Local standards and expertise required</td> </tr> <tr class=\"divider_bottom\"> <td>Grade I</td> <td> <ul> <li>Trivial lack of awareness </li> <li>Euphoria or anxiety </li> <li>Shortened attention span </li> <li>Impairment of addition or subtraction </li> <li>Altered sleep rhythm </li> </ul> </td> <td>Despite oriented in time and space (see below), the patient appears to have some cognitive/behavioral decay with respect to his or her standard on clinical examination or to the caregivers</td> <td>Clinical findings usually not reproducible</td> </tr> <tr> <td class=\"divider_bottom\">Grade II</td> <td class=\"centered\" style=\"vertical-align: middle;\" rowspan=\"3\">Overt</td> <td class=\"divider_bottom\"> <ul> <li>Lethargy or apathy </li> <li>Disorientation for time </li> <li>Obvious personality change </li> <li>Inappropriate behavior </li> <li>Dyspraxia </li> <li>Asterixis </li> </ul> </td> <td class=\"divider_bottom\">Disoriented for time (at least three of the following are wrong: day of the month, day of the week, month, season, or year) &#177; the other mentioned symptoms</td> <td class=\"divider_bottom\">Clinical findings variable, but reproducible to some extent</td> </tr> <tr class=\"divider_bottom\"> <td>Grade III</td> <td> <ul> <li>Somnolence to semistupor </li> <li>Responsive to stimuli </li> <li>Confused </li> <li>Gross disorientation </li> <li>Bizarre behavior </li> </ul> </td> <td>Disoriented also for space (at least three of the following wrongly reported: country, state [or region], city, or place) &#177; the other mentioned symptoms</td> <td>Clinical findings reproducible to some extent</td> </tr> <tr> <td>Grade IV</td> <td> <ul> <li>Coma </li> </ul> </td> <td>Does not respond even to painful stimuli</td> <td>Comatose state usually reproducible</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">All conditions are required to be related to liver insufficiency and/or portosystemic shunting.</div><div class=\"graphic_footnotes\">WHC: West Haven criteria; MHE: minimal hepatic encephalopathy;&nbsp;ISHEN: International Society for Hepatic Encephalopathy and Nitrogen Metabolism; HE: hepatic encephalopathy.</div><div class=\"graphic_reference\">From: Vilstrup H, Amodio P, Bajaj J, et al. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014; 60:715. <a href=\"http://onlinelibrary.wiley.com/doi/10.1002/hep.27210/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1002/hep.27210/abstract</a>. Copyright &copy; 2014 American Association for the Study of Liver Diseases. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 101898 Version 1.0</div></div></div>"},"101899":{"type":"graphic_figure","displayName":"HE description and clinical example","title":"Hepatic encephalopathy descriptors","html":"<div class=\"graphic\"><div style=\"width: 741px\" class=\"figure\"><div class=\"ttl\">Hepatic encephalopathy descriptors</div><div class=\"cntnt\"><img style=\"width:721px; height:234px;\" src=\"images/GAST/101899_HE_description_clinical_ex.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The patient with hepatic encephalopathy (HE)&nbsp;should be characterized by one component from each of the four columns. Example of a recommended description of a patient with HE: \"The patient has HE, Type C, Grade 3, Recurrent, Precipitated (by urinary tract infection).\" The description may be supplemented with operative classifications (eg, the Glasgow Coma Score or psychometric performance).</div><div class=\"graphic_footnotes\">MHE: minimal hepatic encephalopathy.</div><div class=\"graphic_reference\">From: Vilstrup H, Amodio P, Bajaj J, et al. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014; 60:715. <A href=\"http://onlinelibrary.wiley.com/doi/10.1002/hep.27210/abstract\" target=_blank>http://onlinelibrary.wiley.com/doi/10.1002/hep.27210/abstract</A>. Copyright © 2014 American Association for the Study of Liver Diseases. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <A href=\"mailto:permissions@wiley.com\">permissions@wiley.com</A> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<A href=\"http://onlinelibrary.wiley.com/\" target=_blank>http://onlinelibrary.wiley.com</A>).</div><div id=\"graphicVersion\">Graphic 101899 Version 1.0</div></div></div>"},"101912":{"type":"graphic_table","displayName":"Converting from subcutaneous mealtime to inhaled insulin","title":"Converting from subcutaneous mealtime insulin to inhaled insulin","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Converting from subcutaneous mealtime insulin to inhaled insulin</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Injected mealtime insulin dose</td> <td class=\"subtitle1\">Recommended inhaled insulin</td> <td class=\"subtitle1\">4-unit cartridge</td> <td class=\"subtitle1\">8-unit cartridge</td> <td class=\"subtitle1\">12-unit cartridge</td> </tr> <tr> <td class=\"centered\">Up to 4 units</td> <td class=\"centered\">4 units</td> <td class=\"centered\">Use one</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">5 to 8 units</td> <td class=\"centered\">8 units</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Use one</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">9 to 12 units</td> <td class=\"centered\">12 units</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Use one</td> </tr> <tr> <td class=\"centered\">13 to 16 units</td> <td class=\"centered\">16 units</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Use two</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"centered\">17 to 20 units</td> <td class=\"centered\">20 units</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Use one</td> <td class=\"centered\">Use one</td> </tr> <tr> <td class=\"centered\">21 to 24 units</td> <td class=\"centered\">24 units</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Use two</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101912 Version 2.0</div></div></div>"},"101913":{"type":"graphic_table","displayName":"Applicable neuromonitoring modalities by type of surgery","title":"Applicable neuromonitoring modalities by type of surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Applicable neuromonitoring modalities by type of surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">EEG</td> <td class=\"subtitle1\">EMG</td> <td class=\"subtitle1\">SSEP</td> <td class=\"subtitle1\">BAEP</td> <td class=\"subtitle1\">MEP</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Spine surgeries</td> </tr> <tr> <td class=\"indent1\">Thoracoabdominal deformity correction</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\"> <p>X</p> (especially to detect radiculopathy/pedicle screw testing)</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Lower lumbosacral spine</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">Less commonly used below level of spinal cord</td> </tr> <tr> <td class=\"indent1\">Cervical spine</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Intramedullary spinal tumor</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\"> <p>X</p> (often to identify dorsal-median sulcus)</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\"> <p>X</p> (especially D-wave)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cauda equina or tethered cord</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Intracranial surgeries</td> </tr> <tr> <td class=\"indent1\">Neurovascular</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Supratentorial tumor resection</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Skull base/posterior fossa/brainstem</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\"> <p>X</p> (such as \"safe entry zone\" identification)</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Cardiovascular surgeries</td> </tr> <tr> <td class=\"indent1\">Carotid</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\"> <p>X</p> (subcortical monitoring)</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Aortic</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Otolaryngology surgeries</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Anterior neck surgeries</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"6\">Interventional neuroradiology procedures</td> </tr> <tr> <td class=\"indent1\">Intracranial</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td class=\"indent1\">Spine</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EEG: electroencephalography; EMG: electromyography; SSEP: somatosensory evoked potential; BAEP: brainstem auditory evoked potential; MEP: motor evoked potential.</div><div id=\"graphicVersion\">Graphic 101913 Version 4.0</div></div></div>"},"101914":{"type":"graphic_figure","displayName":"Characteristic changes in the EEG with ischemia","title":"Characteristic changes in the EEG with ischemia","html":"<div class=\"graphic\"><div style=\"width: 705px\" class=\"figure\"><div class=\"ttl\">Characteristic changes in the EEG with ischemia</div><div class=\"cntnt\"><img style=\"width:685px; height:504px;\" src=\"images/ANEST/101914_Char_changes_EEG_ischemia.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">EEG frequency: Beta &gt;12 Hz, theta 4-8 Hz, delta 0-4 Hz.</div><div class=\"graphic_footnotes\">CBF: cerebral blood flow; EEG: electroencephalogram.</div><div class=\"graphic_reference\">Reproduced from: Jameson LC, Janik DJ, Sloan TB. Electrophysiologic monitoring in neurosurgery. Anesthesiol Clin 2007; 25:605. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101914 Version 2.0</div></div></div>"},"101915":{"type":"graphic_figure","displayName":"EMG recordings during surgery near motor nerves","title":"Electromyographic recordings during surgery near motor nerves","html":"<div class=\"graphic\"><div style=\"width: 678px\" class=\"figure\"><div class=\"ttl\">Electromyographic recordings during surgery near motor nerves</div><div class=\"cntnt\"><img style=\"width:658px; height:575px;\" src=\"images/ANEST/101915_EMG_muscle_monitor_surgery.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electromyographic recordings during surgery near motor nerves. Shown in A&nbsp;are a large burst response from nerve stimulation or brief nerve irritation (eg, mechanical touch) and&nbsp;three smaller spontaneous muscle activities. When a large number of the smaller responses are seen in multiple muscles, this is consistent with light anesthesia. Shown in B&nbsp;are continuous, high-frequency trains known as neurotonic discharges, suggestive of forces that can cause nerve injury.</div><div class=\"graphic_footnotes\">EMG: electromyography.</div><div id=\"graphicVersion\">Graphic 101915 Version 4.0</div></div></div>"},"101916":{"type":"graphic_figure","displayName":"Measuring amplitude and latency in evoked responses","title":"Measuring amplitude and latency in evoked responses","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Measuring amplitude and latency in evoked responses</div><div class=\"cntnt\"><img style=\"width:423px; height:175px;\" src=\"images/ANEST/101916_Msr_ampltd_ltncy_evk_rspns.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The peak of interest is chosen in the evoked response to represent the anatomic structure at risk (eg, sensory cortex) or from a structure that is located such that the anatomic structure at risk is between the peak and the stimulation site (eg, using the cortical response during spine surgery). Measuring evoked responses for monitoring is measuring the time from stimulation to the peak of interest (latency) and the peak to adjacent peak amplitude (amplitude). The term \"onset\" represents the time from stimulation to the beginning of a multi-peaked muscle response (compound muscle action potential).</div><div id=\"graphicVersion\">Graphic 101916 Version 2.0</div></div></div>"},"101917":{"type":"graphic_table","displayName":"Key assumptions regarding intent of SCP","title":"Key assumptions regarding the intent of the Survivorship Care Plan, as agreed upon by participants in the ASCO (American Society of Clinical Oncology) Clinical Expert Panel on survivorship care planning","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key assumptions regarding the intent of the Survivorship Care Plan, as agreed upon by participants in the ASCO (American Society of Clinical Oncology) Clinical Expert Panel on survivorship care planning</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Key assumption</td> </tr> <tr> <td class=\"indent1\">The SCP is a two-part tool, a treatment summary and care plan, intended to facilitate communication and coordination of care between the patient, oncology providers, primary care providers, and other providers.</td> </tr> <tr> <td class=\"indent1\">The SCP does not replace discussions but rather is an adjunct to those discussions. The SCP should be given to the patient, but delivery of an SCP without discussion is not desirable. This discussion should occur between the oncology provider and patient at the conclusion of acute treatment. The SCP should also be delivered to the patient's PCP and any other key healthcare providers.</td> </tr> <tr> <td class=\"indent1\">The SCP should be as simple, clear, and understandable as possible to meet the needs of the intended users; if actions are identified, the SCP should include who is primarily responsible.</td> </tr> <tr> <td class=\"indent1\">The SCP is not intended to be or replace the medical record; detailed original source documentation may be needed by providers for clinical care.</td> </tr> <tr> <td class=\"indent1\">The SCP developed in this process is intended for patients treated with curative intent for adult cancers regardless of tumor type. Future development of SCPs intended for other patients (eg, survivors with advanced cancer) is needed.</td> </tr> <tr> <td class=\"indent1\">The SCP developed in this process is intended to be presented to patients who have completed active therapy and have no evidence of disease; survivors may be on maintenance or ongoing therapy (eg, hormonal therapy) beyond the acute treatment period.</td> </tr> <tr> <td class=\"indent1\">The SCP can be an evolving document in that it may be updated and reissued as needed. It may not always be developed and/or presented in an electronic format, but its documentation should be included in the survivor's medical record along with a copy sent to the primary care provider.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SCP: survivorship care plan; PCP: primary care provider.</div><div class=\"graphic_reference\">From: Mayer DK, Nekhlyudov L, Snyder CF, et al. American Society of Clinical Oncology clinical expert statement on cancer survivorship care planning. J Oncol Pract 2014; 10(6):345-51. Reprinted with permission. Copyright &copy; 2014 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101917 Version 3.0</div></div></div>"},"101918":{"type":"graphic_figure","displayName":"Somatosensory evoked potentials (SSEPs)","title":"Somatosensory evoked potentials (SSEPs)","html":"<div class=\"graphic\"><div style=\"width: 756px\" class=\"figure\"><div class=\"ttl\">Somatosensory evoked potentials (SSEPs)</div><div class=\"cntnt\"><img style=\"width:736px; height:634px;\" src=\"images/ANEST/101918_Somatosensory_evoked_ptntls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The SSEP is produced by stimulation of a peripheral nerve (arrow). The electrical activity enters via the dorsal nerve root and ascends the spinal cord via the dorsal column pathway, which mediates the senses of proprioception and vibration. It synapses at the cervicomedullary junction and crosses the midline ascending in the medial lemniscus to the ventral posterolateral nucleus of the thalamus, where it has a second synapse. From there it ascends to the sensory cerebral cortex. SSEP recordings can be made along the pathway; shown are responses from the peripheral nerve, spinal cord, cervical spine, and cerebral cortex.</div><div class=\"graphic_footnotes\">SSEP: somatosensory evoked potential.</div><div class=\"graphic_reference\">Reproduced from: Jameson LC, Sloan TB. Monitoring of the brain and spinal cord. Anesthesiol Clin 2006; 24:777. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101918 Version 2.0</div></div></div>"},"101919":{"type":"graphic_table","displayName":"ASCO survivor guidelines: Key components of treatment summary","title":"ASCO Statement on Cancer Survivorship Care Planning: Key components of the treatment summary","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ASCO Statement on Cancer Survivorship Care Planning: Key components of the treatment summary</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Key component</td> </tr> <tr> <td class=\"indent1\">Contact information of the treating institutions and providers</td> </tr> <tr> <td class=\"indent1\">Specific diagnosis (eg, breast cancer), including histologic subtype (eg, non-small-cell lung cancer) when relevant</td> </tr> <tr> <td class=\"indent1\">Stage of disease at diagnosis (eg, I to III)</td> </tr> <tr> <td class=\"indent1\">Surgery (yes versus no); if yes:</td> </tr> <tr> <td class=\"indent2\"> <p>Surgical procedure with location on the body</p> Date of surgery (year required, month optional, day not required)</td> </tr> <tr> <td class=\"indent1\">Chemotherapy (yes versus no); if yes:</td> </tr> <tr> <td class=\"indent2\"> <p>Names of systemic therapy agents administered (listing individual names rather than regimens)</p> End date of chemotherapy treatment (year required, month optional, day not required)</td> </tr> <tr> <td class=\"indent1\">Radiotherapy (yes versus no); if yes:</td> </tr> <tr> <td class=\"indent2\"> <p>Anatomic area treated with radiation</p> End date of radiation treatment (year required, month optional, day not required)</td> </tr> <tr> <td class=\"indent1\">Ongoing toxicity or adverse effects of all treatments received (including those resulting from surgery, systemic therapy, and/or radiotherapy) at the completion of treatment; any information concerning the likely course of recovery from these toxicities should also be covered</td> </tr> <tr> <td class=\"indent1\">For selected cancers, genetic or hereditary risk factors or predisposing conditions and genetic testing results if performed</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Mayer DK, Nekhlyudov L, Snyder CF, et al. American Society of Clinical Oncology clinical expert statement on cancer survivorship care planning. J Oncol Pract 2014; 10(6):345-51. Reprinted with permission. Copyright &copy; 2014 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101919 Version 2.0</div></div></div>"},"101920":{"type":"graphic_figure","displayName":"Pathway and peaks of the auditory brainstem response","title":"Pathway and peaks of the auditory brainstem response","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Pathway and peaks of the auditory brainstem response</div><div class=\"cntnt\"><img style=\"width:526px; height:477px;\" src=\"images/ANEST/101920_Pathway_peaks_ABR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The first seven peaks of the ABR are produced near the structures in the brainstem, as described in the text. Typically, waves I, III, and V are seen during monitoring.</div><div class=\"graphic_footnotes\">ABR: auditory brainstem response.</div><div class=\"graphic_reference\">Original figure modified for this publication. Aravabhumi S, Izzo KL, Bakst BL. Brainstem auditory evoked potentials: Intraoperative monitoring technique in surgery of posterior fossa tumors. Arch Phys Med Rehabil 1987; 68:142. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101920 Version 2.0</div></div></div>"},"101921":{"type":"graphic_table","displayName":"ASCO survivor guidelines: Components of the follow-up care plan","title":"ASCO Expert Statement on Survivorship Care Planning: Key components of the follow-up care plan","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ASCO Expert Statement on Survivorship Care Planning: Key components of the follow-up care plan</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Key component</td> </tr> <tr> <td class=\"indent1\">Oncology team member contacts with location of the treatment facility (repeat if separate document)</td> </tr> <tr> <td class=\"indent1\">Need for ongoing adjuvant therapy for cancer</td> </tr> <tr> <td class=\"indent2\"> <p>Adjuvant therapy name</p> <p>Planned duration</p> Expected adverse effects</td> </tr> <tr> <td class=\"indent1\">Schedule of follow-up-related clinical visits (to be presented in table format to include who will provide follow-up visits and how often and where these will take place)</td> </tr> <tr> <td class=\"indent1\">Cancer surveillance tests for recurrence (to be presented in table format to include who is responsible for ordering or carrying out the tests, the frequency of testing, and where these will take place)</td> </tr> <tr> <td class=\"indent1\">Cancer screening for early detection of new primaries; to be included only if different from the general population (presented in table format to include who is responsible for carrying out tests, the frequency of testing, and where these will take place)</td> </tr> <tr> <td class=\"indent1\">Other periodic testing and examinations (rather than outlining specific testing, the group suggested an inclusion of a general statement to \"continue all standard non-cancer-related health care with your primary care provider, with the following exceptions: [if there are any]\")</td> </tr> <tr> <td class=\"indent1\">Possible symptoms of cancer recurrence (rather than including a list of possible symptoms, the group suggested inclusion of a general statement: \"Any new, unusual, and/or persistent symptoms should be brought to the attention of your provider\")</td> </tr> <tr> <td class=\"indent1\">A list of likely or rare but clinically significant late and/or long-term effects that a survivor may experience based on his or her individual diagnosis and treatment if known (including symptoms that may indicate the presence of such conditions)</td> </tr> <tr> <td class=\"indent1\">A list of items (eg, emotional or mental health, parenting, work/employment, financial issues, and insurance) should be covered with standard language stating that survivors have experienced issues in these areas and that the patient should speak with his or her oncologist and/or PCP if having related concerns; include a list of local and national resources to assist the patient in obtaining proper services</td> </tr> <tr> <td class=\"indent1\">A general statement emphasizing the importance of healthy diet, exercise, smoking cessation, and alcohol use reduction may be included; statements may be tailored if particularly pertinent to the individual</td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Mayer DK, Nekhlyudov L, Snyder CF, et al. American Society of Clinical Oncology clinical expert statement on cancer survivorship care planning. J Oncol Pract 2014; 10(6):345-51. Reprinted with permission. Copyright &copy; 2014 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101921 Version 2.0</div></div></div>"},"101922":{"type":"graphic_table","displayName":"Dermoscopy algorithms","title":"Dermoscopic algorithms for skin lesion triage","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dermoscopic algorithms for skin lesion triage</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"4\">Pigmented</td> <td class=\"subtitle1\">Non-pigmented</td> </tr> <tr> <td class=\"subtitle2\">Three-point checklist</td> <td class=\"subtitle2\">AC rule</td> <td class=\"subtitle2\">Blue-black rule</td> <td class=\"subtitle2\">Chaos and clues</td> <td class=\"subtitle2\">Prediction without pigment</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Asymmetry</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Color variation</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Atypical network</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Blue-white structures</strong></td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Ulceration</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Shiny white structures</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Keratin clues</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> <tr> <td><strong>Vascular pattern</strong></td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">&nbsp;</td> <td class=\"centered\">X</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Ashfaq A Marghoob, MD,&nbsp;and Natalia Jaimes, MD.</div><div id=\"graphicVersion\">Graphic 101922 Version 1.0</div></div></div>"},"101923":{"type":"graphic_figure","displayName":"Pathway and typical responses of the motor evoked potential","title":"Pathway and typical responses of the motor evoked potential","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Pathway and typical responses of the motor evoked potential</div><div class=\"cntnt\"><img style=\"width:714px; height:728px;\" src=\"images/ANEST/101923_Pathway_typicl_motor_evoked.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Motor evoked potentials (MEPs) are produced by stimulation of the motor cortex (arrow). The electrical activity descends following the corticospinal tract to the anterior horn of the spinal cord. After synapsing, the response then further descends to the peripheral nerve, traverses the neuromuscular junction, and produces a muscle response. The MEP can be measured in the epidural space as D- and I-waves or as a compound muscle action potential (CMAP).</div><div class=\"graphic_footnotes\">MEP: motor evoked potential; CMAP: compound muscle action potential; NMJ: neuromuscular junction.</div><div class=\"graphic_reference\">Reproduced from: Jameson LC, Sloan TB. Monitoring of the brain and spinal cord. Anesthesiol Clin 2006; 24:777. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 101923 Version 2.0</div></div></div>"},"101925":{"type":"graphic_table","displayName":"Effects of common agents on the cortical SSEPs and muscle MEPs","title":"Effects of common agents on the cortical SSEPs and muscle MEPs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Effects of common agents on the cortical SSEPs and muscle MEPs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">SSEP amplitude</td> <td class=\"subtitle1\">MEP amplitude</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td>Isoflurane</td> <td>Decrease</td> <td>Decrease</td> <td>SSEP usually recorded at &#60;1 MAC, MEP &#60;0.5 MAC</td> </tr> <tr> <td>Sevoflurane</td> <td>Decrease</td> <td>Decrease</td> <td>Similar to isoflurane</td> </tr> <tr> <td>Desflurane</td> <td>Decrease</td> <td>Decrease</td> <td>Similar to isoflurane</td> </tr> <tr> <td>N<sub><span style=\"font-size: 13px;\">2</span></sub>O</td> <td>Decrease</td> <td>Decrease</td> <td>Similar to isoflurane, synergistic when combined with halogenated agents</td> </tr> <tr> <td>Propofol</td> <td>Decrease</td> <td>Decrease</td> <td>SSEP and MEP usually recorded at anesthetic doses but MEP may be lost at high doses</td> </tr> <tr> <td>Opioids</td> <td>Minimal</td> <td>Minimal</td> <td>SSEP and MEP usually recorded even at high doses</td> </tr> <tr> <td>Etomidate</td> <td>Increase at low doses &ndash; decrease at higher doses</td> <td>Increase at low doses &ndash; decrease at higher doses</td> <td>Enhancement of SSEP and MEP seen at low doses, depression at very high doses</td> </tr> <tr> <td>Ketamine</td> <td>Minimal, increase at low doses</td> <td>Minimal, increase at low doses</td> <td>Enhancement SSEP and MEP seen at low doses</td> </tr> <tr> <td>Benzodiazepines</td> <td>Minimal at low doses</td> <td>Minimal at low doses, prolonged decrease at higher doses</td> <td>SSEP and MEP usually recorded with small doses for amnesia</td> </tr> <tr> <td>Dexmedetomidine</td> <td>Minimal</td> <td>Minimal &ndash; decrease at higher doses</td> <td>SSEP and MEP usually recorded at low doses but MEP lost at higher doses</td> </tr> <tr> <td>Lidocaine</td> <td>Minimal</td> <td>Minimal</td> <td>Can be used as intravenous supplement in SSEP and MEP</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Anesthetic effects may be significantly greater in young children (immature pathways) and adults with significant neural dysfunction. Latency increases generally occur as amplitude is decreased.</div><div class=\"graphic_footnotes\">SSEP: somatosensory evoked potentials; MEP: motor evoked potentials; MAC: minimum alveolar concentration;&nbsp;N<SUB innerHtml>2</SUB>O: nitrous oxide.</div><div class=\"graphic_reference\">Adapted from: Shils JL, Sloan TB. Intraoperative neuromonitoring. Int Anesthesiol Clin 2015; 53:53.</div><div id=\"graphicVersion\">Graphic 101925 Version 3.0</div></div></div>"},"101926":{"type":"graphic_table","displayName":"Checklist of intraoperative neuromonitoring changes","title":"Checklist of intraoperative neuromonitoring changes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Checklist of intraoperative neuromonitoring changes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Anesthesia</td> </tr> <tr> <td class=\"indent1\">Halogenated agents, nitrous oxide</td> </tr> <tr> <td class=\"indent2\"> <p>Added agent</p> Change in concentration</td> </tr> <tr> <td class=\"indent1\">IV agents</td> </tr> <tr> <td class=\"indent2\"> <p>Bolus dose</p> <p>Change infusion</p> <p>Dose wearing off</p> Muscle relaxation change</td> </tr> <tr> <td class=\"indent1\">Epidural, intrathecal, or regional block</td> </tr> <tr> <td class=\"subtitle1_single\">Physiology</td> </tr> <tr> <td class=\"indent1\">Temperature</td> </tr> <tr> <td class=\"indent2\"> <p>Whole body temperature</p> Local change (irrigation, cold IV fluids)</td> </tr> <tr> <td class=\"indent1\">Ventilation</td> </tr> <tr> <td class=\"indent2\"> <p>Hypoxemia</p> Hyper or hypoventilation</td> </tr> <tr> <td class=\"indent1\">Ischemia/reduced blood flow</td> </tr> <tr> <td class=\"indent2\"> <p>Hypotension, poor cardiac output, bleeding</p> <p>Local ischemia (retractor, clip, vasospasm)</p> <p>Rheology/blood volume (change HCT, colloids)</p> <p>Loss autoregulation (hypoxia, hypercarbia, injury)</p> Vascular steal/Robin Hood</td> </tr> <tr> <td class=\"indent1\">Other</td> </tr> <tr> <td class=\"indent2\"> <p>Raised intracranial, CSF, or tissue pressure</p> Hypoglycemia, electrolyte abnormalities</td> </tr> <tr> <td class=\"subtitle1_single\">Positioning</td> </tr> <tr> <td class=\"indent1\"> <p>Mechanical stretch/pressure on plexus/nerves</p> Vascular occlusion to area</td> </tr> <tr> <td class=\"subtitle1_single\">Surgical</td> </tr> <tr> <td class=\"indent1\"> <p>Blunt or surgical trauma</p> <p>Mechanical effect (device, retractor, pledget pressure)</p> <p>Vascular occlusion to area</p> <p>Applied medications surface or intravascular (lidocaine, papaverine)</p> <p>Surgical stimulation</p> Tissue resection</td> </tr> <tr> <td class=\"subtitle1_single\">Technical</td> </tr> <tr> <td class=\"indent1\">Stimulation</td> </tr> <tr> <td class=\"indent2\">Electrodes&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">&ndash;</span> Dislodged, edema, wrong location</td> </tr> <tr> <td class=\"indent1\">Recording</td> </tr> <tr> <td class=\"indent2\"> <p>Electrodes&nbsp;<span style=\"font-size: 10pt; font-family: 'Verdana','sans-serif';\">&ndash;</span> Dislodged, edema, wrong location</p> <p>Poor or mismatched impedance</p> <p>Electrical noise from new equipment</p> Myoclonus or seizures</td> </tr> <tr> <td class=\"indent1\">Machine</td> </tr> <tr> <td class=\"indent2\"> <p>Malfunction</p> <p>Display settings changed</p> Testing paradigm settings changed</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">When changes occur in electrophysiologic responses, possible causes can be organized into five areas, as shown in this checklist.</div><div class=\"graphic_footnotes\">IV: intravenous; HCT: hematocrit; CSF: cerebrospinal fluid.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Sloan TB. Evoked potentials. In: Textbook of Neuroanesthesia with Neurosurgical and Neuroscience Perspectives, Albin MA (Ed), McGraw-Hill, New York 1997. p.221.</LI>&#xD;&#xA;<LI>Koht A, Sloan T, Toleikis JR. Monitoring the Nervous System for Anesthesiologists and Other Health Care Professionals, Springer, New York 2012.</LI></OL></div><div id=\"graphicVersion\">Graphic 101926 Version 3.0</div></div></div>"},"101928":{"type":"graphic_table","displayName":"Bronchiolar disorders","title":"Bronchiolar disorders in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bronchiolar disorders in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"6\">Bronchiolar disorders in adults</td> </tr> <tr> <td class=\"subtitle2\">Disorder</td> <td class=\"subtitle2\">Clinical features</td> <td class=\"subtitle2\">HRCT</td> <td class=\"subtitle2\">Histopathology</td> <td class=\"subtitle2\">Diagnosis</td> <td class=\"subtitle2\">Treatment</td> </tr> <tr class=\"divider_bottom\"> <td>Bronchiolitis obliterans (also known as obliterative bronchiolitis or constrictive bronchiolitis)</td> <td>Dyspnea, cough; PFTs normal or show airflow limitation without bronchodilator reversibility; predisposing process (eg, inhalational or drug exposure, rheumatic disease, lung or hematopoietic transplant)</td> <td>Expiratory air trapping (mosaic or diffuse) and bronchial wall thickening (eg, \"v\" or \"y\" shaped branching linear opacities), centrilobular nodules</td> <td>Fibroproliferative thickening of the bronchiolar walls causing narrowing of the bronchiolar lumen, which may progress to the complete obliteration of bronchioles</td> <td>Lung biopsy except in patients with compatible presentation and strong predisposition (eg, food flavoring exposure, lung transplant)</td> <td>Optimal treatment unknown: Stop exposure to potential culprit agents, symptomatic treatment with inhaled bronchodilators and oxygen; other possibilities include macrolides, glucocorticoids, immunosuppressive agents, antireflux therapy, lung transplantation</td> </tr> <tr class=\"divider_bottom\"> <td>Proliferative bronchiolitis</td> <td>Usually seen in the context of cryptogenic or secondary organizing pneumonia or nitrogen dioxide exposure</td> <td>Diffuse or patchy ground glass or consolidative opacities</td> <td>Fibroblast proliferation and an organizing, polypoid intraluminal exudate in respiratory bronchioles and alveolar ducts</td> <td>Lung biopsy</td> <td>Stop any culprit drug; systemic glucocorticoids</td> </tr> <tr class=\"divider_bottom\"> <td>Follicular bronchiolitis</td> <td>Progressive dyspnea; associated with rheumatic diseases, immunodeficiency, hypersensitivity pneumonitis</td> <td>Centrilobular nodules; may have patchy ground glass opacity</td> <td>Lymphoid hyperplasia of bronchus-associated lymphoid tissue; germinal centers</td> <td>Lung biopsy</td> <td>Treat underlying disease</td> </tr> <tr class=\"divider_bottom\"> <td>Respiratory bronchiolitis</td> <td>Almost exclusively in smokers; asymptomatic finding on biopsy performed for another reason</td> <td>Diffuse or patchy ground glass opacities or fine centrilobular nodules and air trapping; bronchial wall thickening</td> <td>Mild bronchiolar inflammation, tan-pigmented macrophages within the lumens of first and second order respiratory bronchioles</td> <td>Lung biopsy</td> <td>Cigarette smoking cessation</td> </tr> <tr class=\"divider_bottom\"> <td>Airway-centered interstitial fibrosis</td> <td>Chronic nonproductive cough; usually seen in smokers; PFTs restrictive or obstructive; percentage of lymphocytes on bronchoalveolar lavage is less than 40%</td> <td>Peribronchovascular ground glass opacities, traction bronchiectasis, and thickening of bronchial walls</td> <td>Centrilobular and bronchiolocentric inflammatory infiltrate with peribronchiolar fibrosis and an absence of granulomas</td> <td>Lung biopsy</td> <td>Systemic or inhaled glucocorticoids</td> </tr> <tr> <td>Diffuse panbronchiolitis</td> <td>History of sinusitis (75%) and productive cough; generally limited to patients in Japan</td> <td>Diffuse centrilobular opacities, nodular and linear (tree-in-bud) opacities, thickened and dilated bronchiolar walls, and large cystic opacities with dilated proximal bronchi (in advanced disease)</td> <td>Bronchiolar transmural infiltrate composed of lymphocytes, plasma cells, and distinctive lipid-laden \"foamy\" macrophages</td> <td>Compatible clinical findings in a patient in Japan; otherwise lung biopsy</td> <td>Macrolide antibiotic for six months or longer</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HRCT: high resolution computed tomography; PFTs: pulmonary function tests.</div><div id=\"graphicVersion\">Graphic 101928 Version 1.0</div></div></div>"},"101929":{"type":"graphic_table","displayName":"Features of bronchiolar disorders","title":"Histopathologic and radiographic features of bronchiolar disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Histopathologic and radiographic features of bronchiolar disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical syndrome</td> <td class=\"subtitle1\">Histopathology</td> <td class=\"subtitle1\">Findings on HRCT</td> </tr> <tr> <td>Bronchiolitis obliterans/obliterative bronchiolitis</td> <td> <p>Constrictive bronchiolitis: concentric narrowing or complete obliteration of airway lumen</p> <p>Bronchiolar hypertrophy</p> <p>Bronchiolectasis</p> Few lymphocytes</td> <td> <p>Mosaic attenuation</p> <p>Air trapping seen on inspiratory and expiratory views</p> Bronchial wall-thickening</td> </tr> <tr> <td>Organizing pneumonia</td> <td> <p>Proliferative bronchiolitis: Intraluminal fibrotic buds, called Masson bodies, in the respiratory bronchioles</p> Foamy macrophages in alveoli</td> <td>Peripheral, patchy air-space consolidation or ground-glass opacities, small nodular opacities, and bronchial wall thickening with dilation</td> </tr> <tr> <td>Infectious bronchiolitis (eg, viral, mycoplasma)</td> <td>Acute (cellular) bronchiolitis: Bronchiolar epithelial cell necrosis and peribronchiolar lymphocytic infiltration</td> <td> <p>Centrilobular nodules</p> \"Tree-in-bud\" pattern</td> </tr> <tr> <td>Follicular bronchiolitis</td> <td>Follicular bronchiolitis: Lymphoid hyperplasia of BALT</td> <td> <p>Centrilobular nodules</p> Ground glass opacities when associated with LIP</td> </tr> <tr> <td>RB-ILD</td> <td> <p>Respiratory bronchiolitis:</p> <p>Tan-pigmented macrophages in the respiratory bronchioles</p> Patchy submucosal and peribronchiolar infiltrate of lymphocytes and histiocytes</td> <td> <p>Ill-defined centrilobular nodules</p> <p>Patchy ground-glass opacities</p> <p>Air-trapping</p> \"Tree-in-bud\" opacities</td> </tr> <tr> <td>Diffuse panbronchiolitis</td> <td>Diffuse panbronchiolitis: transmural infiltrate of lymphocytes, plasma cells, and lipid-laden foamy macrophages</td> <td> <p>Centrilobular nodules</p> <p>\"Tree-in-bud\" opacities</p> <p>Thickened and dilated bronchiolar walls (bronchiolectasis)</p> <p>Large cystic opacities are a late finding</p> </td> </tr> <tr> <td>Airway-centered interstitial fibrosis</td> <td>Airway-centered interstitial fibrosis: centrilobular and bronchiolocentric inflammatory infiltrate with peribronchiolar fibrosis and an absence of granulomas</td> <td>Peribronchovascular ground glass opacities, traction bronchiectasis, and thickening of bronchial walls</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HRCT: high resolution computed tomography; BALT: bronchus-associated lymphoid tissue; LIP: lymphocytic interstitial pneumonia; RB-ILD: respiratory bronchiolitis-interstitial lung disease.</div><div id=\"graphicVersion\">Graphic 101929 Version 1.0</div></div></div>"},"101930":{"type":"graphic_picture","displayName":"Dermoscopy three-point checklist melanoma-BCC","title":"Dermoscopic evaluation of pigmented skin lesions using the three-point checklist algorithm: Melanoma in situ and pigmented basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 816px\" class=\"figure\"><div class=\"ttl\">Dermoscopic evaluation of pigmented skin lesions using the three-point checklist algorithm: Melanoma in situ and pigmented basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:796px; height:411px;\" src=\"images/DERM/101930_Drm_thr_pnt_chckls_mlnm_BCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The three-point checklist uses three criteria (asymmetry, atypical network, and blue-white structures) and assigns one point to each. A score of ≥2 is considered positive.<br />(A) Melanoma in situ revealing an atypical network and asymmetry of pattern and distribution of dermoscopic structures. Using the three-point checklist, this lesion has a total score of 2 points, which is considered positive, and should be removed and submitted for histopathologic evaluation.<br />(B) Basal cell carcinoma: Under dermoscopy, blue-white structures (ie, blue-white veil) and asymmetry of pattern and distribution of dermoscopic structures are seen. Using the three-point checklist, a total score of 2 points is obtained; thus, it should be removed or submitted for further evaluation.</div><div class=\"graphic_reference\">Reproduced with permission from: Ashfaq A Marghoob, MD,&nbsp;and Natalia Jaimes, MD.</div><div id=\"graphicVersion\">Graphic 101930 Version 1.0</div></div></div>"},"101931":{"type":"graphic_picture","displayName":"Dermoscopy AC rule - melanoma","title":"Dermoscopic evaluation of pigmented skin lesions using the AC rule algorithm: Acral melanoma","html":"<div class=\"graphic\"><div style=\"width: 698px\" class=\"figure\"><div class=\"ttl\">Dermoscopic evaluation of pigmented skin lesions using the AC rule algorithm: Acral melanoma</div><div class=\"cntnt\"><img style=\"width:678px; height:677px;\" src=\"images/DERM/101931_Dermos_AC_rule_melanoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Acral melanoma. Using the AC rule, this lesion demonstrates <STRONG>asymmetry</STRONG> in distribution of dermoscopic structures and colors, and <STRONG>color variation</STRONG> (ie, dark black, blue-gray, brown, and&nbsp;white). Therefore, this lesion should be removed or referred.</div><div class=\"graphic_reference\">Reproduced with permission from: Ashfaq A Marghoob, MD, and Natalia Jaimes, MD.</div><div id=\"graphicVersion\">Graphic 101931 Version 1.0</div></div></div>"},"101932":{"type":"graphic_figure","displayName":"Melanoma-specific dermoscopy structures","title":"Melanoma-specific structures on dermoscopy","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Melanoma-specific structures on dermoscopy</div><div class=\"cntnt\"><img style=\"width:596px; height:1332px;\" src=\"images/DERM/101932_Melanoma_spec_dermos_struct.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Seidenari S, Pellacani G, Martella A. Acquired melanocytic lesions and the decision to excise: role of color variegation and distribution as assessed by dermoscopy. Dermatol Surg 2005; 31:184.</li>&#xD;&#xA;    <li>Unified Dermoscopy Algorithm study, in progress. Preliminary results.</li>&#xD;&#xA;    <li>Agero AL, Taliercio S, Dusza SW, et al. Conventional and polarized dermoscopy features of dermatofibroma. Arch Dermatol 2006; 142:1431.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Ashfaq A Marghoob, MD, and Natalia Jaimes, MD.</div><div id=\"graphicVersion\">Graphic 101932 Version 1.0</div></div></div>"},"101934":{"type":"graphic_picture","displayName":"Dermoscopy blue-black rule BCC","title":"Dermoscopic evaluation of pigmented skin lesions using the blue-black rule: Basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">Dermoscopic evaluation of pigmented skin lesions using the blue-black rule: Basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:602px; height:689px;\" src=\"images/DERM/101934_Drmscpy_blue_black_rule_BCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Using the blue-black rule (combination of blue and black color in at least 10% of the lesion surface area), this lesion was classified as suspicious and subjected to biopsy. Histopathology demonstrated a basal cell carcinoma.</div><div class=\"graphic_reference\">Reproduced with permission from: Ashfaq A Marghoob, MD, and Natalia Jaimes, MD.</div><div id=\"graphicVersion\">Graphic 101934 Version 1.0</div></div></div>"},"101935":{"type":"graphic_algorithm","displayName":"Chaos and clues dermoscopy algorithm","title":"Chaos and clues algorithm for dermoscopy","html":"<div class=\"graphic\"><div style=\"width: 788px\" class=\"figure\"><div class=\"ttl\">Chaos and clues algorithm for dermoscopy</div><div class=\"cntnt\"><img style=\"width:768px; height:760px;\" src=\"images/DERM/101935_Chaos_clues_dermoscopy_algo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Illustration of the chaos and clues algorithm for the dermoscopic evaluation of pigmented skin lesions.</LI>&#xD;&#xA;<LI>Chaos: Asymmetric distribution of dermoscopic structures or colors.</LI>&#xD;&#xA;<LI>Clues for malignancy: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Eccentric structureless area of any color, except skin color </LI>&#xD;&#xA;<LI>Thick lines, reticular or branched </LI>&#xD;&#xA;<LI>Gray or blue structures (ie, lines, circles, clods and dots)</LI>&#xD;&#xA;<LI>Black dots or clods, located along peripheral edge </LI>&#xD;&#xA;<LI>Radial lines or pseudopods, segmental (or focal) </LI>&#xD;&#xA;<LI>White lines, including lines arranged perpendicularly to each other (only seen with polarized dermoscopy) and reticular white lines (seen with both polarized and non-polarized dermoscopy) </LI>&#xD;&#xA;<LI>Polymorphous vessels (more than one vessel morphology) </LI>&#xD;&#xA;<LI>Lines parallel, ridges (volar) or chaotic (nails)​</LI></UL></LI></UL></div><div class=\"graphic_footnotes\">* Any exception to chaos? If yes, perform a biopsy.&#xD;&#xA;<ol>&#xD;&#xA;    <li>Changing lesion in an adult</li>&#xD;&#xA;    <li>Lesion on the head or neck with gray appearance</li>&#xD;&#xA;    <li>Pigmented nodular lesion</li>&#xD;&#xA;    <li>Acral lesion with parallel ridge pattern</li>&#xD;&#xA;</ol></div><div class=\"graphic_reference\">Reproduced with permission from: Ashfaq A Marghoob, MD, and Natalia Jaimes, MD.</div><div id=\"graphicVersion\">Graphic 101935 Version 5.0</div></div></div>"},"101936":{"type":"graphic_table","displayName":"Dermoscopy chaos and clues","title":"Terminology used in the \"chaos and clues,\" \"prediction without pigment,\" and \"two-step\" algorithms for dermoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Terminology used in the \"chaos and clues,\" \"prediction without pigment,\"&nbsp;and \"two-step\" algorithms for dermoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Chaos and clues, prediction without pigment</td> <td class=\"subtitle1\">Two-step algorithm</td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Eccentric structureless area of any color, except skin color </li> </ul> </td> <td> <ul> <li>Atypical (off-centered) blotch </li> <li>Peripheral brown structureless areas </li> <li>Scar-like depigmentation </li> <li>Blue-gray ovoid nest </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Thick lines, reticular or branched </li> </ul> </td> <td> <ul> <li>Atypical network </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Gray or blue structures (ie, lines, circles, clods and dots) </li> </ul> </td> <td> <ul> <li>Atypical dots and globules </li> <li>Granularity (also known as peppering) </li> <li>Blue-white veil </li> <li>Large blue-gray ovoid nests </li> <li>Multiple blue-gray non-aggregated globules </li> <li>Brown or gray dots arranged in a linear distribution within (but usually towards the periphery of) the lesion </li> <li>Asymmetric gray perifollicular openings </li> <li>Angulated lines </li> <li>Rhomboidal structures </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Black dots or clods, located in the periphery </li> </ul> </td> <td> <ul> <li>Atypical dots or globules </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Radial lines or pseudopods, segmental (or focal) </li> </ul> </td> <td> <ul> <li>Streaks (ie, pseudopods and radial streaming) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>White lines, including: <ol> <li>Reticular white lines (seen with both polarized and non-polarized dermoscopy) </li> <li>Polarizing-specific white lines, which are arranged perpendicularly to each other (only seen with polarized dermoscopy) </li> </ol> </li> </ul> </td> <td> <ul> <li>Crystalline structures (also known as shiny white lines), seen with PD </li> <li>Negative network (also known as inverse or reverse network), seen with PD and NPD </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Polymorphous vessels (more than one vessel morphology) </li> </ul> </td> <td> <ul> <li>Polymorphous vessels (more than one vessel morphology within the same lesion) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Lines parallel, ridges (volar) or chaotic (nails) </li> </ul> </td> <td> <ul> <li>Parallel ridge pattern (volar) </li> <li>Irregular pattern (nails) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Ulceration </li> </ul> </td> <td> <ul> <li>Ulceration </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>White lines, including: <ol> <li>Reticular white lines </li> <li>Polarizing-specific white lines </li> </ol> </li> </ul> </td> <td> <ul> <li>Negative network (also known as inverse or reverse network), seen with PD and NPD </li> <li>Crystalline structures (also known as shiny white lines), seen with PD </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>White circles </li> </ul> </td> <td> <ul> <li>Rosettes </li> <li>Keratin pearls </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>White structureless areas </li> </ul> </td> <td> <ul> <li>Shiny white blotches </li> <li>Scar-like depigmentation </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <ul> <li>Surface keratin </li> </ul> </td> <td> <ul> <li>Keratin scale </li> </ul> </td> </tr> <tr> <td> <ul> <li>Vascular patterns: <ul> <li>Clods-only </li> </ul> </li> </ul> </td> <td> <ul> <li>Vascular patterns: <ul> <li>Lacunae </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PD: polarized dermoscopy; NPD: nonpolarized dermoscopy.</div><div class=\"graphic_reference\">Reproduced with permission from: Ashfaq A Marghoob, MD, and Natalia Jaimes, MD.</div><div id=\"graphicVersion\">Graphic 101936 Version 3.0</div></div></div>"},"101937":{"type":"graphic_table","displayName":"CMV diagnostic tests","title":"Diagnostic tests for cytomegalovirus*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic tests for cytomegalovirus*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"6\" width=\"13%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Serology</td> <td class=\"subtitle1\">Quantitative PCR<sup>&#182;</sup></td> <td class=\"subtitle1\">Antigenemia<sup>&#916;</sup></td> <td class=\"subtitle1\">Culture</td> <td class=\"subtitle1\">Histopathology<sup>&#9674;</sup></td> <td class=\"subtitle1\">Resistance testing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Immunocompetent</td> </tr> <tr> <td class=\"indent1\">Acute or recent infection</td> <td>IgM or fourfold increase of IgG</td> <td>Plasma or whole blood</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Past infection</td> <td>IgG</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Critically ill</td> <td>&nbsp;</td> <td>Plasma or whole blood; consider BAL</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Immunocompromised</td> </tr> <tr> <td class=\"indent1\">Assessing risk of CMV disease</td> <td>IgG</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Diagnosis of disease</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Viral syndrome</td> <td>&nbsp;</td> <td>Plasma or whole blood</td> <td>PBMCs</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Pneumonitis</td> <td>&nbsp;</td> <td>Plasma or whole blood; consider BAL</td> <td>PBMCs</td> <td>BAL or lung tissue</td> <td>BAL or lung tissue</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Gastrointestinal disease</td> <td>&nbsp;</td> <td>Plasma or whole blood<sup>&#167;</sup></td> <td>PBMCs<sup>&#167;</sup></td> <td>Tissue</td> <td>Tissue</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Central nervous system disease</td> <td>&nbsp;</td> <td>CSF, plasma, whole blood</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Retinitis</td> <td>&nbsp;</td> <td>Vitreous or aqueous fluid</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Decisions regarding preemptive therapy</td> <td>&nbsp;</td> <td>Plasma or whole blood</td> <td>PBMCs</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Monitoring response to therapy</td> <td>&nbsp;</td> <td>Plasma or whole blood</td> <td>PBMCs</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\">Treatment failure</td> <td>&nbsp;</td> <td>Plasma or whole blood</td> <td>PBMCs</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Yes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCR: polymerase chain reaction; IgM: immunoglobulin M; IgG: immunoglobulin G; BAL: bronchoalveolar lavage; CMV: cytomegalovirus; CSF: cerebrospinal fluid; PBMCs: peripheral blood polymorphonuclear leukocytes.<br />* Refer to&nbsp;the UpToDate topic reviews on diagnosis of CMV for detailed recommendations regarding the use of these assays. This table does not address diagnostic testing for CMV infection in neonates with congenital or perinatal CMV infection. For details on diagnostic testing in newborns, refer to the UpToDate table on laboratory tests for the detection of CMV in neonates with suspected congenital infection and topic reviews on congenital and perinatal CMV infection.<br />¶ Quantitative PCR assays offer several advantages over the antigenemia assay, including better assay standardization, increased stability of the specimen, smaller specimen volume, and the ability to test patients with leukopenia. For these reasons, quantitative PCR assays are more widely used than the antigenemia test, and we prefer them for the diagnosis and monitoring of immunocompromised patients with CMV infection and disease.<br />Δ The CMV antigenemia assay is insensitive when the patient has a low neutrophil count (&lt;1000 cells/microL).<br />◊ This includes histopathology and immunohistochemical staining.<br />§ Negative results are common with gastrointestinal disease.</div><div id=\"graphicVersion\">Graphic 101937 Version 2.0</div></div></div>"},"101938":{"type":"graphic_picture","displayName":"Chaos and clues - BCC and melanoma","title":"Dermoscopic evaluation of pigmented skin lesions with the \"chaos and clues\" algorithm: Basal cell carcinoma and melanoma","html":"<div class=\"graphic\"><div style=\"width: 821px\" class=\"figure\"><div class=\"ttl\">Dermoscopic evaluation of pigmented skin lesions with the \"chaos and clues\" algorithm: Basal cell carcinoma and melanoma</div><div class=\"cntnt\"><img style=\"width:801px; height:294px;\" src=\"images/DERM/101938_Chaos_clues_BCC_melanoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Basal cell carcinoma demonstrating \"chaos,\" defined as the asymmetric distribution of dermoscopic structures or colors.<br />(B) Using the chaos and clues algorithm, this lesion does not demonstrate \"chaos.\" However, it reveals two of the eight \"clues\" for malignancy, including gray or blue structures and reticular white lines (also known as negative network). Thus, the lesion is considered suspicious and a biopsy should be performed. Histopathologic examination demonstrated a spitzoid melanoma.</div><div class=\"graphic_reference\">Reproduced with permission from: Ashfaq A Marghoob, MD, and Natalia Jaimes, MD.</div><div id=\"graphicVersion\">Graphic 101938 Version 1.0</div></div></div>"},"101940":{"type":"graphic_algorithm","displayName":"Prediction without pigment algorithm","title":"Prediction without pigment algorithm for dermoscopy","html":"<div class=\"graphic\"><div style=\"width: 522px\" class=\"figure\"><div class=\"ttl\">Prediction without pigment algorithm for dermoscopy</div><div class=\"cntnt\"><img style=\"width:502px; height:780px;\" src=\"images/DERM/101940_Prediction_without_pigment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Illustration of the dermoscopic algorithm \"prediction without pigment\" for the evaluation of nonpigmented skin lesions.</div><div class=\"graphic_footnotes\">* Ulceration without history of trauma.</div><div class=\"graphic_reference\">Reproduced with permission from: Ashfaq A Marghoob, MD, and Natalia Jaimes, MD.</div><div id=\"graphicVersion\">Graphic 101940 Version 2.0</div></div></div>"},"101941":{"type":"graphic_picture","displayName":"Prediction without pigment - melanoma and BCC","title":"Dermoscopic evaluation of nonpigmented lesions: Amelanotic melanoma and basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Dermoscopic evaluation of nonpigmented lesions: Amelanotic melanoma and basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:725px; height:336px;\" src=\"images/DERM/101941_Prdctn_wtht_pgmnt_mlnm_BCC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Amelanotic melanoma (A) and basal cell carcinoma (B). Using the \"prediction without pigment\" algorithm,&nbsp;dermoscopy reveals ulceration (B), white clues (A, B), and polymorphous vessels (A, B). Thus, with any of these structures, a biopsy should be performed.</div><div class=\"graphic_reference\">Reproduced with permission from: Ashfaq A Marghoob, MD, and Natalia Jaimes, MD.</div><div id=\"graphicVersion\">Graphic 101941 Version 1.0</div></div></div>"},"101944":{"type":"graphic_algorithm","displayName":"Triage amalgamated dermoscopic algorithm","title":"Triage amalgamated dermoscopic algorithm","html":"<div class=\"graphic\"><div style=\"width: 642px\" class=\"figure\"><div class=\"ttl\">Triage amalgamated dermoscopic algorithm</div><div class=\"cntnt\"><img style=\"width:622px; height:856px;\" src=\"images/DERM/101944_Triageamalgamateddermalg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Triage amalgamated dermoscopic algorithm (TADA). This algorithm is for lesions on nonglabrous skin. It does not apply to lesions on palms, soles, nails, and mucosae.</div><div class=\"graphic_footnotes\">* Diagnosis of dermatofibroma and seborrheic keratosis may require toggling between polarized dermoscopy and nonpolarized dermoscopy.<br />&para; Patients should continue self-monitoring, and changes in morphology or symptoms should raise concern.<br />&Delta; Algorithm is based on use of <strong>polarized dermoscopy</strong>.<br /><span class=\"lozenge\">&loz;</span> Ulceration without history of trauma.<br />&sect; Monitoring can include short-term, long-term, or self-monitoring for change.</div><div class=\"graphic_reference\">Reproduced with permission from: Ashfaq A Marghoob, MD, and Natalia Jaimes, MD. Published in: Jaimes N, Marghoob AA. Pocket Guide to Dermoscopy, 1st ed, JayPee Brothers Medical Publishers, New Dehli, 2017.</div><div id=\"graphicVersion\">Graphic 101944 Version 2.0</div></div></div>"},"101945":{"type":"graphic_picture","displayName":"TADA algorithm skin cancers","title":"Dermoscopic evaluation of skin lesions with the Triage Amalgamated Dermoscopic algorithm: Melanoma and basal cell carcinoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Dermoscopic evaluation of skin lesions with the Triage Amalgamated Dermoscopic algorithm: Melanoma and basal cell carcinoma</div><div class=\"cntnt\"><img style=\"width:269px; height:800px;\" src=\"images/DERM/101945_TADA_algo_skin_cancers.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Asymmetric distribution of colors and/or structures in a superficial spreading melanoma (A), basal cell carcinoma (B), and acral melanoma (C).</div><div class=\"graphic_reference\">Reproduced with permission from: Ashfaq A Marghoob, MD, and Natalia Jaimes, MD.</div><div id=\"graphicVersion\">Graphic 101945 Version 1.0</div></div></div>"},"101946":{"type":"graphic_picture","displayName":"TADA algorithm skin cancers 2","title":"Dermoscopic evaluation of skin lesions with the Triage Amalgamated Dermoscopy Algorithm","html":"<div class=\"graphic\"><div style=\"width: 719px\" class=\"figure\"><div class=\"ttl\">Dermoscopic evaluation of skin lesions with the Triage Amalgamated Dermoscopy Algorithm</div><div class=\"cntnt\"><img style=\"width:699px; height:723px;\" src=\"images/DERM/101946_TADA_algo_skin_cancer_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Using the Triage Amalgamated Dermoscopic Algorithm (TADA), symmetric skin lesions that present with blue-black or gray color are considered suspicious. Two melanomas presenting as symmetric lesions with black color (A) and blue-gray color (B) were classified as suspicious and a biopsy was performed. If skin lesions are amelanotic or hypopigmented, the presence of white structures or negative network are considered suspicious for malignancy, as seen in this basal cell carcinoma with white structures (C). Lesions without any of the previous structures but with ulceration or vascular structures are also considered suspicious, as seen in this squamous cell carcinoma (D).</div><div class=\"graphic_reference\">Reproduced with permission from: Ashfaq A Marghoob, MD, and Natalia Jaimes, MD.</div><div id=\"graphicVersion\">Graphic 101946 Version 1.0</div></div></div>"},"101950":{"type":"graphic_picture","displayName":"Subcorneal pustular dermatosis half-half blisters","title":"Subcorneal pustular dermatosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Subcorneal pustular dermatosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/101950_Sbcrn_pstlr_drmts_hlf_blstr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bullae with purulent collections in the lower portion (\"half-half blisters\").</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 101950 Version 1.0</div></div></div>"},"101954":{"type":"graphic_algorithm","displayName":"Melanonychia dermoscopic differential diagnosis","title":"Approach to the dermoscopic differential diagnosis and management of longitudinal melanonychia","html":"<div class=\"graphic\"><div style=\"width: 1012px\" class=\"figure\"><div class=\"ttl\">Approach to the dermoscopic differential diagnosis and management of longitudinal melanonychia</div><div class=\"cntnt\"><img style=\"width:992px; height:468px;\" src=\"images/DERM/101954_Melanonychia_diff_diagnosis.gif\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 101954 Version 1.0</div></div></div>"},"101955":{"type":"graphic_figure","displayName":"High ankle sprain mechanism","title":"High ankle sprain mechanism","html":"<div class=\"graphic\"><div style=\"width: 520px\" class=\"figure\"><div class=\"ttl\">High ankle sprain mechanism</div><div class=\"cntnt\"><img style=\"width:500px; height:440px;\" src=\"images/SM/101955_High_ankle_sprain_mechanism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High ankle sprains typically occur during high-intensity athletic activities such as competitive American football, soccer (football), and hockey. An external rotation force applied to a dorsiflexed ankle is the most common mechanism. This can happen when the leg is rotated forcefully against a planted foot or toe. Often, such injuries occur during contact with other athletes when the athlete is standing.</div><div id=\"graphicVersion\">Graphic 101955 Version 1.0</div></div></div>"},"101967":{"type":"graphic_picture","displayName":"Distal tibiofibular ligaments","title":"Distal tibiofibular ligaments","html":"<div class=\"graphic\"><div style=\"width: 731px\" class=\"figure\"><div class=\"ttl\">Distal tibiofibular ligaments</div><div class=\"cntnt\"><img style=\"width:711px; height:464px;\" src=\"images/SM/101967_Distal_tbfblr_lgmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Hagins M, Pappas E. Biomechanics of the Foot and Ankle. In: Basic Biomechanics of the Musculoskeletal System, Nordin, M, Frankel VH (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" spellcheck=\"true\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 101967 Version 1.0</div></div></div>"},"101973":{"type":"graphic_diagnosticimage","displayName":"Imaging pilon fracture of distal tibia","title":"Pilon fracture of the distal tibia on radiography and CT","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Pilon fracture of the distal tibia on radiography and CT</div><div class=\"cntnt\"><img style=\"width:762px; height:439px;\" src=\"images/RADIOL/101973_Imag_pilon_frctr_tibia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">An A-P (A) and lateral radiograph (B) of the ankle show a tibial fracture (arrow) involving the tibio-talar joint surface (arrow) associated with a spiral fracture of the fibula (arrowhead). Image C is a CT reconstructed in the sagittal plain showing the tibial fracture (arrow).</div><div class=\"graphic_footnotes\">A-P: anteroposterior; CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 101973 Version 1.0</div></div></div>"},"101975":{"type":"graphic_diagnosticimage","displayName":"Imaging intrarenal obstruction","title":"Imaging intrarenal obstruction","html":"<div class=\"graphic\"><div style=\"width: 796px\" class=\"figure\"><div class=\"ttl\">Imaging intrarenal obstruction</div><div class=\"cntnt\"><img style=\"width:776px; height:507px;\" src=\"images/RADIOL/101975_Imag_intrarenal_obstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) An IVP shows focal hydronephrosis of a left upper pole infundibulum (asterisk) caused by a stone in the renal pelvis (arrow).<br />(B)&nbsp;A longitudinal scan of the kidney and shows clot within the collecting system (arrow) causing intrarenal hydronephrosis (asterisk).<br />(C) An&nbsp;axial CT scan through the upper abdomen and shows lymphomatous infiltration of the left collecting system and focal hydronephrosis (asterisk).</div><div class=\"graphic_footnotes\">IVP: intravenous pyelogram; CT: Computed tomography.</div><div id=\"graphicVersion\">Graphic 101975 Version 2.0</div></div></div>"},"101976":{"type":"graphic_diagnosticimage","displayName":"Imaging hydronephrosis enlarged prostate","title":"Enlarged prostate gland causing hydronephrosis","html":"<div class=\"graphic\"><div style=\"width: 885px\" class=\"figure\"><div class=\"ttl\">Enlarged prostate gland causing hydronephrosis</div><div class=\"cntnt\"><img style=\"width:865px; height:496px;\" src=\"images/RADIOL/101976_Img_hydrnphrs_enlrg_prstt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperative ultrasound of the right (A) and left (B) kidneys show moderate hydronephrosis (asterisk). Image C is a retrograde cystogram and shows signs of outlet obstruction including a small volume hypertrophied bladder with a diverticulum (arrow) and trabeculation of the bladder wall (arrowhead). Post-prostatectomy ultrasound of the right kidney (D) shows resolution of the hydronephrosis. There is mild residual hydronephrosis of the left kidney (arrow).</div><div id=\"graphicVersion\">Graphic 101976 Version 1.0</div></div></div>"},"101977":{"type":"graphic_diagnosticimage","displayName":"CT nephrographic and pyelographic phase","title":"Nephrographic and pyelographic phases on CT","html":"<div class=\"graphic\"><div style=\"width: 914px\" class=\"figure\"><div class=\"ttl\">Nephrographic and pyelographic phases on CT</div><div class=\"cntnt\"><img style=\"width:894px; height:318px;\" src=\"images/RADIOL/101977_CT_nphrgrphc_pylgrphc_phs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) A CT scan through the upper abdomen shows the nephrographic phase of the kidneys (arrow). The left kidney is small and contains a small cyst (arrowhead).<br />(B) Shows the pyelographic phase (arrow).</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 101977 Version 2.0</div></div></div>"},"101981":{"type":"graphic_table","displayName":"Pharmacologic properties of systemic azole antifungals","title":"Pharmacologic properties of systemic azole antifungals","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacologic properties of systemic azole antifungals</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Available preparations</td> <td class=\"subtitle1\">Oral bioavailability, percent</td> <td class=\"subtitle1\">Metabolism and clearance</td> <td class=\"subtitle1\">Enzyme/transporter inhibition*</td> <td class=\"subtitle1\">Protein binding, percent</td> <td class=\"subtitle1\">Half-life in adults (hours)</td> <td class=\"subtitle1\">Availability of therapeutic drug monitoring<sup>&#182;</sup></td> </tr> <tr> <td><strong>Fluconazole</strong></td> <td> <p>Tablet</p> <p>Oral solution</p> IV solution</td> <td>&#62;90 (unaltered by food or elevated gastric pH)</td> <td> <p>Renally as unchanged drug (80%) requiring dose adjustment in renal impairment:</p> Hepatic metabolism (11%)</td> <td>CYPs 2C19 (strong), 2C9 (strong), 3A4 (moderate, more consistently observed with fluconazole &#8805;200 mg/day)</td> <td>11 to 12</td> <td>Approximately 24; prolonged in renal impairment</td> <td>No</td> </tr> <tr> <td><strong>Isavuconazole (formulated as prodrug isavuconazonium sulfate)</strong></td> <td> <p>Capsule</p> IV solution</td> <td>98 (unaltered by food or elevated gastric pH)</td> <td>Hepatically by CYP3A4 and UGT glucuronidation</td> <td>CYP3A4 (moderate), P-gp efflux</td> <td>&#62;99</td> <td>130</td> <td>No</td> </tr> <tr> <td><strong>Itraconazole</strong></td> <td> <p>Capsule<sup>&#916;</sup></p> <p>Tablet<sup>&#916;</sup></p> <p>Oral solution<sup>&#916;</sup></p> IV solution<sup>&#9674;</sup> (not available in United States)</td> <td> <p>Oral capsule and tablet: approximately 55 (with food and acidic beverage); drugs that elevate gastric pH (PPI, H2 antagonists) decrease absorption of capsule</p> <p>Oral solution: approximately 75 (without food)</p> </td> <td>Hepatically by CYP3A4 to active metabolites</td> <td>CYP3A4 (strong), P-gp efflux</td> <td>99</td> <td>25 to 50</td> <td> <p>Yes</p> Target trough &#8805;1 mcg/mL by HPLC or &#8805;3 mcg/mL by bioassay</td> </tr> <tr> <td><strong>Posaconazole</strong></td> <td> <p>Tablet (delayed release)</p> <p>Oral suspension</p> IV solution<sup>&#9674;</sup></td> <td> <p>Tablet (delayed release): 54 (preferably with some food)</p> <p>Oral suspension: variable (optimally absorbed with a high-fat meal in divided doses; however, absorption may be sufficient with any type of meal, a nutritional supplement, or an acidic beverage)</p> </td> <td>Minimally metabolized; most drug (66%) is cleared unchanged in feces; approximately 17% undergoes hepatic UGT glucuronidation</td> <td>CYP3A4 (strong)<sup>&#167;</sup></td> <td>&#62;98</td> <td> <p>Tablets: 26 to 31</p> <p>Suspension: approximately 35 (range 20 to 66)</p> Intravenous: approximately 27</td> <td> <p>Yes</p> <p>Prophylaxis: target trough &#8805;0.7 mcg/mL</p> Treatment: target trough &#8805;1 mcg/mL</td> </tr> <tr> <td><strong>Voriconazole</strong></td> <td> <p>Tablet</p> <p>Oral suspension</p> IV solution<sup>&#9674;</sup></td> <td>&#62;90 (tablet and oral suspension, taken without food); absorption is decreased &#8805;30% when taken with food</td> <td>Hepatically by CYPs 2C19 (major)<sup>&#165;</sup>, 2C9, and 3A4</td> <td>CYP2C19 (moderate), 2C9 (moderate), 3A4 (strong)</td> <td>58</td> <td>Variable<sup>&#135;</sup>; dependent upon dose, serum concentration, and patient-specific characteristics (eg, CYP2C19 polymorphism)</td> <td> <p>Yes<sup>&#135;</sup></p> Target trough 1 to 5.5 mcg/mL</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Azole antifungals are subject to numerous (potentially over 1000) drug interactions, particularly with drugs that are substrates of, inhibit, or induce CYP3A drug metabolism. Some interactions can lead to undetectable serum concentrations and failure of azole antifungal therapy or dangerously toxic levels of other drugs such as immunosuppressants used in solid organ or hematopoietic cell transplantation, cardiovascular drugs, and chemotherapeutic agents. Observed effect of azole antifungal interactions may be altered by dose, timing, and route of administration. Thus, patients receiving azole antifungals should have their medication regimen analyzed for drug interactions particularly when initiating and adjusting therapy; this may be done by use of the Lexi-Interact program included with UpToDate.</div><div class=\"graphic_footnotes\">CYP: cytochrome P450 metabolism; HPLC: high-performance liquid chromatography; IV: intravenous; P-gp: P-glycoprotein efflux transporters; PPI: proton pump inhibitor; UGT: uridine 5'-diphospho-glucuronosyltransferase glucuronidation (ie, phase II [non-CYP] hepatic metabolism).<br />* Only moderate to strong CYP inhibitor effects are listed. <br />¶ Therapeutic targets listed are based on limited study data and should be regarded as only general guidance. Decisions about dose modification must always be made within the context of the clinical status of the patient as detailed in the UpToDate topic reviews.<br />Δ Itraconazole capsules and tablets are not bioequivalent to oral solution and should not be interchanged on a milligram basis.<br /><FONT class=lozenge>◊</FONT> Intravenous solution contains a cyclodextrin vehicle that can accumulate in patients with renal impairment; refer to the topic review on the pharmacology of azoles for detailed recommendations.<br />§&nbsp;Preliminary data suggest that&nbsp;posaconazole may inhibit&nbsp;P-gp transporters; however,&nbsp;a clinically relevant effect has not been established.<br />¥&nbsp;CYP2C19 metabolism of voriconazole is highly polymorphic; serum concentrations may be elevated two- to fourfold in patients with low CYP2C19 expression (3 to 5% Caucasians and African-Americans, 15 to 20% Asians) relative to extensive metabolizers (ie, most patients).<br />‡&nbsp;Voriconazole exhibits nonlinear pharmacokinetics and metabolism appears to be saturable; thus, alteration of serum concentrations observed following a dose change can be disproportional to the adjustment. For example, a 50% dose increase can lead to a 150% increase in serum concentration. Refer to the topic review on the pharmacology of azoles for details.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy (2010); 30:842.</LI>&#xD;&#xA;<LI>Obeng OA, Egelund EF, Alsultan A, et al. CYP2C19 polymorphisms and therapeutic monitoring of voriconazole: Are we ready for clinical implementation of pharmacogenomics. Pharmacotherapy (2014); 34:703.</LI>&#xD;&#xA;<LI>Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: Guidelines from the British Society for Medical Mycology. J Antimicrob Chemother (2014); 69:1162.</LI>&#xD;&#xA;<LI>Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</LI></OL></div><div id=\"graphicVersion\">Graphic 101981 Version 5.0</div></div></div>"},"101983":{"type":"graphic_table","displayName":"Upper airway anatomic regions and structures","title":"Upper airway anatomic regions and structures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Upper airway anatomic regions and structures</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <p><strong>Nasal </strong></p> <ul> <li>Nares </li> <li>Nasal valves </li> <li>Septum </li> <li>Inferior turbinates </li> <li>External cartilages (upper and lower lateral cartilages) </li> <li>Nasal bones </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Oral </strong></p> <ul> <li>Mandible </li> <li>Maxilla/hard palate </li> <li>Oral tongue </li> <li>Teeth </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Upper pharyngeal</strong> (nasopharynx, velopharynx, upper oropharynx) </p> <ul> <li>Adenoid </li> <li>Soft palate </li> <li>Palatopharyngeus muscle </li> <li>Tonsils </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Lower pharyngeal</strong> (lower oropharynx, hypopharynx) </p> <ul> <li>Tongue base </li> <li>Lingual tonsil </li> <li>Lateral pharyngeal wall </li> </ul> </td> </tr> <tr> <td> <p><strong>Laryngeal</strong> </p> <ul> <li>Epiglottis </li> <li>False vocal folds </li> <li>True vocal folds (glottis) </li> <li>Arytenoids </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101983 Version 1.0</div></div></div>"},"101985":{"type":"graphic_table","displayName":"Examples of upper airway anatomic abnormalities","title":"Examples of upper airway anatomic abnormalities","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples&nbsp;of upper airway anatomic abnormalities</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <p><strong>Nasal </strong></p> <ul> <li>Narrow nares </li> <li>Wide columella </li> <li>Alar rim collapse </li> <li>Nasal tip ptosis </li> <li>Narrow piriform aperture </li> <li>Nasal valve compromise </li> <li>Nasal bone deformity </li> <li>Nasoseptal deformity </li> <li>Inferior turbinate hypertrophy </li> <li>Functional turbinate obstruction (eg, rhinitis of recumbency) </li> <li>Concha bullosae </li> <li>Nasal polyposis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Oral </strong></p> <ul> <li>Small mouth </li> <li>Macroglossia/oral tongue hypertrophy </li> <li>Tori mandibularis </li> <li>Retrognathia or micrognathia </li> <li>Trismus </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Upper pharyngeal </strong></p> <ul> <li>Adenoid hypertrophy </li> <li>Tornwaldt cyst </li> <li>Antrochoanal polyp </li> <li>Posteriorly positioned soft palate </li> <li>Palatine tonsillar hypertrophy </li> <li>Functional obstruction (eg, palatal or velopharyngeal collapse) </li> <li>Macroglossia/junctional tongue hypertrophy </li> <li>Cervical osteophyte </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p><strong>Lower pharyngeal</strong> </p> <ul> <li>Elongated soft palate </li> <li>Lingual tonsillar hypertrophy </li> <li>Macroglossia/tongue base hypertrophy </li> <li>Posteriorly positioned tongue base </li> <li>Retrognathia or micrognathia </li> <li>Functional obstruction <ul> <li>Tongue collapse </li> <li>Lateral wall collapse </li> </ul> </li> <li>Cervical osteophytes </li> </ul> </td> </tr> <tr> <td> <p><strong>Laryngeal </strong></p> <ul> <li>Retroflexed epiglottis </li> <li>Omega epiglottis </li> <li>Vocal fold polyp </li> <li>Vocal fold edema (Reinke's edema) </li> <li>Posterior laryngeal edema (eg, reflux laryngopharyngitis) </li> <li>Arytenoid collapse </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101985 Version 1.0</div></div></div>"},"101986":{"type":"graphic_table","displayName":"Examples of nasal procedures","title":"Examples of nasal procedures used in the surgical treatment of obstructive sleep apnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of nasal procedures used in the surgical treatment of obstructive sleep apnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <p>Turbinate reduction </p> <ul> <li>Radiofrequency </li> <li>Turbinate outfractures </li> <li>Submucous resection </li> <li>Intramural cauterization </li> <li>Cryotherapy </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Septoplasty </p> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Nasal valve surgery </p> <ul> <li>Stabilization suture </li> <li>Suspension suture </li> <li>Flaring suture </li> <li>Valvuloplasty </li> <li>Spreader grafts </li> <li>Batten grafts </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Functional rhinoplasty </p> </td> </tr> <tr> <td> <p>Endoscopic procedures </p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101986 Version 2.0</div></div></div>"},"101987":{"type":"graphic_table","displayName":"Examples of uvulopalatopharyngoplasty (UPPP) variants","title":"Examples of uvulopalatopharyngoplasty (UPPP) variants for the surgical treatment of obstructive sleep apnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of uvulopalatopharyngoplasty (UPPP)&nbsp;variants for the surgical treatment of obstructive sleep apnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <p>Uvulopalatal flap</p> </td> </tr> <tr> <td> <p>Expansion sphincter pharyngoplasty</p> </td> </tr> <tr> <td> <p>Lateral pharyngoplasty </p> </td> </tr> <tr> <td> <p>Palatal advancement pharyngoplasty </p> </td> </tr> <tr> <td> <p>Relocation pharyngoplasty </p> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101987 Version 3.0</div></div></div>"},"101988":{"type":"graphic_table","displayName":"Examples of lower pharyngeal and laryngeal procedures","title":"Examples of lower pharyngeal and laryngeal procedures used in the surgical treatment of obstructive sleep apnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Examples of lower pharyngeal and laryngeal&nbsp;procedures used in the surgical treatment of obstructive sleep apnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td> <p>Tongue reduction </p> <ul> <li>Midline glossectomy </li> <li>Lingualplasty </li> <li>Lingual tonsillectomy </li> <li>Radiofrequency reduction </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td> <p>Tongue advancement/stabilization </p> <ul> <li>Genioglossus advancement </li> <li>Hyoid suspension </li> <li>Tongue suspension </li> <li>Mandibular advancement </li> </ul> </td> </tr> <tr> <td> <p>Epiglottis correction </p> <ul> <li>Epiglottidectomy </li> <li>Epiglottopexy </li> <li>Hyoepiglottoplasty </li> <li>Hyoid suspension </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101988 Version 3.0</div></div></div>"},"101989":{"type":"graphic_table","displayName":"Global upper airway procedures","title":"Global airway procedures used in the surgical treatment of obstructive sleep apnea","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Global airway procedures used in the surgical treatment of obstructive sleep apnea</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td>Maxillomandibular advancement</td> </tr> <tr class=\"divider_bottom\"> <td>Tracheotomy <ul class=\"decimal_heading\"> <li>Cannula </li> <li>Skin-lined </li> </ul> </td> </tr> <tr> <td>Upper airway stimulation</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 101989 Version 3.0</div></div></div>"}};